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The C3b receptor (CRI) was first isolated from human erythrocyte 
membranes in 1979 and shown to be a large single chain polypeptide 
glycoprotein with a molecular weight of 205,000 daltons. CRI isolated 
from erythrocyte membranes has been shown in vitro to possess cofactor 
activity for the I mediated cleavage of C3b to iC3b and C4b to iC4b. It 
also plays a role in the prevention of lysis of bystander erythrocytes by 
its ability to cause the decay dissociation of C4b2a3b and C3bBb formed 
on these cells. In addition erythrocyte CRI in vivo is thought to play a 
role in the transport of opsonised immune complexes from the circulation 
to the te h c o ic -£ndo(iw2Uc2-l sxjgjftf where they can be removed. On unstimulated 
phagocytic cells the primary function of CRI is the binding of complexes 
opsonised with C3 and C4 degradation while on stimulated phagocytes CRI 
is able to directly mediate the phagocytosis of opsonised particles. CRI 
may play a role in the regulation of B lymphocyte function and on kidney 
podocytes CRI may serve to prevent complement activation on the basement 
membrane of the glomerulus.
The level of erythrocyte CRI is diminished in patients with systemic 
lupus erythematosus and at the onset of this study it had not been
established if these reduced levels were inherited or if they were 
acquired as a result of the disease process. One of the main aims of this 
study was the comparison of CRI expression on the erythrocytes of 
monozygotic and dizygotic twins in order to establish the relative roles 
of genetic and environmental factors on the regulation of erythrocyte CRI 
numbers In the normal population.
In order to quantify the number of CRI sites per erythrocyte CRI was
purified from human erythrocyte membranes and a polyclonal antiserum was 
prepared. When the monoclonal antibody, Ell became available this was 
used instead of the polyclonal antiserum as one point determinations
could be performed. Using Ell the number of CRI sites on the
erythrocytes of 62 dizygotic and 61 monozygotic twins was calculated. The
CRI levels on these tv/ins were found to be distributed in a log-normal 
fashion with no evidence of distinct groups of individuals having high or 
low phenotypes. Also there was no significant difference in CRI levels 
between the sexes nor was there any differences associated with age. 
Analysis of variance of the lag 1 0 transformed CRI sites/erythrocyte 
revealed that the intra-pair variance for identical twins was not 
significantly different from the .inter-pair variation between all the 
twins and the F ratio to compare monozygotic intra-pair variance with 
dizygotic intra-pair variance v/as not significant, These results suggest 
that as the differences between dizygotic twins were no greater than the 
differences between monozygotic twins, differences in erythrocyte CRI 
levels may arise largely or wholly as a result of environmental factors.
As the structural gene for CRI is present on the gene cluster with C4bp 
and H, and all three are cofactors for I, the serum levels of C4bp, H and 
I were measured for each of the twins. It was found that there was no 
significant genetic influence on the regulation of any of these proteins. 
However there was a significant increase in the levels of all of these 
proteins with age. Correlations were found between H and C4bp and between 
C4bp and I but there were no correlations found between CRI and any of 
the other proteins,
Having established that environmental factors play a significant role in 
the regulation of erythrocyte CRI numbers in normal individuals, 
experiments were performed to determine which environmental factors 
could modulate erythrocyte CRI expression. Overnight storage of 
erythrocytes at 4 ’C or 37’C in RPMI/BSA or autologous serum did not 
result in a significant reduction in CRI sites/erythrocyte and storage 
for two days at 37 *C in autologous plasma did not result in an inability 
to immunoprecipitate CRI from radiolabelled erythrocytes. Thus it was 
concluded that spontaneous shedding of CRI from erythrocytes in vivo was 
unlikely. High concentrations of the proteolytic enzymes trypsin and 
elastase removed all CRI detectable by radioimmunoassay, but at 
physiological concentrations these enzymes plus thrombin, pla-smin, 
kallikrein and cathepsins C and D had no effect on the number of CRI
sites/erythrocyte. The results of an in vitro and an in vivo experiment
suggest that reduction in erythrocyte CR1 numbers could occur as a result 
of blockade of the receptor by immune complexes. In vitro it was shown 
that CR1 numbers on the erythrocytes of two individuals were 
considerably reduced in the presence of large opsonised IgG aggregates as 
compared with CR1 levels in the presence of large unopsonised aggregates. 
In . vivo numbers of CR1 sites on erythrocytes were reduced in six
individuals two hours after drinking 1,2 litres of cows milk which is a
rich source of food antigens. These experiments suggest that E CR1 
numbers are not a stable heritable characteristic but may be strongly 
influenced by simple environmental factors.
Having investigated CR1 on erythrocytes attention was then turned to the 
study of GR1 on polymorphonuclear leukocytes. The number of 
polymorphonuclear leukocyte CR1 sites/cell was calculated on 14 normal 
individuals and on lb patients with systemic lupus erythematosus using 
the polyclonal anti-CRl antiserum. It was shown that polymorphonuclear 
leukocytes express three distinct pools of CR1. CR1 expression was lowest 
at O X  (mean 87,593 ± SEM 7,350) but increased when the cells were
incubated at 37 X  (124,939 ± 16,188) or when the cells were exposed to
the chemotactic peptide N-formyl-methionyl-leucylphenylalanine (FMLP) at 
37 X  (206,591 ± 21,396), The increased expression at 37 X  was not
dependent upon an intact cytoskeleton or energy, Although the response to 
FKLP did not require de novo protein synthesis, increased CR1 expression 
was dependent upon an intact cytoskeleton and energy. Trypsinisation of 
polymorphonuclear leukocytes removed all CR1 detectable by
radioimmunoassay^ however after incubation for one hour at 37 'C the 
surface expression of CR1 was restored almost to normal levels. The 
return of CR1 was not affected by inhibitors of protein synthesis or 
inhibitors of cytoskeleton assembly. All three polymorphonuclear leukocyte 
CR1 pools were reduced in patients with active systemic lupus
erythematosus, the most severely depleted pool being that which was 
mobilised in response to chemotactic agents. Polymorphonuclear leukocyte 
CR1 numbers were normal in patients with inactive systemic lupus
erythematosus, Serial studies performed on three systemic lupus
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erythematosus patients showed that polymorphonuclear leukocyte CR1 
numbers were low during periods of disease activity and increased during 
remission. These data suggest that low polymorphonuclear leukocyte CR1 
numbers in systemic lupus erythematosus are a consequence of the
disease.
An attempt was made to study the synthesis of CR1 in cultured monocytes 
and lymphocytes from normal individuals, The aim of this was to compare 
the rate of synthesis of CR1 in normal cells with the rate of synthesis 
of CR1 in the cells from, patients with SLE in order to determine if the
reduced CR1 levels associated with the disease were as a direct
consequence of the cells inability to synthesise the protein. Although CR1 
was successfully immunoprecipitated from one lymphocyte and two monocyte 
cell cultures, the method did not prove to be sufficiently reliable to be 
considered suitable for the study of CR1 abnormalities in systemic lupus 
erythematosus patients.
Clearly environmental factors are important in the reduction of CR1
numbers on the erythrocytes and polymorphonuclear leukocytes of patients 
with systemic lupus erythematosus. Although immune complexes will reduce 
CR1 numbers on erythrocytes in vitro it is not known if this is the 
cause in vivo. The cause of the reduction of polymorphonuclear leukocyte 
CR1 in patients with systemic lupus erythematosus is unknown and needs 
to be resolved. In addition the biological significance of reduced CR1 
numbers in polymorphonuclear leukocytes remains to be investigated.
OHAFTER ONE
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1.1 History of Complement
As early as 1792 it was noted that blood putrified more slowly than 
other substances, but it was not until almost a century later that 
studies on the capability of blood serum to kill certain microorganisms 
led to the discovery of complement. Following earlier work by Grohmann 
(1884) and Uuttall (1888), Buchner (1889) showed that bacteria could be 
killed and lysed by fresh cell free serum and that this activity was 
destroyed if the serum was heated to 5 5 ’C for 30 minutes. He called this 
activity "alexin”, meaning a protective substance, and he considered the 
killing action to be due to serum proteins with enzymatic activity since 
it was heat; labile and most readily demonstrable at body temperature. 
Following this, Pfeiffer and Issaeff (1894) showed that the destruction 
of some microorganisms, for example, Vibrio cholera, required specific 
antibody as well as alexin. This was a major advance the real 
significance of which became evident three years later from the work of 
the Belgian Jules Bordet (1898). Bordet noted that rabbit erythrocytes 
(E) were dissolved by the addition of horse serum which had been injected 
previously with rabbit E. If this immune serum was heated to 55 X  it lost 
this activity, but activity could be restored by the addition of serum 
from an unimmunised guinea pig which had no haemolytic effect on its 
own. From this Ehrlich and Morgenroth (1900) concluded that there were 
two substances concerned in the haemolysis reaction: the first, which
they called "the immune body", was developed in serum by the process of 
immunisation and was heat resistant; the second, which was present in 
fresh serum and was susceptible to heat, they called "complement". 
Ehrlich went on to show that complement could only act to lyse E when it 
was linked to the E via the immune body.
Host of the fundamental discoveries concerning complement action were 
made during the first quarter of this century and sprang from the 
recognition that complement was a multi-component system. Ferrata 
(1907) noted that dialysis of fresh guinea pig serum against water 
yielded a precipitate and a supernatant. On adding the supernatant to' 
sensitised E no haemolysis was observed but if the dissolved precipitate 
was recombined with the supernatant then haemolysis was restored. Brand 
(1907) called the factor in the precipitate "midpiece" and the factor in 
the supernatant "endpiece". These names were given to imply the 
sequential nature of complement action. The Sndpiece was found to 
contain two components called respectively "the second component" and 
"the third component". The third component was relatively heat stable 
and could be removed from serum by the action of zymosan or yeast. 
Serum treated in this way became inactive although it still contained the 
first and second components. Gordon, Whitehead and Vormal (1926) 
demonstrated the existence of a fourth component which could be 
destroyed by treatment with ammonia. Ueno (1938) showed the sequence of 
action of these four components: E sensitised with antibody first
combined with midpiece, now known as activated Cl, then with the fourth 
component C4, and then with endpiece containing C2 and C3.
Page 28
In 1946 a major advance in the study of complement was made possible by 
the development of a means to measure quantitatively the extent of
haemolysis. This enabled a more detailed study of the conditions which 
influenced the action of complement. By 1961 Mayer (1961) had 
demonstrated that the sequence of interaction was Cl, C4, C2 and C3 with 
a requirement for calcium and magnesium. He also introduced the theory, 
that only one lesion per E was necessary for lysis, this was termed "the • 
one hit theory of haemolysis".
Complement research proceeded rapidly: by 1969 C5, C6, C7, C8 and C9 had
been purified. By then it was known that complement was a system
comprising at least 11 glycoproteins and several inhibitors which could 
be activated by aggregated immunoglobulins. It was also during the
1960's that the breakdown of the complement proteins C3, C4 and C5 to 
smaller inflammatory fragments was recognised. With this discovery came 
the realisation that the complement system not only aided the
immunologically specific effects of antibody by the opsonisation and
lysis of E and bacteria but also the release of these smaller peptides
had effects on the activation of the immune system itself. The study of 
the role of complement in defence against microbial infections and auto­
immune diseases has therefore come to occupy a central position in 
clinical medicine.
1.2 Hlst.Qr.y-Qf--tha...AlteriiaMY.e-. Pathway
During the early part of this century there was much controversy over the 
mechanisms involved in the apparent ability of the body to destroy 
bacteria and viruses despite the fact that it had not been previously
challenged with these organisms. While some attempted to explain this
natural immunity on the basis that the body had natural antibodies which 
could destroy foreign organisms immediately on their first encounter, 
others felt that there was an alternative means of protection which did 
not involve specific antibody.
In 1954 Pillemer isolated a new serum protein which he believed could be 
the mediator of natural immunity. This protein was called "properdin" 
from the Latin pro perdere: to prepare to destroy (Pillemer et al 1954),
Pillemer observed that when zymosan particles were added to serum 
haemolytic complement activity was depleted and the zymosan particles 
became coated with properdin. This activation step occurred in the 
absence of antibody and the concentration of the early components Cl, C4 
and C2 remained unaltered. Thus it was postulated that the properdin 
system comprised an alternative means of activating the later components 
without involving the classical pathway. This claim was substantiated by 
the work of Schur and Becker (1963) which showed that antigen-antibody 
(Ag/Ab) complexes containing only rabbit F(ab')^ fragments could only 
turn over complement to a limited extent. To turn aver the remainder, 
the whole antibody molecule was necessary, indicating that there were two 
kinds of complement in serum, one which bound to F(ab' ) 2 and one which 
could only bind to the whole molecule.
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Sandberg, Oliveira and Osier (1971) studied the ability of the two 
subclasses of guinea pig lgG to activate complement. IgG^ could utilise 
all the complement components while IgGi was only capable of reducing 
the late components. If IgG^ was digested to yield F(ab ' ) 2 fragments 
then only the late components could be activated. It appeared that there 
were two different sites on IgGa-, one on the Fc portion which could 
activate the early components and one on the F(ab')s portion which could 
activate the terminal components. This second pathway was subsequently 
found to be activated by microorganisms, endotoxins, certain classes of 
immunoglobulin and immunoglobulin fragments (Gewurz, Shin and 
Mergenhagen 1968, Muller-Eberhard and Schreiber 1980).
Further evidence for the existence of an alternative pathway came from a 
different area of research, the study of snake venom. A factor from 
snake venom was found to activate the terminal components with little 
consumption of the early components. (Gotze and Muller-Eberhard 1971). 
Purification of this factor resulted in the ability to analyse more fully 
the molecular mechanisms of the alternative pathway. It was found that 
cobra venom factor interacted with two serum proteins termed "factor D" 
and "factor B" to form a C3 convertase which cleaved C3 and resulted in 
the activation of the terminal components (Cooper 1973). The knowledge 
gained from these early studies formed the basis of the current 
understanding of the alternative pathway which will be reviewed later in 
this thesis.
1.3 Complement.
To date recent research has shown that the complement system is 
comprised of 20 proteins which are for convenience divided into four 
groups: the classical pathway, the alternative pathway, the terminal
sequence and a group of control proteins. The proteins of the classical 
and alternative pathways form two enzyme cascades which proceed in an 
orderly sequential fashion similar to the activation of the coagulation 
and fibrinolytic systems. These enzyme cascades are activated when 
inactive precursor molecules lose a small fragment through limited 
proteolysis by a membrane-bound enzyme. The loss of this small fragment 
reveals a nascent membrane binding site on the remaining larger enzyme 
precursor which can then bind to the membrane. This membrane-bound 
enzyme becomes the next functionally active enzyme of the sequence. Each 
membrane-bound enzyme can activate many substrate molecules so that each 
step is amplified. The end result of both pathways is the cleavage of C3 
which is the central event in the complement system. Following this the 
proteins of the terminal sequence become assembled into membrane attack 
complexes which are responsible for the lethal lytic lesions in the lipid 
bilayers of invading microorganisms. As has been previously described 
much of the early work on complement focused on the lysis of sheep E in 
an attempt to define the mechanism of cell lysis. This lysis step was 
originally thought to be the major role of complement in vivo however, 
in the light of current research the known biological activities of
com plem ent nave expa.uo.ecv cOi'Sio?!7i'>i.y so t h a t  th e re  ace now pue.; ie  bried. 
to  oe a t  le a s t  f i v e  v :t a l  iu n o t io n s  p e rfo rm e d  by th e  sys tem  (T a b le  1,1),.
t .4
The conj.poa.ents of the classical pathway and the terminal sequence are 
designated numerically in order of their discovery, eg Cl, C2, C3, C4, Co, 
C6, C7, C8, C9. This numbering system can be slightly confusing as the 
numbers do not necessarily correspond to the order in which the 
components react. The fragments formed from these native complement 
components by limited proteolysis are assigned small letters, eg C4a, C4b, 
C4c, G4d, The alternative pathway components are termed factors and each 
is represented by a letter, eg- factor B, factor D» factor P (properdin). 
These names can be abbreviated to 3, D and P respectively, The control 
proteins are referred to by their trivial names indicating their' 
functional or historical meaning eg. Cl inhibitor (C1BTH), C4 binding 
protein <C4bp>, C3b inactivator (C3bIIA) and $1H globulin (01H), C3bIIA 
and 01H have recently been renamed I and H respectively, The polypeptide 
chains of each component are suffixed with a Greek letter with a for the 
largest then B then s, eg C4cc, Ci-B and C4Y.
1.5 The-Classical... Complement, Pathway
The classical pathway (Fig 1,1) is the name given to the series of plasma 
proteins which are involved in the assembly of the C3 splitting enzyme, 
the C3 convertase. It is distinguished from the alternative pathway in 
that it usually requires the binding of an antigen to its specific 
antibody for its activation. Once activated a series of reactions occur 
during which five proteins are transferred from the fluid-phase onto the 
membrane of the target cell surface. These five proteins are Clq, Clr, 
Cls, C4 and C2, To ensure that the classical pathway proteins are not 
activated continuously three control proteins operate, these are ClIII!, 
C4bp and 1.
1.6 Activation of Cl
Cl is the recognition unit of the classical pathway. It consists of three 
distinct protein molecules, Clq, Clr and Cls (Lepow et al 1963; Gigli, 
Porter and Sim 1976), These are held together by a calcium dependent- 
bond, Cl circulates in the plasma as a pentamolecular complex containing 
one molecule of Clq, two molecules of Clr and two molecules of Cls, to 
give a structural formula of Clqi, Clr-, Cls^.
During activation of the complement pathway Clq is able to recognise and 
bind to antigen/antibody complexes containing IgM antibodies or Hue IgG 
subclasses, IgG?, IgG- and IgG- all activate the system with IgG-: being 
the most potent. However, IgG*. does not activate the pathway and neither 
do IgA, IgD or IgE. Clq binds to the Ch 2 domain of IgG and probably to 
the Ch.4 domain of Igl> this binding leads to a conformational change in 
the Clr molecules which subsequently results: in the acquis it foe o*
enqy ;-C‘ i  b . acc.i.v’-L iy  oy coo m o  i_.-—...» c u -m ii
Table 1.1
Activity Product
Er.ozi ni 1 arnnat or y
1. Increased vascular permeability C4a, C3a. C5a, C2~kinin
2. Chemotaxis C5a, C5a desarg, C5b67, C3bBb
3. Lysosomal enzyme secretion C3b
Cytolytic C5b-9
Bystander .lysis C5b-7
Qpsonic.
1. Adherence to receptors C4b, C3b, iC3b, C3d
2. Enhancement of phagocytosis C3b
3. Increased intracellular killing 
of bacteria C3b
4. Increased intracellular degradation 
of immune complexes C3b
Solubilisation, of ..Complexes C3b ± C4b
Antibodv Production
1. T-dependent responses C3
2. Generation of B memory cells C3
Fig 1.1 Classical-Pathway . Activation.
Diagram showing classical pathway activation. A ~  above a symbol 
indicates that the component has undergone a conformational change. A bar 
above a symbol indicates that the component is in its activated state. 
(From Whaley, K, (1980)).
C1q
Ag/Ab ►
, v
C1q
C1s
C1r
C2
C1s
C1-INH
C4
C42
C3a
C3 >C3b
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Clq lias a molecular weight of 410,000 daltons it is formed from 18 
peptide chains in three subunits of six. When visualised in the electron 
microscope each six peptide subunit resembles a bunch of six tulips with 
the lower half of the stem comprising two pairs of triple peptide helices 
joined together and the upper half of the stem splitting to farm six
separate stems, each ending in a globular head (Porter and Reid 1978).
The sites for attachment of Clq to the Fc portion of IgG are found in 
these heads, thus imposing on Clq the potential for multivalent
attachment to immune complexes. Indeed for activation of Cl, Clq must 
bind to at least two IgG antibody molecules although one IgM antibody 
molecule is sufficient (Reid and Porter 1981). The remaining portions of 
the Cl molecule, Clr and Cls, bind to Clq through Clr which in the 
presence of calcium ions will bind to the central region of the stalks of 
the Clq molecule. Cls does not interact with the antibody bound Clq 
molecule and therefore it is Clr which acts as a bridge between the two 
molecules. The ultrastructure of both Clr and Cls is now known. They 
both have molecular weights of 83,000 daltons and are both chemically 
very similar, each comprised of a single polypeptide chain. Exactly how 
Clq is able to activate Cls is unknown as Clq has no known enzymatic 
activity. It is thought that when the heads of the Clq molecule bind to 
IgG they undergo a conformational change which results in the realignment 
of the Clr molecule. This realignment of Clr may allow an enzymatic site
within the molecule itself to attack one of its own peptide bonds, thus
autocatalysing the conversion of inactive Clr to its enzymatically active 
form, CTr, Clr has the ability to enzymatically activate Cls by cleaving 
a single peptide in the molecule. Once Cls acquires proteolytic enzyme 
activity it can activate the next two proteins in the sequence C4 and C2 
thus causing continuation of the cascade. After formation of Cls the
initial recognition phase of the classical pathway' is completed and the
antibody is no longer required. The control protein C1IRH, which is a 
single chain polypeptide molecule with a molecular weight of 150,000
daltons, binds to the active sites of Clr and Cls. This results in the 
release of the Clr:Cls:Cl IFH complex into the fluid-phase where it no
longer has any ability to cleave C4 or C2 (Cooper 1985).
1.7 Activation of C4 and C2 by Cls.
The next phase in the classical pathway is the formation of C4b2a, the 
classical pathway C3 convertase. This bimolecular complex is formed only 
after the cleavage of C4 and C2 by Cls. C4 is composed of three 
disulphide linked polypeptide chains, an a chain of molecular weight
93,000 daltons, a J3 chain of molecular weight 75,000 daltons and a If 
chain of molecular weight 33,000 daltons (Schreiber and Miiller-Eberhard 
1974). ~CTs cleaves a single peptide from the a chain of C4 to produce 
C4a and a nascent C4b molecule. C4a is released into the fluid-phase 
while C4b binds covalently through its labile binding site to activating 
target particles. If C4b does not bind within 50 milliseconds, then the 
molecule is released into the fluid-phase.
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In addition to its labile binding site, C4b possesses two additional 
stable binding sites. One of these stable binding sites is able to bind 
to C2 in the presence of magnesium ions to form a C4bC2 complex. C2 has 
a molecular weight of 100,000 daltons -Xt binds to C4b, initially in an 
inactive form, but upon cleavage by Cls, the fragments C2a and C2b are 
generated. The enzymatic site is present on C2a the largest of these two 
fragments (Nagasawa and Stroud 1977). C2a remains bound to C4b to form 
the C3 convertase C4b2a (Ichihara et al 1986).
1.8 Cleavage .of C3 by C4b2a
The substrate for the classical pathway C3 convertase is C3. This 
protein is functionally the most important component of the complement 
system. The molecule consists of two polypeptide chains: an a chain of
molecular weight 120,000 daltons and a J3 chain of molecular weight 75,000 
daltons. These are linked together by disulphide bridges to give a 
combined molecular weight of 195,000 daltons. Cleavage of the N-terminal 
end of the a chain of C3 results in the formation of a small peptide C3a 
(molecular weight 9,000 daltons). C3a is an anaphylotoxin which has a 
number of biological functions, (i) it directly acts on smooth muscle 
causing it to contract; (ii) it stimulates mast cells and basophils to 
release histamine, (iii) it stimulates platelets to release serotonin,
(iv) it can induce platelet aggregation and (v) at very high 
concentrations (50 pg/ml) it may also be a chemotactic factor. C3a is 
released into the fluid-phase where it exerts these biological effects for 
a short while before being inactivated by carboxypeptidase N. The 
remainder of the a chain and the intact £ chain comprise C3b (molecular 
weight 185,000 daltons), C3b is able to bind to target surfaces via its 
labile binding site which consists of an internal thiolester linking 
together a cysteinyl and a ‘tf-glutamyl residue (Law and Levine 1977; Tack 
et at 1980). Upon cleavage of C3 by the C3 convertase, the labile 
binding site becomes exposed due to structural rearrangement of the 
molecule so that the glutamyl residue is available for covalent binding 
of C3b to hydroxyl or amine groups on the surface of cell membranes or 
immune complexes. This binding site is available for only a few 
milliseconds after which the molecule undergoes secondary changes which 
cause it to lose its binding site. This inactive C3b remains in the 
fluid-phase where it is unable to participate in formation of a C5 
convertase. Approximately 10% of the C3b molecules bind leaving the 
remaining 90% inactive in the fluid-phase. C3b also possesses a stable 
binding site which can bind to specific membrane receptors on a variety 
of cell types, including E, polymorphonuclear leukocytes (PMN), monocytes, 
macrophages and lymphocytes. Once bound to these cells many important 
biological functions are elicited. These receptors and their functions 
are the subject of this thesis and will be discussed more fully in a 
later section.
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1.9 Regulation..g£-QAh2a Formation
Since uncontrolled proteolysis of C3 would result in the total depletion 
of the classical pathway components and consequently an inability to 
destroy pathogens by this means, regulation of the C3 convertase is 
vital. For this reason there are a number of control mechanisms.
Internal regulation results from the fact that the labile binding site of 
C4b is available for a very short period, after which the binding 
activity is lost. This means that large numbers of C4 molecules must be 
cleaved to ensure binding of some onto the activating particle. Even 
when formed, the C4b2a complex is unstable and it decays rapidly by
spontaneous dissociation, releasing C2a into the fluid-phase in an
inactive form. The natural decay of the enzyme is accelerated by the
action of the control protein C4bp (Cooper 1975). C4bp binds to the
stable binding site on C4b accelerating the intrinsic decay 
dissociationof the C3 convertase by displacing C2a from C4b. Recently it 
has been shown with the aid of monoclonal antibodies that C4b has two 
stable binding sites. One monoclonal antibody was able to inhibit the 
binding of both C2 and C4bp to C4b and it could also accelerate the 
decay dissociation of the C3 convertase. This indicated that the binding 
sites for C2 and C4bp on C4b are the same or that they partially overlap 
(Ichihara et al 1986). As well as its ability to decay dissociate the C3 
convertase, C4bp can also act as a cofactor for the cleavage of C4b by a 
third control protein, I (Fujita and Bussenzweig 1978; Gigli, Fujita and 
Bussenzweig 1979).
I was originally discovered by Belson (1966) who noted the ability of 
this protein to abrogate both the haemolytic and immune adherence 
activity of G3 fixed to sheep E. Fearon (1977) and Pangburn, Schreiber 
and Muller-Eberhard (1977) isolated I and showed it to be a serum 
glycoprotein of molecular weight 93,000 daltons which was composed of 
two non-identical polypeptide chains held together^ by disulphide bridges. 
I, together with its cofactor, C4bp, cleaves the a chain of fluid-phase 
and substrate-bound C4b into the four chain iC4b intermediate (Pangburn 
et al 1977).
In addition to the cofactor activity of C4bp, the presence of a membrane 
glycoprotein termed "CR1" can also help to control formation of the C3 
convertase (Fearon 1979). This protein was first isolated by Fearon in 
1979 and found to have a molecular weight of 205,000 daltons. It was 
subsequently identified as the C3b receptor responsible for the immune 
adherence first described by Belson (1953).
Iida and Bussenzweig (1981) showed that CR1 had the ability to inhibit C3 
convertase activity by competing with C2 for the stable binding site on 
C4b. In this way it could cause acceleration of the decay dissociation of 
the convertase in an analogous manner to C4bp. In the presence of high 
concentrations of I and high concentrations of C4b, CR1 can also promote 
the degradation of C4b to C4c and C4d by I (Medof and Bussenzweig 1984).
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This cofactor activity of CR1 is 1 O'3-fold greater than C4bp. 
Additionally, when C3b molecules are also present on the substrate, CR1 
is able to mediate the cleavage of C4b even when C4b, CR1 and I are
present in low concentrations. Thus before deposition of C3b, C4b is 
less subject to inactivation (Medof and Bussenzweig 1984).
Apart from the necessity to control C3 convertase formation on target 
particles there is a further requirement for the protection of the hosts 
own cells. Accidental formation of convertases on these cells would
result in their destruction. A protein has been isolated from the
membranes of human E, which has the ability to decay-dissociate C3
convertases formed on E membranes. This protein has been termed "decay, 
accelerating factor" (DAF) and it is proposed that DAF is responsible for 
intrinsic regulation of convertase formation.
DAF was originally isolated from guinea pig E stroma by butanol
extraction (Bicholson-Veller, Burge and Austen 1981) and it had a 
molecular weight of 65,000 daltons. Although DAF had the same activity 
as C4bp, antisera raised against DAF did not react with C4bp. These two
proteins thus appeared to be distinct. Bicholson-Veller et al (1982)
isolated a similar protein from human E and it was found to cause an 
accelerated decay of C4b2a. DAF was found to be five times more active 
in decaying the classical pathway convertase than the alternative pathway 
convertase, whereas the opposite was true of CR1, which decayed the
alternative pathway convertase with a ten times greater efficiency than 
the classical pathway convertase.
Formation of a fluid-phase C3 convertase would result in the undirected 
activation of the complement system. To prevent this from occuring, 
fluid-phase C4b can be inactivated by I in the presence of C4bp
which is present in high concentrations in the serum, 500 »iy/W.
There is now evidence for a soluble form of CR1\
which is structurally and functionally related to membrane-bound CR1 and
therefore it too may act as a cofactor for the I mediated cleavage of
fluid-phase C4b (Yoon and Fearon 1985).
Recently a third group of proteins have been isolated from human 
leukocytes which may function alongside CR1 and DAF to prevent 
autologous complement activation. Cole et al (1985) isolated a group of 
C4b/C3b binding proteins from PMB, lymphocytes and mononuclear cells. 
These proteins had molecular weights between 45,000 daltons and 70,000 
daltons and were thus termed "gp 45-70". They could be isolated by both 
iC4- and iC3-Sepharose affinity chromatography showing that they have an 
affinity for both C4b and C3b. These proteins did not appear to be 
functioning as receptors as polyclonal anti-CRl inhibited rosette 
formation between C3b coated E and PMB, monocytes and B lymphocytes. It 
was therefore postulated that they could be analogous to DAF in that they 
could bind to C4b and prevent formation of a C3 convertase. Seya, Turner 
and Atkinson (1986) have also isolated C4b/C3b binding proteins with a 
molecular weight within the range of 45,000 to 70',000 daltons from human
Page 35
blood platelets. These proteins are identical to those isolated from 
human leukocytes and are 50 times more efficient than H in the cofactor 
I mediated first cleavage of C3b. They also have cofactor activity for 
the cleavage of C4b but are not as efficient as C4bp. However they do 
not mediate the decay dissociation of the classical or alternative
pathway C3 convertase. These C4b/C3b binding proteins have been re­
named "membrane cofactor protein" (MCP).
1.10 Terminal Sequencei-Earmatlon .of the Classical Pathway. 05 Gony.ertase
The terminal sequence is activated when C3 is cleaved by C4b2a, 
hydrolysing an arginyl serine bond in the N-terminal end of the cx chain 
of C3, resulting in the formation of C3a and C3b. C3b molecules which
bind in close proximity to C4b2a on the cell surface change the
specificity of this enzyme to one which is capable of cleaving C5. This 
is termed the C5 convertase C4b2a3b.
C5 consists of a double polypeptide chain with a molecular weight of
185,000 daltons. When C5 binds to the C3b portion of the enzyme it
renders it susceptible to proteolysis by C2a, resulting in the production 
of two fragments, C5a and C5b with molecular weights of 12,000 daltons 
and 173,000 daltons respectively, C5a is released into the fluid-phase 
where it exerts a number of effects; (i) it is a potent chemotactic agent, 
causing neutrophil migration into sites of tissue damage, (ii) it 
activates neutrophils by triggering the bactericidal oxidative burst, 
(iii) it switches on neutrophil production of leukotrienes, (iv) it 
increases vascular permeability, (v) it causes most cell degranulation and 
(vi) it causes smooth muscle contraction.
The larger fragment, C5b possesses a labile binding site which is exposed 
only for a few milliseconds. During this time a small percentage of C5b 
molecules will bind to the cell surface. Both bound and fluid-phase C5b 
may bind to C6 the next protein in the terminal sequence to form an 
active C5b-6 complex. This complex then binds to C7 to form C5b67. 
Fluid-phase C5b67 has a labile binding site which is available for a 
short while during which it may bind to any lipid layer within its
diffusion radius. If it then binds to C8 and C9 cytolysis of adjacent 
host cells may result. To increase the efficiency with which C5b67 binds 
to target cells it is thought that these complexes may bind reversibly to 
fixed C3b molecules scattered over the surface of the cells. Hammer,
Abramovitz and Mayer (1976) showed that sheep E bearing rabbit antibody
and guinea pig C4b and C3 (EAC4b3) could adsorb C5b6 reversibly. This 
served to increase the efficiency of the terminal sequence by 100 times 
over that of cells which had no fixed C3b. In addition, reversible
binding meant that C5b could be bound transiently to the C5 convertase, 
be released and bind to an adjacent C3b molecule leaving the C5 
convertase free to cleave another C5 molecule.
C5b6 is a hydrophilic complex, but upon binding to C7 its ability to bind 
lipid increases, The C5b67 complex becomes firmly attached to the
phospholipid bilayer of the cell membrane where it then, binds to €8. This 
binding initiates the cytolytic reaction which is considerably accelerated 
by the binding of C9 to €8. The complex which is formed from these five 
proteins, C5b~C9 is termed the Membrane attack complex (Podack, 
Biersecker and Huller-Eberkard 1978). In a dimeric form the C5b-C9 
complex becomes inserted into the lipid bilayer of the cell membrane to 
form a transjueiabrame channel. The disruption of the membrane in this 
manner leads to the breakdown of the cells ability to control the 
exchange of ions across its membrane and thus eventually to the lysis of 
E, the killing of nucleated cells, bacteria and the destruction of 
enveloped viruses CIuller-Eberhard and Schreiber 1980).
1.11 Control of C5 Convertase Formation
The last enzymatic step in the complement pathway is the cleavage of C5 
to form C5b which then initiates the whole of the terminal sequence. As 
with the C3 convertase, there are a number of mechanisms which exist to 
ensure that the C5 convertase does not activate the terminal components 
in an uncontrolled manner.
Intrinsic control results from the fact that like C4b, the labile binding 
site of C3b is available for a very short half life of approximately 50 
milliseconds. Within this time there is competition between water 
molecules in the surrounding solution and the protein and carbohydrate 
moieties on the substrate for the binding site on nascent Ob, This 
means that only a very small proportion of the G3b molecules will 
actually bind to the substrate in the vicinity of the C3 convertase to 
allow formation of a C5 convertase.
C4b is a component of both enzymes and as such it regulates the activity 
of the G5 convertase in a similar way to its regulation of the C3 
convertase. C4bp • and DAF bind to C4b and cause the displacement 
of C2a and thus the active disassembly of the C5 convertase (lida and 
Bussenzweig 1981). CR1 has also been shown to be an inhibitor of the C5 
convertase. Here it is likely that Cfil competes with C5 for a binding 
site on the C3b subunit of the enzyme rather than by binding directly to 
C4b as is the case with the C3 convertase. Fishelsom, Schreiber and 
Huller-Eberhard (1985) showed that addition of Ijug of CR1 inhibited the 
binding of C5 to zymosan particles bearing C3b by 75%. Addition of 
purified C5 also blocked the binding of C3b to CR1 of E, thus 
demonstrating that C5 and GK1 compete for the same site on C3b.
1.12 Formation of the Alternative Pathway C3 Convertase
The development of a strain of guinea pigs which were totally deficient 
in haemolytically active G4 and yet could display normal complement 
dependent inflammatory responses (Frank et al 1971) confirmed the earlier 
claim by Pillemer (Pillemer et al 1954) that there was an alternative 
pathway into the complement system. This pathway was subsequently found 
to be activated in the absence of specific antibody and to result in the
generation of an alternative pathway C3 convertase which could generate 
C3 molecules (Big 1.2). The alternative pathway can be activated by a 
variety of complexes, which include, polysaccharides, fungi, bacteria,
lipopolysaccharides, certain immunoglobulins and some animal cells and 
parasites. (Gotze and Mu 1 ler-Eberhard 1976). Four serum proteins are 
required for the generation of the alternative pathway C3 convertase: C3 
itself, B, B and ?.
Initiation of the pathway is a result of the binding of G3b to B. This 
binding will only occur in the presence of magnesium ions. The complex 
which is formed, C3bB, has in itself no enzymatic activity; it requires to 
be activated by another serum serine protease D which is present in
serum in its active form. D cleaves B once it has bound to C3b and 
produces two fragments: a small one with a molecular weight of 33,00 
daltons termed "Ba" and a larger one with a molecular weight of 66,000 
daltons termed "Bb" (Lesavre and Hiiller-Eberhard 1978). This larger 
fragment contains the active site and it remains in complex with the C3b, 
It is still uncertain whether Ba is released into the fluid-phase or
whether it remains in association with Bb. The resulting enzyme which is 
formed C3bBb is known as the alternative pathway C3 convertase. D is 
not incorporated into the enzyme and so it is always available in the 
fluid-phase to activate more C3bB complexes. B is essential for
activation of the alternative pathway in whole serum although serine 
proteases such as trypsin and plasmin may also be able to cleave C3bB 
complexes (Brade et al 1976). Formation of the C3 convertase results in 
the proteolytic cleavage of C3 to 03a and C3b. Thus a positive feedback 
reaction is set in motion where the product of the enzyme action, C3b, is 
incorporated into the enzyme itself. This is known as the alternative 
pathway amplification loop.
At present it is uncertain how the first C3b molecule which activates the 
whole alternative pathway is generated. There are two main hypothesis.
The first is that native 03 may interact in solution at physiological
concentrations with B, B and magnesium ions to form the initial 03Bb 
(Schreiber et al 1978). The 03b molecule produced by this enzyme could 
then participate in the feedback mechanism. The second is that it may be
possible for native 03 to undergo spontaneous hydrolysis as a result of
nucleophilic attack on its internal thiolester bond (Pangburn and Muller- 
Eberhard 1980). The generation of a 03 molecule which is haemolytically
inactive but which has properties similar to 03b would enable it to bind
to B to form a convertase. This haemolytically inactive 03 has been 
termed 03(H20), "03b like 03", 03u or iC3. Certain chemical groups on the 
surface of cells may facilitate the cleavage of a thiolester bond in 03 
and result in the binding of C3(H20) to the cell surface via the active
carbonyl group present in the putative thiolester. Like 03b, C3(H--0) is
cleaved by I in the presence of CR1, gp45-70 or H to iC3(H20) which is 
similar to iC3b being unable to bind with B to form an alternative 
pathway 03 convertase thus preventing uncontrolled accumulation of 03bBb 
on the cells surface.
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Legend.
Diagram showing alternative pathway activation. A // above a symbol 
indicates that the component has undergone a conformational change. A bar 
above a symbol indicates that the component is in its activated form. 
(From Whaley, K. (1985)),
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1.13 Formation_□£.. the Alternative Pathway C5 Convertase
A build up of C3b around the C3bBb complex is required to form the C5 
convertase (Daha, Fearon and Austen 1976). It was realised that the 
formation of the C5 convertase required more molecules of C3b than the 
C3 convertase following experiments which showed that in the fluid-phase 
combination of C3b, D and B led to very limited lysis of E. However if 
C3b molecules were fixed to antibody coated sheep E and then the 
components C3 to C9 were added, the haemolysis reaction was completed 
with comparable efficiency to that of the classical pathway (Fearon,
Austen and Ruddy 1973). Thus the C5 convertase was only formed when the 
C3 convertase could interact with additional C3b molecules. It is now 
known that the additional C3b molecules are required since both C5 and B
compete for the same or closely adjacent binding sites on C3b, This
competition would result in steric inhibition between the two molecules 
thus preventing formation of a C5 convertase.
The C3/C5 convertase is capable of initiating the cytolytic membrane 
attack complex, but as with the classical pathway C3 convertase, the
alternative pathway C3 convertase is thermodynamically unstable and 
decays rapidly within two to three minutes due to spontaneous 
dissociation of Bb. The binding of P stabilises the convertase such that 
its half life is extended to approximately 30 seconds (Fearon and Austen 
1975; Medicus, Gotze and Muller-Eberhard 1976). Properdin was first 
recognised by Pillemer et al (1954) and thought to be an essential
component of the alternative pathway. This however is now known not to 
be the case for, although the activity of the already farmed C3
convertase is considerably enhanced by its presence, the alternative
pathway can function in the absence of P.
Stabilisation of the convertase can occur by two additional means. In the
sera of patients with membrane proliferative glomerulonephritis an 
autoantibody termed "C3 nephritic factor" (Nef) binds to its antigen 
C3bBb, reducing the natural rate of decay and increasing the half life of 
the enzyme. As a result, C3 cleavage is considerably augmented and a 
severe depletion of C3 occurs in the serum of these patients (Daha, 
Austen and Fearon 1978).
The second means of stabilisation is by addition of cobra venom factor 
(CoVF) to serum. Cobra venom contains a factor which produces
alternative pathway turnover. Isolation of the factor and the 
demonstration of its crossreactivity with antibody to human C3 showed 
that the factor was cobra C3b antibody. Cobra C3b forms a complex with 
human B thus forming the alternative pathway C3 convertase, As cobra 
C3b is resistant to the action of H and I the convertase is extremely
stable and large amounts of C3 are converted to C3b (Alper and Balavitch
1976; Hagaki et al 1978).
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1.14 Conlr-Ql..Qf Alternative Pathway Convertase Formation
The ability of C3b to amplify its own production requires that a number 
of control mechanisms operate to ensure that the system does not become 
exhausted. This control is mediated by the action of two control 
proteins, H and I,
H was purified from human plasma and characterised by Whaley and Ruddy 
(1976) It was shown to be a single polypeptide chain glycoprotein with a 
molecular weight of 150,000 daltons. Antisera against this glycoprotein 
reacted with a protein which had previously been known as C3b 
inactivator accelerator (A C3bIUA) because of its ability to enhance the I 
mediated cleavage of C3b to haemolytically inactive iC3b. From this study 
it was proposed that H was responsible for this cofactor activity. In 
this respect it is analogous in function to C4bp of the classical pathway 
since they both prevent formation of a C3 convertase. In addition to 
this cofactor activity H has been shown to have two other regulatory 
actions. It causes decay dissociation of both the C3 and C5 alternative 
pathway convertase and it can prevent the interaction of C3b with C5 and 
B thus controlling formation of both classical and alternative pathway C5 
convertases. The mechanism by which it exerts this effect is by direct 
binding to C3b. Evidence for this came from studies which showed the 
binding of fluorescent and radiolabelled H to C3b coated particles. This 
binding was in direct proportion to the amount of C3b on the particles 
and was not observed if the particles were coated with C4 or C2 (Conrad, 
Carlo and Ruddy 1978), Thus H can bind directly to C3b and displace Bb 
from the convertase. It can also compete directly with B and C5 for a 
site on C3b. If H binds in preference to B then no alternative pathway 
C3 convertase can be formed and if it binds in preference to C5 then no 
C5 convertase is formed. C3b which has been bound by H is subject to 
inactivation by I. The iC3b molecule which is formed is unable to bind 
B. Ross et al (1983) proposed that the B binding site in C3b was 
probably destroyed totally by cleavage with I as no binding of B to iC3b 
was detected even in the presence of low ionic strength and nickel 
cations, conditions which enhance the binding of factor B to C3b. Thus 
formation of a C3 convertase is inhibited, Whether C3b will bind to H or 
to B depends primarily on the nature of the surface to which the C3b is 
fixed. Surfaces which favour the interaction of B with C3b and thus the 
formation of the alternative pathway C3 convertase are known as 
"activators". The surface of certain parasites, bacteria, fungi and animal 
cells are able to activate the alternative pathway by favouring the 
uptake of B onto C3b (Miiller-Eberhard and Schreiber 1980). In this way 
mang microorganisms become coated with large quantities of C3b which 
eventually leads to their lysis or their ingestion by phagocytic cells. 
It is possible to convert non-activating surfaces to activating surfaces 
by chemical modification. This is the case with sheep E which are non­
activators. Removal of 80% of their membrane sialic acid results in 
activation of the alternative pathway and lysis of the cell. The removal 
of sialic acid from human E does not cause such activation because of the 
protective function of CR1. As mentioned previously CR1 is a regulator of
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the classical pathway C3 convertase, but it was first described as an 
inhibitor of C3bBb because of its ability to decay dissociate this enzyme 
and its ability to act as a cofactor for the I mediated cleavage of C3b 
(Fearon 1979). CR1 thus functions in an analogous manner to H but it 
differs in that its decay dissociation activity is independent of 
membrane surface sialic acid. Removal of sialic acid from E
results in an increase in the amount of H required to decay dissociate 
50% of the C3bBbP sites on the E whereas the amount of CR1 required 
remains the same (Fearon 1979). Differences have also been found in the 
ability of H and CR1 to inactivate the NeF stabilised C3 convertase. 
Approximately 100 times more H is required to inactive the C3bBbNeF 
convertase to the same degree as the C3bBb convertase (Veiler et al 
1976), while CR1 is five times more efficient at inactivating C3bBbNeF 
than H (Daha, Kok and Vanes 1982). Thus in patients with NeF, CR1 may 
serve to protect the host from tissue injury.
DAF causes decay acceleration of the alternative pathway C3 convertase in 
addition to the classical pathway C3 convertase. In contrast to CR1 
which is ten times more efficient in decaying C3bBb than C4b2a, DAF is 
five times more effective in decaying C4b2a than C3bBb, DAF acts by 
binding to Bb and causing dissociation of the convertase (Pangburn 1986). 
In patients with paroxysmal nocturnal haemoglobinuria (PNH), the host red 
blood cells are unusually sensitive to lysis by complement surviving only 
six days in comparison to normal E which survive from 80 to 100 days. 
These patients have an inability to accelerate the decay of C3 
convertases which are formed on E due to the random deposition of C3b 
from the fluid-phase. It was originally proposed that C3 was deposited 
onto the surfaces of cells from the fluid-phase and that this would 
result in the continual deposition of low levels of C3 on both host cells 
and foreign particles alike (Muller-Eberhard, Dalmasso and Calcott 1966). 
As described earlier spontaneous hydrolysis of C3 results in C3b like G3 
which if randomly deposited on cells would be able to bind B and activate 
the alternative pathway. Normally CR1 and DAF act to protect the E from 
formation of a C3 convertase but in PNH patients there may be a 
deficiency of these control proteins. Severely affected PNH-E (type 111 
PNH-E) are completely deficient in surface expression of DAF but CR1 from 
these E appears to be normal as determined by antigenic number, binding 
affinity, decay accelerating activity and cofactor activity (Roberts et al 
1985). From this study it would appear that a deficiency in DAF is a 
more important contributory factor to the disease than CR1 deficiency. 
CR1 may be more important in decaying C3 convertases and for 
inactivation of C3b by I on adjacent surfaces than DAF which may be 
primarily responsible for regulation of C3 convertases and breakdown of 
C3b formed on the same cell.
It has recently been reported that CR1 and DAF are restricted from 
interacting with the alternative pathway C3 convertase to different 
extents on different cell surfaces. The regulatory activity of DAF 
towards C3bBb bound to zymosan particles and rabbit E is reduced whereas 
it is normal when C3bBb is bound to sheep E or bovine E. CR1 has
decreased regulatory activity towards C3bBb on sheep E and on zymosan 
but not on rabbit E (Pangburn and Tyiska 1965). Thus it may be concluded 
that the regulatory properties of CR1 and DAF are complex.
1.15 DegiiasiaAiQiJL. ol—C3b
Breakdown of C3b exposes a number of binding sites within C3 for a
variety of membrane receptors. The first step in the degradation of C3b 
is the'cleavage by I to iC3b. Pangburn et al (1977) showed that in the
fluid-phase I in the presence of its cofactor H could cleave the a chain 
of C3b, This cleavage resulted in a molecule which had the same
molecular weight as intact C3b and was termed inactive C3b (iC3b). The 
two a chain fragments remained bound to the j3 chain by means of
disulphide bonds, It was later shown that in fact I can produce two 
cleavages in the a chain resulting in the release of a tiny fragment
termed C3f (molecular weight 3,000 daltons) (Harrison and Lachraann 1980). 
Cleavage of substrate bound C3b by I can proceed in the absence of H 
(Whaley and Ruddy 1976) although breakdown occurs very slowly. Pangburn 
et al (1977) showed that dissociation of the a chain from the J3 chain
of iC3b only occured in vitro after the addition of tryptic enzymes such
as trypsin or elastase. Addition of these enzymes resulted in the 
production of two fragments termed C3c (molecular weight 14,000 daltons 
and C3d (molecular weight 30,000 daltons). C3c was released into the 
fluid-phase leaving C3d bound to the substrate.
Lachmann, Pangburn and Oldroyd (1982) used monoclonal antibodies to
investigate the breakdown of C3. They found one monoclonal antibody
which bound to C3c and one which bound to C3d and one which bound to an 
antigen present in native C3. This last monoclonal antibody was found to 
be reacting with a fragment termed C3dg. A modified scheme of their 
proposed breakdown of C3 is shown in Fig 1.3.
Thus iC3b degradation does not result in the immediate formation of C3d, 
but in the production of C3dg which was previously known as cx2D. 
In vivo it is thought that C3dg is not cleaved to C3d and C3g as only 
C3dg has been detected as the final fragment of complement activation on 
E (Lachmann 1981; Ross et al 1985). It is also uncertain which of the 
serum proteases are responsible for the in vivo cleavage of iC3b to C3c
and C3dg. In vitro proteolytic enzymes such as trypsin and plasmin act
on iC3b resulting in the generation of C3dg. They may also be 
responsible for in vivo cleavage of iC3b (Lachmann et al 1982). Plasma 
kallikrein can also cleave iC3b to produce a fragment termed C3d-k (Meuth 
et al 1983), C3dk is larger than C3d (molecular weight 41,000 daltons) 
and it was suggested that it could be similar to C3dg and that kallikrein
may be the protease responsible for cleavage of iC3b in vivo. C3d-k is
capable of inhibiting mitogen, antigen and alloantigen induced T 
lymphocyte proliferation, functions which are not expressed by C3c, C3a 
or C3b. It is also capable of inducing a two- to three-fold increase in 
the number of circulating leukocytes when it is intraveneously injected 
into rabbits. This ability to induce leukocytosis has also been
Fig 1.3 Peg r adaJJLoii_QL_£l
Schematic diagram showing the structure of C3 fragments produced by I 
proteolysis of substrate-bound C3b fragments. In reaction 1 the a 
polypeptide chain of C3 is cleaved by a 03 convertase to generate the
9,000 dalton (9K) molecular weight C3a polypeptide and the 186K molecular 
weight C3b polypeptide. In the presence of H or CP.l, I cleaves the cx- 
chain of C3b at two closely spaced sites (I» , and I*}. This cleavage 
releases a 3K molecular weight fragment termed C3f, and generates the 
three chain C3bi fragment. In reaction 3, I in the presence of H or CR1 
cleaves the a C3dg chain of C3bi, to release the C3c fragment into the 
fluid phase leaving the C3dg fragment bound to the substrate, Although 
the 8K molecular weight C3g fragment may be cleaved from the C3dg 
fragment by various proteases forming fluid-phase C3g and substrate- 
bound C3d (33K), it is not thought that this final breakdown occurs in 
the blood.
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attributed to a fragment termed C3e which is presumed to be cleaved from 
the a chain of C3c by an as yet unknown proteolytic reaction. This 
fragment was isolated by Ghebrehiwet and Muller-Eberhard (1979), it had a 
molecular weight between 10,000 and 12,000 daltons and it could induce a 
two- to three-fold increase in the number of circulating leukocytes in
rabbits. Meuth et al (1983) concluded that as C3d-k and C3e could both
induce leukocytosis that C3d-k contained both the C3e and C3d portions.
1*16 Ike.Role of H. C4bp and CR1 in the Proteolytic Breakdown of C3b
As previously mentioned H is an essential cofactor for the I mediated 
cleavage of C3b in the fluid-phase, being more important for this
cleavage than C4bp. Fujita and tfussenzweig (1979) showed that on a
weight basis H was 20 times more efficient than C4bp in acting as a 
cofactor for the cleavage of C3b in solution. In the case of cell-bound 
C3b, although I can function in the absence of H, the presence of H can 
potentiate the cleavage of C3b by approximately 30 fold (Whaley and 
Ruddy 1976). C4bp is without effect even at 300 times the amount of H 
on a weight basis (Fujita and Nussenzweig 1979)). Therefore it is likely 
that the main function of C4bp is directed towards cleavage of C4b and 
not C3b.
CR1 has been reported to be 10* to 10s times more effective on a weight 
basis than H in acting as a cofactor for the I mediated conversion of 
substrate-bound C3b to iC3b (Medof et al 1982; Medof and Nussenzweig 
1983). It has also been proposed that under physiological conditions CR1 
acts as a cofactor for the further cleavage of iC3b to C3c and C3d 
(Medicus, Melamed and Arnaout 1982; Medof et al 1982; Ross et al 1982). 
Medicus et al (1982) reported that in the presence of CR1, I could cleave 
iC3b bound to human or sheep E to release C3c into the fluid-phase. In 
the presence of I depleted serum no other serum enzyme was capable of 
cleaving iC3b bound to human E. Thus it appeared that CR1 and not H was 
responsible for the further breakdown of iC3b. In vivo this suggested 
that one of the functions of CR1 was to allow breakdown of iC3b to 
smaller degradation fragments thus avoiding an inappropriate 
inflammatory response caused by biologically active fragments of C3b. 
These conclusions were supported by the findings of Ross et al (1982) 
who observed that sheep E coated with C3b and incubated with isotonic 
heat inactivated serum for four hours at 37 #C had little or no bound 
C3dg. If however the EC3b were treated in the same serum in the presence 
of lOpg/ml of purified CR1 for 1 hour at 37 *C, 50% of the bound iC3b was 
cleaved into bound C3dg. In the presence of low ionic strength and heat 
inactivated serum, 95% of the bound iC3b was converted to C3dg, 
indicating that under low ionic strength conditions H can act as a 
cofactor for the cleavage of iC3b.This suggests that under physiological 
serum concentrations in whole blood that it is CR1 rather than H which 
is the cofactor for I.
Medof et al (1982) investigated a previous observation which had shown 
that when soluble immune complexes are added to a mixture of normal
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human serum and autologous unseparated whole blood cells they fix 
complement and become bound to E via C3 fragments (Medof and Oger 1982), 
This binding could not be prevented by preincubation of the complexes 
with I and H, indicating that E could bind iC3b containing complexes. 
Subsequent addition of I alone to the E resulted in the release of the 
complexes and the concomitant release of C3c indicating that E CR1 was 
capable of cleaving membrane-bound iC3b to C3dg and C3c in the presence 
of I. These findings have been interpreted as meaning that processing of 
C3b containing immune complexes in vivo occurs on the surface of red 
cells. This function of E CR1 will be discussed more fully in a later 
section.
Medof and Nussenzweig (1984) have reported that the presence of C4b 
molecules can enhance the CR1 cofactor I mediated cleavage of iC3b. This 
enhancement can be inhibited by addition of anti-C4b antiserum or C2a 
thus indicating that C4b molecules are responsible. This effect was 
explained by postulating that C4b acts to promote the interaction of iC3b 
with CR1. CR1 may be present on the membrane of PMN and monocytes in 
discrete clusters (Petty et al 1980; Abrahamson and Fear on 1983). 
Clusters of C4b and C3b could serve as more effective ligands for CR1 
allowing formation of multiple bonds between ligand and CR1, This in 
turn may explain why CR1 is a more effective cofactor for I than H on 
substrate-bound C3b. Medof and Nussenzweig (1983) showed that in the 
fluid-phase H and CR1 support the cleavage of C3b to iC3b with 
comparable efficiency. However CR1 was 103 times more effective than H 
in the cleavage of substrate-bound C3b and this efficiency increased as 
the number of C3b molecules increased due to clustering around the C5 
convertase. Thus in vivo it may be that CR1 is capable of inactivating 
C3b found clustered around the C5 convertase whereas H is able to bind 
to and inactivate unclustered fluid-phase C3b molecules,
Although it is generally accepted that the breakdown of surface-bound 
iC3b is mediated by I plus CR1, recent studies by Malhotra and Sim (1984) 
and Jepsen et al (1986) suggest that breakdown could be mediated not by 
I plus CR1 but by leukocyte proteases which may be present in the 
experimental systems used due to the contamination of E by leukocytes. 
Evidence also exists to suggest that the cleavage of soluble iC3b is 
mediated by proteases. Sim and Sim (1983) could not demonstrate the 
breakdown of purified soluble iC3b in the presence of I and CR1, and Yoon 
and Fearon (1985) found that the breakdown of soluble iC3b in the 
presence of I required a concentration of CR1 which was two orders of 
magnitude higher than the concentration of the receptor which was 
detectable in the plasma.
1.17 Introduction to Complement Receptors.
As can be seen from the preceding account, the receptor for C3b, CR1, 
plays an important role in many of the functions of the complement 
system. However, although researchers have been aware of the existence 
of such a receptor for more than 30 years it is only within the past ten
Page 44
years that significant advances have been made in understanding its 
properties and functions. The remainder of this introduction will 
address itself specifically to CR1 and to the additional receptors which 
have been discovered for the further proteolytic cleavage products of C3b 
namely CR2, CR3 and CR4,
1.18 History of . Complement Receptors
In 1953 Nelson (1953) observed that treponemes isolated from testicular 
syphilomas of rabbits would in the presence of antiserum from syphilitic 
patients adhere to normal human E. This adherence was found to be 
dependent on the presence of a specific antibody and some component of 
normal human serum which was thought to be complement. Nelson termed 
this immunologically specific reaction immune adherence. 7>£?/ity three, years 
before this Duke and Wallace (1930) had described an adhesion phenomenon 
in which, under certain conditions, red blood cells from a monkey adhered 
to Treponema pallidium in the presence of specific trypanosomal antibody. 
They called this "red cell adhesion". In 1959 Nelson and Nelson (1959) 
characterised the nature of this adhesion bond and found it to be 
temperature sensitive, destroyed by trypsin treatment, and stable at high 
salt concentrations and over a wide pH range. They therefore suggested 
that as adhesion was destroyed by trypsin a receptor may have been 
responsible for the bond. In the years which followed attempts were made 
to discover which components of complement were responsible for immune 
adherence. Nishioka and Linscott (1963) noted that although guinea pig 
and human complement were equally reactive in immune adherence the 
guinea pig serum was more haemolytically reactive than the human serum. 
This implied that there was a difference in the participation of
complement in immune adherence and in haemolysis. They postulated that
a complex intermediate step between the first three reactive complement 
components and the final lysed E may be responsible for immune 
adherence. By preparing sheep E sensitised with antibody against the 
Forssman antigen on E and then coated with Cl, C4 and C2 (EAC142) they 
were able to demonstrate that no immune adherence occurred. However if 
C3 was added to the EAC142 the E became reactive in immune adherence. 
The work of Nelson (1963) confirmed these results and also provided 
evidence that complement could function as an opsonising agent. When
EAC1423 were mixed with leukocytes from a guinea pig there was a marked 
increase in the rate and degree of phagocytosis of the complex as 
compared to phagocytosis when C3 was absent from the complex. A year 
later Gigli and Nelson (1968) provided further support for the theory 
that C3 was the ligand responsible for both immune adherence and
opsonisation of immune aggregates. They showed that C4 and C3 were 
essential for immune adherence and immune phagocytosis and that neither 
the removal of Cl and C2 from the complement coated E nor the addition 
of C5, C6, C7 or C8 changed their reactivity in these reactions.
It therefore seemed possible that receptors on leukocytes which reacted 
specifically with C3 bound to the surface of E or immune complexes could 
promote phagocytosis and immune adherence.
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Lay and Nussenzweig (1968) presented evidence for the existence of such a 
C3 receptor. While investigating the binding of mouse leukocytes to 
sheep E it was found that the leukocytes would cluster around E which 
had been sensitised with antibody and then incubated in fresh normal 
mouse serum (EAC). These clusters were called rosettes. This was the 
first semi-quantitative method for evaluating the interaction of receptors 
and ligands on various cell surfaces. Using this technique it was found 
that E sensitised with IgG antibody (EAIgG) formed spontaneous rosettes 
with mouse peritoneal cells but not with blood lymphocytes-, further 
incubation of EAIgG with serum caused a large increase in the percentage 
of rosettes formed on blood lymphocytes, monocytes and PMN. However, E 
sensitised with IgM antibody (EAIgM) did not form rosettes with any 
cells unless they had first been incubated in fresh mouse serum where­
upon they rosetted with peritoneal cells and some blood leukocytes. 
These results indicated that there were at least two different types of 
receptor involved in adhesion of leukocytes to E. One which involved IgG 
and which has become known as the Fc receptor and one which involved 
some component of complement, Huber et al (1968) reported that human 
monocytes also had distinct receptors for complement and IgG. Monocytes 
bound to and ingested EAIgG; this binding was inhibited by the addition 
of fluid-phase IgG, but binding could be restored by addition of Cl, C2, 
C4 and C3. Thus he proposed that these two receptors cooperated in 
attachment and ingestion of particles. Bianco, Patrick and Nussenzweig 
(1970) showed that B lymphocytes had a receptor for complement. It was 
noted that T lymphocytes did not bind to EAC complexes whereas B 
lymphocytes did and it was proposed that binding to EAC could be used as 
a marker to distinguish between the two populations. The B lymphocytes 
were called complement rosetting lymphocytes (CRL). C3 was necessary 
for this rosetting since, (i) EAC prepared with C4 alone did not bind,
(ii) depletion of C3 by CoVF also destroyed rosetting and (iii) addition 
of papain F(ab) fragments of rabbit anti-mouse C3 inhibited rosetting 
(Eden, Bianco and Nussenzweig 1971). As C3 on EAC1423 cleaved to C3b it 
was proposed that C3b was the ligand involved in the binding of EAC to 
CRL. It seemed possible that there could be an intimate relationship 
between the immune adherence receptor on human B lymphocytes, monocytes
and PMN since both require the presence of C3 or its breakdown product
C3b.
Cooper (1969) demonstrated that the immune adherence receptor on E could 
also bind C4b as well as C3b. It was not then known if there was a 
separate receptor for C4b or if the same receptor for C3b was
recognising a common reactive group on both proteins. However, Ross and 
Polley (1975) showed that human E, B lymphocytes, monocytes and PMN all 
had a receptor activity for C4b and for the C3c region of C3b thus 
demonstrating that the immune adherence receptor of these cells was 
specific for both C4b and C3b.
The existence of a second complement receptor on lymphocytes was
discovered following a consideration of questions raised by a study to 
determine if lymphocytes from patients with chronic lymphatic leukemia
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(CLL) resembled more closely e or T cells (Ross et al 1973a''. This study 
showed, that the leukemic cells reacted poorly with human C3 as compared - 
with mouse C3. EAC mouse (EACm) could detect up to 20-fold more CRL 
than EAC human (EAChu). Since this .finding was in marked contrast to 
normal CEL which reacted mote strongly with EAChu, Ross proceeded to 
investigate why this should be so ('Foss et al 1973b). It was found that 
EACm which had been prepared with C3b deficient mouse serum contained 
two forms of o3, C3b and a product of C-3b cleavage C3d while EAChu which 
had been prepared with purified complement components contained only 
C3b.- ihus it was propused that a second complement receptor for C3d
existed, Trie discovery of the C3d receptor made it possible to 
understand the results of the first study (Ross et al 1973a). Leukemic 
lymphocytes reacted poorly with EAChu because they lacked the C3b 
receptor but they reacted strongly with EACm indicating that they 
possessed a C3d receptor. This Cod receptor on leukemic lymphocytes was 
antigenically related to a receptor found on normal B lymphocytes as
antisera to leukemic cells could inhibit rosettes between normal
lymphocytes and EACth.
Confirmation of the existence of a. second, complement receptor for" C3d
was provided by Eden, Miller and Nussenzweig (1973) who demonstrated
that normal B cells could bind to EAC3b and EAC3d, while granulocytes
could only bind to EAC3b. It was concluded that human B cells possessed 
a complement receptor for C3d and also one for C3b while granulocytes 
only possessed one for C3b.
Reynolds et al (1975) reported the existence of a C3d receptor on human 
monocytes and alveolar macrophages, However this receptor was only 
detected when EA were reacted sequentially with individual complement 
components to form EAC3d and not when fresh human serum was used as the 
complement source. Later work revealed that the C3 used to prepare EAC3d 
was contaminated with traces of H and I which had resulted in the 
conversion of C3b to iC3b (Pangburn et al 1977) and. not to C3d as was 
originally thought. EAC3d complexes prepared with whole serum did contain 
C3d as the presence of serum enzymes allowed the further- cleavage of 
iC3b to C3d. Therefore it seemed possible that monocytes and 
macrophages could in fact be binding to a third stable binding site for 
iC3b.
Ross and Rabelliao (1979) tested a variety of cells with EAC3d prepared
with H and I and enzymes and EACobi prepared with II and I alone, They
found that PMN and monocytes were imreactive with EAC3d whereas variable 
proportions of these cells formed rosettes with EAC3bi. These iC3b 
rosettes could not be inhibited with fluid-phase C3c or C3d fragments 
which inhibit the C3b receptor and the C3d receptor respectively. Thus 
PMN and monocytes were proposed to possess a receptor fur iC3b which 
was distinct from the receptor fur C3d and C3b.
Usinv fluorescent microspheres (ms) coated, with iC3b, Ro^ r> and Lambris 
(1982) reported that, E, PMN. monocytes and a proportion of lymphocytes
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bound to these ms. This binding on nonlymphoid cells could not be 
inhibited by fluid-phase C3b, C3c or C3d or antiserum against the C3b 
and C3d receptors. On B cells the situation was more complex as binding 
of iC3b to the C3d receptor occurred by way of the d region of the intact 
iC3b molecule. A small population of B cells were found to rosette with 
iC3bms even when all the C3d receptor sites were blocked with fluid- 
phase C3d. This subset of B cells were separated on a fluorescent 
activated cell sorter and were found to contain all the natural killer 
(NK) activity in the human blood (Ault and Springer 1981). These NK 
cells also reacted with the monoclonal antibody M170 directed against the 
iC3b receptor (Beller, Springer and Schreiber 1982).
The realisation that specific fragments of C3 could have a binding site 
for more than one ligand meant that the distribution of the receptor 
types on different cells required reappraisal. Ross et al (1983) 
demonstrated that iC3b could bind to all three of the complement 
receptors but with differing affinities. Fluorescent ms coated with iC3b 
bound to E in the presence of ethylenediamine tetra-acetic acid (EDTA), 
which inhibited binding to the iC3b receptor. The addition of fluid- 
phase C3b or iC3b inhibited this binding and indicated that E possessed 
only one receptor for C3b which could also bind iC3b. The binding of 
iC3b to E was weak and required ten-fold more iC3b molecules than C3b 
molecules to achieve the same level of adherence. In addition, iC3b 
binding only occured at low ionic strengths and not at physiological salt 
concentrations. Microspheres coated with iC3b were also found to rosette 
with Raji cells which bear only the C3d receptor. This result confirmed 
the earlier work of Ross and Lambris (1982) which had proposed that 
lymphocytes could bind iC3b complexes to the C3d receptor by way of the 
d region of the molecule.
Monocytes and PMN were also studied for their ability to rosette with 
EC3d, C3dms, EC3dg and C3dgms. It was found, in agreement with other 
studies, that these phagocytic cells did not bind to C3d, having no C3d 
receptor. They did however bind C3dgras and EC3dg. This binding 
occurred in the presence of EDTA and anti-CRl antisera indicating that 
C3dg was not binding to the iC3b receptor or to the C3b receptor. 
Addition of soluble C3d sheep E membrane complexes (C3d-0R) did inhibit 
rosettes. This suggested two possible explanations. First, it was 
proposed that phagocytic cells express C3d receptors but in very low 
numbers detectable only with C3dg which has a higher affinity for the 
C3d receptor than C3d. Secondly, it was suggested that these cells may 
possess a fourth receptor similar in ligand specificity but different in 
structure from the C3d receptor of lymphocytes. In support of this 
second theory Frade et al (1985a) showed that neutrophils could form 
rosettes with E bearing large amounts of C3dg. This rosetting could not 
be inhibited by the addition of excess anti-C3d. From this observation 
the receptor on phagocytic cells has tentatively been described as the 
fourth complement receptor.
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Since the receptors had originally been named according to the ligand to 
which they bound the discovery of their ability to bind to more than one 
ligand threatened terminological confusion. It was therefore decided to 
rename the receptors according to their order of discovery. 
Accordingly, the nomenclature is now CR1, the original immune adherence 
C3b receptor, CR2, the C3d receptor, CR3, the iC3b receptor and CR4, the 
C3dg receptor, Table 1.2 lists the specificity and cellular distribution 
of these four receptors.
1.19 Isolation ..and.. Structure of CR1
Most recent research on complement receptors was made possible by the 
ability to isolate the receptors thus allowing a more detailed study of 
their structure and function.
Following the observation that desialated human E were protected from 
lysis in normal human serum, Fearon (1979) attempted to discover if a 
regulatory protein was responsible for this. He succeeded in isolating a 
glycoprotein (gp) of molecular weight 205,000 daltons from human E. This 
protein was found to accelerate the decay of the properdin stabilised 
amplification C3 convertase, C3BbP, by displacing Bb from C3b. It could 
also promote cleavage of C3b by I. Attempts to identify the protein 
showed that anti-gp 205 could block in a dose dependent manner the 
ability of human E, PMN monocytes and B cells to rosette with sheep 
EAC3b (Fearon 1980). This inhibitory effect of anti-gp 205 was specific 
for C3b as it did not inhibit rosettes between monocytes and EiC3b or 
lymphocytes and EC3d. These experiments established gp 205 as CR1.
Prior to this discovery, Dierich and Reisfeld (1975) had succeeded in 
solubilising C3 receptor material from a human lymphoid cell line. The 
protocol for this involved three main steps: (i) isolation of membrane
fragments bearing receptors for C3b and C3d by nitrogen cavitation, (ii) 
solubilisation of the fragments in potassium bromide (2 mol I-1) and
(iii) characterisation of the receptors which revealed them to be highly 
complex structures. Seven years later Mussell et al (1982) carried out a 
more detailed characterisation of CR1 from human E. Following hypotonic 
lysis of E and solubilisation in potassium bromide (2 mol l-1), the 
lysate obtained was passed over a C3-Sepharos<& column which was then 
eluted with potassium bromide (2 mol I-1). Though the activity isolated 
in this manner could inhibit the immune adherence reaction between E and 
EAC14oxy23b it could not agglutinate EAC1423b and for this reason it was 
termed a monovalent C3b receptor. When analysed by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) it was revealed to 
have a molecular weight of 55,000-66,000 daltons. This protein was 
thought to be the head portion of gp 205.
Fearon's (1979) method of isolating CR1 employed the use of the nonionic 
detergent Nonidet (NP-40). Solubilisation of E was followed by a series 
of chromatographic procedures, cation exchange chromatography, affinity 
chromatography and gel filtration, in an attempt to purify the receptor
Table 1.2 Jfextoa.ne rs&ap-tprs for bound fragments of C3: CP.l. CR2, CR.3 
and CP.4
Receptor Type Specificity Cell Type Distribution
CR1 C3b, C4b, Erythrocytes, Granulocytes,
iC3b, C3i,C3c Monocytes, B and some T
Lymphocytes, Kidney Podocytes 
Dendritic Reticulum Cells
CR2 iC3b, C3dg, B Lymphocytes, Dentritic
C3d, C3b Reticulum Cells
CR3 iC3b Monocytes, Macrophages,
Granulocytes, Natural Killer 
Cells, Dentritic Reticulum Cells
CR4 iC3b, C3dg, C3d Monocytes, Macrophages,
Granulocytes
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to homogeneity. The protein isolated by this means ran as a single band 
on SDS polyacrylamide gels under reducing and nonreducing conditions 
indicating that CR1 consisted of a single polypeptide chain. In the 
reduced form its molecular weight was 205,000 daltons and it was a 
glycoprotein as indicated by its ability to bind to C3-Sepharose and 
lentil lectin-Sepharose. Employing a different procedure Gerdes and Stein 
(1980) also attempted to isolate CR1. Following solubilisation of human 
E in potassium bromide (2 mol I-1), the CR1 active lysate was 
radioiodinated and passed over a gel filtration column. All of the 
material which possessed CR1 activity eluted as a single sharp peak in 
the void volume of the column, indicating a molecular weight of more than
100.000 daltons. Immunoprecipitation of this fraction with antisera 
prepared from crude CR1 active membrane fragments, revealed three bands 
on SDS polyacrylamide gels having molecular weights of 100,000-130,000 
daltons, 80,000 daltons and 60,000 daltons. This suggested that E CR1 
was a raacromolecule with a molecular weight greater than 100,000 daltons 
and that the protein moiety consisted of non-covalently linked protein 
molecules of molecular weight 80,000 daltons and 60,000 daltons.
As can be seen from the preceding account the isolation and 
characterisation of CR1 has been a complex process. However, in the
light of results from recent research workers it is now generally 
accepted that Fearon’s view of CR1 structure is correct. Iida and
Nussenzweig (1981) isolated a protein of 200,000 daltons from human E. 
This protein had the ability to decay dissociate both the classical and 
alternative C3 convertases and was also found to be a powerful inhibitor 
of the classical pathway C5 convertase. Using a modification of Fearon's 
technique Dobson, Lambris and Ross (1981) solubilised CR1 from E. Their 
protein had a molecular weight of 195,000 daltons in the reduced and 
nonreduced form and was identified as CR1 by its ability to bind to
EAC3b and EAC14b in a dose dependent manner and by the blocking of
rosetting activity between E and leukocytes with antiserum raised against 
this protein.
1.20 Polymorphism of CR1
CR1 was initially thought to be homogeneous with respect to size, but in 
the past few years two groups have independently described a structural 
polymorphism of CR1.
Previously when isolating CR1 from E it was necessary to use a large 
pool of donors in order to obtain a sufficient volume of blood. However 
by immunoprecipitation of E CR1 from individual donors Dykman et al 
(1983a) were able to reveal a hitherto unknown polymorphism of the 
receptor. Erythrocytes from each donor were radiolabelled prior to 
solubilisation in NP-40. The lysates were immunoprecipitated with 
monoclonal anti-CRl and samples analysed by SDS-PAGE and autoradiography 
which revealed three types of CR1 structure, one with a major band of
190.000 daltons, the second with a major band of 220,000 daltons and the 
third with two major bands of 190,000 daltons and 220,000 daltons.
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Characterisation of the receptors of 33 unrelated individuals revealed 
that the major band of 190,000 daltons, which was assigned the name "type 
a" was present in 70% of individuals, the major band of 220,000 daltons 
named "type b" was present in 3% of individuals and 27% of individuals 
were found to have both bands named "type c". The fact that type a CR1 
structure was found in the majority of donors could be the reason why 
purification of CR1 from pooled donors only revealed this CR1 structure 
and not the less frequent types. Family studies suggested that this 
polymorphism was governed by two codominant alleles at a single 
autosomal locus. This was shown by the fact that parents who were 
homozygous for the type a CR1 structure only had children with type a 
CR1 structure. Families where one parent had type a CR1 structure and 
one parent had type b CR1 structure only had children with type c CR1 
structure and parents who were homozygous (type a) and heterozygous 
(type c) had children with type a or type c CR1 structure. Thus there 
were postulated to be two alleles termed A for the more frequent one and 
B for the less frequent one.
A second group studying polymorphism of CR1 reported similar findings, 
(Wong, Wilson and Fearon 1983). Again two forms of CR1 were found 
having molecular weights of 250,000 daltons and 260,000 daltons. 
Individuals expressed either one of these major bands as in types a and b 
described by Dykman et al (1983a) or both as in type c. The higher 
molecular weights found by this group could be accounted for by the 
difference in the analytical systems used. The two bands were assigned 
the letters F for fast and S for slow to signify the speed at which they 
migrated into the gel. The F band corresponded to the 190,000 dalton
band found by Dykman et al (1983a) while the S band corresponded to the
220.000 dalton band. The presence of an. F band or an S band alone 
represented the type a or type b CR1 structure respectively while the 
presence of both the F and S band corresponded to the type c CR1
structure. Analyses of the occurrence of F and S forms in 15 families 
yielded the same conclusion as Dykman et al (1983a), viz. that these two 
forms were regulated by two alleles which were transmitted in an
autosomal codominant manner.
Both Dykman et al (1983b) and Wong et al (1983) found that polymorphism 
of CR1 was also evident on peripheral blood leukocytes with these cells 
expressing the same phenotypes as E. Further experiments revealed the
presence of an additional two alleles one coding for a CR1 of molecular 
weight 160,000 daltons was assigned the letter C (Dykman, Hatch and 
Atkinson 1984) and the other, coding for a CR1 of molecular weight
250.000 daltons was assigned the letter D (Dykman et al 1985). The
160.000 dalton band was found on individuals with either the 190,000
dalton band or the 220,000 dalton band and it was found to be most 
prevalent in patients with systemic lupus erythematosis (SLE), In a 
study of 104 unrelated normal individuals 69.2% expressed the AA 
phenotype, 24% expressed the AB phenotype, 3.8% expressed the BB
phenotype and 2.9% the AC phenotype. No individuals expressed the CC 
phenotype. These phenotypic frequencies agree. with the expected values
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from calculations based upon the Hardy Weinberg equation for three 
codominant alleles at a single locus. In 45 SLE patients the frequencies 
for the different CR1 phenotypes were similar to normal, but three SLE 
patients with the 160,000 dalton band demonstrated a higher intensity of 
labelling in this band than normal. Since a healthy brother of one of 
the patients also had a large amount of the 160,000 dalton band it was 
considered unlikely that this was acquired and accordingly it was 
suggested that a heritable factor governed expression of this band. The 
fourth allelic form was found on one donor from a total of 200 which 
were tested. This donor also possessed a 190,000 dalton band and was 
assigned the phenotype AD (Dykman et al 1985),
Treatment of all four forms of CR1 with endoglycosidase F, an enzyme 
which removes both simple and complex sugars, decreased their molecular 
weight by 10,000 daltons while treatment with endoglycosidase H, which 
removes high mannose sugars, had no effect (Wong et al 1983; Atkinson 
and Jones 1984; Dykman et al 1985). It is therefore probable that CR1 
possesses N-linked complex sugars with no high mannose sugars though it 
is unlikely that differences in N-linked sugars alone can account for the 
wide variation in the polymorphic forms of CR1. The contribution of 0- 
linked carbohydrates is as yet unknown. These carbohydrates can account 
for 40,000 dalton molecular weight differences in other proteins but it 
remains to be determined if differences are due to this or to differences 
in the protein structure itself.
The functional capacities of the variants appear to be similar. Seya, 
Holers and Atkinson (1985) have isolated CR1 variants A, B and C and 
assessed their individual functional capacity as cofactors for the I 
mediated cleavage of C3b and for their ability to decay dissociate fluid- 
phase C3 convertases and found them all to be equal.
It would appear that the gene coding for polymorphism of CR1 is not 
linked to the human leukocyte antigen (HLA) region, which is located on 
chromosome six. Hatch et al (1984) reported that family studies 
indicated that while siblings could inherit identical CR1 phenotypes from 
a heterozygous parent they could inherit different HLA haplotypes from 
the same parent. The reverse was also true that siblings from a 
heterozygous parent could inherit different CR1 phenotypes and identical 
HLA haplotypes,
1.21 Biosynthesis of CR1
Little has been reported on the biosynthesis of CR1. One study on the 
human promyelocytic leukemia cell line HL—60 has indicated that CR1 may 
be initially present as a 188,000 dalton intracellular precursor (Atkinson 
and Jones 1984). These cells can be induced to differentiate into 
F^ciiiu locy tss |)y q number of components including dimethy lsulphoxide 
(DMSO). Once differentiated these cells synthesise relatively large 
amounts of CR1 as assessed by their increased ability to form rosettes 
with EAC43b and the ability to isolate large quantities of CR1 by
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immunoprecipitation with anti-CRl antiserum or affinity chromatography 
on iC3-Sepharose. Fallowing the acquisition of the receptor over various 
time intervals it was revealed that there was a progressive increase in 
CR1 over a period of two days. Pulse studies were therefore performed 
after two days in culture. Cells were pulsed for eight hours with 35S- 
methionine, or alternatively incubated for eight hours in media and then 
surface labelled with 12SI. Comparison of cells after these different 
treatments revealed that while both expressed CR1 with a molecular weight 
of 210,000 daltons, the pulsed cells had an additional band of molecular 
weight 188,000 daltons. This was designated pro-CRl. Pro-CRl could be 
detected at 0 hours after a 15 min pulse but it took a further 60 min for 
conversion to the 210,000 dalton molecular weight form to occur. The half 
life for the disappearance of CR1 from the cell surface was 10 hours. The 
molecular weight of pro-CRl was reduced by treatment with 
endoglycosidase H, suggesting that it contained high mannose 
oligosaccharides and that it was the partially glycosylated form of CR1.
1.22 Binding Site Characteristics of CR1
CR1 is known to bind to a number of ligands apart from its major ligand 
C3b. These include C4b, iC3, C3c and iC3b which like C3b may all be bound 
in both soluble and particulate form.
Binding of solid phase C3b to human cells has been studied mainly using 
the rosette technique^ however most of the information regarding the 
interaction between CR1 and C3b has come from the measurement of the 
direct binding of radiolabelled fluid-phase dimers and monomers of C3b to 
CR1. Treatment of purified native C3 with trypsin followed by application 
to a gel filtration column yields two distinct peaks, the first containing 
soluble monomeric C3b and the second dimeric C3b formed from the 
covalent association of C3b monomers. Arnaout et al (1981) studied the 
binding of radiolabelled dimeric and monomeric C3b to sheep and human E. 
Sheep E do not bear CR1 and did not bind significant amounts of these 
two ligands. Human E bound seven times more dimer and one and a half 
times more monomer than sheep E indicating that the dimer was more
effective than the monomer in binding to CR1. Specific binding of
radiolabelled monomer and dimer was followed using increasing amounts of 
12SI monomer or dimer with and without increasing amounts of the 
appropriate unlabelled dimer or monomer. Specific saturable binding was 
only observed with the .dimer. Scatchard plot analysis revealed that the 
binding affinity of the dimers to human E was 6,5x107 mol I-1 which was 
similar to the binding affinity to other human cell types. Later 
experiments revealed that fluid-phase C3b monomer could also be bound
specifically to CR1 in a saturable manner, but this only occurred in low
ionic strength buffer (p=0.0513) with a binding affinity of 2.2xl07 mol 
I-1 which is very much lower than the affinity of the dimer under low 
ionic strengths (ka=2.36xl0e ) (Arnaout et al 1983), These data suggest 
that the interaction of C3b and CR1 involves ionic forces, a conclusion 
supported by the finding that elution of solubilised CR1 from C3— 
Sepharose requires the combination of high salt and nonionic detergent.
The higher affinity of the L3b dimer probably results from the
interaction of the aimer with pt ©clustered CR1 (Abrahamson and Fearon 
1983). In support of this, it may be noted that oligomeric C3b prepared 
by cross-linking dimeric Cob with dimethylsuberimidate, has a binding
affinity for CR1 which is 3.3 fold higher than C3b dimers.
As previously mentioned (1.13), iC3b is a ligand for CR1 (Ross et al
1983) although it binds at low .ionic strengths and only when there is a 
high density of iC3b molecules (B.bxiQVE) on the E.
C4b is also a ligand for CR1. Cooper (1969) was the first to show that
C4b was involved in immune adherence. He found that EAC14 could adhere 
to E and the titre of adherence was dependent on the number of C4 
molecules per E, Bokish and Sobel (1974) found that cell-bound C4b and 
C3b seemed to coooperate to enhance the binding of cells to EAC1423. When 
batches of EAC14 were prepared with differing amounts of C4, if was 
found that the number of C3b molecules required to achieve maximum 
binding was reduced if the EAC14 contained a large number of C4b
molecules. In vivo this cooperative function may be of importance in the 
degradation of immune complexes coated with both C4b and C3b. Medof and 
Nussenzweig (1934) have reported that the cofactor activity of CR1 is 
enhanced by the deposition of clusters of C4b and C3b adjacent to one 
another on the substrate. They also found CR1 to be a more effective 
cofactor for the I mediated cleavage of C4b than C4bp when the density 
of C4b molecules was greater than 3xi03/cell. Addition of C3b to EAC14 
promoted in a dose dependent fashion cleavage of C4b by I and CR1 and 
this enhancement was observed even when cells contained low densities of 
C4b molecules. The converse was also true that C4b could enhance the 
factor I plus CR1 mediated degradation of C3b and iC3b on EAC143b.
The CR1 binding site for C3b, iC3b and C4b is found in the c region of 
the C3b fragment. Ross and Polley (1975) observed that the binding of 
EAC143b to tonsil lymphocytes and human E could be inhibited by the 
addition of fluid-phase C3c. Later it was shown, that fluorescent 
microspheres coated with C3c could bind to CR1 on E, monocytes and 
neutrophils and that this binding could be inhibited by anti-CRl or 
fluid-phase C3b, iC3b and C3c. C3c microspheres did not bind to Raji
cells which bear only CR2 (Ross et al 1983).
Whether native C3 is able to bind to CR1 without prior cleavage to C3b
has occassioned considerable controversy. The issue is of importance 
because, since 03 is present in plasma in such high quantities, an ability 
to bind CR1 directly would result in the occupation of the majority of 
CR1 on phagocytic cells and their consequent inability to participate in 
multi valent interactions with C3b on opsonised particles. Berger et al
(1981) showed that native C3 did not inhibit rosette formation between 
EAIgMC43b and PMN or E whereas C3b did. This was confirmed by Berger 
and Fleischer (1983) who showed the inability of C3 to block rosettes 
between EAIgMC43b and lymphocytes. However Sim and Sim (1931) reported 
that fluid-phase C3 did inhibit rosette formation between EAC143b and
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tonsil lymphocytes over the same concentration range as fluid-phase C3b 
and that this binding was not due to cleavage of C3 to C3b. These results 
were similar to those of Frade and Strorainger (1980), who explained the 
binding of C3 to lymphocytes as being due to its cleavage to C3b during 
the binding reaction. Dixit et al (1982) isolated CR1 from rabbit alveolar 
macrophages and showed that the purified receptor had a greater binding 
affinity for C3b than for C3. The binding affinity of C3 for CR1 could be 
increased by treatment with methjiamine which causes hydrolysis of an 
internal thioester bond in C3 to reveal a sulfhydryl group which is 
normally only found present in the a chain of C3b which contains its 
labile binding site. Spontaneous hydrolysis of this bond can occur after 
prolonged storage or after denaturation with ammonium. This C3 is 
haemolytically inactive and is designated iC3. Originally, Pangburn and 
Miiller-Eberhard (1980) reported that spontaneous hydrolysis of C3 in 
plasma resulted in iC3 which could bind to B and H. Dixit et al (1982) 
showed that this iC3 could inhibit the rebinding of purified CR1 to C3b- 
Sepharose as well as to C3c and C3b indicating that iC3 displays binding 
activity for CR1. Findings by Berger et al (1981) support the conclusion 
that iC3 has a binding site for CR1 since they showed that haemolytically 
active C3 had a much lower affinity for CR1 than did iC3. The previous 
reports that C3 could bind to lymphocyte CR1 may have been due to the 
presence of a mixture of C3 molecules with spontaneous lysed internal 
thiolester bonds along with haemolytically active C3. It is therefore 
probable that in vivo CR1 sites on phagocytic cells are unoccupied by 
native C3.
1.23(a) Function of Erythrocyte CR1.
CR1 is the only C3 receptor which has been detected on E. Although E 
possess lower numbers of CR1 than any other CR1 bearing cells, the 
proportion of E in peripheral blood, in comparison to these other cell 
types, is such that 95% of CR1 in peripheral blood is found on E (Siegel, 
Liu and Gleicher 1981).
As already discussed, E CR1 plays a role in the prevention of lysis of 
bystander cells by its ability to decay dissociate convertases on these 
cells and by its cofactor activity for the I-mediated cleavage of C3b to 
the smaller degradation fragments iC3b and C3dg and the cleavage of C4b 
to iC4b (Iida and Nussenzweig 1981). In addition to this important 
function a role for E CR1 in the processing of immune complexes has been 
proposed. Nelson (1953) first described a role for E in immune defence 
after he observed that presensitised Treponema pallidium adhered to human 
E. Prior to this Duke and Wallace (1930) had reported the adhesion of 
monkey E to Trypanosomes in the presence of specific trypanosomal 
antibody. This clearance of microorganisms from the serum has also been 
observed in rabbits, guinea pigs and mice where CR1 on blood platelets 
can stick to bacteria and thus remove them from the circulation (Taylor 
et al 1985). It is now postulated that E in primates and platelets in 
non-primates are essential components of their respective immune systems, 
in that they bind opsonised soluble immune complexes via CR1 and remove
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them from the circulation (Siegel et al 1981; Medof and Oger 1982;
Cornacoff et al 1983; Jepsen et al 1986; Sherwood and Virella 1986). The 
fact that 95% of CRlj peripheral human blood is present on E means that a 
circulating immune complex has a 500 to 1000 times greater chance of 
meeting a red blood cell than a white blood cell (Siegel et al 1981), It 
would be highly advantageous if red blood cells could bind to these 
complexes and carry them to a phagocytic cell for disposal. Such a role 
for E CR1 has been studied in vitro by Medof and Oger (1982) and in vivo 
by Cornacoff et al (1983). In vitro it was found that when radiolabelled 
BSA anti-BSA complexes, which had been incubated with normal serum, were 
added to unfractionated whole blood the majority of immune complexes 
became associated with the red blood cells rather than the white blood 
cells. The lack of immune complex binding after depletion of C3b from the 
serum by heat inactivation or treatment with zymosan suggested that this 
binding of immune complexes was to E CR1. Thus under certain conditions 
the E in human blood were able to compete successfully for immune 
complexes and remove them from the fluid-phase. The possibility that this 
occured in vivo was shown by Cornacoff et al (1983). Radiolabelled BSA 
anti-BSA complexes were infused intravenously into baboons and blood 
samples removed from a variety of veins after specific time intervals. 
The areas where E had bound immune complexes were determined by 
measuring the amount of radiation associated with the cells. Erythrocytes 
drawn from the portal vein had large amounts of associated immune
complexes in comparison to E drawn from the hepatic vein. This suggested 
that as the blood traversed the liver, immune complexes had been removed 
from the E. The E themselves were returned undamaged to the circulation. 
The release of immune complexes from E in the liver may have resulted 
from the degradation of C3b in the immune complex to iC3b and C3dg by 
the action of CR1 and I (Medof et al 1982). Sherwood and Virella (1986) 
have shown that PMN and monocytes bind significant amounts of immune 
complexes from the surfaces of human E following incubation with immune 
complexes bearing E. Thus binding of immune complexes to E CR1 followed 
by the removal of these complexes by the phagocytic cells in the liver 
would not only prevent deposition of these complexes in susceptible 
tissues, it would also prevent overloading of CR1 bearing leukocytes in 
the circulation.
1.23(b) CR1 Number on Erythrocvt.es.
The number of CR1 expressed per E appears to be highly variable among
individuals. A functional variation in expression of CR1 on E from 
different donors was described by Miyakawa et al (1981) after the 
observation that the immune adherence reactivity of E could vary by as 
much as 10 to 100 fold in different individuals. Variations in E CR1 
number have also been described quantitatively using the direct binding 
of anti-CRl antibodies. This variation is termed numerical or quantitative
polymorphism.
A wide variety of figures are cited in the literature to indicate the 
average number of CR1 molecules per E. Using a polyclonal anti CR1
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antiserum Fearon (1980) reported that there were 950 molecules of CR1 
per E, while Vilson et al (1982) reported an average of 5,101 and Holme 
et al (1986) an average of 2,200. Using the monoclonal anti-CRl antibody 
57F, Iida, Marnaghi and Nussenzweig (1982) found an average of 1,400 CR1 
sites per E and using the monoclonal anti-CRl antibody Ell, Hogg et al 
(1984) and Ross et al (1985) found 610 and 707 sites per E respectively.
1.23(c) Inheritance of.CRl on Erythrocytes
Vilson et al (1982) observed that the frequency distribution of E CR1 
levels on normal individuals appeared to be trimodal. One group contained 
34% of subjects with E CR1 numbers between 5,500 and 8,500, the second 
group contained 54% of subjects with E CR1 numbers between 3,000 and 
5,499, and the remaining 12% of individuals had E with CR1 numbers 
between 1,000 to 2,999. Analysis of nine families showed that low levels 
of E CR1 were more frequently found in offspring of parents with low CR1 
numbers and high levels of CR1 were found in offspring of parents with 
high CR1 numbers. They therefore proposed that numbers of CR1 on E were 
genetically regulated and described a simple model to explain the
inheritance based on the existence of two co-dominant alleles which
determine high (H) and low (L) numbers of CR1. A phenotype of HH was 
proposed to indicate a person who was homogeneous for the high CR1
allele which was expressed phenotypically in CR1 numbers greater than 
5,500 per cell. LL was the proposed genotype for phenotypically low CR1 
expression, that is, numbers less than 2,999 per E and an HL genotype was 
phenotypically expressed as numbers of CR1 between 3,000 and 5,500 per 
cell. The frequencies with which these phenotypes were observed in the
normal population were consistent with the Hardy Veinberg equation for 
inheritance regulated by two co-dominant alleles at a single locus. Nojima 
et al (1985) also reported a trimodal distribution of E CR1, however
others have found that E CR1 are distributed in a normal fashion (Valport 
et al 1985a; Ross et al 1985) or a logarithmic fashion (Holme et al
1986). Thus it may be that genetic control is more complex than
originally thought involving more than two alleles.
Originally it appeared that there was no relationship between structural 
polymorphism of CR1 and quantitative polymorphism (Vong et al 1983).
Individuals who had the AA, AB, or BB structural phenotypes were all 
expressed along with the HH, HL and LL numerical phenotypes. This 
suggested that the gene which regulated structural polymorphism was 
distinct from that which determined CR1 number. However a recent report 
by Vilson et al (1986a) described a restriction fragment length 
polymorphism of the CR1 structural gene involving fragments of 7 .4kb and 
6.9kb which appeared to correlate with variation in the numerical 
expression of E CR1. Four individuals with high CR1 levels had only the 
7.4kb fragment, four individuals with intermediate E CR1 levels had both 
the 6,9kb and 7.4kb fragments and four individuals with only the 6.9kb 
fragment had low E CR1 expression. The presence of the restriction
fragment was independent of the structural allotype expressed (Vilson et
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al 1985a). These results suggested that a factor controlling quantitative 
polymorphism may be linked to the CR1 structural gene.
1>24 Lqm— Erythrocyte— Cfil— Numbers on Patients with Systematic Lupus
Erythematosus (SLE)
SLE is a disease which is associated with a number of defects in the 
immune system, these defects include the presence of large amounts of 
circulating antigen/antibody complexes (CIC) and the formation of auto­
antibodies (Tan et al 1982). As previously mentioned one of the functions 
hypothesised for E CR1 is the processing and removal of immune complexes 
from the circulation. Much evidence is accumulating to suggest that the 
reason for the large amounts of CIC in patients with SLE is due to a 
defect in the ability of their E CR1 to perform this function.
While investigating the agglutination of human E by immune complexes 
bearing C3b it was found that the reactivity of E from patients with SLE 
was considerably lower than in the normal population. Out of a group of 
56 SLE patients studied in Japan 37 did not show any detectable 
reactivity with the C3b-coated complexes, while only one out of 51 
normals was found to be unreactive (Miyakawa et al 1981). This low 
immune adherence haemagglutination (IAHA) reactivity was shown to be a 
stable characteristic which persisted during active and inactive phases 
of the disease, suggesting that the defect was inherited and not acquired 
as a result of the disease state. The finding that six out of 24 healthy 
relatives (251) of patients with SLE had low IAHA reactivity compared 
with 2% of the normal population suggested that low IAHA reactivity might 
be a genetic marker for SLE.
Since this initial observation additional studies have been performed 
which provide further support for the existence of lower CR1 numbers and 
impaired CR1 activity on E from patients with SLE (Iida et al 1982; 
Vilson et al 1982; Valport et al 1985a; Holme et al 1986). However, the 
main point of contention is in deciding if this abnormality is inherited 
or acquired. Iida et al (1982) using the monoclonal antibody 57F found 
that whereas the mean number of CR1 on E from 52 normal individuals was 
1,410, the mean number obtained from 34 SLE patients was significantly 
lower at 600. Following four patients throughout phases of disease 
activity and inactivity revealed that while two patients expressed larger 
amounts of CR1 when in remission, two others did not change at all. The 
low level of CR1 was expressed independently of steroid therapy as 
treatment of asthmatics with prednisolone did not result in CR1 levels 
out with the normal range. In addition low levels of CR1 correlated with 
low levels of C4 and with high levels of CIC. These results had two 
possible explanations, one was that CR1 levels were inherited genetically 
and that the low numbers of CR1 predisposed these patients to the 
disease. This is consistent with the finding that CR1 levels did not 
change in two patients irrespective of disease activity. Alternatively the 
low number of receptors could have been a secondary manifestation of the 
disease caused by either blockade of the receptor with CIC or auto-
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antibodies to CR1, or by the removal of the receptor by an unknown 
mechanism. This explanation is supported by the finding that two patients 
increased expression of CR1 numbers when in remission and by the fact
that low numbers of CR1 correlated with high levels of CIC and high
turnover of the complement pathway.
Vilson et al (1982) studied E CR1 from 38 SLE patients in Boston and 
found that the reduced numbers of CR1 could be detected on this group 
using both radiolabelled dimeric C3b and radiolabelled polyclonal anti-
CRl. The ratio of the sites determined by the two methods was the same
on both the normal and the patient group with approximately nine 
molecules of antibody bound per functional CR1 site. Thus the lower 
number of CR1 detected in the patient group was due to an absolute 
reduction in the number of receptors and not to a reduction in the number 
of functional receptor sites. Family studies showed that the healthy 
relatives of SLE patients expressed low CR1 numbers. The frequency 
distribution of patients and their relatives was very much different from 
the normal frequency predicted by the Hardy Veinberg equation. The 
families of SLE patients expressed a three- to four-fold higher frequency 
of the LL phenotype than did the families of normal individuals and the 
HH phenotype did not occur. Thus the results of Vilson and his colleagues 
suggested that the low CR1 numbers in SLE patients were an inherited 
characteristic.
Minota et al (1984) determined CR1 sites by radioimmunoassay with 
monoclonal anti-CRl and CR1 activity by IAHA. The majority of SLE
patients had low CR1 sites and low IAHA. The binding of radiolabelled 
monoclonal anti-CRl to E and to E lysates was distributed continuously in 
a wide range for both normal controls and SLE patients. Vhen however the 
number of CR1 sites determined on 120 controls were standardised on the 
basis of wheat germ agglutinin binding sites to avoid errors due to 
differences in E surface area, there appeared to be three distinct peaks 
corresponding to low, intermediate and high CR1 expression. Thirty six
percent of control subjects had high CR1 sites, 53% had- intermediate
numbers and 11% had low numbers. Of SLE patients, the number of CR1 
sites were high in 0%, medium in 52% and low in 48%. They proposed that 
as the prevalence of the high phenotype exceeded that predicted by the
Hardy Veinberg equation, the expression of CR1 may be governed by
multiple genes.
Nojima et al (1985) determined the reactivity of CR1 by measuring the 
capacity of E to bind to radiolabelled heat aggregated human gamma 
globulin (AHG) in the presence of complement. Normal E showed a range of 
high, intermediate and low binding capacities while E from SLE patients 
bound the radiolabelled complexes at a low or intermediate level but 
never at a high level. This low binding of SLE persisted during steroid 
therapy which improved other parameters of disease activity such as E
sedimentation, leukocyte count and complement titre. Thus the persistence
of low binding of SLE E during active and inactive phases of disease
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favoured the genetic control of CR1 expression and argued against the 
view that CR1 expression was dependent on disease activity.
However the bulk of recent experimental evidence supports the view that 
reduced numbers of CR1 in patients with SLE are acquired as a result of 
the disease. Inada et al (1982; 1983a) reported that defective CR1
activity in SLE patients correlated with the presence of CIC in serum. 
This group used a new method to detect CR1 activity. Sheep E coated with 
antibody and C3b (EAC3b) were incubated with a detergent solubilised 
lysate of the test E. Depending on the amount of CR1 available in the 
lysate to bind with the EAC3b, when indicator human E were added there 
were variable amounts of inhibition of agglutination detected. Normal 
human E totally inhibited haemagglutination at a lysate concentration of 
6% while lysate from 95% of patients with CIC present in their serum did 
not inhibit IAHA. When a comparison was made between patients with CIC 
and those without CIC, it was found that approximately 68% of patients 
with CIC had no inhibitory activity while only 2% of patients without IC 
showed no inhibitory activity. Circulating immune complexes disappeared 
from the patients serum as the patient entered remission and concomitant 
with this there was an increase in the activity of CR1. These results 
suggested that the defects in CR1 activity were not genetically
controlled but were dependent on the availability of CR1 sites which in 
the active disease state may have been blocked due to the increased 
amount of CIC. Uko et al (1985) found CR1 deficiency in 37% of the SLE 
patients studied as measured by the lack of ability of these E to
agglutinate in the presence of opsonised heat aggregated human IgG. 
Serial studies performed on E from seven normal individuals showed very 
little variation in IAHA titres while IAHA titres of three SLE patients 
varied from negative to positive IAHA and vice versa. The reduction in 
IAHA was usually associated with rises in serum anti-DNA binding and 
increases in in vivo complement activation, which are indicative of a 
rise in auto-antibodies and in CIC respectively. These experiments
indicated that CR1 numbers were probably acquired and were in agreement 
with the observation of Yoshida et al (1985) who found that CR1 values 
on some SLE patients correlated with complement titres and changed in 
parallel with clinical status.
Family studies by Valport et al (1985a) have also indicated that reduced 
CR1 levels in SLE are acquired and not inherited. No significant
difference was found between the distribution of CR1 in normal families 
and the distribution of CR1 in relatives of patients with SLE, findings 
that are in contradiction to those of Wilson et al (1982). In addition 
four SLE patients who were shown to express the genotype for high CR1 
expression, phenotypically expressed low CR1 numbers. In agreement with 
these data Holme et al (1986) reported that an SLE patient with 
phenotypically low CR1 levels was the progeny of parents with high and 
intermediate genotype. These results suggest that while inheritance may 
play a role in determining CR1 numbers in healthy individuals, CR1 
numbers in SLE patients may be modulated by certain physiological 
factors associated with the disease.
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A major area of controversy at the present moment is whether reduced 
numbers of CR1 occur as a result of the actual loss of the receptor from 
the E membrane by proteolysis, or as a result of blockade of the receptor 
by CIC or auto-antibodies. Blockade of CR1 by auto-antibodies to CR1 may 
result in the inability to detect CR1 by polyclonal or monoclonal anti- 
CRl as in the case of one SLE patient (Vilson et al 1985b). In this 
patient periods of disease activity were associated with absence of 
detectable CR1 on E and high titres of auto-anti-CRl. Uko et al (1985) 
have also reported a reduction in IAHA which is associated with increases 
in auto-antibodies to DNA. However in an earlier study Vilson et al
(1982) could detect no auto-antibodies to CR1 in seven SLE patients or 
their relatives. In the same study blockade of CR1 by immune complexes 
was not considered to be a possible cause of lower CR1 numbers as only 
two out of 22 patients studied had serum levels of immune complexes 
which were out with the normal range. Ross et al (1985) found no 
evidence to indicate that reduced CR1 levels were due to surface-bound 
immune complexes as E from SLE patients did not contain abnormal amounts 
of C3 antigen, which is necessary for the binding of C3b or iC3b bearing 
complexes to CR1,
Patients with proliferative glomerular nephritis have very low or totally 
negative staining with anti-CRl on frozen kidney sections. This 
reduction in CR1 activity is not thought to result from blockade of the 
receptor by immune complexes as kidney podocyte CR1 still retains the 
ability to bind to polyclonal anti-CRl even after the kidney sections 
have been preincubated with normal human serum containing aggregated IgG, 
treatment which blocks the binding of podocytes to EAC3b (Kazatchkine et 
al 1982). This indicates that even although receptors may be blocked 
with complexes the antibody can still recognise and bind to an epitope on 
CR1. This is in agreement with the result of Hogg et al (1984) who 
showed that as Ell binds to a specific site in CR1 which is not part of 
the C3b binding site that CR1 numbers may be quantified even when
receptors were occupied with soluble complexes, and with results of Ross
et al (1985) who found that the binding of Ell to E CR1 was unaffected 
even when E were shown to be binding to circular double stranded (ds) 
DNA anti-dsDNA immune complexes, as assessed by their content of C3.
Although most experimental data seem to imply that blockade of CR1 by 
immune complexes is not the reason for reduced numbers of CR1 in SLE 
patients, work in our own laboratory by Dr E Holme. suggests that the true 
picture may be more complex. It was found that large opsonised immune 
complexes could bind to E and block uptake of both monoclonal and
polyclonal anti-CRl, whereas small opsonised complexes did not block this 
uptake. Thus in some SLE patients reduced levels of CR1 may be due to 
the binding of large complexes which sterically hinder the binding of 
radiolabelled probes.
Alternative explanations for low CR1 numbers include the proteolytic 
stripping of CR1 from the E surface (Ross et al 1985; Ripoche and Sim 
1986) or the presence of an inhibitory substance in SLE serum which may 
modulate CR1 expression. Yoshida et al (1985) suggested that CR1 levels
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may be controlled by a factor in the serum of the SLE patient which 
causes removal of the receptor. The presence of a substance in SLE serum 
which may inhibit CR1 function has been suggested by the work of Ng 
(Personal Communication 1986). It was found that serum from an SLE 
patient could inhibit the binding of immune complexes to E in the 
presence of normal human serum. This inhibitory activity was destroyed 
by heat inactivation of the SLE serum. As yet there is no published work 
to support this theory. Experiments by Ross et al (1985) favour the view 
that CR1 is physically lost from the E cell surface in SLE patients. 
This may result from the stripping of the receptor from the membrane 
along with the immune complex as the E traverses the liver and spleen. 
His basis for this theory was the observation that SLE patients with low 
CR1 have a larger than normal amount of fixed C3dg molecules on their 
surface. Less than 100 molecules of C3dg per E were found in normal 
subjects while 100 to 800 molecules per E were found in patients with 
SLE. This larger amount of fixed C3dg was thought to have arisen from 
increased complement activation caused by the presence of auto-antibodies 
or CIC. Other diseases which were associated with complement activation 
such as chronic cold agglutinin disease, auto-immune haemolytic anemia 
Sjogrens syndrome and paroxysmal nocturnal haemoglobinuria (PNH) type 11 
also had reduced E CR1 numbers and excess amounts of fixed C3dg per E. 
In active phases of disease SLE patients had reduced levels of E CR1 and 
low complement activity which correlated with high levels of fixed C3dg. 
As the patients entered remission E CR1 numbers increased and the levels 
of fixed C3dg fell. Incubation of fresh normal blood with dsDNA anti-DNA 
complexes in vitro, resulted in the deposition of C3dg on E, but this 
deposition was not accompanied by a reduction in E CR1 numbers, 
suggesting that neither CIC nor serum enzymes were responsible for the 
removal of CR1. Ross therefore explained his results by proposing that 
the receptor was lost during interaction of the E bearing complement 
coated immune complexes, with the macrophage phagocytic system during 
circulation through the liver or spleen. In agreement with this Valport 
et al (1985b) found that transfusion of E with high CR1 numbers into 
patients with low E CR1 numbers resulted in a gradual loss of receptors 
from the transfused blood. CR1 levels on the transfused blood fell from 
493 to 202 CR1 sites per E over 112 hours. This was accompanied by the 
deposition of 410 C3dg molecules per E.
The finding of a soluble form of CR1 (Yoon & Fearon 1985) which was 
structurally and functionally similar to E CR1 may indicate that cellular 
shedding of CR1 occurs in vivo. It would be of interest to examine serum 
levels of CR1 in patients with SLE to determine if they are higher than 
normal, a finding which may lend support to the theory of increased 
receptor shedding in SLE.
1.25 Binding Of dna anti-DNA Complexes to .Erythrocytes
A number of experiments have now been performed which show that reduced 
E CR1 numbers are associated with reduced E binding of complement coated 
immune complexes. Taylor et al (1983a) analysed the ability of E from
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normal individuals and E from patients with SLE to bind to opsonised 
antibody/dsDNA immune complexes, They found that while normal 
individuals bound approximately 88% of a standard amount of these 
complexes half of the SLE patients studied had pronounced defects in 
their ability to bind the complexes. This defect could not be overcome 
by the addition of more E from the patient. This finding is consistent 
with the hypothesis that for immune complexes to bind to E there must be 
clustering of CR1 (Medof and Nussenzweig 1984). If this is the case then 
lower CR1 densities would result in less clustering and consequently lead 
to a reduced ability to bind complexes.
Horgan and Taylor (1984) studied the kinetics of binding of the DNA 
complexes to both normal and SLE E. Complexes opsonised in normal human 
serum bound rapidly within 4 minutes to normal E at 37 X  and at a 
reduced extent at OX. Binding to patients E occurred very slowly 
requiring 30 minutes to reach equilibrium with less complexes being 
bound. Previously Taylor et al (1983a; b ) had reported that as less 
than 100 DNA anti-DNA immune complexes could bind to each normal E 
bearing approximately 500 CR1 sites per cell that the complexes probably 
bound via multivalent attachments to clusters of CR1. Clustering of CR1 
requires movement of receptors in the plane of the membrane and in the 
case of SLE E the longer time taken to achieve maximum binding could 
reflect the longer time taken to organise CR1 into clusters. This theory 
is consistent with the finding that at temperatures below 2 1*C, the 
transition temperature for alteration of membrane fluidity, binding of 
complexes to normal E occurs more slowly, probably due to restriction of 
CR1 movement in the more rigid membrane (Zimmer and Schirmer 1974).
Thus low E CR1 in patients with SLE could contribute towards the 
pathogenesis of the disease by reducing the ability of the E to clear 
immune complexes from the circulation, thereby increasing the risk of 
complexes becoming deposited in the kidneys or other susceptible tissues 
leading to inflammation and tissue damage.
1.26 CR1 on Dendritic Reticular._Cglla
The B cell dependent areas of both the spleen and the lymph nodes 
contain nonphagocytic cells known as dendritic reticular cells (DRC). 
These cells are postulated to play a role in the retention of antigens in 
lymphoid follicles which is essential for the generation of B memory 
cells (Klaus et al 1980). It has been shown by immunofluorescence and 
autoradiographic studies that antigens are capable of binding to the 
surface of DRC and by so doing they become trapped in the follicular 
region in close proximity to the B cells (Nossal et al 1968). Binding of 
antigen/antibody complexes to DRC is mediated by complement receptors on 
the cells (Klaus et al 1980). This was first suggested by the work of 
Vhite et al (1975) and Klaus and Humphrey (1977) in animal models. Heat 
aggregated human gamma globulin which had been intravenously injected 
into chickens was found to attach to the surface of DRC in the spleen in 
the absence of specific antibody, but not when the complex was treated
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with pepsin such that it could^ activate complement, or when the chicken 
was depleted of complement in vivo by treatment with cobra venom factor. 
This failure to bind complexes was accompanied by the failure of germinal 
centre formation (White et al 1975). Thymectomized mice depleted of 
complement by treatment with cobra venom factor were also unable to bind 
injected complexes to DRC which resulted in ah inability to produce B 
memory cells (Klaus and Humphrey 1977). Gerdes and Stein (1982) were 
able to prove conclusively that DRC possessed complement receptors for 
C3 by staining frozen tissue sections with polyclonal anti-C3R. This 
antiserum was unable to distinguish between the various types of 
complement receptors, but recently using monoclonal antibodies it has 
been shown that DRC possess CR1, CR2 and CR3 (Hogg et al 1984; Reynes et 
al 1985). Monoclonal antibodies against P150/95, the proposed CR4 do not 
bind to DRC (Hogg et al 1986). The presence of CR1, CR2 and CR3 on 
these cells will thus optimise the binding of immune complexes containing 
C3b and its degradation fragments to the surface of the DRC.
1.27 lumber of CR1 on PMN
Human PMN possess CR1 and CR3 and possibly also CR4. The primary 
function of these receptors is to establish contact between soluble 
immune complexes and other opsonised particles prior to their ingestion 
or degradation by cytotoxic reactions. PMN have been reported to possess 
approximately 57,000 specific binding sites for CR1 as determined by the 
uptake of F(ab')^ anti-gp 205 (Fearon 1980). Higher numbers have been 
detected using the monoclonal antibody 57F,(140,000 sites/cell) (Iida et 
al 1982) and lower numbers are found using the monoclonal antibody 
Ell,(46,000 molecules/cell) (Hogg et al 1984). These numbers are known 
to increase significantly upon exposure of cells to chemotactic stimuli 
such as C5a or . N-formyl-methionyl-leucy 1-phenylalanine (FMLP). The first 
indications of this were given by Anwar and Kay (1978) who reported that 
the eosinophil chemotactic factor of anaphylaxic (ECF-A) and histamine 
could selectively enhance rosettes between EC3b and human eosinophils in 
a dose and time dependent fashion. Human neutrophils and monocytes 
could also enhance complement receptors following incubation with 
chemotactic substances (Kay, Glass and Salter 1979). Additionally human 
monocytes increased complement receptor expression upon stimulation with 
casein, a known chemotactic agent of monocytes and after stimulation with 
a synthetic chemotactic peptide FMLP or after stimulation with 
supernatants from lymphocytes stimulated with phytohaemagglutinin (PHA) 
(Glass and Kay 1980). The maximum increase in complement receptors was 
seen by 30 minutes and this increase was dependent on the concentration 
of agent used and on the temperature of the incubation. At 4*C no 
stimulation was seen, whereas at 37*C maximum stimulation was achieved. 
This stimulation was specific for CR1 as there was no concomitant 
increase in Fc receptors. These early experiments were all performed 
using the rosette technique for quantification and thus it could not be 
distinguished between increase in CR1 number and other membrane changes 
which may have resulted in an increased affinity of preexisting CR1 for 
the ligand. Fearon and Collins (1983) provided direct evidence for the
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enhancement of CR1, Employing fluorescein conjugated anti-CRl and 
radiolabelled dimeric C3b they showed that C5a desarg and FMLP caused a 
ten-fold increase in CR1 numbers in whole blood. Whole blood was used 
because it was discovered that isolation procedures alone could increase 
the expression of CR1 on neutrophils. It was suggested that the 
enhancement seen with chemotactic agents was purely a result of warming 
the cells to 37 *C and that the actual response to the chemotactic agent 
was minimal, Berger et al (1984) showed that FMLP did markedly enhance 
CR1 number over the spontaneous increase seen at 37 *C, This work was 
confirmed by Richerson et al (1985) who reported that there was a three- 
to four-fold rise in CR1 following incubation at 37 *C for 30 minutes and 
a further two- to three-fold rise upon stimulation with FMLP. Apart from 
chemotactic agents, phorbol myristate acetate (PMA) a tumour promoting 
agent which causes activation of neutrophils and monocytes (Wright and 
Silverstein 1982) causes an increase in CR1 number on human neutrophils. 
Changelian et al (1985) found that at low concentrations (4ng/ml) PMA 
induced an increase in CR1 expression. This increase which was initiated 
by PMA was abrogated by incubation with FMLP prior to incubation with 
PMA, indicating that the two agents draw the additional CR1 from the
same source. High concentrations of PMA (greater than 16ng/ml) resulted 
in a decrease in CR1 expression. This decrease was not due to receptor 
shedding as the total cellular CR1 remained the same both before and 
after treatment with PMAt Tt was thus concluded that internalisation of 
CR1 had occured. The increase in receptor number which resulted from 
treatment with FMLP or low concentrations of PMA was not accompanied by 
a change in total cellular CR1 indicating that CR1 were probably being 
translocated from an intracellular pool. Evidence for the existence of 
such a pool has come from the work of O'Shea et al (1985a) who found
that neutrophils which were deficient in specific granules increased CR1
expression in a normal fashion after stimulation with FMLP, although
augmentation of CR3 expression was not observed. Neutrophil cytoplasts 
were prepared which were depleted of internal organelles and which
expressed approximately 50% of the total membrane surface area of intact 
neutrophils, These cytoplasts were not found to increase surface
expression of CR1 at 37 *C or upon stimulation with FMLP suggesting that 
additional CR1 come from organelles within the cell. To determine if
this might be the case, normal neutrophils were fixed with acetone to
allow fluoresceinated monoclonal anti-CRl to penetrate the membrane and
bind to internal proteins. After this treatment a large amount of 
internal fluorescence was seen. An attempt was made to locate the 
organelle which contained the intracellular pool of CR1. Neutrophils were 
disrupted and fractionated on sucrose gradients to obtain plasma 
membrane, specific granule, and azurophilic granule enriched fractions. 
Radiolabelled monoclonal anti-CRl bound to the plasma membrane enriched 
fraction but not to any of the other fractions. It was suggested that 
CR1 could possibly be located in the C-olgi apparatus as this organelle 
was present in the plasma membrane enriched fragment. CR3 was thought
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to be located in the specific granules in agreement with the work of Todd 
et al (1984).
Evidence for the in vivo increase in CR1 expression on neutrophils has 
come from studies on patients undergoing haemadialysis. This treatment 
results in activation of the complement system due to exposure of blood 
to fresh cellulose membrane which activates the alternative pathway. C5a
which is generated by this activation may be the in vivo stimulus which
augments CR1 expression on neutrophils. In vitro a direct relationship 
was shown between CR1 numbers on neutrophils and the concentration of 
C5a added. The ability to augment expression of CR1 on neutrophils may 
be an important mechanism for increasing phagocytic activity at sites of 
inflammation in vivo (Lee, Hakim and Fearon 1984).
1.28 Function. _oi CR1 on Phagocytic Cells
The function of CR1 on phagocytic cells is primarily concerned with the 
binding of cells to particles opsonised with fragments of C3 degradation 
which are ligands for the receptor, namely C3b, iC3b, C4b, C3c and iC3. 
Attachment of CR1 to opsonised particles does not necessarily lead to 
their ingestion. Originally it was proposed that CR1 acted in synergy 
with the Fc receptor on phagocytic cells to promote ingestion with CR1 
acting exclusively to establish contact between the cell and the 
opsonised particle and ligation of the Fc receptor being required to 
directly trigger ingestion. Ehlenberger and Nussenzweig (1977) found
that the presence of C3b on a particle could reduce by 100-fold the
amount of IgG required to produce ingestion but other non-immunological 
agents which brought phagocyte and particle into close contact could 
also reduce the amount of IgG required for ingestion. It was thus 
concluded that while CR1 may be necessary to establish a strong contact 
it had no direct role in the phagocytic process. Hewraan and Johnston 
(1979) provided evidence to support this conclusion, when it was 
observed that sheep E coated with C3b were bound but not ingested by 
neutrophils. Addition of small amounts of IgG to the sheep cells 
triggered ingestion and release of superoxide anions .
Studies of the CR1 receptor on resident and thioglycollate elicited mouse 
peritoneal macrophages revealed that nonactivated macrophages bound to 
sheep EAIgMC3 but did not ingest them to a significant degree, while 
activated macrophages bound and ingested these complexes even when Fc 
receptors were blocked by an anti-macrophage IgG fraction (Bianco, 
Griffin and Silverstein 1975). As thioglycollate elicited macrophages 
behave similarly to macrophages that have been stimulated with 
lymphokine Griffin and Griffin (1979) examined the effect on macrophages 
of a soluble factor produced from T cells. They found that macrophages 
treated with this factor could be converted in_yltro. from only mediating 
binding to EAIgMC3b to promoting ingestion of this complex. Thus 
complement receptors on mouse peritoneal macrophages could exist in two 
states an inactive one which mediated only binding and an activated one 
which mediated both binding and ingestion.
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In an attempt to determine the mechanism whereby this transition took 
place, Griffin and Mullinax (1981) studied the topography of CR1 on 
active and inactive mouse peritoneal macrophages. Previously it had 
shown that macrophages plated on coverslips coated with IgG containing 
immune complexes or opsonised IgG immune complexes could mobilise their 
Fc and complement receptors in the plane of the membrane so that they 
accumulated in the basal portion of the membrane in contact with the 
substrate leaving the surface void of these receptors (Michl et al 1979). 
Vhen inactive macrophages were plated onto surfaces bearing unopsonised 
IgG containing immune complexes they could bind to but not ingest sheep 
EAIgMC3b. Macrophages treated with lymphokine could ingest sheep 
EAIgMC3b while plated onto these same surfaces, but binding and ingestion 
was abolished by plating the activated macrophages onto surfaces coated 
with opsonised IgG containing immune complexes. Binding of EAIgMC3b by 
nonactivated macrophages was not altered on surfaces containing 
opsonised IgG containing immune complexes. These results were explained 
by proposing that treatment with the lymphokine resulted in the ability 
of CR1 to trigger ingestion and also to become mobile in the plane of the 
membrane. Inactive macrophages could not mobilise CR1 in the plane of 
the membrane as indicated by the retention of rosetting ability with 
EAIgMC3b while plated on complement coated surfaces thus it was 
postulated that activation of CR1 resulted from its release from a 
normally anchored position allowing it to become active in phagocytosis.
PMA was found to be capable of promoting ingestion of sheep EAIgMC3b in 
cultured human monocytes, Wright & Silverstein (1982) plated monocytes, 
which had been pretreated with PMA, onto IgG coated surfaces. These cells 
were able to both bind and ingest sheep EAIgMC3b and iC3b whereas 
control monocytes could only bind these complexes. However control 
monocytes were able to modulate CR1 in the plane of the membrane unlike 
unstimulated mouse macrophages, which indicated that mobility alone was 
insufficient to promote ingestion. To date the biochemical reaction which 
accounts for the transition of CR1 from an inactive state to an active 
one remains unknown although recent evidence suggests that 
phosphorylation of the receptor may occur. Changelian and Fearon (1985) 
studied phosphorylation of CR1, CR2 and CR3 in phagocytic and 
nonphagocytic cells. Neutrophils, monocytes and lymphocytes were 
labelled with 32:PCU and incubated in buffer alone or in buffer containing 
PMA which is known to increase protein phosphorylation. After an 
appropriate time interval CR1 was immunoprecipitated from cell lysates 
and analysed by autoradiography. CR1 from unstimulated cells was not 
phosphorylated whatever the length of incubation time, PMA stimulation 
induced phosphorylation of CR1 in monocytes and neutrophils and CR2 in B 
lymphocytes. CR3 was not phosphorylated in any of the cells and neither 
was the Fc receptor. Phosphorylation seemed to correlate with 
acquisition of a phagocytic function in monocytes and neutrophils. CR1 
from unstimulated monocytes did not promote ingestion of EAIgMC3b nor 
did it become phosphorylated whereas upon stimulation with PMA CR1 was 
phosphorylated and ingestion occurred. Acquisition of a phagocytic 
function by neutrophils requires prior stimulation with chemotactic
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factors before activation of CR1 by PMA occurs, Treatment of neutrophils 
with FMLP and PMA resulted in phosphorylation of CR1 with the 
concomitant ability to ingest EAIgMC3b. These authors thus suggested 
that phosphorylation of CR1 may be the structural basis for the activated 
state of CR1.
In addition to PMA other proteins have been found which may represent 
physiological regulators of complement receptor function in vivo. 
Pommier et al (1983) found that soluble fibronectin (fn) could induce 
peripheral blood monocytes to ingest sheep EAIgMC3b and could also 
increase the phagocytosis of EAIgG. This activation was not as a result 
of denovo synthesis of CR1 as the response was initiated very quickly 
and could not be prevented by protein synthesis inhibitors. It could 
however be inhibited by the addition of colchicine a microtubule 
depolymeriser. Wright, Craigmyle and Silverstein (1983a) found that 
substrate-bound fn and substrate-bound serum amyloid P component caused 
activation of both CR1 and CR3 on cultured human monocytes. These 
monocytes bound to fn-coated surfaces by way of a' fn receptor, Ligation 
of this receptor on the basal surface of the membrane resulted in 
activation of complement receptors over the whole cell membrane. 
Collagen and fibrin can also bind to fn receptors, these are proteins 
which are usually present at sites of tissue injury and could be 
important in vivo for activation of complement receptors in areas of 
inflammation.
Neutrophils were not initially found to be activated by fn (Wright et al 
1983a). However when they were exposed to chemotactic factors such as 
FMLP, fn was found to activate phagocytosis of EAIgMC3b (Pommier et al
1984). This could be an important in vivo mechanism for effectively
limiting neutrophil phagocytosis to sites of inflammation where they have
accumulated as a result of chemotaxis. Both monocytes and neutrophils
bear a receptor for Clq through which they can attach to Clq-coated
immune complexes. This binding is inefficient and can be enhanced by 
preincubating the cells with fn, which leads to ingestion if C3b or iC3b 
are present on the complex. Fibronectin may act by enhancing the ability 
of Clq receptors to bind to Clq or alternatively fn may itself bind to 
Clq to promote a stronger interaction between immune complex and 
phagocyte. Whatever the explanation the presence of Clq, C3b or iC3b on 
immune complexes greatly enhances their phagocytosis by fn-stimulated 
monocytes. (Bohnsack et al 1985, Sorvillo, Gigli and Pearlstein 1986).
CR1 undoubtedly plays an important role in phagocytosis by its ability to 
promote strong binding between phagocytic cells and opsonised particles', 
however CR3 may be much more effective in triggering ingestion and 
mounting a respiratory burst than is CR1. Wright and Silverstein (1982) 
reported that PMA treated monocytes which were bound to surfaces coated 
with IgG and C3b were still able to bind and ingest EAIgMC3bi by way of 
CR3. The reverse was also true that monocytes bound to surfaces coated 
with iC3b and IgG could bind and ingest EAIgMC3b by way of CR1 however 
CR3 was ten times more effective than CR1 in ingestion of these
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complexes. Ross, Cain and Lachmann (1985) observed that rabbit E coated 
with C3b (RaEC3b) were ingested by monocytes and neutrophils. Addition 
of monoclonal anti-CR3 blocked the ingestion of these E complexes but did 
not affect the binding of the phagocytic cell to E. This implies that 
the CR1 mediated binding of RaEC3b to phagocytes does not induce 
ingestion, but that a synergism between CR1 and CR3 may exist where CR1 
promotes strong binding which allows weak binding to CR3 which in turn 
triggers ingestion.
1.29 Endocytosis by PMN
Phagocytosis of large particles and pinocytosis of soluble material and 
small particles are two processes collectively termed endocytosis. CR1 
of unstimulated neutrophils while being unable to initiate phagocytosis 
can pinocytose small particles and soluble complexes into clathrin-coated 
pits. Fearon, Kaneko and Thomson (1981) noted that PMN preincubated with 
F(ab ' ) 2 anti-CRl fragments at O'C and then subsequently treated with a 
fluorescent second antibody, tetramethylrhodamine isothiocyanate 
(TRITC)IgG F(ab’) 2  fragments demonstrated a patchy fluorescence while PMN 
treated in the same way at 37 *C showed very few fluorescent clusters and 
in some cases none at all. Thus at 37°C anti-CRl F(ab')2; fragments were 
not accessible to the fluorescein labelled second antibody as they had 
been internalised. Subsequent experiments revealed that more than 90% of 
the bivalent F(ab');2 anti-CRl which bound at 37*C became internalised, 
while monovalent anti-CRl Fab fragments were not internalised. Thus 
cross-linking of the receptors was required for internalisation to 
proceed, an indication that the trigger for endocytosis required the 
binding of the ligand to several CR1 simultaneously.
Incubation of PMN with cytochalasin B, an agent which disrupts 
microfilaments (MF) did not affect the uptake of F(ab' ) 2 anti-CRl 
implying that the structural mechanisms leading to this type of ingestion 
differed from that involved in phagocytosis a process which is inhibited 
by cytochalasin B (Allison, Davies and De Petris 1971). It was therefore 
proposed that internalisation was mediated by a structural protein termed 
clathrin, Many nonphagocytic cells have the ability to internalise 
membrane receptors and their ligands as a means of taking up nutritional 
and regulatory proteins from the extracellular fluid. This is achieved by 
the clustering of receptors in specific regions of the plasma membrane 
which overlie clathrin-coated pits. These invaginate into the cell to 
form coated vesicles which transport the receptor-ligand complex to 
lysosomes where the internal contents are degraded (Goldstein, Anderson 
and Brown 1979). Abrahamson and Fearon (1983) were able to visualise 
the intracellular distribution and fate of bound anti-CRl F( ab ' ) 2  
fragments on PMN and monocytes, using a fluorescent- or ferritin- 
conjugated second antibody. In both cell types upon warming to 37 *C for 
20 minutes bright fluorescence was observed in intracellular bodies. The 
ferritin label showed that at 37 *C the complexes were taken into 
clathrin-coated pits within five minutes and subsequently delivered to 
azurophil granules in PMN and lysosomes in monocytes. Hogg et al (1984)
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reported that the monoclonal anti-CRl antibody, Ell, was not endocytosed 
by PMN unless it was firstly cross-linked with F(ab')z: anti-mouse Ig. 
Changelian et al (1985) studied the uptake of the monoclonal anti-CRl 
monoclonal antibody, YZ-1, by neutrophils in response to PMA. High 
concentrations of PMA (over 16ng/ml) resulted in internalisation of the 
receptors. Internalisation occurred when monovalent antibody fragments 
were bound to CR1 indicating that PMA allows endocytosis to proceed even 
in the absence of a cross-linked ligand. O ’Shea et al (1985b) also found 
that a second phorbol ester, phorbol dibutyrate (PDBu) caused 
internalisation of anti-CRl Fab fragments by neutrophils which had been 
stimulated with FMLP and also by unstimulated neutrophils. Monocytes and 
macrophages spontaneously internalised Fab fragments, but this could be 
considerably enhanced by addition of PDBu or PMA. Endocytosis of soluble 
complexes and small particulate material which can be contained within 
the lOOnm clathrin-coated pits may provide an important additional 
clearing mechanism at sites of tissue injury.
1.30 Role of the Cytoskeleton in Endocytosis
In an attempt to understand the mechanisms whereby ligation of CR1 
causes endocytosis the distribution and lateral mobility of CR1 in the 
plane of the neutrophil and monocyte plasma membrane has been studied. 
Clustering of receptors is a prerequisite for the endocytosis of many 
ligands. Some receptors require first to bind to their ligand before 
accumulating in regions of the plasma membrane which overlie clathrin- 
coated pits, others reach these areas without any involvement of their 
ligand. In the former case ligation of receptors may result in an 
alteration in the interaction with the underlying cytoskeleton and in the 
latter case receptors may be actively moved or passively moved as a 
result of membrane flow. Petty et al (1980) reported that CR1 appeared 
to be present in discrete clusters on the membranes of PMN and 
monocytes. This clustered distribution was observed with both bivalent 
and monovalent FITC labelled anti-CRl Fab fragments which indicated that 
the clustering was not due to cross-linking by the antibody. No 
redistribution of fluorescence was seen after photobleaching indicating 
that CR1 was not free to move in the plane of the membrane, Hafeman et 
al (1982) subsequently showed that plating neutrophils onto glass slides, 
as had been the procedure in the previously described experiment, caused 
the redistribution into clusters. Plating onto slides coated with a lipid 
monolayer to which neutrophils do not adhere allowed CR1 to maintain 
their initial uniform distribution. Neutrophils which adhered to glass 
coverslips displayed an erratic fluorescence recovery when measured using 
the photobleaching technique indicating that the clustered receptors were 
not freely diffusing whereas those plated onto a lipid monolayer showed a 
recovery consistent with free mobility in the plane of the membrane. 
These findings may indicate that CR1 is not preclustered but is normally 
uniformly distributed throughout the membrane and only upon binding to a 
particular surface or to its ligand does it became redistributed into 
clusters. This redistribution may involve an association with the 
cytoskeleton an intricate network of microfilaraents (MF), lO^m filaments
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and microtubules (MT) which lies just underneath the cell membrane. It 
is thought that MF may attach to specific integral membrane proteins and 
cause them to be actively moved in the plane of the membrane. This kind 
of movement is energy dependent and sensitive to calcium concentration.
In an attempt to follow the involvement of the cytoskeleton in the 
redistribution of CR1 and Fc receptors on neutrophils Jack and Fearon 
(1984) employed two drugs which interfere with MF function; 
chloropromazine which alters calcium concentration and cytochalasin D 
which is one of a class of compounds isolated from the culture fluid. of 
certain moulds, which can block the polymerization of MF. Neutrophils 
labelled with F(ab' ) 2 anti-CRl followed by a TRITC conjugated second 
layer antibody showed a patchy fluorescence after incubation for five 
minutes at 30*C. Capping of unoccupied CR1 sites was also observed and 
all caps were associated with an intense staining of myosin underlying 
the area of the cap. Previously Jack and Fearon (1983) had reported that 
neutrophils labelled with 13SI-F(ab')s anti-CRl and then solubilised had 
83% of this ligand associated with the insoluble cytoskeleton, while only 
5% of a monovalent ligand remained in association with the cytoskeleton 
thus indicating that cross-linking of CR1 resulted in an association with 
the cytoskeleton. Chloropromazine and cytochalasin D were both found to 
inhibit the redistribution of cross-linked CR1 into patches providing 
further support for the involvement of MF in the redistribution of CR1. 
An additional finding was that capping of CR1 was accompanied by the co­
capping of Fc receptors while distribution of other receptors was not 
altered. The reverse was also true that capping of Fc receptors resulted 
in co-capping of CR1. Both types of receptors become located in the same 
areas of intense myosin staining. This has led to the hypothesis that 
both types of receptor interact with the cytoskeleton such that 
redistribution of one causes the same altered distribution of the other. 
This might explain why phagocytosis is synergistically enhanced following 
the opsonisation of an IgG coated particle with C3b (Ehlenberger and 
Nussenzweig 1977).
Internalisation of monovalent anti-CRl Fab fragments by neutrophils and 
monocytes in response to PMA and PDBu is also considered to arise as a
result of association of CR1 with the cytoskeleton. O'Shea et al (1985b)
showed that treatment of these cells with cytochalasin B prior to 
stimulation with phorbol esters abrogated internalisation of Fab anti-CRl 
fragments. This group also found that PDBu induced a time dependent 
association of CR1 with the cytoskeleton and they suggested that phorbol 
ester mediated internalisation is as a result of association of CR1 with 
the cytoskeleton.
The exact role of MT in endocytosis is not clear although they are 
thought to be responsible for the movement of other surface proteins away 
from the area of plasma membrane where specific receptors are being
internalised. Colchicine, an alkaloid derived from the autumn crdcus 
ColchicuTn ant.nmivri.te, is a potent inhibitor of many cell functions which
involve MT. As colchicine prevents the movement of proteins which are
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not involved in the internalisation process, it is probable that MT are 
involved in the localisation of membrane proteins. In support of this 
theory, capping of Concanavalin A receptors is induced by colchicine 
suggesting that these receptors are held in place by MT and only upon 
depolymerization of MT do the receptors become free to move in the plane 
of the membrane.
1.31 CR1 on B Lymphocytes
Lay and Nussenzweig (1968) were the first to describe a complement 
receptor on blood lymphocytes after they observed that lymphocytes would 
not form rosettes with EAIgM unless the EAIgM had first been incubated 
with serum. The receptor was later shown to be specific for both C3b 
and C4b (Ross and Polley 1975). It is now known that the majority of all 
B lymphocytes from the spleen and peripheral blood express CR1 (Tedder 
et al 1983) while 75%-85% of peripheral blood B lymphocytes also express 
CR2 (Ross et al 1978). B lymphocytes are not thought to express CR3 
(Ault and Springer 1981).
CR1 levels on B lymphocytes have been quantified by the use of polyclonal 
and monoclonal anti-CRl antibodies and by a C3b dimer. The numbers 
reported by these various means are 20,000 (Fearon 1980), 360,000 (Iida 
et al 1982) and 21,000 (Arnaout et al 1981). Fearon and Collins (1983) 
found that unlike PMN these numbers do not spontaneously increase upon 
warming to 3 7 'C nor upon stimulation with chemotactic factors, They 
therefore suggested that B lymphocytes express all their CR1 on the 
plasma membrane and do not have any intracellular pools of CR1 available 
for translocation. However Sim and Sim (1983) found that the rate of 
cleavage of C3b to iC3b in the presence of I and B lymphocytes (a CR1 
source) was greatly increased if the cells were rendered permeable by the 
addition of detergent indicating that B lymphocytes may have 
intracellular pools of CR1.
The ontogeny of CR1 on B lymphocytes was initially studied by Tedder et 
al (1983), Using the technique of indirect immunofluorescence with F(ab' ) 2  
anti-CRl, it was shown that B lymphocytes gradually acquire the ability 
to express CR1 as they become more mature. Fifteen percent of large pre-B 
cells, 35-48% of small pre-B cells, 60-80% of immature B cells and 99% of 
mature B cells were found to express CR1. The receptor was lost when B 
cells differentiated into mature plasma cells.
The function of CR1 on B cells is still largely speculative. Iida and 
Nussenzweig (1983) showed that CR1 on B lymphocytes could inhibit the 
formation of C3 and C5 convertases on sheep E. This inhibition of 
convertase formation could be reversed by approximately 60% by the 
addition of fluid-phase C3b or monoclonal anti-CRl. In the presence of I, 
lymphocyte CR1 could also mediate the release of a C3c fragment from 
EAC14oxy23b. Thus CR1 on lymphocytes, possibly in combination with 
membrane cofactor protein, may act to protect cells from damaging effects
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of complement activation caused by immune complexes trapped in areas of 
B cell activation such as the lymphoid tissue.
B lymphocyte CR1 is also thought to play a role in the triggering of an
antigen specific response by binding to immune complexes containing C3 
and activating B cell proliferation. In vitro studies performed by Daha, 
Bloem and Ballieux (1984) have shown that high doses of F(ab' > 2 anti-CRl 
can enhance in a dose-dependent fashion the production of IgG by B
lymphocytes, when these cells in the presence of T cells and monocytes 
have been stimulated with sub-mitogenic doses of pokeweed mitogen (PVM). 
This suggests that if ligation of more than one CR1 on B lymphocytes 
occurs it can lead to the modulation of antibody production, although 
ligation of CR1 on T cells and monocytes, the other cell types necessary 
for a response to PVM, cannot be ruled out as a prerequisite for the B 
lymphocyte response. Experiments performed by Frade et al (1985b) have 
indicated that CR2 may also be involved in the proliferation of B
lymphocytes. Thus CR1 and CR2 may cooperate in the activation of B cells,
1.32 C R 1 „ on..P.QdQcytes
The existence of a complement receptor on the human renal glomerulus was 
first suggested by Gelfand, Frank and Green (1975) after the observation 
that sheep E or bacteria coated with C3b could adhere to the glomeruli 
in frozen sections of human kidney. This finding was supported by the 
work of Carlo, Nagle and Shin (1978) who observed that C3b coated 
fluorescein labelled bacteria could bind to human renal tissue. The 
receptor was thought to be CR1 as treatment of C3b with H and I resulted 
in the generation of iC3b which did not bind to the kidney. A year later 
sheep E coated with . iC3b were shown to bind to the glomeruli and it was 
thus concluded that perhaps both CR1 and CR3 were present in this tissue 
(Carlo et al 1979). Since that time iC3b has been shown to be a ligand 
for CR1 and monoclonal antibodies against CR2 and CR3 have not been 
found to bind to kidney sections (Kasatchkine and Fischer 1984). In 
addition sheep E coated with C3dg and C3d do not adhere to kidney 
sections indicating that only CR1 is present in the glomerulus (Fischer 
et al 1986).
CR1 is located exclusively in the podocytes of the glomerulus 
(Kazatchkine et al 1982; Emancipator et al 1983), and Fischer et al 
(1986) have estimated that there are approximately 200,000 CR1 molecules 
per podocyte. CR1 is distributed homogeneously on the plasma membrane of 
these cells and as CR1 is seen in the &olgi apparatus it is probable that 
podocytes synthesise the receptor. There are two main proposed functions 
for CR1 on kidney podocytes. The first is a protective function in that 
it may behave similarly to CR1 on other cell types in being able to decay 
dissociate C3 and C5 convertases and being able to act as a cofactor for 
the I mediated cleavage of C3b (Iida and Nussenzweig 1983; Fischer et al 
1986). In‘ this way CR1 on kidney podocytes may help prevent complement 
activation on the basement membrane of the glomerulus. Secondly, CR1 may 
be able to directly mediate adsorptive endocytosis of soluble complexes
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which bear C3b. These complexes may filter through the basement membrane 
if it has been altered in some manner by a disease process (Fischer, 
Appay and Kazatchkine 1984).
Altered patterns of staining on podocytes are seen in patients with 
proliferative SLE nephritis (Kazatchkine et al 1982). These patients have 
very low or totally negative staining with anti-CRl whereas patients with 
non proliferative nephritis have normal staining. SLE is a disease which 
is associated with the deposition of antigen/antibody complexes in the 
glomeruli therefore low numbers of CR1 on the kidney podocytes of these 
patients with proliferative nephritis may affect the efficiency of immune 
complex processing.
1.33(a) CR2., St.mot.ure
Barel, Charriaut and Frade (1981) isolated a CR1 like molecule from the 
membranes of Raji cells. This protein had a molecular weight of 140,00 
daltons and it bound to both G3b-Sepharose and lentil lectin-Sepharose. 
For this reason the protein termed "gp 140" was assumed to be a receptor 
similar to CR1. However in 1983 and 1984 two groups presented evidence 
to suggest that gp 140 was in fact the C3d receptor CR2. Iida, Nadler 
and Nussenzweig (1983) investigated the possibility that a surface marker 
called, "B2" purified from human B lymphocytes, and CR2 were identical. 
Gp 140 was isolated from Raji cells and tonsil lymphocytes. This protein 
had the same molecular weight as the B2 marker and it was found to have 
an affinity for monoclonal antibodies to B2 and also to C3 fragments. 
Anti-B2 partially inhibited rosette formation between tonsil lymphocytes 
and EAC3d, Total inhibition was only observed if the lymphocytes were 
first incubated with anti-mouse IgM, thus indicating that inhibition of 
rosette formation was as a result of cross-linking of B2 receptors and 
not a direct competition between B2 and C3d. These experiments suggested 
that the 140,000 dalton B2 antigen was CR2.
A second lymphocyte surface marker postulated to be CR2 was a protein of 
molecular weight 145,000 daltons recognised by the monoclonal antibody 
HB5 (Weis, Tedder and Fearon 1984). HB5 induced partial inhibition of 
rosetting between EC3d and Raji cells. Again total inhibition was only 
achieved by first cross-linking the HB5 receptors with mouse IgG. When 
detergent lysates of Raji cells were passed over a protein A column to 
which HB5 was bound, a 145,000 dalton protein was extracted from the 
lysates and conferred on the protein A particles the ability to bind 
specifically to EC3d or EC3bi. This directly demonstrated the CR2 
function of HB5. Neither monoclonal antibodies, anti-B2 or HB5 mask the 
ligand binding site of CR2 as they da not prevent the binding of C3d to 
CR2 without prior cross-linking of CR2 by a second antibody. For this 
reason it was uncertain if they did actually represent CR2. A polyclonal 
antisera raised against gp 140 did prevent rosetting of EC3, EC3b and 
EC3d with Raji cells without a second antibody being necessary.
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A series of experiments by Frade et al (1985a) confirmed the identity of 
gp 140 as the C3d/C3dg CR2 and also showed that CR2 was recognised by 
anti-B2, HB5 and 0KB7. The epitopes of CR2 recognised by these three 
antibodies are distinct as binding of one antibody does not prevent the 
uptake of the others.
Previous to these studies a 72,000 dalton glycoprotein had been isolated 
from the medium of B lymphoblastoid cells (Lambris, Dobson and Ross
1981), Antibodies prepared against this protein could inhibit lymphocyte
rosette formation between EAC3d but not EAC3b. Gp 72 was also shown to
bind to EAC3d but not EAC3bi and it was this concluded that B type 
lymphoblastoid cells synthesis and secrete a C3d binding protein into 
their surrounding culture medium and that this protein resembles CR2. 
Recently it has been reported that gp 72 can bind to soluble 135I-C3b 
and induce a cleavage in the C3b molecule (Conseiller et al 1985). It was 
proposed that gp 72 was a serine protease which may function to augment 
cleavage of C3b as well as perhaps representing the fragment of gp 140 
which contains the C3d binding site.
1.33(b) Binding Site Properties of CR2
Binding sites for CR2 were first shown to be present in both C3d and 
iC3b (Ross et al 1973b; Ross and Lambris 1982). Ross et al (1983) showed 
by the binding of fluorescent microspheres coated with C3dg to monocytes 
and Raji cells that CR2 also had a binding site for C3dg. It was 
controversial however if C3b bound to CR2 or not. Frade et al (1985a) 
showed that Raji cells which do not possess CR1 (Lambris, Dobson and 
Ross 1980; Iida et al 1982; Tedder et al 1983) had the ability to bind 
C3b and that this activity was as a result of binding to CR2. All Raji 
cell rosettes between EAC3b, EAC3bi, EAC3dg and EAC3d were completely 
inhibited by anti-gp 140. Rosettes formed between Raji cells and EAC3b 
required approximately 100-fold more fixed C3b molecules per E than fixed 
EAC3bi, C3dg or C3d. This indicated that CR2 probably has a low affinity
for the C3d region of uncleaved C3b.
B lymphocytes bear a membrane receptor specific for the Epstein Barr 
virus (EBV) (Jondal and Klein 1973), EBV is a ubiquitous virus which 
infects essentially all the normal adult population. In vivo it is 
associated with malignancy of many epithelial cells and in vitro it 
induces B cell proliferation with the concomitant ability to secrete 
.immunoglobulins. Vhen the EBV receptor was first discovered its 
biochemical nature was unknown but since that time evidence is 
accumulating to suggest that it is identical with CR2. Yefenof et al 
(1976) performed studies with two colour staining in order to visualise 
the relationship between the two receptors on human B cells. They found 
that two colour fluorescence staining of EBV receptors and CR2 showed 
complete overlapping of red and green fluorescence. In addition capping 
of EBV receptors induced co-capping of CR2 suggesting a close association 
between EBV receptor and CR2 on B cells. Hutt-Fletcher et al (1983) 
isolated fluid-phase CR2 which bound to C3d .fragments on E and which
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could inhibit rosettes between EC3d and B cells, It could not however 
inhibit the binding of B cells to the EBV. Isolated EBV receptor was 
found to inhibit EBV binding to B cells, but did not inhibit binding of 
EC3d to B cells. It was therefore concluded that CR2 was probably not 
the binding site for EBV. This group had however only isolated gp 72
which is now known not to be the. intact CR2. Fingeroth et al (1984)
found that the rank order of binding of fluorescent labelled EBV to four 
lymphoblastoid cell lines was identical to the order of binding of HB5 
and anti-B2, also binding to EBV to a B lymphoid cell line could be
inhibited by pretreating the cells with HB5 and a second antibody to
cross-link the receptors. Finally when CR2 was linked to Staphylcoccus 
aureus (S. aureus) by means of HB5, it resulted in the ability of the 
bacteria to bind 1 1-labelled EBV. Nemerow, Siaw and Cooper (1985)
isolated gp 145 from Raji cells. A dot-blot immunoassay demonstrated the 
ability of gp 145 to bind to either EBV or C3dg indicating that purified 
gp 145 had a binding site for both C3d and EBV. Mold, Cooper and
Nemerow (1985) incorporated purified CR2 into phospholipid liposomes
which were then found to bind to EC3d. This binding was inhibited by 
0KB7. CR2 liposomes bound to a cell line which expressed the EBV
membrane antigen but could not bind if these cells were treated with a 
virus inhibitor. Thus to date the existing experimental data suggests 
that CR2 and the EBV receptor are identical.
1.33(c) Function of CR2
CR2 is expressed exclusively on B cells (Ross 1980) and as such it 
probably plays some role in the regulation of B cell function. Frade et 
al (1985b) have provided some evidence that CR2 is involved in the B cell 
proliferative response to T cell products. ACA-54 a B cell growth factor 
(BCGF) produced from activated T cells caused proliferation of B cells. 
This effect was potentiated by the addition of anti-p-antibody which is 
another stimulator. F(ab ' ) 2 fragments of anti-gp 140 were prepared and
these enhanced in a dose dependent manner the proliferation of B cells in
the presence of ACA-54, but not in its absence. The mechanism whereby 
CR2 exerts this effect is unknown.
Changelian and Fearon (1985) have shown that PMA induces phosphorylation 
of CR2 in B cells, while no phosphorylation of CR1 occurs. This may
indicate that CR2 rather than CR1 may be more important in regulation of 
B cell function.
1.34(a) CR3 Structure
The structure of CR3 like CR2 has been elucidated with the aid of 
monoclonal antibodies. The rat anti-mouse monoclonal antibody anti-Macl 
which defines the antigen M170 or Macl on the surface of mouse
macrophages has been of particular importance in this respect (Ho and 
Springer 1982). M170 is expressed on mouse thioglycolate elicited
macrophages and on other mouse macrophages, blood monocytes, 
granulocytes and NK cells but is absent from lymphocytes. Anti-Macl
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cross reacts with the same cell population in humans (Ault and Springer
1981) and it is probably identical to the OKMI antigen (Breard et al 
1980) and the Mol antigen (Todd et al 1982).
The function of this antigen when it was first discovered was unknown 
although it had been structurally characterised and found to contain two 
noncovalently associated a and $ subunits with molecular weights of
170,000 daltons and 95,000 daltons respectively (Kurzinger and Springer
1982). Beller et al (1982) presented evidence that this antigen was 
intimately associated with or actually represented CR3. They found that 
mouse macrophages were inhibited from forming rosettes with EAC3bi by 
prior incubation of the macrophages with anti-Macl. In confirmation of 
this hypothesis Wright et al (1983b) showed that EAC3bi could bind to S. 
aureus particles coated with OKMI antigen in a similar fashion to their 
ability to bind to phagocytic cells bearing CR3.
Interest in the Macl antigen has been further aroused by the finding that 
it is structurally related to an antigen on cytotoxic T cells. These T 
cells can recognise the presence of a foreign antigen on the surface of a 
particular target cell when it is in association with the correct major 
histocompatability (MHC) products (Springer et al 1982). Monoclonal 
antibodies have been used as probes to determine the surface component 
on the lymphocyte membrane which is responsible for recognising and 
binding to target cells. A monoclonal antibody against the lymphocyte 
function associated antigen (LFA-1) was consistently found to inhibit 
killing by cytotoxic T lymphocytes. Thus LFA-1 was postulated to 
participate in the magnesium-dependent antigen recognition and adhesion 
step of cytotoxic T cell-mediated killing. LFA-1 has also been shown to 
be present on B cells, granulocytes and monocytes and to be involved in 
natural killing and T helper cell responses.
LFA-1 contains an a chain of molecular weight 180,000 daltons and a £ 
chain of molecular weight 95,000 daltons (Kurzinger and Springer 1982). 
The J3 chains of both Macl and LFA-1 are highly homologous although the a 
chains are found by tyrosyl tryptic peptide mapping to be quite 
different, Monoclonal antibodies against Macl and LFA-1 do not cross 
react as revealed by immunoprecipitation experiments. Anti-Macl 
immunoprecipitates Macl from macrophages whereas LFA-1 can not. Anti- 
LFA-1 immunoprecipitates LFA-1 from con A blasts but anti-Macl does not. 
In contrast to this polyclonal antisera prepared against purified Macl 
can immunoprecipitate both Macl and LFA-1. This suggests that the cross 
reaction is between the U subunits and not the a subunits,
Ho and Springer (1983) studied the biosynthesis and assembly of the a 
and J3 subunits of Macl. Their results are consistent with the hypothesis 
that the two subunits of Macl are synthesised separately from different 
messenger RNA's and then they are associated noncovalently to form a,J3 
complexes.
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A third protein with structural similarities to Macl and LFA-1 was 
described by Sanchez-Madrid et al (1983). Monoclonal antibodies against 
the 95,000 dalton J3 subunit immunoprecipitated three a chain structures 
from 1231-labelled granulocytes. These were the a subunit of LFA-1 
(180,000 daltons), the a chain of Macl, (170,00 daltons) and an additional 
subunit of 150,000 daltons. This new oc subunit was found to be 
covalently associated with a J3 subunit of 95,000 daltons in an oh£i 
structure similar to Macl and LFA-1. This new glycoprotein termed 
P150/95 was a distinct protein and not a degradation product or an
immature form of Macl or LFA-1. Thus Macl, LFA-1 and P150/95 appear to 
be a family of related polypeptides with a common J3 subunit and a 
distinct a subunit.
Evidence that these three glycoproteins are related comes from the
observation that patients with recurrent bacterial infections are 
deficient in all three of these proteins (Springer et al 1984). It was 
reported by Todd (1982) that a deficiency in Mol antigen on the surface 
of human granulocytes was associated with defects in the C3 and IgG 
dependent phagocytosis of these cells. Both the a and £ subunits of the 
Mol antigen appeared to be deficient in these patients. In agreement
with these observations. Dana et al (1984) found that patients with Mol 
deficiencies on both granulocytes and monocytes were defective in IgG and 
C3 dependent phagocytosis. Todd et al (1984) studied the subcellular 
location of the Mol antigen and found it to be primarily located in the 
specific granules, with only a small proportion present on the membrane. 
Stimulation of the granulocytes with chemotactic agents led to
translocation of Mol from the specific granules to the plasma membrane
resulting in a five- to ten-fold increase in surface expression. This
increase was associated with an increase in surface adhesion of the 
neutrophils. Neutrophils from two patients who did not express the Mol 
antigen were defective in both adherence and chemotaxis. Arnaout et al
(1984) showed that stimulation of the patients' granulocytes led to an 
increase in surface expression of Mol but this was still considerably 
less than normal. From these experiments it was concluded that Mol 
deficiency may be partly responsible for the functional abnormalities 
which lead to recurrent bacterial infection in these patients. Springer
et al (1984) found that the entire family, of glycoproteins, Macl, LFA-1
and P150/95 were deficient in this group of patients, while CR1 was 
present in normal amounts. Recently monoclonal antibodies have been 
developed against P150/95 (Lanier et al 1985; Springer, Miller and 
Anderson 1986). The monoclonal antibody anti-leu M5 reacts with a 
specific epitope in the 150,00 dalton a subunit. Leu M5 is found to be 
expressed on monocytes and granulocytes but not blood lymphocytes. 
Patients who are defective in Mol and LFA-1 expression also fail to react 
with anti-leu M5. Springer et al (1986) have suggested that the primary 
defect in these patients is the failure to synthesise the common j3 
subunits. It was proposed that while the a chains of the three proteins 
were synthesised normally they require to become associated with the $ 
subunit before being transported to the cell surface and as the £ subunit 
was not synthesised transportation did not occur.
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1.34(b) Binding Site Properties of CR3
CR1, CR2 and CR3 all have binding sites for iC3b. The binding of iC3b to 
CR1 is weak and requires large amounts of fixed iC3b (Ross et al 1983), 
CR3 does not bind to any other C3 fragments apart from iC3b. Because of 
the possibility of iC3b binding to all three receptors, when studying the 
binding of CR3 it is necessary to ensure that CR1 and CR2 sites on the 
cell surface are preblacked with saturating amounts of anti-CRl and anti- 
CR2 antisera. The binding of CR3 to iC3b resembles the binding of bovine 
serum conglutinin (K) to iC3b in that they both require the presence of 
carbohydrates and calcium ions. The sugar, N-acetyl-D-glucosamine (NADG) 
inhibits the binding of both K and CR3 to iC3b. Both K and CR3 binding 
is also inhibited by EDTA (Ross et al 1983). It was originally thought 
that CR3 might be the human homologue of bovine K but the observations 
of Davis and Lachmann (1983) which showed distinct structural differences 
between the two imply that this is not the case. Recently Ross et al
(1985) showed that K like CR3 can bind directly to unopsonized yeast or 
zymosan particles. It was found that neutrophils treated with a 
monoclonal antibody against CR3, (Leu 15) could bind directly to yeast 
particles in the absence of fixed iC3b and trigger their ingestion. 
However these same neutrophils could not bind to EC3bi. When treated 
with the monoclonal antibody, OKMI, the reverse was true, binding to 
EC3bi was normal and no ingestion followed but binding to yeast 
particles was inhibited. The results were explained by suggesting that 
there are two binding sites in the a chain of CR3, one which can be
blocked by Leu 15 and which is responsible for binding to fixed iC3b and 
one which can bind directly to yeast or zymosan without the presence of 
fixed iC3b and which triggers ingestion. This binding site can be
blocked by OKMI.
This conclusion has been supported by Arnaout et al (1985) who also 
using monoclonal antibodies has shown that there are two functional 
domains in CR3. One of these domains is involved in binding iC3b and 
one is involved in inhibiting leukoaggregation, chemotaxis, spreading and 
zymosan induced 0Z~ production. Ross et al (1985) have reported that the 
sugar to which both K and CR3 bind is J3-glucan. Neutrophil binding to 
yeast particles could be inhibited by addition of soluble 0-glucan but 
EC3bi rosettes were not affected by this J3-glucan. This again implies the
presence of two binding sites in CR3, one for yeast 0-glucan and one for
iC3b which is not inhibited by J3-glucan.
1.34(c) Function of CR3
As has already been mentioned CR3 appears to be more effective than CR1 
in promoting ingestion of iC3b opsonised particles (Wright and 
Silverstein 1982). CR3 and CR1 may also act in synergy to promote 
phagocytosis of C3b opsonised particles (Ross et al 1985) with CR3 being 
responsible for triggering ingestion. Ross et al (1985) have indicated 
that CR3 may be able to bind directly to unopsonised zymosan particles 
to promote their phagocytosis. Phagocytosis of unopsonised zymosan
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results in the generation of a respiratory burst a feature which has not 
been found to be associated with phagocytosis of C3b coated particles 
(Newman and Johnston 1979). Even after stimulation of monocytes with 
PMA no respiratory burst was observed (Wright and Silverstein 1982). It 
therefore appears that CR3 may be more effective than CR1 in 
phagocytosis. This may be of particular importance in phagocytosis of 
particles opsonised via the alternative pathway. Particles which activate 
the alternative pathway have surfaces which favour the formation of a C3 
convertase. This might be due to the lower affinity of regulatory 
proteins such as CR1 for fixed C3b on these surfaces. If this is the 
case then ingestion of opsonised particles which contain both iC3b and 
C3b is more likely to be mediated through the binding of iC3b to CR3.
1.35(a) Structure of CR4 and Binding Characteristics
Suggestion that a fourth complement receptor might exist arose from the 
observation that monocytes and neutrophils which were considered to lack 
CR2 bound to fluorescent microspheres coated with C3dg (Ross et al 1983). 
That the rosettes were due to contamination of the C3dg with iC3b or C3b 
was ruled out by the addition of EDTA which blocks CR3 activity and 
anti-CRl which blocks CR1 activity. These observations suggested that 
perhaps phagocytic cells did possess a receptor similar to CR2, but the 
exact nature of this receptor was unknown. Frade et al (1985a) noted 
that neutrophils could form rosettes with E bearing over 45,000 molecules 
of C3dg. This rosetting was not due to the presence of CR2 as 
determined by the lack of uptake of 1231-labelled polyclonal or 
monoclonal anti-CR2 and by the inability of large excesses of anti-CR2 to 
inhibit C3dg rosettes. This receptor on phagocytic cells has tentatively 
been described as CR4. Its structure remains unknown although a report 
by Wright, Licht and Silverstein (1984) suggests that it could be the 
pl50/95 antigen recognised by the monoclonal antibody IB4. IB4 
immunoprecipitates CR3 and LFA-1 and an a chain of 153,000 daltons from 
cultured monocytes. Once stimulated with PMA cultured monocytes formed 
rosettes with EC3d. These stimulated monocytes were allowed to spread on 
surfaces coated with OKMIO, which recognises the a chain of CR3, or on 
surfaces coated with TA-1, which recognises the ot chain of LFA-1 or on 
surfaces coated with IB4. The nonadherent side of the monocytes which 
were spread on these various surfaces were then tested for their ability 
to rosette with EC3d. It was found that only spreading on IB4 abolished 
rosetting activity. They concluded from this that the CR2 like receptor 
was being bound by IB4 at the substrate attached portion leaving the 
apical portion of the membrane void of these receptors. Inada et al 
(1983b) also showed that unstimulated monocytes did not bind EC3d but 
required first to be cultured in the presence of foetal calf serum (FCS) 
whereupon they showed a progressive increase in ability to rosette with 
EC3d. Frade et al (1985a) found that rosettes did not form with E 
bearing over 100,000 molecules of C3d. They did however rosette with E 
bearing 45,000 molecules of C3dg. Vik and Fearon (1985) studied the 
binding of neutrophils to soluble rather than substrate-bound C3. In 
this way they were able to analyse the reversibility, saturability and
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ligand specificity of the reaction. They found that uptake of 1Z5 I- 
labelled C3dg was saturable and specific with approximately 14,000 C3dg 
binding sites per' cell at saturation. This number increased to 21,000 
sites per cell when labelled dimeric C3dg was used. Uptake of labelled 
C3dg was competitively inhibited equally well with C3dg, C3d and iC3b and 
20-fold less well with C3b. The ability of CR4 to bind to iC3b has also 
been suggested by the work of Frade et al (1985a) who showed that E 
bearing over 45,000 molecules were only partially inhibited from binding 
to neutrophils by the addition of anti-CRl and anti-CR3.
The function of CR4 is unknown. It may have a role in the binding of 
soluble complexes released from E bearing C3dg or iC3b. It is uncertain 
at the moment if CR4 is able to induce particle ingestion (Ross and Medof
Vhen this study was begun in 1982 it was known that patients with SLE
had reduced numbers of CR1 sites on their E but it was not known if this
abnormality was acquired or inherited. Family studies conducted that year 
(Valport et al 1982) found that low CR1 numbers on E tended to cluster
in families. This suggested that CR1 numbers on E were inherited but this
hypothesis remained to be proved. Moreover, although it was known that 
reduced CR1 numbers on E was a general feature of the disease it was not 
known if this was also true of other cell types.
This study sought to determine the possible mechanism leading to the 
reduced number of CR1 sites on the E of patients with SLE. In addition 
the CR1 numbers on the neutrophils of SLE patients were quantified in an 
attempt to determine if reduced CR1 numbers in SLE patients were also 
evident on this cell type. The aims of this study were therefore (i) to 
purify CR1 and prepare an antibody to it, (ii) to compare the expression 
of E CR1 on identical and nonidentical twins in order to establish the 
relative roles of genetic and environmental factors in the regulation of E 
CR1 numbers in a normal population, (iii) to investigate the role of 
plasma and tissue enzymes and antigen/antibody complexes in the 
reduction of E CR1, (iv) to study CR1 on neutrophils from SLE patients to 
determine if this cell type also had reduced numbers of CR1, and finally, 
(v) to study the biosynthetic rates of CR'l in monocytes and lymphocytes 
from normal individuals and from patients with -SLE.
1.35 (b)
1985).
1.36
CHAPTER TWO
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2.1 Introduction
The isolation of CR1 and the production of a polyclonal antiserum was a 
prerequisite for this project. Using the method described by Fearon 
(1979) a small quantity of CR1 had previously been isolated by Dr W S 
Kilpatrick. This purified CR1 was shown to be homogeneous by analysis on 
5% SDS-PAGE gels which were run under reducing and nonreducing 
conditions. These revealed a single band of molecular weight 200,000 
daltons when stained with 0.1% PAGE blue G-90. Antiserum raised to this 
preparation was shown to be specific by its ability to give a single line 
of identity with a crude CR1 preparation using double immunodiffusion in 
agarose gel and also by its ability to agglutinate human E, but not human 
E which had been trypsinised to remove CR1. As supplies of this original 
material were limited it became necessary to prepare a new batch.
Three attempts were made to purify CR1 from human membranes, only the 
last of which resulted in a homogeneous preparation of the protein. Each 
of the three attempts will be described and the modifications to the 
method which resulted from the experience gained over the course of the 
procedure will be discussed.
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Materials and Methods
2.2 Chemicals and Reagents
Chemicals and other reagents were obtained from the following companies:
Aldrich Chemical Company. Gillingham. Dorset
Benzamidine
Ethanolamine
Amersham International Buckinghamshire
14C Methylated Molecular Weight Markers
British Drug Houses (BDH) Chemicals Ltd. Poole. Dorset
All reagents were of Anlar quality
Acetic Acid 
Agarose 
Barbitone 
Calcium Chloride 
Copper Sulphate 
D-Glucose
Dimethylsulphoxide (DMSO)
Dipotassium Hydrogen Phosphate 
Disodium Hydrogen Phosphate 
Ethylenediaminetetraacetic Acid (EDTA)
Gelatin
Glycine
Hydrogen Chloride 
Magnesium Chloride 
Methanol 
Monidet (MP-40)
Potassium Dihydrogen Phosphate
Potassium Iodide
Sodium Azide
Sodium Barbitone
Sodium Carbonate
Sodium Chloride
Sodium Dihydrogen Phosphate
Sodium Hydroxide
Sodium Potassium Tartarate
Trichloroacetic Acid
Tris(hydroxylmethyl)methylamine (Tris)
Sigma Chemical Company,, Fancy Rd... PQQlax.-DQr.sst
Acrylamide
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Ammonium Persulphate 
Alpha-Methylmannoside 
IT '-Methylene Bisacrylamide 
Bovine Serum Albumin (BSA)
Chloramine T 
Coomasie Blue
Cyanogen Activated Sepharose 4B 
Dowex-1 (mesh 100-200)
Folin and Ciocalteu's Phenol Reagent
Glycerol
Lentil Lectin
2' Mercaptoethanol
High Molecular Weight (HMW) Markers 
If If N.'N'-Tetramethylenediamine (TEMED) 
Phenylmethanesulphonyl Fluoride (PMSF)
Sodium Dodecylsulphate (SDS) 
Polyoxyethylenesorbitan monolaurate (Tween 20) 
Tyrosine 
Zymosan
Flow Laboratories, Irvine. Ayrshire 
Sheep E in Alsever's solution
Difco Laboratories. PQ Box 14B, Central Ave. Moisey. Surrey
Freund's Incomplete Adjuvant
Linbro. Flow LaboratoriesIrvine,_Ayrshire
Microtitre Plates
Luckman Ltd. Victoria Gds, Burgess. Hill, Sussex 
LP3 Tubes
Scientific Instrument Centre Ltd, Unit 34D, Parham Dr. Eastleigh»
Hampshire
Yisking Tubing
Pharmacia House. Midsummer Boulevard. Milton Keynes 
Cellophane Membrane
Amicon Corporation, Lexington. Mass 02173, USA 
Am icon PI 10 Membrane
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Amicon PM 30 Membrane
Bio-Rad. Laboratories Ltd. Caxton Way. Watford, Hertfordshire 
Biogel A5-M
Biorex 70 (mesh 200-400)
Silver stain kit
Millipor-S (UKI. Ltdi_Peter.borough RoadxJiarrow,..Middlesex 
Pellicon Cassette,
Blood Transfusion Service. Law Hospital. Carluke 
Units of fresh and expired packed red cells,
Isotope.Dispensary..,.- Western Infirmary, Glasgow 
12BI carrier free
2.3 Optical Density (QD) Readings
OD readings were measured on a Shimadzu spectrophotometer, Model Mo 
UV120-02.
2.4 Conductivity Measurements
Conductivity was measured at O'C on a conductivity meter, Model CD M3 
(Radiometer Copenhagen).
2.5 pH,. Readings
pH was measured on a pye model 292 pH meter (Pye Unicam).
2.6 General Methods
2.6(a) Preparation of Normal Rabbit Serum ( M S I
Rabbit blood was allowed to clot at 37 X  for 30 min and then placed on 
ice for 30 min to allow the clot to retract. After centrifugation at 
2000g for 5 min at 4 X  the clear serum was separated from the clotted 
red cells. The serum was heat inactivated for 30 min at 5 6 X  and stored 
at -20X  until required,
2.6(b) Dialysis.
Visking tubing was boiled 3 times in EDTA (1 mmol l"1) before being 
rinsed in deionised water. An appropriate length of tubing was cut and 
tied at one end, the open end was filled with the sample to be dialysed
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and then tied firmly leaving no air spaces. The dialysis sac was then 
placed into the appropriate buffer.
2.6(c) Measurement of Protein Concentration by Folin Assay (Lowry et al 
1951)
Buffers ..and Solutions 
PBS. moL-lZll
8g of sodium chloride, 1.21g of dipotassium hydrogen orthophosphate and 
0.34g of potassium dihydrogen orthophosphate were mixed together in 1 
litre of deionised water.
0.1%(w/v) BSA/PBS
O.lg of BSA was dissolved in lOOmls of PBS.
Reagent„A
Reagent A was prepared by dissolving 2g of sodium carbonate and 20mg of 
sodium potassium tartarate in lOOmls of sodium hydroxide (0.1 mol T 1).
Reagent-B
Reagent B was a 0.15%(w/v) solution of copper sulphate in deionised 
water.
Reagent.. G.
Reagent C was made up fresh daily by mixing 5mIs of A with lOOpl of B. 
Reagent D
Reagent D consisted of a 1 in 2 dilution of Folin and Ciocalteu’s phenol 
reagent in deionised water.
Procedure
Two millilitres of reagent C were added to a series of glass test tubes 
to which a 50pl aliquot of the sample to be tested was then added, After 
addition of 200pl of reagent D the tubes were mixed thoroughly and left 
to stand at room temperature for 30 min. The tubes were spun at 2000g 
for 5 min at 4*C and the ODyoonm of the supernatant was measured. 
Controls included a background, to which 50pl of sample buffer had been 
added, and a set of standards which comprised of a series of tubes to 
which different quantities (5pg to lOOpg) of a 0.1%(w/v) BSA/PBS solution 
had been added. The background reading was subtracted from all the 
other readings and the protein concentration determined by constructing a 
standard curve with the BSA concentration of the standards plotted
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against the OD?oonm (Fig 2.1). From this graph the protein concentration 
in the samples could be determined.
Measurement of Protein Concentration .ia.^.mples_gQiit.aiiilngJ!LEr.4.Q.
As NP-40 in buffers interfered with direct spectrophotometer readings at 
ODssorm, the protein content in such samples was measured by Folin assay. 
After the 30 min incubation at room temperature the tubes were 
centrifuged at 2000g for 5min at room temperature and the clear 
supernatant was removed from the precipitated NP-40. The OD/ocmm of the 
supernatant was then measured,
2.6(d) Radiolodination of Anti-CRl IgG__ by the Chlorainins I Method.
(McConahey and Dixon 1966)
Reagents.
Rabbit anti-CRl IgG
Rabbit anti-CRl IgG had previously been prepared by Dr W S Kilpatrick, 
Buffers and Solutions 
0.1%(w/v) BSA/PBS
O.lg of BSA were dissolved in lOOmls of PBS.
ChlflL&ffline,!.
5mg of chloramine T were dissolved in 1ml of PBS.
L~Tyrosine
0.5mg of L-tyrosine were dissolved in lral of sodium hydroxide 
(0.1 mol 1-' ).
10%(w/v) BSA/PBS
lOg of BSA were dissolved in lOOmls of PBS.
20%(w/v) TCA
20g of TCA were dissolved in lOOmls of deionised water.
Fig 2,1 BSA Standard Curve
A linear standard curve for BSA was constructed by plotting the OD/ 
of a known concentration of BSA against that concentration.
OO VKO
X N
Optica! Density 700nm
e. to
40200
yug of BSA
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Chromatog raphic Pla te r ia  1 
E Pjjw ii
Dowex, an anion exchange resin, was washed 3 times in 0.1%(w/v> BSA/PBS 
before pouring into a 10ml glass pipette. The column was washed with 
this buffer until it had equilibriated.
Er.QQe.dy.rn
Anti-CRl IgG (lmg/ml) was dialysed for 3 hours against 3 litres of PBS 
at 4T. One millilitre of this solution was placed into a glass vial 
containing 1 mCi (37MBq) of carrier free 1 '-SI. After the contents were 
mixed thoroughly, lOpl of a freshly prepared solution of chloramine T 
Were added and mixed for 90 seconds. The reaction v/as stopped by the 
addition of 50jj.1 of L-tyrosine, To separate the protein which had bound 
125I from the unbound the solution was passed over the Dowex
column. One millilitre fractions were collected and screened by counting
a 1:100 dilution of each in an automatic gamma ( '0 counter. An elution
profile was drawn by plotting the cpm in each fraction against the 
fraction number (Fig 2.2). Fractions containing the highest counts were 
pooled as indicated and analysed by trichloroacetic acid (TCA) 
precipitation to determine the percentage of radiolabelled protein to free 
,25L
2.6(e) Acid Precipitation of Frotein
Two hundred microlitres of a 10%(w/v> BSA/PE.S solution were added to a 
microcap centrifuge tube and 1 0 pl of a 1 : 1 0 0 dilution of the pooled 
fractions were added followed by 1ml of 20%(w/v) TCA solution. The tube 
was mixed thoroughly and centrifuged at 1 0 ,0 0 0 g for 5 min at room 
temperature. The supernatant was decanted into a glass tube and. the
pellet was cut from the bottom of the microcap tube and placed into a 
second glass test tube. The l:2Bi content of the supernatant and the
pellet were determined using an automatic 'i counter. The percentage of 
TCA-precipitable radioactivity v/as determined according to the following 
formula:
CPM in pellet - CPM in background (Bg)
------------------        y i nr)
(cpm in pellet-cpm in Bg)+(cpm in supernatant-cpm in Bg)
The background was determined by adding iOpl of PBS to the microcap tube 
instead of the labelled sample, following by treatment in the same way as 
the sample.
If the TCA precipitation was less than 83% the label was not used. The 
efficiency of labelling was determined by expressing the number of counts
Fig 2,2 Purification of 1 ^ I-Labelled...anti-CRl IgQ from Free Iodine
Legend
Purification of 1 ^ I-labelled anti-CRl IgG from free iodine using a 10ml 
Bowes: column. Fractions<500jil) were collected and the amount of iasI-cpm 
in a 1:100 dilution of each, fraction was plotted against the fraction 
number. The peak contains 1:resI-bound to anti-CPI IgG as determined by 
acid precipitation with TCA. Fractions 5 and 6 were pooled.
1251 cpm x10"fc
«
3
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in the pooled fractions as a percentage of the total counts put over the 
column.
The protein concentration of the pooled fractions was obtained by 
measuring the ODs q o  of the pool and subtracting the OD^so of the 
0,1% (w/v) BSA/PBS solution from the 0D;?eo of the pooled fractions.
2.6(f) Double Immunodiffusion in Agarose Gels (Ouchterlony 1958)
Buffers,. 
Barbitone..Buffer
9.21g of barbitone, 51.44g of sodium barbitone and 5g of sodium azlde 
were dissolved separately in hot deionised water before being mixed 
together and made up to a final volume of 5 litres.
Preparation of Agarose Gel
Agarose (5g) was added to 500mls of hot barbitone buffer. When 
dissolved 15g of polyethylene glycol (PEG) with a molecular weight of
4,000 daltons were added.
Procedure
Hot agarose gel (5ml) was poured onto a glass slide which had been 
washed, swabbed with alcohol and placed onto a levelling tray. Once set 
wells were punched in the gel using a template (Fig 2,3). The agarose 
plugs were removed by vacuum pump suction and a sufficient volume of 
antiserum to fill each peripheral well was added. CE1 C32/ig/ml> was 
added to the central well and the plate was left for 48 hours in a humid 
atmosphere to allow precipitation lines to develop.
Staining Ouchterlony, Plates.
Buffers and Solutions
Half Normal Saline_
0.45g of sodium chloride were dissolved in 1 litre of deionised water.
0.1% Coomassie Blue Solution
A methanol: acetic acid: water solution was made up in the proportions 
1:1:8 (v/v/v). To lOOmls of this solution O.lg of coomassie blue were 
added.
begand
Each well is Sjmr in diameter and there is a distance of 10mm between the 
centre point of the central well and the centre of the peripheral ^ wells.
3 m m
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De.staiiL-Sol.ut ion
A methanol: acetic acid: water solution was made up in the proportions 
1:1:8 (v/v/v).
Procedure
The plate was washed extensively in half normal saline for 1 day and 
then in deionised water for 1 day. The plate was dried overnight between 
sheets of filter paper. When dried, the plate was soaked for 2 to 3 min 
in 0.1% coomassie blue solution after which it was destained by soaking 
overnight in destain solution.
2.6(g) Preparation of Anti-CRl Antiserum
One millilitre of purified CR1 (32pg/ml) plus 1ml of PBS were emulsified 
in an equal volume of Freund's complete adjuvant. Two millilitres of this 
solution were injected subcutaneously into 2 rabbits. This primary
immunisation was fallowed by 2 weekly injections of the same quantity of 
CR1 until the antiserum obtained by test bleeds was assessed to be 
specific for CR1 by double immunodiffusion in agarose gels.
2.6(h) Sodium Dodecvlsulphate Polyacrylamide Gel Electrophoresis (SDS- 
PAGE) (Laemmli 1970)
Buffers and Solutions 
Electr.QphQr.esis Buffer:
lOmls of 10%(w/v) SDS, 33mls of Tris (0.75 mol l"1) and 220mls of 
glycine (0,86 mol l"1) were mixed together in a total volume of 1 litre 
in deionised water,
Sample Buffer(reducing)
3mls of 10%(w/v) SDS, 0.85mls of Tris (0,75 mol l” 1), 1ml of glycerol, 
150pl of bromophenol blue (0.1% w/v), 0.5ml 2-mercaptoethanol and 5mls of 
deionised water were mixed together.
Acrylamide/Bisacrylamide -Solution
30g of acrylamide and 0.8g of bisacrylamide were made up to lOOmls with 
deionised water and stored at 4°C for up to 4 weeks.
10% Gelatin Solution
lOg of gelatin were dissolved in lOOmls of deionised water by heating in 
a pressure cooker this solution was then stored at 4*C. Prior to use the 
gelatin solution was desolidified by placing in boiling water.
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Coomassie Blue Stain Solution
A methanol: acetic acid water solution was made up in the proportions 
5:1:4 (v/v/v), 0.1% (w/v) coomassie blue was then dissolved in this.
Destain Solution
Destain solution was made up as previously described in section 2.6(f).
Gei-Reclpes
Separating Gel
I Gel Ac rylamide/ 
Bisacrylamide
Water
(ml)
Tris (0.75 mol T 1 
pH 8.8) (ml)
10% 
SDS(pi)
TEMED
(pi)
Ammonium/Per- 
Sulphate (mg)
5 10 19,4 30 0,6 30 40
714 10 9.6 20 0.4 20 60
SlackLngJiel
* Gel Acrylamide/
Bisacrylamide
Water
(ml)
Tris (0,75 mol I'1 
pH 8,8) (ml)
10*
SDS(pl)
TEMED
(pi)
Ammonium/Per- 
Sulphate (mg)
3 1.8 13 3 0,18 9 18
Procedure
Slab gels were poured between glass plates 20cmx20cm separated by 1mm 
spacers and sealed with 10% gelatin. The separating gel was poured first 
and allowed to polymerise for 1 hour at room temperature with a layer of 
water carefully added to the surface to prevent evaporation. After setting 
the water was removed carefully and the stacking gel was poured. A 
spacing comb was placed into the stacking gel prior to setting to allow 
formation of lanes. The gel was then clipped into the electrophoresis 
tank which had been filled with electrophoresis buffer.
2.6(i) Preparation of Samples.for SDS-FAGE
To 40pl of sample, 40pl of sample buffer were added and the samples 
boiled for 2 min. The reduced samples were then layered carefully into 
the individual lanes using a micropipette and electrophoresed for 3 hours
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at 35mA at room temperature. Once the electrophoresis was complete the 
gel was treated by staining with coomassie blue or the silver 
impregnation technique.
2.6(j) Coomassie Blue Staining
The gel was fixed and stained for 1 hour at 37 °C in stain and then
destained overnight in destain solution at 37°C. This type of staining 
does not detect proteins with a concentration of less than 0 .2 pg and
therefore some gels were silver stained as this is a more sensitive
method of staining being able to detect 2- to 5-fold lower protein 
concentrations than coomassie blue staining.
2.6(k) Silver..Staining
Gels were silver stained using a silver stain kit. After the protein in 
the gel had been fixed for 30 min in 400mls Of 40% methanol/10% acetic 
acid(v/v), the gel was washed twice in 10% ethanol/5% acetic acid 
(v/v)(15 min each wash). This was followed by addition of 200mls of
oxidising solution for 5 min and then by sufficient washes in deionised
water to ensure that all colour was removed from the gel. The silver
reagent (2 0 0 mls) was added and the incubation continued for 2 0  min after 
which a quick wash in deionised water was followed by the addition of 
the developing reagent. The reaction was stopped by the addition of 
5 %(v/v) acetic acid once the protein bands had reached the desired 
intensity.
The molecular weight of unkown protein samples was determined by running 
on the same gel a series of proteins of known molecular weight from 
which a standard curve could be constructed (Fig 2.4). In the case of 
gels stained with coomassie blue nonradioactive high molecular weight 
markers were used and 1 aC methylated molecular weight markers were used 
if the gel was to be subjected to autoradiography. By calculating the
relative mobility (Rf valve) of the unknown sample, which is equivalent
to:
the distance travelled by the protein 
the distance travelled by the dye front
the molecular weight of the protein could be determined from the standard 
curve.
2.7 Screening Columns for GR1
Over the course of the 3 CR1 preparations 3 different methods were used 
for screening the columns for CR1 activity, radioimmunoassay,
agglutination of EAC43b and inhibition of alternative pathway C3 
convertase activity.
Fig 2,4
Legend
A standard curve was constructed by plotting the known molecular weight 
of a series of proteins against the relative mobility (Rf value) of that 
sample. The proteins used in the construction of this curve were BSA 
(molecular weight 69,000 daltons), phosphorylase b (molecular weight
92,000 daltons) and myosin (molecular weight 200,000 daltons).
Molecular Weight
0.00 8 .20  0 .40  0 .60  0 .00  X.00
R ela tive  M ob ility  (R f)
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2.7(a) Radioimmunoassay For Screening Columns (Iida et al 1982)
Reagents.
ca.
C3 was purified by Dr E Holme. It was diluted in PBS to a final 
concentration of 50pg/ml.
Anti-CRl...IgG
Anti-CRl IgG had previously been prepared by Dr V S Kilpatrick and was 
radiolabelled as described in (2.6(d)).
Buffers 
Blocking.-Buffer.
lg of BSA was dissolved in lOOmls of PBS/BSA. 
flask. Buffer
PBS/BSA containing 0.005%(v/v) Tween 20.
Rrflcedure
Fifty microlitres of purified C3 (50/j.g/ml) were added to plastic LP3 
tubes and the tubes incubated for 2 hours at room temperature. The C3 
was then removed by vacuum suction and the tubes washed 3 times in 
blocking buffer after which lOOjul of blocking buffer were added and the 
tubes left to incubate overnight at room temperature to allow blockage of 
free binding sites. After removal of the buffer, 25pl of test sample or 
25pl of diluted purified CR1 (1:5 to 1:20) were added and the tubes 
incubated at 37 °C for 2 hours to allow binding of CR1 to C3 after which 
the sample was removed and the tubes washed 3 times with wash buffer. 
Twenty five microlitres of 125I anti-CRl IgG (500pg/ml) diluted in 
blocking buffer were added and incubation continued for 1 hour at room 
temperature. Finally the label was removed and the tubes washed 4 times 
in wash buffer. The amount of bound 1:25l anti-CRl IgG was measured as 
cpm by counting the plastic tubes in an automatic ¥ counter. The 
background from a control tube containing 25pl of PBS instead of sample 
material was subtracted from each reading to give the specific cpm for 
each sample.
Standard Curve for.CRL
A small quantity of CR1 had previously been purified by Dr V S Kilpatrick 
but as there was an insufficient volume of the material to allow an 
accurate estimation of protein content the assay could not be 
standardised in terms of its sensitivity to detect CR1. However, the
.purified CR1 was used at a 1:5 to 1:20 dilution to form a standard curve 
for the RIA (Fig 2.5). There was a linear relationship between the titre 
of CR1 and the number of cpm in the assay. For this reason the total 
number of cpm in a sample v/as taken as an estimate of the amount of CR1 
in the sample assuming that the CR1 present had not lost any of its 
activity.
2.7 (b) Agglutination of EAC4-3b
The presence of CR1 in a sample can be detected by its ability to 
agglutinate EAC43b. The concentration of CR1 present is indicated by the 
titre of sample at which haemagglutination is obtained.
Reagents Anti-sheep E stroma Ig/J) antibody was prepared by 
Professor K Whaley.
5xVBS (Veronal 5k buffer).
85g of sodium chloride and 3.75g of sodium barbitone were mixed together 
in 1 litre of deionised water, This was then heated until almost boiling 
whereupon 5.57g of barbitone we re added and the solution made up to 2 
litres with deionised water,
lxVBS (Isotonic VBS)
A 1:5 dilution of 5xVBS was made in deionised water.
GYBd-
lOmls "of a 10% gelatin solution (lOg of gelatin per 100 mis of deionised 
water) were added to 200rals of 5xVBS which was then made to 1 litre with 
deionised water.
OVBg"
lOmLs of a 10% gelatin solution were added to 200.mls of 5xVBS after 
which 5mls of calcium chloride (0.03 mol I"1) and lOmls of magnesium 
chloride (0.1 mol I-1 ) were added and the solution made to 1 litre with 
deionised water.
50g of D-glucose were dissolved in 750mls of deionised water after which 
5mls of calcium chloride (0,03 mol I"1) and lOmls of magnesium chloride 
(0,1 mol I"1) we re added and the solution, made to 1 litre with deionised 
water.
D5VSI
Fig 2.5
Leg.en.fi
A linear standard curve for purified CR1 was constructed by plotting the 
1 2 SI-cpm of a known dilution of CR1 against that dilution.
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DG1B ?.Z.
An equal volume of D5W:,7‘~V and GVB7!'1' were mixed together.
ED.1A GVB'fLl.. (0.04 mol I"1)
230mls of EDTA (0.086 mol 1 1 ) pH 7.4 were mixed with 200mls of GVB2!~. 
Isotonic EDTA (0.086 mol I"1 pH 7.4)
22.3g of EDTA were dissolved in 500mls of deionised water to make a 
0.12 mol I-1 EDTA solution. 3.6g of sodium hydroxide were dissolved in 
300mls of water to make a 0.3 mol I-1 solution, 500mls of EDTA (0.12 mol 
l-1) were then mixed with 185mls of sodium hydroxide (0.3 mol l"1) to 
result in a pH of 7.4.
Normal Saline
0.9g of sodium chloride were dissolved in lOOmls of deionised water. 
Preparation^ of EAIgMC43b for Agglutination Assay
Sheep E in Alsever's solution were centrifuged at 2 ‘C for 5 min at 
2000g. The supernatant, plasma and buffy coat were removed by 
aspiration. The cells were then washed 3 times in EDTA GVB2" (0.01 mol 
l"1) and resuspended in this buffer. One hundred microlitres of the E 
suspension was added to 2.9mls of deionised water and the OD was 
measured on a spectrophotometer at 541nm wavelength (ODs^inm). An OD 
reading of 0.385 corresponds to a sheep E concentration of lxl09 /ml 
(Whaley 1985). Thus the E were adjusted to lxl09/ml using the formula:
0Ds 4.i Measured
Vol E required = Initial volume X  o '385------
El
Anti-sheep E stroma IgM antibody was titrated to find the maximum
subagglutinating dose. Fifty microlitres of PBS were added to the wells 
of a microtitre plate, 50pl of the neat rabbit anti-sheep IgM was then 
added to the first well and serially diluted out to 1: 2000. Sheep E 
(50/ji1 lxl09/ml) were added to each well and the plate was mixed and left 
to stand at room temperature for 1 hour and the haemagglutination pattern 
observed. The lowest dilution of antibody which did not cause
agglutination was used for the preparation of antibody sensitised sheep E 
(EA). The maximum subagglutinating concentration of IgM antibody diluted 
in 0.01M EDTA GVB*~ (0.01 mol I’1) was warmed to 37’C and added to pre­
warmed E (lxl09 /ml) and the mixture continually shaken for 30 min at
3 7 *C. The EA were centrifuged at 2,000g for 5 min at 2*C and washed once
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in GVB:X~~ EDTA (0.01 mol 1 1) and twice in GVB2"*' and resuspended to 
lxlO-Vml in GVB2 *.
Preparation of R3
One hundred milligrammes of zymosan were suspended in lOmls of isotonic 
VBS and boiled for 30 min then centrifuged at 2000g for 5 min at room 
temperature. The pellet was washed twice in isotonic VBS and resuspended 
in lOmls of isotonic VBS, One millilitre of this zymosan (lOmg/ml) was 
put into a test tube and centrifuged at 2000g for 5 min at room 
temperature, Ten millilitres of fresh NHS were added to the pellet and 
the mixture incubated for 1 hour at 37 *C. The zymosan was centrifuged at 
2000g for 5 min at 2 ’C and the supernatant which contained R3 was 
decanted and stored in aliquots at -70 °C.
Preparation., of EAC43.
Nineteen millilitres of EAIgM (2xlOe/lml) were warmed to 37 °C. One 
millilitre of R3 pre-warmed to 37 *C was added to the EA in a shaking 
water bath. Incubation was continued for 75 seconds whereupon 200/il of 
pre-warmed antrypol (lOOmg/ml) were added and incubation continued for a 
further 2 min. The cells were then diluted in an equal volume of ice- 
cold EDTA (0.01 mol l-1) GVBS“ and centrifuged at 2000g for 5 min at 2 ’C 
then resuspended in this buffer and incubated for 2 hours at 37 *C to
decay off the C2, after which the cells were again centrifuged at 2000g 
for 5 min at 2 ’C, resuspended in DGVB2""-, washed once and finally
resuspended to lxl08/ml in DGVB2 H .
Procedure
One hundred microlitres of PBS were added to each well of a microtitre 
plate. Five microlitres of test sample were added to the first well and 
serially diluted out to 1:2500. Fifty microlitres of EAC43 (Ixl0s /ml) 
were then added to each well and the plate was shaken and left to stand
at room temperature for 3 hours to allow the cells to sediment. The
pattern of haemagglutination was then noted. Control wells had no test 
sample added and were always haemagglutination negative.
2.7(c) Inhibition of Alternative Pathway C3 Convertase Activity:
CR1 has been reported to accelerate the decay of C3bBbP, the alternative 
pathway C3 convertase (Fearon 1979; Iida and Nussenzweig 1981). The 
presence of CR1 can be measured by determining the ability of a sample 
to inhibit the lysis of EAC43bBbP.
Paagents 
C Rat
Rat serum was used at a 1:15 dilution in EDTA (0.04 mol 1 1) GVB2
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Factors B, D and P were kindly donated by Professor K Whaley. The optimal 
concentrations of these factors had been predetermined by titration of 
each one individually.
EAC43bBb
EAC43bBb were prepared by incubating an equal volume of EAC43b (1x10®/ml) 
in DGVB2'*' with DGVB2* containing the appropriate dilutions of B, D and P 
for 30 min at 30 *C. The EAC43bBbP were centrifuged at 2000g for 5 min at 
2*C, the supernatant was decanted and the wells washed once in ice-cold 
EDTA (0.01 mol l” 1 ) GVBS” and resuspended in this buffer at lxl0s/ml
Procedure
Samples to be tested were diluted 1:25 in EDTA (0.01 mol I"1) GVB2^ '. 
EAC43bBbP (lOOpl) were incubated with lOOpl of the diluted sample for 15 
min at 30*C to allow CR1 in the sample to accelerate the decay of the C3 
convertase. C rat (300pl) was added to each tube to supply the terminal 
components in order to develop haemolytically active sites. Incubation 
was continued for 1 hour at 37°C during which lysis of E occurred, the 
extent depending on the amount of convertase activity remaining on the 
cells. A series of control tubes were set up the contents of which are 
shown below;
Materials Added
Controls 0.01M EDTA/GVB2" EAC43bBbP EAC43 C-Rat
Reagent Blank IOOjjI - lOOpl 300/j.l
Cell Blank 400p.l lOOpl -
Complement Colour 2 0 0 /j.l - 300/j.l
100% Lysis lOOpl lOOpl 300pl
Solo 1 0 0 /j.l 1 0 0 pl 300pl
The reaction was stopped after 1 hour by the addition of 2 mls of saline 
to each tube except the 1 0 0 % lysis control to which 2 mls of deionised 
water were added instead. The tubes were then centrifuged at lOOOg for .5 
min at 4*C and the OD^.ia was read on a spectrophotometer.
The results were calculated according to the formula described, by Gigli, 
Ruddy and Austen (1968) which is shown below;
Z' = -In
OD,i. wt inhibitory sample - OD4 i 4 reagent blank 
OD4 14 solo - OD4 14 reagent blank
Where Z 1 is a measure of the degree of inhibition of lysis.
Phosphate Buffers
A stock solution of disadium hydrogen phosphate (0.1 mol 1""’) and a 
stock solution of sodium dihydrogen phosphate (0.1 mol I"'1) were 
prepared. These 2 solutions were added together until the desired pH was 
obtained and then diluted to give the appropriate molarity.
Wash Buffer
9g of sodium chloride were dissolved in 1 litre of deionised water.
Sodium phosphate buffer (5 mmol 1" 1 pH 7.8) containing PMSF 
(0.5 mmol I"'1) and 0 ,0 2 %(w/v) sodium azide.
Sodium phosphate buffer (5 mmol I” 1 pH 7.5) containing sodium chloride 
(0.15 mol I"1), 1%(v/v) IP-40, PMSF (0.5 mmol 1 ‘1) and 0.02%(w/v) sodium 
azide.
Blares Fqu.il ihriating .Buffer.
Sodium phosphate buffer (0.05 mol I-1 pH 7.2) containing sodium chloride 
(0.02 mol l-1) and 0.2%(v/v) HP-40.
Phosphate buffer (0.01 mol I" 1 pH 7.5)
1 x VBS, prepared as described in chapter 2.7(b), containing 0.1%(v/v) IP- 
40.
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Lentil Lectin Equilibriating Buffer
Tris (0.01 mol I-1 ) hydrogen chloride (Tris HC1) pH 7.4 containing sodium 
chloride (0.2 mol I"1), calcium chloride (0.7 mmol l"1), manganous 
chloride (0.7 mmol I-1), magnesium chloride (0.7 mmol I” 1) and 0.1%(v/v) 
NP-40.
These buffers were used in the first and second CR1 purification
attempts. In the third purification the following inhibitors were added to
the afore mentioned buffers, benzamadine (0.01 mol I"1), PMSF
(0.5 mmol I-1), 0.02%(w/v) sodium azide, and isotonic EDTA
(0.5 mmol I-1 pH 7.4). In addition these inhibitors were added to the
water which was used to dilute material before application to the
chromatography columns.
2.9 Preparation of Chromatographic Material 
2.9(a) Bior.ex
Biorex, a cation exchange resin, was equilibriated in 5 litres of 
equilibriating buffer, degassed and poured into a column (5x30cm). The 
column was equilibriated at 4°C by the passing through of 5 column 
volumes of equilibriating buffer. When the conductivity at 0*C and the pH 
of the eluate buffer were the same as the equilibriating buffer the column 
was ready for use.
2.9(b) Cyanogen Bromide (CNBr) Activated Sepharose 4B-C3 
Reagents
C3L
Purified C3 was kindly donated by Dr E Holme.
Buffers used in the Preparation of Cyanogen Bromide Activated .Sepharose 
4B-C3
Sodium Carbonate Buffer (Coupling Buffer)
A stock solution of sodium carbonate (1 mol I-*1) and a stock solution of 
sodium hydrogen carbonate (1 mol I-1) were prepared and mixed together 
until the desired pH of 9 was obtained. After dilution to give the 
appropriate molarity, 0.1 mol I"1, sodium chloride (0.5 mol I"1) was 
added.
Acetate. Buffer
A stock solution of sodium acetate (1 mol I -1) and a stock solution of 
acetic acid (1 mol I-1) were prepared and mixed together until a pH of 4
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was obtained. This solution was diluted to give a 0.1 mol T"1 solution 
after which sodium chloride (1 mol l-1 ) was added.
Borate Buffer
A stock solution of boric acid (1 mol I-1) and a stock solution of 
sodium tetraborate (1 mol I-1) were prepared and mixed together to 
obtain a pH of 8. This was then diluted to give a 0.1 mol I-1 solution 
after which sodium chloride (1 mol l"1) was added.
Procedure
CNBr-activated Sepharose 4B (6g) was washed in a Buchner funnel for 15 
min with HC1 (1 mmol I-1) and then mixed with C3 (7mg/ml) in coupling 
buffer. The Sepharose beads and C3 were mixed end over end on a Matburn 
mixer for 2 hours at room temperature, centrifuged at 2000g for 5 min 
and then resuspended and washed 3 times in coupling buffer. Any 
remaining active groups on the Sepharose were blocked by exposure to an 
equal volume of ethanolamine (1 mol l'"1 pH 8.0) and then mixed end over 
end for 2 hours at room temperature. The beads were then washed in 
acetate buffer and then in borate buffer. This washing cycle was 
repeated 3 times before the beads were finally resuspended in C3- 
Sepharose equilibriating buffer, poured into a 10ml syringe barrel and 
washed with a sufficient quantity of buffer to equilibriate the column.
2.9(c) Biogel-Ar.SM
Biogel was equilibriated in VBS containing 0.1% HP-40 degassed and poured 
into a column (2.6x90cm). This column was equilibriated by passing 1 
column volume of equilibriating buffer through the column.
2.9(d) Lentil Lee tin-Sepharose.
The Sepharose beads were washed as previously described and mixed with 
20mg of lentil lectin in coupling buffer plus a methylmannoside (0.1 mol 
l-1). The beads were rotated end over end at 4°C overnight and then 
washed in coupling buffer 3 times before being mixed with ethanolamine 
(1 mol I-1 pH 8.0) for 2 hours at room temperature. This was fallowed 
by 3 cycle washes with acetate and borate buffer before resuspension in 
lentil lectin equilibriating buffer. The beads were then poured into a 
lml Pasteur pipette which had been plugged with glass wool and washed 
with lOmls of equilibriating buffer.
2.10 Purification of _GR1 from Erythrocyte Membranes (1st and 2nd.
Attempts)
Ten (500ml) aliquots of expired blood were centrifuged at 4*C at 2000g 
far 10 min. The plasma and buffy coat were removed and the cells were 
washed 3 times in wash buffer. The packed red cells were then lysed by 
stirring overnight at 4°C in 15 litres of lysis buffer. The lysed
Page 100
membranes were centrifuged in a Beckman Ultracentrifuge model L2-65B at 
50,000g for 30 min at 4*C and the membranes collected as a flocculent 
pellet. The membranes were washed in 9 litres of lysis buffer by 
continual centrifugation at 50,000g for 30 min until they were free of 
haemoglobin after which they were suspended overnight at 4 ’C in 1.5 
litres of solubilisation buffer. The solubilised membranes were 
centrifuged at 50,000g for 30 min at 4 ’C and the supernatant collected.
The supernatant was diluted with sufficient ice-cold water to lower the 
conductivity to below 6mS at O ’C and applied to the equilibriated Biorex 
column by means of a peristaltic pump at a constant flow rate of lOOmls 
per hour. The insoluble Biorex particles contain mobile positively charged 
ions on the surface and these ions exchange with positively charged 
molecules (such as CR1) in the applied sample. These molecules were 
eluted by application of a linear salt gradient of 500mls with the limit 
buffer containing sodium chloride (0,6 mol T~D. Ten millilitre column 
fractions were collected and screened for CR1 activity by R1A. The 
fractions containing CR1 activity were pooled and concentrated by 
positive pressure ultrafiltration using an Amicon PM-30 membrane.
This pool was diluted with 600mls of ice-cold water to lower the 
conductivity to below 6mS and applied at 4°C to the C3-Sepharose column. 
This column was washed through with equilibriating buffer and then 
sequentially with equilibriating buffer containing 0.1% NP-40,
equilibriating buffer containing sodium chloride (0.2 mol l"1 ) and 
equilibriating buffer. These washes were to ensure the removal of 
molecules bound weakly by both hydrophobic and charge interactions to 
the C3-Sepharose. Elution of solubilised CR1 from the C3-Sepharose 
followed application of equilibriating buffer containing both 0,1% NP-40 
and sodium chloride (0.2 mol I"1). Ten millilitre fractions were collected 
and screened in a similar way to the Biorex column. Those with CR1 
activity were pooled and concentrated using an Amicon PM-30 membrane.
Five millilitres of the concentrated pool were carefully layered onto the 
Biogel column. Fractions (3mls) were collected and screened by R1A. 
Those with greatest CR1 activity were pooled and concentrated using an 
Amicon PM-10 membrane.
This pool was then added to the lentil lectin column. CR1 has a 
carbohydrate moiety which binds to the lentil lectin and which can be 
eluted by addition of equilibriating buffer containing a methylraannoside 
(0.2 mol 1” D  which has a stronger affinity for the lentil lectin than 
CR1.
2.11 Washing Ervthrocvte Membranes with the...P.ellicQn Cassette System.
Eighteen packs of mixed fresh and expired blood were washed 3 times in 
wash buffer and lysed overnight at 4°C in 7 litres of lysis buffer. The 
lysates were washed free of haemoglobin in the Pellicon cassette. This 
apparatus allowed the E ghost membranes to be passed over a 0.45pM
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Durapore filter cassette, which retained the membranes while allowing the 
haemoglobin to pass through the filter into a filtrate channel which was 
then discarded. The membranes were pumped back into a reservoir to 
which lysis buffer was added and the membranes were then allowed to flow 
back over the filter where more haemoglobin was removed and the retained 
membranes were cycled back to the reservoir to repeat the process until 
the membranes were completely free of haemoglobin. Erythrocyte membranes 
were washed in 100 litres of lysis buffer to remove all haemoglobin. In 
the final cycle 2,2 litres of solubilisation buffer were added to the
membranes in the reservoir. This was collected and the E were left to 
solubilise overnight at 4 ’C. The insoluble membrane fragments were
separated from the supernatant by centrifugation at 50,000g for 30 min at 
4*C, The supernatant containing solubilised CR1 was diluted with 500mls 
of ice-cold water to lower the conductivity to 6mS at O ’C and applied to 
a Biorex column (5x30cm). This column was eluted with a linear sodium 
chloride gradient as before. Thereafter a similar chromatographic
procedure to that described for the first and second purification
attempts was followed with some modifications which will be described in 
the results section. All columns in the third purification attempt were 
screened by measuring the ability of each fraction to agglutinate EAC43b.
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Results
2.12 Elcst-CRl Purification Attempt
The starting material for the Biorex column contained approximately 
750mg of protein which represented 47% of the original solubilised 
membranes (Table 2.1). This was eluted from the Biorex by application of 
a linear sodium chloride gradient. The conductivity and protein 
concentration of each fraction was recorded and the column was then 
screened for CR1 activity by radioimmunoassay (Fig 2.6). Two peaks of CR1 
activity eluted between 8 and 13mS and the fractions containing this 
activity were pooled. The pool contained approximately 171mg of protein 
representing 23% of the applied protein. After concentration using an 
Amicon PM-30 membrane and dilution with water to lower the conductivity 
the material was applied to a C3-Sepharose column. Elution of this column 
revealed 2 fractions which contained CR1 activity (Fig 2.7). As the 
exclusion fractions also contained CR1 activity these were concentrated 
as before and recycled over the C3-Sepharose column. The fractions 
containing CR1 activity which eluted from this second column were added 
to the pool from the first column and the concentrated pool which 
contained 15.3mg of protein, representing 15% of the applied protein, was 
subjected to gel filtration on a Biogel column.
CR1 did not filter as a distinct peak from this column but represented a 
broad band of activity between 50% and 80% of the bed volume (Fig 2.8). 
The pool of CR1 activity from the Biogel was concentrated to llmls using 
an Amicon PM-10 membrane. This contained 2.42mg of protein representing 
6.8% of the applied protein. The pool from the Biogel column was 
subjected to affinity chromatography on a 1ml lentil lectin column and 
the bound CR1 eluted with equilibrating buffer containing a 
methylmannoside (0.2 mol I'"1). Each fraction was dialysed into VBS 0.1% 
NP-40 and assayed for CR1 activity (Fig 2.9). No CR1 activity appeared to 
have eluted from this column and so a higher concentration (0.5 mol l"1 
and 1 mol 1“1 ) of a methylmannoside was added to the equilibrating 
buffer in an effort to elute any protein which may have stuck to the 
column. This again proved unsuccessful.
To exclude the possibility that CR1 was present, but was not being
detected fractions were screened for their ability to decay dissociate
C3bBbP as CR1 is known to accelerate the decay of this enzyme (Fearon 
1979, Iida and Fussenzweig 1981). However, none of the fractions 
contained convertase activity. Thus it appeared that all CR1 activity 
had been lost.
2.13 Second Attempt at .CR1 Purification.
A second CR1 purification was attempted using 15 units of packed red 
cells with a protein content of 3600mg. The same protocol for obtaining 
the solubilised receptor was used and the resultant material containing
2680mg of protein was applied to a Biorex column. This gave a similar
Table 2.1
Total Protein CR1cpm(25pl) Total cpm cpm/mg Volume
Solubilised
Membranes 1600mg ND ND ND 1500ml
Solubilised
Supernatant 750mg 168 10x10s 13333 1500ml
Pool from 
Biorex 171 mg 736 3,6x10s 21052 125ml
Pool from C3- 
Sepharose 15,3mg ND ND ND 5m 1
Pool from 
Biogel 2,42mg 246 0,11x10s 44628 11ml
Pool from 
Lentil lectin 0 0 0 0
F ig 2.6 B.iar£2LXflliun.ii
Legend.
Purification of CE1 from solubilised E membranes by passage over a 
Biorex column (5x30cm), Fractions (10ml) were collected and screened for
CR1 activity by RIA (x x). Protein concentration was determined by
Folin analysis (x_,_._.x) and conductivity was measured at Q*C
(x x).The arrows on the X axis represent: 1 the application of the
solubilised membranes to the column, 2 the washing of the column with 
equilibrating buffer and 3 the application of a linear sodium chloride 
gradient. Fractions 245 to 285 were pooled as they contained the greatest 
CR1 activity.
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Fig 2.7 C3-Sepharose Column
Legend.
Purification of CR1 from the concentrated pool obtained from the Biorex 
column by passage over a C3~Sepharose column (10ml). Fractions (10ml)
were collected and screened for CR1 activity by RIA (x x). Protein
concentration was determined by Folin analysis (x______ x). The arrows on
the X axis represent: 1, application of the Biorex pool, 2, wash with 
equilibrating buffer, 3, wash with equilibrating buffer containing 0.1% 
UP-40, 4, wash with equilibrating buffer containing sodium chloride (0.2 
mol l"1), 5, application of elution buffer containing UP-40 and sodium 
chloride. Fractions 47 and 48 were pooled as well as fractions 5 to 11 
from the exclusion peak.
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Legend
Purification of CR1 from the concentrated pool obtained from the C3- 
Sepharose column by application to a Biogel gel filtration column 
(2.6x90cm). Fractions (3ml) were collected and screened for CR1 activity
by RIA (x_x). Protein concentration was determined by Folin analysis
(x_._._.x). Fractions 47 to 63 were pooled.
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Fig 2.9 Lentil Lectin Column
Legend
Purification of CR1 from the concentrated Biogel pool by application to a 
1 ml lentil lectin affinity chromatography column. Fractions (1ml) were
collected and screened for CR1 activity by RIA (x x). Protein
concentration was determined by Folin analysis (x______ x). The arrow (1)
on the X axis represents the application of the elution buffer.
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profile to the one shown in Fig 2,6 with CR1 activity eluting between 8 
and 13ms. The CR1 active fractions from this column were concentrated 
down to a pool of 50 in Is containing 14 2mg of protein. This pool was 
divided into 4 lots of 20mls. Each 20iuls was then diluted with lOOrals of 
ice-cold water prior to application to a C3~Sepharose column. All of the 
CR1 active fractions from each column were pooled to give a pool of 
45mls with a total protein content of 2.12mg. Instead of putting this 
material over a Biogel column, the pool was dialysed into the 
equilibrating buffer for' the Biorex column and put over a 1 in 1 Biorex. 
column to concentrate CR1 activity. Elution of this column with 
equilibrating buffer containing sodium chloride (0,6 mol I-1 ) resulted in 
no detectable CP.l activity in any fraction as assessed by RIA or the 
C3bBbP converta.se inhibition assay.
2,14 Purification__oJL_GE1_he Fellicon Cassette System
The membranes from 18 units of mixed fresh and expired blood were 
collected and washed until they were free of haemoglobin in a Fellicon 
cassette. This procedure took 1 day. The haemoglobin free membranes were 
then solubilised as before, centrifuged and the supernatant containing the 
solubilised CR1 retained. The protein content of this starting material 
was 2015mg, it was diluted with oOOmls of ice-cold water and applied to 
a Biorex column v.rhich was washed and eluted as previously described. 
Each fraction was screened for CR1 activity by agglutination of EAC43b 
(Fig 2.10).
CR1 activity eluted as a single peak between 8 and IQraS. The fractions 
containing the highest CP.l activity were pooled and concentrated to 
234mls. This pool gave a positive haemagglufiliation at up to a 1 in 320 
dilution (Plate 2,1), and contained 166mg of protein (Table 2.2)
representing 8.27 of the starting material. One hundred millilitres of 
this pool were diluted with 400mIs of ice-cold water and the remainder 
was stored at -70X, The diluted material was applied to C3~Sepharose 
and eluted as before (Fig 2,11). The protein content of the material
eluted from this column could not be accurately measured, however, 
positive haema.gglutination was seen in a number of the fractions, with 
the highest titre being 1:1280, Fractions containing CR1 activity were 
pooled and dialysed into the equilibrating buffer for the lentil lectin 
column. This pool which had a total volume of 45mis with agglutinating 
activity of 1:320 was applied to a lentil lectin column. Elution with a -  
methyiraannoside(0,2 mol T~ ') revealed that CR1 activity eluted as 2 very 
sharp peaks with peak CR1 activity at 1:1280 dilution (Fig 2,12) (Plate
2.1), Two pools were made from these fractions, The first pool was
concentrated to 2mis and contained 48/j.g/nil of protein while the second 
was concentrated to 2.5mls and contained 32pg/ral of protein. Samples from 
both of these pools were analysed by SPS-PAGE on 5% gels. The gels were 
either silver stained or stained wj.th coomassie brilliant blue. Silver 
stain analysis of both pools revealed a band of molecular weight 230,000 
daltons (Plate 2.2). Ro minor lower molecular weight contaminating bands 
were present indicating that the preparation was homogeneous, Samples of
Fig 2.10 Biorex Column
Legend
Purification of CR1 from solubilised E membranes by passage over a 
Biorex column (5x30cm). Fractions 15ral were collected and screened for
CR1 activity by agglutination of EAC43b (x______ x). Protein concentration
was measured by Folin analysis (x_._._.x> and conductivity was measured
at 0°C (x x). The arrows on the X axis represent: 1, application of
protein, 2, wash with equilibrating buffer and 3, application of a linear 
sodium chloride gradient. Fractions 270 to 300 were pooled as these 
contained the greatest CR1 activity.
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Plate 2.1
A sample (5/il) of fraction 27 from the lentil lectin column (Fig 2.12) 
was serially diluted out in PBS to 1:2500 (row 1). A sample (5/j.I) of 
fraction 285 from the Biorex column (Fig 2.10) was also serially diluted 
out in PBS to 1:2500 (row 2), as was a sample (5pl) of an exclusion 
fraction from the Biorex column (Fig 2.10) (row 3). After addition of 
EAC43b the haemagglutination pattern was noted. Row 1 shows the 
haemagglutination at up to a 1:1280 dilution of purified CR1 from the 
lentil lectin column, row 2 shows the haemagglutination of EAC43b at up 
to a 1:320 dilution of CR1 from the Biorex pool and row 3 shows the 
haemagglutination of EAC43b at up to a 1:20 dilution of the exclusion 
fraction from the Biorex column. The last well in each row represents the 
control wells in which no test sample was added.

Table 2.2 Protein.Profile for. the Third CR1 Purification
Protein(mg/ral) Haemagglutination Titre Volume
Solubilised
Membranes ND 1:160 1300ml
Solubilised
Supernatant 1.55 1: 160 1300ml
Pool from
Biorex 0.71 1:3*0 234ml
Pool from C3-
Sepharose 0* 1:320 45ml
Pool from (i)48pg/ml 1:1280 2 ml
Lentil Lectin (ii) 32 jig/ml 1:1280 2. 5 ml
Mote: 0*; No protein could be detected.
Fig 2.11 C3-Sepharose Column
Legend
Purification of CR1 from the concentrated pool obtained from the Biorex 
column by application to a C3-Sepharose affinity chromatography column 
(10ml). The arrows on the X axis represent: 1, application of protein
(15ml exclusion fractions were collected), 2, wash with equilibrating 
buffer (5ml fractions were collected), 3, wash with equilibrating buffer 
containing NP-40 (5ml fractions were collected), 4, wash with 
equilibrating buffer (5ml fractions were collected), 5, wash with 
equilibrating buffer containing sodium chloride (0.2 mol I"1 ) (5ml 
fractions were collected), 6, wash with equilibrating buffer (5ml 
fractions were collected) and finally, 7, application of elution buffer 
(2ml fractions were collected). Fractions were screened for CPI activity
by agglutination of EAC43b (x________ x) and protein concentration was
determined by Folin analysis ( x _ , x ) . Fractions 92 to 104 were pooled 
as these contained the greatest CR1 activity,
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Fig 2.12 Lentil Lectin Column
Legend
Purification of CR1 from the concentrated C3-Sepharose pool by 
application to a 1ml lentil lectin affinity chromatography column. 
Fractions (2ml) were collected and screened for CR1 activity by
agglutination of EAC43b (x x>. No protein could be detected by Folin
analysis. The arrows on the X axis represent: 1, application of protein, 
2, wash with equilibrating buffer and 3, application of elution buffer. 
Two pools were made, the first containing fractions 23 to 25 and the 
second containing fractions 26 to 31.
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Plate 2.2 Silver Stain of Purified CR1.
The purity of the CR1 which was obtained from the lentil lectin column 
was assessed by SBS-PAGE analysis. Samples from both of the pools from 
the lentil lectin column (Fig 2.12) were analysed on a 5% slab gel run 
under reducing conditions. A band with a molecular weight of 230,000 
daltons (230K) was seen in both cases (track a, pool 1; track b, pool 2) 
after the gel was silver stained. Ho other contaminating bands were 
observed. The last track represents the high molecular weight markers 
(HMV).
230 K
116K
97K
fpV 66K
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the lentil lectin beads were also analysed by SDS-PAGE and silver
staining revealed a band with a molecular weight of 230,000 daltons 
(Plate 2.3)
2.15 Specificity of the CR1 Antiserum
Antiserum to the purified CR1 was raised in rabbits. The serum obtained 
from 20mls of clotted rabbit blood was serially diluted into PBS and
tested against purified CR1 by double immunodiffusion in agarose gel. 
Single lines of precipitation were seen between CR1 and each of the
diluted anti-CRl samples. This indicated that the antiserum was specific
for CR1 (Plate 2,4).
To d e te rm in e  i f  CS1 hod s lu e d  i n  e v e r s ib ly  to  th e  l e n t i l  l e c t in  colum n  
s a m p le s  o f  S ep b a ro s e  beads from  id s  column (F ig  2 ,1 2 )  w ere  a n a ly s e d  on a 
5 s  s la b  g e l ru n  under re d u c in g  c o n d it io n s . A band o f  m o le c u la r  weight 
230,000 daitons was seen after silver staining (track a). This is 
identical to toe molecular weight of purified CR1 and it was therefore 
concluded that this band represented CR1. The first track represents the 
high molecular weight markers (HMW).
Plate 2.4 Immunodiffusion in Agarose Gels Between Anti-CRl and CR1
Double immunodiffusion in agarose gels of purified CRl(48pg/ml>, (central 
well) against rabbit anti-CRl antiserum, Img/ml (well a), 0,5mg/ml (well 
b), 0.25mg/ml (well c) and 0.125mg/ml (well d). A precipitin line of 
identity was formed between CRi and each of the anti-CRl samples.
200K
230K
2 .1 6  D is c u s s io n
It was realised after the failure of the first 2 preparations that, as CRI 
was an extremely labile protein (Sim 1985; Ripoclie and Sira 1986), some 
modifications would have to be made to the purification procedure. It was 
decided to shorten the length of the procedure in 2 ways, (i) by speeding 
up the washing of the E membranes and (ii) by using a quicker method of 
screening the columns. In addition extra protease inhibitors were added 
to the buffers in an attempt to cut down proteolysis of the receptor.
In order to decrease the time spent washing the membranes, a Pellicon 
cassette system was used. This system had previously been successfully 
utilised by Wong et al (1985) in their preparation of CRI. The efficiency 
with which this machine operated meant that the cells were ready to be 
put over the Biorex column within 24 hours of beginning the preparation. 
As both the RIA and the C3bBbP convertase inhibition assay were time 
consuming, agglutination of EAC43b was used instead to screen the 
columns. This was a sufficiently reliable method to ensure that CRI 
activity could be detected quickly and accurately.
Two modifications were made to the chromatographic procedures, (i) only 
lOOinls of the concentrated pool from the Biorex column were applied to 
the C3-Sepharose column. This helped to decrease the overloading of the 
column which had occured in the first preparation (Fig 2.7) and (ii) the 
Biogel column was not used as previous experience had suggested that this 
column did not greatly add to the purity of CRI and may have in fact 
diluted the receptor pool (Fig 2.8). The pool from the C3-Sepharose 
column was therefore dialysed into the equilibrating buffer for the lentil 
lectin column, followed by application to the column and successful 
elution of 2 peaks of CRI activity by oc methylmannoside (0.2 mol I'"1) 
(Fig 2.12). When pooled these 2 peaks both gave a positive 
haemagglutination titre of 1:1280, The first of these pools when 
concentrated had a total protein content of 96/jg and the second a total 
of 80pg. This gave a combined total of 176/jg of purified CRI from lOOmls 
of the original Biorex pool. If the remaining 134mls from the Biorex pool 
were to yield a comparable amount of CRI then it can be estimated that 
from this purification 412pg of CRI were obtained. This is 3 times in 
excess of the amount of purified CRI which Fearon obtained although the 
amount of protein in the initial Biorex starting material was comparable 
in both cases (Fearon 1979),
The purified CRI was analysed by 5% SDS-PAGE and a single band of 
molecular weight 230,000 daltons in the reduced form was seen with 
coomassie blue staining, Vhen the gel was silver stained, a process which 
is 2- to 5-fold more sensitive than coomassie blue staining, no 
additional bands were observed indicating that the preparation was pure 
(Plate 2.2).
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The specificity of the anti-CRl antiserum was shown by the observation 
that a single precipitin line was formed when it was tested by double 
diffusion in agarose gels against purified CRI (Plate 2.4).
CHAPTER THREE
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3.1 Introduction
In 1965 Klopstock et al (1965) observed a wide variation in the immune 
adherence activity of E from different individuals. From the results of 
family studies they concluded that the capacity of E to mediate immune 
adherence was inherited, Since that time it has become generally accepted 
that E CR1 numbers in the normal population are inherited (Wilson et al 
1982; Minota et al 1984; Valport et al 1985a; Holme et al 1986). Wilson et 
al (1982) enumerated CR1 on E from a section of the normal population 
and found that the numbers appeared to fall into a trimodal distribution. 
On this basis they suggested the existence of a genetic locus with 2 
codominant alleles (encoding high (H) and low (L) expression) determining 
the level of E CR1 expression. The data of Walport et al (1985a) also 
indicated that in the normal population there was a heritable component 
in the expression of CR1 number. However this group did not agree with 
the simple model of inheritance proposed by Wilson et al (1982) 
considering it more likely to be under polygenetic control.
The numerical polymorphism of CR1 has aroused considerable interest due 
to the discovery that patients with SLE have reduced E CR1 levels. This 
finding has been unequivically proven by studies in laboratories from 
different parts of the world (Miyakawa et al 1981; Iida et al 1982; 
Wilson et al 1982; Taylor et al 1983a; Ross et al 1985; Holme et al 1986). 
The mechanism whereby this reduction occurs is unknown, although 2 
general mechanisms have been proposed, (i) low CR1 numbers are inherited 
by means of an allele(s) associated with low CR1 number or (ii) they are 
acquired as a result of a pathological process. Most recent evidence 
indicates that low E CR1 numbers in SLE patients are acquired with the 
level of CR1 expression being related to disease activity (Ross et al 
1985; Holme et al 1986).
In order to compare the influence of genetic and environmental factors on 
E CR1 expression in the normal population, it was decided to undertake a 
study of E CR1 levels in twins. The twin study method was first proposed 
as a technique for differentiating between the influence of heredity and 
environmental factors by Sir Francis Galton (1875). He reasoned that 
since monozygotic twins have exactly the same hereditary structure, any 
difference between the pair must be caused by environmental factors. The 
converse, that if a pair of monozygotic twins are alike in any given 
trait that this trait is inherited is not necessarily true as twins
usually share a close common environment. Unless this limitation is 
recognised the role of genetic factors may be overestimated. Thus the
twins study method is possibly more useful for demonstrating that 
environmental rather than hereditary factors are important in the 
development of any given trait (Buchanan et al 1967).
In addition to measuring E CR1 numbers on the twins, the serum levels of
C4bp, H and I were measured by enzyme linked immunosorbent assay 
(ELISA). CR1 is known to be closely related in function and binding 
activity to the other cofactor proteins H and C4bp (Iida and Nussenzweig
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1981), Moreover Rodriguez de Cordoba et al (1985) have shown that the 
structural genes for CR1, H and C4bp are closely linked and recently the 
structural genes for CR1, H and C4bp have all been mapped to chromosome 
1 (Klickstein et al 1985). The genetic linkage and the functional 
homologies have led to the hypothesis that these 3 proteins, (and 
possibly DAF and gp45~70 also) may comprise a new human complement- 
regulatory gene family analogous to the C4/C2/B and C6/C7 gene families 
already described (Holers et al 1985).
This chapter will describe the analysis which was performed to determine 
the relative roles of genetic and environmental factors on E CR1 
expression and on the serum concentrations of H, C4bp and I. In addition 
the levels of each of the proteins were examined to see if age or sex had 
any influence on them. Finally an analysis was carried out to determine 
if there were any correlations evident between CR1, C4bp, H and I.
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Materials and Kethoda
3.2 Chemicals and Reagents
Chemicals and other reagents were obtained from the following sources:
Sigma Chemical Company. Fancy Rd. Poole. Dorset.
Caprylic Acid
Hydrogen Peroxide (HaO^)
o-Phenylene-Diamine (QPD)
Polyvinyl Pyrrolidone (PVP)
Dynatech ..Laboratories _Ltd. Daux Rd, Billingshurst. Sussex.
Flat Bottomed Micro-Elisa Plates 
Flow. Laboratories. Irvine. Ayrshire
RPMI-1640 medium without sodium bicarbonate, without glutamine, with 
HEPES.
Pharmacia House. Midsummer Boulevard. Milton Keynes 
Sephadex G-50, (medium)
Pierce .and Varriner. UK. Ltd> .44t -Hpp£r...jQr±hgata_St>_.Chgs.ter, ..Cheshire 
Iodo-Beads 
British Oxygen
Liquid nitrogen was supplied by British Oxygen.
3.3 Twins.
One hundred and twenty three sets of twins were recruited into this study 
as a result of an advertising campaign on radio and in the local and 
national press. The zygosity, sex and age distribution of the twins are 
shown in Fig 3.1. Both members of each twin pair were interviewed at the 
same time and the presence of existent disease noted. Hone of the twins 
had any chronic inflammatory rheumatic disease.
3.4 Blood Samples
At the time of interview, 60mls of venous blood were taken, 40mls were 
allowed to clot at room temperature for 1 hour and then incubated on ice 
for 30 min to allow the clot to retract. The clot was separated from the
Fig 3.1 Zygosity. Sex and Age DiatLLbu.jJ.un.-o£../.theLJdailS.
Legend.
Frequency histograms showing the age distribution of each set of twins; 
(a) all twins, (b) monozygotic female, (c> monozygotic male, (d) dizygotic 
female, (e) dizygotic male, (f) dizygotic male and female.
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serum by centrifugation at 2000g for 5 min at room temperature. The 
serum was removed and stored in aliquots at -70‘C.
The remaining 20mls of blood were anticoagulated with heparin and frozen 
as described in section 3.5.
3.5 Freezing Blood Samples 
Reagents
3Q%Iw/v)__ Polyyinyl/Pyrrolidone (PVP)
30g of polyvinyl/pyrrolidone were added to lOOmls of PBS in a glass 
bottle. The bottle was then put into a pressure cooker and heated until 
the polyvinyl/pyrrolidone had dissolved.
RB.MIXBSA
lg of BSA was added to lOOmls of RPMI.
Procedure
Six millilitres of 30%(w/v) PVP were added dropwise to 20rals of 
heparinised blood from each of the twins. Using a Pasteur pipette the
blood/PVP mixture was then added dropwise into a steel bowl containing
liquid nitrogen. The individual frozen pellets were collected and stored 
at -70 #C in plastic universals prior to measurement of CR1 numbers and 
blood group analysis.
3.6 Thawing Blood Samples
Vhen required the blood droplets were thawed out by adding one droplet 
to 0.5mls of warm (37*C) RPMI. The thawed cells were centrifuged at 
2000g for 5 min at room temperature and the buffy coat removed by 
aspiration, As the thawing process resulted in a variable degree of 
lysis each twin sample was given 5 50ml washes in warm (37 *C) RPMI and 
resuspended in RPMI/BSA. One hundred micralitres of the E suspension was
then added to 2.9mls of deionised water and the optical density was
measured at 541nm. The E were adjusted to 2.5xl0e/ml using the following
formula:
ODsai Measured
Volume of E required = Initial volume . X ----- Q"l85-------  ^ ^
3.7 Determination of Zygosity
The first priority in any twins study is to establish the zygosity of the
twins. In this case zygosity was determined by similarities in the
physical appearance of the twins (eg. hair colour, eye colour, facial 
appearance) and the reply to the question, "Have you always been
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considered to be identical twins?". On this basis 61 pairs were 
considered to be monozygotic and 62 pairs dizygotic. Erythrocytes from 
the monozygotic twins were then subjected to blood group analysis. This 
analysis was carried out by the Department of Haematology in the Western 
Infirmary, Glasgow. The groups studied were ABO, Rh CDE, Ms Ns, Pi, Le®, 
K, Fy® and JK ®. There was no discordance between any of the twin 
members tested. The chances of dizygosity based on the twins being 
members of the same sex and the results of blood group analysis were low 
ranging from 2% to 14% This analysis did not take into account their 
physical appearance (other than sex), so clearly the possibilities of 
dizygosity were less than 2% to 14%.
3.8 Detfirjn.inatlQii.pi. E..CR1 Number. Using ..the Monoclonal Antibody Ell
E CR1 number on the twins was measured by means of a RIA which employed 
the use of a radiolabelled monoclonal antibody to CR1, Ell, Before Ell 
could be labelled the IgG fraction was isolated from the mouse ascites 
fluids this fraction was then labelled with 1:EKI using Iodo-beads.
3.8(a) Isolation of IgG Fractions from. Mouse Ascites Fluid
(Steinbuch and Audran 1969)
Reagents
The monoclonal antibody anti-CRl (Ell) was a gift from Dr N Hogg, 
Cambridge, England.
Buiiers
Acetic Acid (Q.l mol I"1)
600pl of glacial acetic acid were added to 99.4mls of deionised water. 
Saturated. Ammon i unL.Sulphat.fi... ._(S AS)
760g of ammonium sulphate were added to 1 litre of almost boiling 
deionised water. The solution was stirred until as much of the ammonium 
sulphate as possible had dissolved. The SAS was left overnight at room 
temperature and the pH was adjusted to 7.2 with sulphuric acid before 
use,
£roce.d.ULe,
The Ell mouse ascites fluid (1ml) was adjusted to pH 4.5 by addition of 
acetic acid (0.1 mol l'"1). Caprylic acid was then added such that a 5% 
(v/v) caprylic acid solution was obtained. The solution was shaken 
vigorously by hand and then centrifuged at 10,000g for 7 min at room 
temperature. The supernatant was carefully removed and the pellet 
discarded. While the supernatant was being stirred on a magnetic stirrer 
an equal volume of SAS was added dropwise to the supernatant. Stirring
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was continued for 2 hours at room temperature to allow precipitation of 
IgG, The solution was then centrifuged at 10,000 for 7 min at room
temperature and the supernatant removed. The pellet containing IgG was
redissolved in 2mls of PBS. This was then placed into dialysis tubing 
and dialysed against 2 litres of PBS overnight at 4'C. Following this, 
protein concentration was determined spectrophotometrically by reading 
the optical density at 280nm and dividing this number by 1.43 which is 
the extinction coefficient for IgG. The protein solution was then divided 
into aliquots which were stored at -20’C.
The purified IgG fraction showed a single line of identity with rabbit 
anti-mouse IgG in double immunodiffusion agarose gels, a technique which 
has been described previously in chapter 2.6(f)-*
3.8(b) Radioiodination. of Ell Using Iodo-Beads (Markwell 1982)
Each of the nonporous Iodo-beads are covalently modified with an
oxidizing agent which facilitates the smooth and reproducible iodination 
of the tyrosine residues of peptides. This system of iodination is 
gentler than the chloramine-T method and it was therefore used to
radiolabel the monoclonal anti-CRl antibody Ell.
Buffers 
Sodium Phosphate. Buffer
A stock solution of phosphate buffer was prepared as described in chapter 
2.8. This was made to a pH of 7.4 and diluted to give a 0.05 mol I-1 
solution.
Erosedur-S
The Iodo-beads were washed twice with sodium phosphate buffer, each time 
using 1ml of buffer per 2 beads. The beads were then dried on filter 
papers and added to ImCi of carrier free 12SI which had been diluted
with 200pl of phosphate buffer. The beads were incubated with the '2Si
for 5 min at room temperature with occassional mixing by hand. Ell
(lmg/ml) was then added to the preloaded Iodo-beads in the reaction vial 
(2 Iodo-beads were used to label lmg of protein). A 15 min incubation at 
room temperature with occassional mixing by hand was the reaction time 
for maximal incorporation of 125I into the protein. Following this
incubation the bound and free iodine were separated by putting the
reaction mixture over a 10ml Sephadex G-50 column which had been
equilibrated with PBS. Gel filtration separates molecules on the basis of
molecular weight thus the iodinated proteins, being heaviest, were eluted 
first from the column before the free iodine, thus separating the bound 
from the free iodine. Fractions (500pl) were collected and screened for 
125I content by counting a 1:100 dilution of each fraction in an
automatic K counter (Fig 3.2). In this case fraction 6 and 7 were pooled 
and tested for precipitable counts by the acid precipitation technique
1351 cpm x ID"*
150
a
122 e 10 14 IS 200 4
Column Fraction
Legand.
Purification of 12S I-labelled IgG from free iodine using a 10ml Sephadex 
G-150 column. Fraction (500p.l) were collected and the amount of 12SI-cpm 
in a 1:100 dilution of each fraction was plotted against the fraction 
number. The first peak contained ' *5 I~bound to Ell as determined by acid 
precipitation with TCA. Fractions 6 and 7 were pooled. The second peak 
contained free iodine.
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which has been described in chapter 2.6(e). The percentage of acid
precipitable counts was always greater than 95%. The protein
concentration of the pool was then determined spectrophotometrically. 
This concentration was usually between 0.2 and 0.3rag/ml.
3.8(c) Quantification of CR1 sites/E using Ell
Firstly the amount of CR1 specific IgG in the mouse ascites fluid was 
quantified. This was achieved by incubating a vast excess of E (lxlO10)
with 250ng of 1 ^ I-Ell-IgG in the presence and absence of a 100-fold
molar excess of unlabelled Ell-IgG. This experiment was performed with 
cells from 3 individual donors. The mean percentage of specific binding 
of Ell-IgG was 32%. It was therefore decided to add 700ng of purified 
Ell-IgG to SxKPE. Of this 32% was capable of binding to CR1 which 
represents 224ng of specific Ell-IgG which was sufficient to saturate all 
available CR1 sites.
Reagents
Bibutylphthalate/Dinonylphthalate
60mls of dibutylphthalate were mixed with 40mls of dinonylphthalate. 
Procedure
Triplicate aliquots (200pl) of E (2.5xl0e/ml) in RPMI/BSA were 
transferred to microcap tubes. To each tube 700ng of I:25I-E11 were added 
and then the E were incubated for 1 hour at 4°C with end over end mixing 
on a Matburn mixer. In order to assess nonspecific binding of 12:SI-E11, a 
10-fold molar excess of unlabelled Ell was added to separate triplicate 
aliquots (200pl) of E (2.5xl0'3/ml). These cells were incubated for 30 min 
at 4*C with end over end mixing on a Matburn mixer before addition of 
700ng of 12SI-E11 and incubation for a further 1 hour at 4*C. Vhen the 
incubation periods were complete the E were layered onto 300pl of 
dibutylphthalate/dinonylphthalate in microcap tubes and the bound and 
free 12SI-E11 separated by centrifugation at 10,000g for 2 min at room 
temperature. The supernatant was removed and the red cell pellet was cut 
from the bottom of the tube using a hot scalpel blade. The pellets 
containing 12:SI-E11 bound to E were placed into glass carrier tubes and 
counted in an automatic H counter,
3.8(d) Calculation of E..CR1 Nuroh&c.
The amount of radioactivity bound in the absence of unlabelled Ell 
represents the total amount of 12SI-E11 bound to the E. The amount of 
radioactivity bound in the presence of unlabelled Ell represents the 
nonspecific binding of 1:2BI-E11. The specific number of bound cpm were 
obtained by subtracting the mean of the nonspecific binding from the 
mean of the total binding. The number obtained represented the number of
bound cpm to 5xl07E. To convert the bound cpm into CR1 antigenic sites 
per cell the following calculations were performed.
The number of molecules in lcpm =
2.8f x 1013 
lumber of cpm in 700ng of IgG anti-CRl
The number of antigenic sites per cell =
The number of molecules in lcpm x The number of bound cpm in 5x10rE
5x1 O'7
The explanation for this calculation is as follows, 1 mole of IgG
contains 150,000g or 6.03 x I0a3 molecules (Avagadro's number), therefore 
700ng of IgG molecules contains 2.<32x10’ * molecules. For each assay the 
number of molecules in lcpm were determined by dividing 2.82xl01;3: by the 
number of cpm in 700ng of IgG anti-CRl. This input at 700ng varied for 
each assay according to the natural decay of the ' 3 S I label. Having
obtained the number of molecules in lcpm it was then possible to
calculate the number of molecules contained in the number of bound cpm 
which was for the total E input of 5xl0'7/tube, Division of this number by 
5x1 O'7 resulted in the number of CR1 molecules (antigenic sites) per E.
3.9 Control .for E LysigLJQuring Determination of E CR1 lumber
As already mentioned (3.6) the thawing process resulted in a variable
degree of lysis. Although before standardisation each sample was given 5 
washes in RPMI until no further lysis occured, during the assay procedure 
itself additional lysis occurred. To control for this a 1ml E sample 
(2.5xlOs /ral) from each twin was placed into a microcap tube and subjected 
to the same conditions as the test samples. After centrifugation over 
dibutylphthalate/dinonylphthalate a lOOpl aliquot of the supernatant was 
removed and added to 2,9mls of deionised water and the ODs /m  was 
measured. The number of lysed E were then calculated and subtracted from 
the total input into each microcap tube. This number was then used in the 
calculation described in 3.8(d) instead of 5xlO'7.
Electron microscopy of the E pellet revealed that the membranes from 
the lysed E were not pelleted out during the centrifugation procedure and 
therefore did not contribute to the final E CR1 number.
3.10 r.eesa/Ihawiiig.
To ensure that the freezing and thawing process did not result in 
alterations of E CR1 number the following control experiments were 
performed. Venous blood (20mls) was collected from 5 donorsp this was 
divided into 2 10ml aliquots. The E from 1 of the aliquots from each 
donor was washed and standardised to 2.5xlOeVral and E CR1 number
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determined. The remaining aliquot from each donor was frozen and stored 
at -70 “C. Following storage the E were thawed and CR1 number determined. .
3.11 Intra~ Assay.-V.ar ialion
In order to assess the reproducibility of the assay a blood sample was 
taken from 1 individual and divided into 3 aliquots. Each aliquot was 
treated as a separate sample and the E CR1 number for each was 
calculated. All of the assays were performed at the same time. Table 3.1 
shows that for 3 donors the greatest variation was ±9% from the mean.
3.12 Inter-Assay Variation
In order to assess the inter-assay variation, aliquots of frozen red cell 
pellets from the same twin sample were thawed out on 2 separate 
occassions and E CR1 number determined. As is shown in Table 3.2 the 
greatest inter-assay variation for 6 donors was ±7% from the mean.
3.13 Enzyme Linked Immunosorbent Assay (ELISA)
The basis for this method involves the attachment of antibody to plastic 
microtitre plates. Following blockade of any free binding sites left on 
the microtitre plate with BSA, antigen was added to the wells. Antigen 
bound to antibody is detected by the addition of a second antibody to the 
antigen labelled with horseradish peroxidase (HRP). This enzyme catalyses
the reduction of hydrogen peroxide and oxidation of OPD from a clear to a
coloured solution. The intensity of colour, which is an indication of 
antigen concentration, is measured spectrophotometrically at an 
absorbance of 492nm on an ELISA reader.
Reagents 
Coating Antibodies
Coating antibodies were donated by Dr L Morrison. They were stored at 
-20*C and contained 0,01% thiomersal as a preservative. Prior to use they 
were diluted in coating buffer to the concentrations indicated below.
Anti-H (5pg/ml)
Anti-C4bp (10jig/ml)
Anti-I (lOpg/ml)
Conjugates
All conjugates were kindly donated by . Dr L Morrison, they were stored at 
4*C and contained 0.01% thiomersal as a preservative. Prior to use they 
were diluted in 0.05% (v/v) Tween/PBS to the concentrations indicated 
below:
Sample Aliquot 1 Aliquot 2 Aliquot 3 MeantSD % Variation
1 271 313 295 293±21 +7 -7
2 1105 1096 953 1051±85 t*9 +5
3 1046 1100 1023 1056+39 *3 +4
Bote: The mean of each set of 3 measurements was calculated. The 
difference between the 2 extremes and the mean in each set was then 
expressed as a percentage of the mean.
Table 3.2
CR1 Sites/E
Sample 1st
Measurement
2nd
Measurement
Mean % Variation 
from the mean
1 618 683 650 +5 -5
2 1856 2117 1986 +7 -7
3 752 754 753 0
4 1536 1385 1460 +5 -5
5 635 705 670 +5 -5
6 953 927 940 +1 -1
Bote: The mean for each 2 measurements was calculated. Each number was 
then expressed as a percentage of this mean.
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HRP anti-C4bp (diluted 1:250)
HRP anti-H (diluted 1:10,000)
HRP anti-1 (diluted 1:100)
Slandand
A serum standard consisting of a pool of serum from 50 normal donors 
was used in each assay. This standard contained H (300/jig/ml), C4bp
(250pg/ml) and I (50pg/ml). This standard was diluted in Tween/PBS from
1:500 to 1:512,000 for the H ELISA, from 1:2,000 to 1:128,000 for the C4bp 
ELISA and from 1:20 to 1:5120 for the I ELISA.
Iain Serum. Samples
The twin serum samples were diluted in 0.05% (v/v) Tween/PBS to the
dilutions indicated below.
C4bp (1:8,000), H (1:32,000) and I (1:320)
Substrate
17mg of OPD were dissolved in 50mls of phosphate/citrate buffer.
Immediately before use 20pl of hydrogen peroxide (H^Os) were added to 
this solution.
Buffers
Tween/PBS 0.05%(v/v)
0,5mls of Tween 20 were added to 1 litre of PBS,
Coating Buffer (carbonate/bicarbonate buffer (0.05 mol I"1 pH 9.6))
0,79g of sodium carbonate and 1.46g of sodium hydrogen carbonate were 
made up to a final volume of 500mls with deionised water.
Blacking Buffer
0.5g of BSA were added to 500mls of PBS.
Phosphate/Citrate Buffer
llmls of citric acid (0.1 mol l”1) were mixed with 14mls of disodium 
hydrogen phosphate (0.2 mol I-1) to give a final pH of 5.6, 25mls of 
deionised water were then added.
the p la t©  way aspirated and w
at US
5 tin es
Ida following m c r n i n ■ 
?ween/?3S ensuring that
a i l  th e  w e lls  w ere f i l l e d  to  th e  to p  w ith  sack  wash, Any re m a in in g  f r e e  
s i t e s  on the m i c r o t i t r e  p la t e  were blocked by incubation w ith  2 5 0 /j.l o f 
VBB/BBk fo r 1 h ou r a t  room te m p e ra tu re  in  a  humid a tm o s p h e re , The p la te  
was a s p ir a t e d  and washed 5 t im e s  with Tween/PBS and th e n  d u p lic a te  
aliquots (100/j.l) o f  th e  serum  s ta n d a rd  a t  th e  d ilu tions  in d ic a te d  were  
added to  th e  to p  2 row s o f  w ells . T r i p l i c a t e  a l iq u o ts  (lO O p l) o f a 
s u i ta b le  d ilu tio n  o f  th e  tw in  s e ra  w ere th e n  added to  th e  re m a in in g  w e lls  
and th e  p la te  was in c u b a te d  a t  room te m p e ra tu re  fa r  2 h ou rs  in  a hum id  
a tm o s p h e re . The p la t e  was th e n  a s p ir a t e d  and w ashed 5 t im e s  w ith  
Tween/PBS and lO O p l of the HRP-conjugated IgG f r a c t io n  of th e  same 
antiserum used for coating the w e lls  was added and the p la t e  was 
incubated a t  roam  te m p e ra tu re  f o r  1 hour in  a hum id atmosphere. The p la ts  
was a s p ir a t e d  and  washed 10 t im e s  w ith  Tween/PBS and iOOp.1 of th e  
substrate was added , The p la t e  was in c u b a te d  fo r 30 min in  th e  d a rk  in  a
hum id a tm o s p h e re , b e fo re  a d d i t io n  o f  25p .l o f  s u lp h u r ic  a c id  (4 m ol 1 1 >
to each w ell to stop the reaction, The absorbance of each w ell at 492rio 
was then read using an automatic ELISA reader.
3 .1 4  C a lc u la t io n  ox Serum C o n c e n tra t io n s  o f  C 4bp. H a nd I
The concentration o f  each p articu la r protein in  the standard serum pool 
was calculated fo r each d ilu tio n  of the standard c u rv e . T h is  was plott?-. i  
onto semilag paper against the mean of the ODass obtained from the ELISA 
assay fo r the standard d ilu tions  (Fig 3 ,3 ) ,  The loguo  values o f  the. serum  
concentrations were obtained and these values were used as the
coordinates and the of each of the d ilu tio n  were used as the y
coordinates in a lin ea r regression analysis. I f  the correlation
co effic ien t of the lin e  obtained was greater than 0.995 then th is  linn  
was used to determine the serum concentrations o f the p a rticu la r protein  
under study. I f  the corre la tion  co effic ien t was lower than 0 ,9 9 5  th e n  any 
points on the graph which deviated from the s tra ig h t lin e  were o m it te :  
from the calculation. Usually the highest and lowest d ilu tions  were 
omitted as the lin e  tended to curve a t its  upper and lower lim its . I f  th e  
0D4.3 S; of the sample f e l l  outwith the lin ear portion of the s ta n d a rd  cures 
the assay was repeated using a more appropriate serum d ilu tion .
3.15 ,Iiitmrlaaay,.,Iaxia.f.iQrL...£Qr_t.he_ELlSA.....ismy
The in t r a - a s s a y  v a r ia t io n  f o r  th e  d i f f e r e n t  ELISA p ro c e d u re s  ru e  re d  ■::
th e  mean,
Fig 3.3 Standard Curve of Serum Pq.qI
Legend
A standard curve was constructed by plotting the QlUss: of a dilution of 
the standard containing a known concentration of H against that 
concentration. The linear regression analysis performed on these points 
gave a correlation coefficient of 0.996.
Optical Density 492nm
i.ca j—
t.00
a.25
e.Oe
Concentration of H in the Serum Standard (ng-1
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3.16 Inter-Assay Variation for the ELISA Assay
The inter-assay variation for all the proteins tested was ±6% of the 
mean.
3.17 S ta .tis tlca l_A naly.gis  
3.17(a) Genetic Analysis
The most commonly employed techniques in the genetic analysis of 
continuous characteristics are the study of intra(within)-pair and 
inter(between)-pair variances (Osborne and De George 1959) and the intra­
class correlation coefficient.
The Intra-pair Variance
The intra-pair variance is calculated by the equation shown below (which 
has If degrees of freedom):
E ( A - 0 ) *  
2H
where A and B are the assay results for a pair of twins and E donates 
summation over a set of If pairs.
The Inter-pair Variance
The int&Ci-pair variance (which usually has IT-1 degrees of freedom) is 
calculated by the equation shown below:
1
"DF
E ( A + B ) : Z (A+B): 
“ 21
where DF, the degrees of freedom is at most equal to U-l. However when 
corrections were made for batch effect several degrees of freedom were 
lost and this affected the calculation.
Variances were compared by dividing the larger by the smaller, the ratio 
being referred to as 'F\ the statistical significance of which can be 
determined from standard tables of F values.
Intra-class Correlation Coefficient-ir!
In measuring correlations between twins it is not possible to decide 
which measurement on a pair of twins is x and which is y. For this 
reason, the intra-class correlation coefficient (r), which treats each
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pair of twins symmetrically, is preferred to the most usual inter class 
correlation coefficient. It is equal to:
Inter-pair Variance - Intra-pair Variance 
Inter-pair Variance + Intra-pair Variance
3.17(b) Batch Effect.
When E CR1 numbers and serum concentrations of H and C4bp were measured, 
each member of a twin pair was measured in the same batch. This may have 
led to similarities between twins which were purely as a result of the 
twins being in the same batch. Statistical tests were therefore performed 
to determine if there was a batch effect. One way analysis of variance 
showed that there was a significant difference between batches for each 
of the 3 proteins. Therefore each measurement was first corrected by 
subtracting its corresponding batch mean and adding to this number the 
grand mean of all the measurements for that particular protein. These 
corrected numbers were subsequently used to test for age effects and for 
correlations between sets and subsets of twins,
3.17(c) Age.Effect
A pair of twins may resemble each other not only because they have the 
same genes but also because they have the same age. The correlations of 
H, C4bp and I levels with age were significant, with serum concentrations 
of each increasing with age. It was therefore necessary to age-adjust the 
measurements to ensure that age effects would not contribute to any 
correlation between the twins. This was achieved by calculating the 
increase observed each year and subtracting this from the measurements 
for each year above the mean age of the population studied and adding the 
increase on for every year below the mean age.
3.17(d) Mean Values
In this analysis the geometric mean values are quoted as opposed to the 
arithmetic mean values. The geometric mean value is the anti-log of the 
mean value of the logio value of each protein. This is more 
representative of a positively skewed distribution than is the arithmetic 
mean, because the latter is very sensitive to measurements at the high 
end of a skewed distribution.
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Results.
3.18 Validity of CR1 Number, after Freeze/Thawing.
Before any of the twin blood samples were collected and frozen it was 
first of all established that the freezing and thawing process did not 
alter E CR1 expression. Table 3.3 shows the number of CR1 sites/E 
calculated on unfrozen blood samples and on the same sample after it had 
been frozen and thawed. As can be seen from the table the largest 
percentage variation in CR1 number was ±6% of the mean,
3.19 Distribution of CR1 Sites/E in all of the_Twins Studied
Using the raw data a histogram was constructed showing the distribution 
of CR1 sites/E in all of the twins studied (1 pair of twins is missing in 
all of the CR1 data) (Fig 3.4(a)). As can be seen from Fig 3.4(a) this 
approximates to a log-normal distribution. For the purposes of 
statistical analysis it was necessary to transform each of the CR1 
measurements to the logio value (Fig 3.4(b)). The anti-log geometric mean 
of CR1 sites/E was 837.
3.20 Comparison of CR1 Measurements in Males_and Females
After correction for batch effect the geometric mean E CR1 values for 
males and females were compared to determine if there was a relationship 
between CR1 and sex. The geometric mean for males was 839 and that for 
females was 829. As these mean values were almost identical it may be 
concluded that sex does not influence the mean value of E CR1.
3.21 Effect of Age on.CRl
The CR1 numbers from all the twins were used to test for age effects. The 
correlation coefficient between CR1 and age was not significant. Therefore 
it may be concluded that there is no relationship between CR1 and age.
3.22 Genetic Analysis of CR1 Sites/Erythrocyte
The intra-pair and inter-pair variances and the intra-class correlation 
coefficients were calculated far all the sets and subsets of twins. The 
results are shown in Table 3.4.
ITone of the F values quoted in
Table 3.4 are significant (apart from the F value for the batch 
variation). This indicates that the differences between dizygotic twins 
were no greater than the differences between monozygotic twins. There is 
also no evidence of any correlations between any of the sets or subsets 
of twins (Fig 3.5(a),(b) and (c)). Thus it may be concluded that the 
genetic influence on E CR1 numbers in the normal population, if it exists, 
was too small to detect. Differences between twins must therefore arise 
largely as a result of environmental factors,
Table 3.3 CQmpar.isQii_.Qf_.CRl. Sites/E Before and After Freeze/Thawing
Donor Unfrozen Blood Frozen Blood Mean % Variation from the Mean
1 466 473 469 + 1 -1
2 333 337 335 + 1 -1
3 258 229 243 +6 -6
4 338 362 350 +3 -3
5 219 214 216 +1 -1
Bote: CR1 number was calculated on freshly isolated E. An aliquot of E
from the same donor was then frozen and stored at -70 *C. The blood was 
thawed and CR1 number determined taking into account the degree of lysis. 
The mean of both determinations was calculated for each set of 
measurements. Both measurements were then expressed as a percentage of 
the mean.
Fig 3.4(a) Distribution of CR1 Sit.es/IL
Frequency histogram showing the distribution of CR1 sites/E on 122 pairs 
of twins.
Fig 3.4(b) Distribution of login Transformed CR1 Sites/E 
Legend
Frequency histogram showing the distribution of CR1 sites/E in 122 pairs 
of twins after transformation of each to the logio.
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+ This figure was obtained by subtracting each individual measurement 
from the grand mean of all the measurements, squaring this figure and 
then adding up all the squares, It gives an indication of what the 
variation from the mean is in each of the groups indicated under 
source of variance.
" The degrees of freedom for the inter-pair variation are low because 
of correction for batch effect. This correction is not necessary for 
intra-pair variation as the pairs of twins were measured in the same 
batch and therefore the difference between one individual and his twin 
is always the same,
U  The mean square is obtained by dividing the sum of squares by the 
degrees of freedom. This figure corresponds to the intra-pair or 
inter-pair variance.
* Variances were compared by dividing the inter-pair mean square by 
each mean square the ratio being referred to as F. This figure 
indicates whether the difference within a pair of twins is 
significantly different from the differences between pairs of tv/ins.
This F value is significant. This indicates that there was a 
significant difference between batches, larger than might be expected 
by random sampling error. Correction for batch effect was necessary 
because of this.
US = Not Significant
DF = Degrees of Freedom
F = Female
M = Male
Source of Sum of+ DF"
Variance Squares
Mean Cl F Ratio* Significance 
Square
Total 26,4236 243
Batch Effects 11,4381 40 0.2859 3. 644H; P
Age Effects 0.0012 1 0.00116 67.269 MS
Inter-pair 6.24256 80 0.78032
Intra-pair 8.74181 122 0.071654 1. 089 IS
. . . divided, as follows
Monozygotic 5.00698 60 0.083450 1. 069 IS
Dizygotic 3.73483 62 0.060239 1.295 IS
...and subdivided as follows
Monozygotic F 4.54759 53 0.085804 1.100 IS
Monozygotic M 0.459390 7 0.065627 1.189 IS
Dizygotic F-F 2.78563 35 0.079589 1. 020 IS
Dizygotic M-F 0,801119 21 0.038149 2. 045 IS
Dizygotic M-M 0,148083 6 0.024681 3. 162 IS
0. 001
Fig 3.5(a) Correlations Between CR1 Levels in Twins.
Scatter graph showing a plot of logio E CR1 levels in twin 
twin 1. The correlation coefficient was not significant.
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Fig 3.5(b) Correlations Between CRI Levels in Twins
Legend
Scatter graph showing a plot of logic E CRI levels in identical twins 
only. Twin 2 is plotted against twin 1. Again the correlation coefficient 
was not significant.
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Fig 3.5(c) Correlations Between CRI Levels in Twins
Legend
Scatter graph showing a plot of logio E CRI levels in nonidentical twins 
only. Twin 2 is plotted against twin 1. The correlation coefficient was 
not significant.
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3.23 .A nalysis q£ Serum Concentr.at.iQns -.Qf  HLln, Twins
The distribution of H levels in all of the twins studied is shown in Fig 
3.6(a). The distribution shows a strong positive skew. As in the CRI 
assay the H levels had to be transformed to a normal distribution for 
the purposes of statistical analysis. This was achieved by subtracting 80 
from each of the original measurements and taking the logic of this 
number (logio (H-80)) (Fig 3.6(b)). The mean value of logic(H-80) in all 
the samples tested was 2.39, which corresponds to a concentration of 
324pg/ml.
3.24 Effect of Age on Serum Concentration of H
The correlation between transformed H levels and age was 0.43. This 
number is significant (p < 0.005) (Fig 3.7). Thus H levels do appear to 
increase significantly with age. The data was therefore corrected for 
both batch and age effect as described earlier and analysed for 
differences between males and females.
3.25 Comparison of H Levels in Males and Females
To determine if males and females have different amounts of H, the mean 
values of H were calculated for males and females. The mean for males was 
341pg/ml and the mean for females was 320pg/ml. As there was no 
significant difference between the two it may be concluded that there is 
no difference in serum concentrations of H between males and females.
3.26 Genetic Analysis of H Levels
The data were corrected for both batch effect and age affect and the 
results of the analysis of variance are shown in Table 3.5.
There was some resemblance between twins of various sets and subsets, as 
seen by the fact that the intra-pair variances were generally smaller
than the inter-pair variance. These resemblances showed moderate degrees 
of statistical significance as is indicated in Table 3.5. However, when 
the F ratio to compare dizygotic intra-pair variance (0.03005) with 
monozygotic intra-pair variance (0.02540) was calculated the value
obtained 1.18311, was not at all significant (P > 0.1). There was
therefore no evidence at all of any genetic influence on H levels.
3.27 Analysis of C4bp Measurements in Twins
Once again there was a strong positive skew in C4bp distribution when
the raw data were plotted as a frequency histogram (Fig 3.8(a)). The 
distribution was made almost normal by subtracting 85 from each of the 
original measurements and taking the logic of this number (logic(C4bp- 
85)). (Fig 3.8(b)). The mean of this transformed data was 1.943, which
corresponds to a C4bp concentration of 173/j.g/ml,
Fig 3.6(a)
Frequency histogram showing the distribution of serum levels of H in 123 
pairs of twins.
Fig 3.6(b) Distribution of Logio (H-80) Levels 
Legendl
Frequency histogram showing the distribution of serum levels of H in 123 
pairs of twins after transformation of each to logio (H-80).
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Fig 3>7 Correlation Between H Levels an<:
Scatter graph showing a plot of serum concentration of H against the age 
of the twin. The correlation coefficient was 0.43 which is significant.
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Source of Sum of DF
Variance Squares
Total 9.65146 245
Batch Effect 0.686055 8
Age Effect 0.62553 1
Inter-pair 4.92002 113
Intra-pair 3. 41256 123
,..divided as follows
Monozygotic 1.54919 61
Dizygotic 1.86337 62
...subdivided as follows
Dizygotic F 1.1310 35
Dizygotic M/F 0.47144 21
Dizygotic M 0,26093 6
Mean F Ratio
Square
0.0357569 1.9696
0.62553 14.3668
0.04354
0.02774 1.5696
0.0254 1.7142
0.03005 1,4489
0.03231 1.3476
0.02245 1.9394
0.04349 1.0001
Significanc
P ~ 0.05 
P < 0.005
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P <0.025 
MS
KS
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NS
Fig 3.8(a)
Legaufi
Frequency histogram showing the distribution of serum levels of C4bp in 
123 pairs of twins.
Fig 3.8(b)
Frequency histogram showing the distribution of serum levels of C4bp in 
123 pairs of twins after transformation of each to logic* (C4bp-85).
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There was a s ig n if ic a n t co rre la tion  between age and C4bp levels r=0.457 
(Fig 3 ,9 ). I t  was calculated that fo r a C4bp concentration of 173 pg/ml 
th a t each years increase in age would, on average, resu lt in an increase 
of about 1.6 pg/ml of C4bp (ie  almost 1% per annum). The data were
corrected fo r batch and age e ffe c t as described fo r CRI assays and then
analysed fo r d ifferences between maies and females,
3.29 Comparison of C4bp Levels in Hales and.■Females
The mean value of C4bp levels in males was 173 pg/ml and th a t fo r
females was 173 pg/ml. Thus i t  may be concluded th a t there is  no 
difference a t a l l  between males and females in C4bp levels.
The resu lts  of analysis of variance are shown in Table 3.6. The F ra tio  
to  compare d izygotic  in tra -p a ir  variance (0.0455295) w ith monozygotic 
in tra -p a ir  variance (0.044597) was 1.0209 which is  not s ig n if ic a n t (P > 
0.1). Therefore there was no evidence or suggestion of genetic influence  
on the levels of C4bp.
3.31 Analy.sl'S_Qi_J... JLeasursmen t  s_ wins.
The d is tr ib u tio n  of I levels  in a l l  of the twins is  shown in Fig 3 .10 (a ), 
The d is tr ib u tio n  shows a strong positive  skew and was transformed to a 
normal d is tr ib u tio n  by taking the log to values of I measurements (Fig  
3 .1 0 (b )). The geometric mean value of I  levels was 55/j.g/ml. As 
ind iv iduals , not twins were assigned randomly to batches fo r assay of I 
no batch correction was necessary,
3.32 E ii£c_L jD l^g £^n _I_L aY .e la
There was a s ig n if ic a n t correction between age and I levels (r=0.186; P 
< 0.005) (Fig 3 .11). Each years increase in  age was associated w ith an 
increase of about 0.00223 in Logto I levels. Therefore the I level 
increased by about 5% fo r every 10 years increase in age, A fter  
correction fo r age e ffe c t the Log to I levels were analysed fo r  
differences between the sexes.
3.33 Comparison of I Measurement in Hales and Females
The mean values of I were calculated fo r males and females. For. males 
there was a mean of 58/jg/ral of I and for females a mean of 55/jg/ml.There 
was no s ig n if ic a n t d ifference between I values in males and females as 
revealed by a pooled T te s t. Therefore i t  may be concluded th a t males 
and females have the same mean levels of I.
Fig 3.9 Correlation Between C4bp Lev els.. and _ Age.
Legend
Scatter graph showing a plot of serum concentration of logio(C4bp-85) 
against the age of the twin. The correlation coefficient is 0.457 which is 
significant.
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Table 3.6 iiia l^ i5 ^ i-X a riig ^r^ ..-Q L _ L .u g j^_ _ IQ ij2 p -852_L.gy.ela
Source of 
Variance
Sura of 
Squares
DF Mean Square F-Ratio Significance
Total •
Batch Effect 
Age Effect 
Inter-pair 
Intra-pair
20.3986 
3.74195
3.47885 
7.64428 
5.53349
245
10
1
111
123
0.374195
3.47885 
0.056315 
0.068867 
0.0444988
5.4336 
50,5155
1.5368
P < 0.001 
P < 0.001
P ~ 0.01
...divided as follows
Monozygotic 2.7204 61 0.044597 1.5442 P < 0.05
Dizygotic 2.82283 62 0,0455295 1.5126 P < 0.05
...subdivided as follows
Dizygotic F 1.918 35 0.0548 1.2567 NS
Dizygotic M/F 0.775587 21 0.0369327 1.8647 MS
Dizygotic M 0.129243 6 0.0215405 3.1971 NS
Monozygotic F 2.24031 53 0.04227 1.6292 P '
Monozygotic M 0.480086 8 0.0600107 1.1476 NS
Fig 3.10(a) DistributiQii-uiL-L-Lgygla
Legend
Frequency histogram showing the distribution of serum levels of I in 123 
pairs of twins.
Fig 3.10 (b) LLsdriLii.ti.Qn -OlJLagi.c-.I Levels.
Legend
Frequency histogram showing the distribution of serum levels of I in 123 
pairs of twins after transformation of each to logio I.
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Fig 3.11 Correlation Between I Level and Age
Scatter graph showing a plot of serum concentration of I against the age 
of the twin. The correlation is 0.186 which is significant.
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3.34 Genetic Analysis of I Levels
The intra-pair and inter-pair variances and intra-class correlation 
coefficients were calculated for each set and subset. The results are 
shown in Table 3.7. They indicate that there is no real evidence of any 
correlation between twins of any category and therefore no evidence of 
any genetic influence on I levels.
3.35 Correlations Among C4bp. H. I and CR1
All the analysis for correlation between the proteins were carried out 
using assay results which had been corrected for batch and age, whether 
or not the batch and age effects were statistically significant. (Even if 
too small to be significant, various batch and age effects might in 
principle contribute cumulatively to an inter-protein correlation which 
would be significant but spurious),
The 4 protein levels of, C4bp, H, CHI and I transformed and corrected for 
age and batch were then tested for male-female difference because, if 
present, the differences could violate the assumption of homogeneous data 
on which correlation analysis depends, and might give rise to spurious 
inter-protein correlations. As previously recorded there was no 
evidence of any difference between males and females and this was not 
changed by correction for batch and age effects.
Inter-protein correlations were then sought; these are recorded in Table 
3.8(a) (b) and (c).
This was a preliminary screening analysis as for correlation analysis to 
be strictly valid, the individual items of data must be mutually 
independent. As the data come from sets of twins this requirement is not 
met, and the observed correlations may be rather more prone to extreme 
deviations from the true values than would be observed in a population of 
unrelated independent individuals.
However, the negative results from the analysis should be dependable, as 
the resemblance between twins can only exaggerate the random sampling 
error, not reduce it. Therefore it is reasonable to conclude that there 
is no correlation between CR1 and any of the other 3 proteins. Nor is 
there any significant difference in the correlation coefficients between 
the two sexes.
A further negative conclusion may be drawn concerning the correlation 
between I and C4bp, Since both of these factors correlate fairly well 
with H, one would expect that they would have to correlate with each 
other. Partial correlation analysis showed that the correlation between I 
and C4bp could be explained entirely by their correlation with H.
More formal rigorous analysis depended upon the division of each twin 
pair into 2 sets, Set 1 consisted of the member of each pair who had
Table 3.7 Analysis of Variance of Logic I Levels
Set of Number Intra-pair Inter-pair r P Signif icance
Twins of Pairs Variance Variance
Dizygotic F 35 0,029882 0,025297 -0,08309 0,63 NS
Dizygotic H/F 21 0.035302 0,0430768 0,09920 0,66 NS
Dizygotic M 6 0,009451 0,0279919 0,49518 0,26 NS
Monozygotic F 53 0,025089 0,033723 0,22579 0,1 NS
Monozygotic M 8 0,011929 0,0472148 0,59661 0,03 NS
Dizygotic 62 0,029741 0,032557 0,0452 0,72 NS
Monozygotic 61 0,023363 0,0399456 0,26194 0,04 7
All Twins 123 0,026578 0,0373 0,16785 0,062 NS
Sot as
r = intra-class correlation coefficient.
Table 3.8 Iriter-Pr.gtein Qorrel.at.lon .Gus.£f.isi gnt.s. 
Ca) Whole Data Set
C4bp (r) H (r) CR1 (r)
H 0.427 (P < 10-*)
CR1 0.066 (NS) 0.074 (NS)
I 0. 188 (P < 0. 005) 0.248 (P < 10“*) 0.048 (NS)
(b) Esma'Les Only
C4bp (r) H (r) CR1 (r)
H 0.447 (P <10”s )
CR1 0.028 (NS) 0.049 (NS)
I 0. 17 (P < 0.02) 0.243 (P <10~3 ) 0.006 (NS)
<c) Males Qnlv
C4bp (r) H (r) CR1 (r)
H 0.342 (P < 0. 02)
CR1 0,241 (NS) 0.210 (NS)
I 0. 287 (P < 0.05) 0.247 (NS) 0.257 (NS)
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the lower serum serial number while Set 2 consisted, of the member of 
each pair who had the higher serum serial number. Studying set 1 alone, 
for evidence of inter-protein correlation was completely valid and set 2 
was also studied for confirmation. When analysis of the 2 twin sets were 
performed separately, as expected, there was no significant difference 
between the P values obtained for the inter-proteins correlations.
Therefore the evidence from twin 1 and twin 2 was combined to obtain a 
combined confidence level, or P value. These P values are shown in Table 
3.9. Fig 3.12(a) and (b) illustrate correlations between C4bp and H and 
between I and H respectively.
In addition to calculating the inter-protein correlation coefficients for 
twin 1 and twin 2, the inter-protein correlation coefficients were also 
calculated for the differences between twins ie twin 1 - twin 2, and for 
the sums of twin 1 + twin 2. This further analysis was undertaken in an
attempt to determine if the factors responsible for the correlations
between the different proteins occured as a result of genetic or
environmental influences. If the correlation was a result of genetic 
factors then the correlation would be more apparent in the sum and not 
the difference between twins. This occurs when each individual in the
twin pair has the same amount of a particular protein. The subtraction
of one from the other cancels out the genetic influence, and what remains
must be due to the environmental effect. Conversely if the serum levels
of 2 proteins correlated because they were both influenced by the same 
environmental factors, then the correlation of the differences between 
individual twins would be stronger than the correlation of the sum of the 
values of each set of twins.
The correlation based on the sum of pairs of assays ie twin 1 + twin 2 
are listed in Table 3.10 and those based on the differences between pairs
are listed in Table 3.11.
The results of these studies show that the correlation between H and C4bp 
and between C4bp and I are rather more apparent in the differences
within twin pairs than in the sums of twin pairs. This might imply that
environmental influences were predominant in determining the 
correlations. However, this conclusion did not satisfy any formal 
significance tests. On the other hand the correlation between H and I 
was marginally more apparent in the sums of twin pairs than in the 
differences. This might indicate a genetic influence on the inter-protein 
correlation but again this conclusion was not supported by any formal 
statistical tests.
In summary the main conclusions which can be drawn from this correlation 
analysis are (i) CR1 numbers did not correlate with C4bp, H or I, (ii) H 
levels correlated significantly with C4bp (r=0.427; P < 0.00001), (iii) H 
levels correlated significantly with I (r-0.248; P < 0.0001), (iv) C4bp 
and I correlated with each other (r=0.188; P < 0.01) but this is no more 
than would be expected from conclusions (ii) and (iii), (v) there is no 
evidence of any male-female differences in the mean values of any of the
Table 3.9 Inter~.Frotein Correlation Coefficients for, the .CQ.mb.ined
CR1 <r)C4bp (r)
0.074 (IS)0.066 (IS)CR1
0.003 (IS)
Table 3.10
C4bp (r) H (r) CR1 (r)
0.339 (p < 0.001)
CR1 0.008 (IS) -0.020 (IS)
0.114 (IS) 0.280 (P < 0.002) -0.063 (IS)
Table 3.11 Intgr~.FrQt.eln. Correlation Coefficients for Twin 1 - Twin-2
C4bp (r) H (r) CR1 (r)
H 0.552 (P < 10~e )
CR1 0.125 (IS) 0.169 (IS)
I 0.290 (p < 0.001) 0.205 (P < 0.005) (IS)
Scatter graph showing serum levels of C4bp plotted against serum levels 
of H. There is a significant correlation (r = 0,427).
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Scatter graph showing serum levels of I plotted against serum levels of
H. There is a significant correlation (r = 0.248).
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4 proteins and finally (vi) C4bp, H and I all increased significantly 
with age.
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Mendel was the first to explain heredity simply in terms of genes. His 
experiments with pea varieties that differed in qua. &tative clear-cut
visible traits such as size and colour showed that some differences were 
simply inherited and caused by one pair of alleles at a single gene
locus. However, not all inheritance is so clear-cut: variations such as 
those in stature, weight and skin colour in humans are quantitative 
rather than qualitative and can be accounted for by supposing that 
continuously varying traits are due to the joint action of several or 
many genes each of which has individually only a small effect on the 
traits in question. Such inheritance is said to be under polygenic 
control. Polygenes, the genes that bring about heritable variations in 
quantitative traits are genes, the alleles of which, produce small 
phenotypic differences, which are similar to differences which could be 
caused simply by environmental factors.
The number of CR1 sites per E have been shown to vary by as much as 10-
fold among normal healthy individuals as assessed functionally by
binding of dimeric C3b as well as antigenically using polyclonal or 
monoclonal antibodies (Wilson et al 1982; Iida et al 1982; Minota et al 
1984; Ross et al 1985; Valport et al 1985a; Holme et al 1986). A genetic 
basis for this variation has been proposed.
Wilson et al (1982) enumerated CR1 on E from a section of the normal 
population and noted that the numbers appeared to fall into a trimodal 
distribution. They suggested that the difference in CR1 numbers was 
clear^ cut with individuals having 2 codominant alleles coding for either 
low or high CR1 expression, This model was used to explain why patients 
with SLE had reduced E CR1 levels as it was concluded that these 
patients had an increased prevalence of the allele determining low 
numerical expression of E CR1. In agreement with this model of 
inheritance, Nojima et al (1985) found that the capacity of E to bind to 
radiolabelled aggregated human * globulin(125I-AHG) was distributed in a 
trimodal fashion in the normal population. Thirteen percent of normals 
showed low binding capacity, 58% intermediate and 29% high. These 
frequencies did not deviate significantly from frequencies calculated from 
the Hardy-Weinberg equilibrium assuming a 2 codorainant allele model 
determining low and high binding values. Others have disagreed with this 
simple model of inheritance suggesting that inheritance is as a result of 
the contribution of many genes (Walport et al 1985a). This proposal is 
based on the observation that E CR1 numbers in the normal population are 
distributed continuously and not in clearly defined .groups of individuals 
with high, intermediate or low CR1 numbers (Ross et al 1985; Walport et 
al 1985a; Holme et al 1986). Normally distributed quantities are usually 
the result of a number of factors both genetic and environmental*; however 
the distribution by itself gives no indication as to how many of these 
factors are environmental and how many are genetic. Walport et al (1985a) 
studied CR1 numbers on 86 normal subjects. The range of CR1 numbers was 
large (145-1214 sites/E) and they were distributed in a normal fashion
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with no evidence of a trimodal grouping. In an attempt to study the 
genetic influence on this distribution the mean parental CR1 numbers for- 
10 normal families were plotted against the CR1 numbers of each of their 
children . A strong correlation (r=0.58, P < 0.001) was found between CR1 
numbers in parents and children. They stated that although their data 
was insufficient to establish the precise nature of inheritance which may 
be controlled by one or more genes, their data fitted a polygenic model 
of inheritance (ie influenced by many genes) analogous to that involved 
in the control of height. However upon closer analysis of their data it 
would appear that some fundamental errors were made in the calculation of 
their correlation coefficient between parents and children. Firstly their 
data were not homogeneous in that a mixed population of normal and SLE 
families were included in the calculation;' secondly for a valid 
correlation all data must be independent-; this was not the case as more 
than one child from each family was included and thirdly they did not 
state whether grouping of samples into batches for E CR1 assays were 
random. A spurious correlation could have arisen simply because all 
samples from the one family were measured in the same batch. For a valid 
correlation the data must be homogeneous, independent and necessary 
corrections must be made for batch effects when required, As this 
correlation was presented as their strongest evidence for an inherited 
component in the expression of E CR1 their conclusions must be viewed 
with caution.
In order to study the proposed genetic inheritance of CR1 in the normal 
population it was decided to study E CR1 levels in monozygotic and 
dizygotic twins. This study involved the collection of blood samples from 
123 pairs of twins. It was necessary to freeze the blood as CR1 sites 
could not be measured at the time of venous blood sampling. Thawing of 
blood samples resulted in a variable degree of lysis. However as can be 
seen from Table 3.3 when the number of E which had lysed were accounted 
for the final E CR1 number was within the inter-assay error for a fresh 
unfrozen sample.
CR1 levels in the twins were distributed in a log-normal fashion similar 
to that observed by Holme et al (1986). This distribution was transformed 
to a normal bell shaped distribution by converting each measurement to 
the logic. The frequency histogram obtained by this transformation (Fig 
3.4(b)) showed that the transformed data approximated to a normal 
distribution. There was no evidence of distinct groups of individuals 
having high or low phenotypes. Thus the distribution was not consistent 
with a simple model of genetic inheritance. The geometric mean value of 
CR1 sites/E obtained for all the twins studied was 837. This is within 
the normal range of 300-1200 sites/E reported by Hogg et al (1984) who 
used the same monoclonal antibody to quantify CR1 sites on the E of 38 
normal subjects.
Using the logic transformed E CR1 numbers statistical analyses were 
performed to determine if there were significant differences between the 
sexes or if there were differences associated with age. No significant
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differences were found between CR1 number in males or females and there 
were no significant correlations between CR1 and age. The results are in 
agreement with reports from various other groups. Iida et al (1982) found 
that there was no significant difference in CR1 number according to age, 
sex or blood type. Jouvin et al (1986) found that CR1 number was 
independent of age and sex of the donors and Wilson et al (1982) found 
no significant difference in CR1 numbers between males and females.
The data were then analysed to determine how much the distribution was 
dependent on genetic factors . The basis for the genetic analysis of CR1 
levels on the E of identical and nonidentical twins was the comparison of 
differences in CR1 levels within sets of twins (intra-pair variance) and 
between sets of twins (inter-pair variance). If it is to be supposed that 
CR1 numbers are inherited then the numbers of CR1 sites on the E from 
identical twins should be closer than the number of CR1 sites on the E 
from nonidentical twins. This in turn implies that the intra-pair 
variation in identical twins should be smaller than the inter-pair 
variation between all twins if CR1 numbers are genetically controlled.
This however was not found to be the case as there was no resemblance 
between twins of any of the sets or subsets as seen by the fact that the 
intra-pair variances were not any smaller than the inter-pair variances 
(Table 3.4) The F ratio to compare monozygotic intra-pair variance with 
dizygotic intra-pair variance was not significant which indicates that 
the difference between monozygotic twins was not any smaller than the 
difference between dizygotic twins.
From this genetic analysis it was concluded that the data failed to 
demonstrate any genetic influence on E CR1 levels in normal twins. It 
must therefore be supposed that differences in E CR1 levels must arise 
largely or wholly as a result of environmental factors. In support of
this conclusion experiments in our own laboratory by Dr E Holme have 
shown that E CR1 levels on the cord blood of new born monozygotic twins 
differ quite markedly from each other.
A recent publication which would seem to contradict this conclusion is 
that by Wilson et al (1986a) which states that there appears to be a 
restriction fragment length polymorphisim involving fragments of 7.4kb 
arid 6.9kb which correlates with variation in the quantitative expression 
of E CR1. In a preliminary study they showed that 4 individuals with high 
CR1 levels had only the 7.4kb fragment, 4 individuals with intermediate 
CR1 levels had both the 7.4kb and the 6.9kb fragments and 4 individuals 
with only the 6.9kb fragment had low CR1 numbers. However even in this 
small sample there were exceptions. Two individuals with intermediate 
expression had only the 6.9kb fragment. A larger study of 50 normal
individuals showed that E CR1 numbers in groups with the 7.4kb fragment 
overlapped the group with the 7.4kb and 6.9kb fragments, while the group 
with the 6.9kb fragment had low CR1 numbers. These data would appear to 
suggest that while low E CR1 numbers are genetically controlled the
phenotype of those with the restriction fragment length polymorphism 
associated with high CR1 numbers is modified by factors which are not
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the product of the CR1 structural gene. These results suggest to me that 
it is not possible to make clearly defined groupings on the basis of' 
possession of one or other or both of these fragments.
As mentioned in the introduction to this chapter CR1, C4bp and H are 
thought to comprise a new human complement regulatory gene family 
(Holers et al 1986). They each have similar roles in that they all
interact with either C4b or C3b. In addition they all act as cofactors 
for either the I mediated cleavage of C3b or C4b. There may also be 
structural similarities in that they all might possess a homologous
domain involved in C3b/C4b binding (Sim 1985; Sim et al 1986). Sequence 
studies on C4bp have indicated that it is composed of 8 internally
homologous repeating segments about 60 amino acids long. H is made up of
20 of the same repeating structures and CR1 is thought to contain at 
least 8 of these repeating units (Sira et al 1986).
Gene linkage studies by Rodriguez de Cobra et al (1985) have shown that 
the structural genes for each of the proteins are closely linked. Because 
of the close association between these 3 proteins it was decided to study 
C4bp and H levels in the serum collected from the twins to see if the 
levels of these proteins correlated with levels of CR1 and also to 
investigate the influence of genetic factors on C4bp and H. In addition, 
I, the enzyme for which all these proteins are cofactors, but which itself 
is not part of this complement family, was studied as a control.
It was found that like CR1 there was no difference in levels of H and 
C4bp between males and females. However, unlike CR1 there was a 
significant age effect on levels of H and C4bp, both of which increased 
with age (Fig 3.7 and Fig 3.9). Like CR1 there did not appear to be any 
evidence of a genetic influence on H or C4bp levels (Tables 3.5 and Table 
3.6). There were no correlations found between CR1 levels and C4bp or H 
levels although there was a significant correlation between H and C4bp 
levels (Fig 3.12(a)).
Thus it would appear that there are differences between the regulation of 
CR1 levels and the regulation of the levels of the other 2 cofactor 
proteins. This may in part be accounted for by the fact that H and C4bp 
are plasma proteins whereas CR1 is a membrane-bound protein. In addition 
CR1 has a number of unique roles which are not possessed by the other 
cofactor proteins. It is thought to act as a cofactor for the I mediated 
breakdown of surface-bound iC3b to C3dg and C3c (Medof et al 1982). It 
is also involved in phagocytosis and the accompaning metabolic events 
(Pommier et al 1984; Changelian and Fearon 1985). It may play a role in 
the regulation of immunoglobulin secretion from lymphocytes (Daha et al 
1984) and in the retention of antigens in lymphoid follicles (Reynes et 
al 1985) and m — y.ivQ it has been shown that E CR1 is involved in the 
transportation of immune complexes (Medof and Dger 1982; Cornacoff et al 
1983).
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Levels of E CR1 are significantly reduced in patients with active SLE 
(Miyakawa et al 1981; Ross et al 1985; Holme et al 1986) and so are- 
levels of C4bp and H (Whaley, Schur and Ruddy 1979; Daha et al 1983). The 
cause of the reduced levels of 3 proteins which control complement 
turnover is not known. However the environmental factors which result in 
the reduction of E CR1 in active SLE may be different to those which
result in the reduction of H and C4bp levels as in normals expression of
CR1 and H or C4bp do not correlate.
Analysis of I revealed that there was no significant difference in serum
concentration of I between males and females. There was a significant
increase in I levels with age (Fig 3.11) (r=0.186; P < 0.005). Increase in 
I, C4bp and H levels with age may be as a response to an increasing 
requirement for the regulation of complement activation.
There was no evidence for any genetic influence on I levels (Table 3.7). I 
levels correlated significantly with H and C4bp levels but not with CR1. 
Correlations between I and C4bp and H may be of biological value as I 
requires the presence of one of its cofactors to mediate cleavage of C3b 
and C4b. Correlations between H and I have previously been noted by 
Whaley et al (1979).
Thus it may be concluded from this study that environmental factors and 
not genetic factors are mainly or wholly responsible for variations in 
the expression of I, C4bp, H and CR1. The environmental factors which 
influence CR1 expression appear to be different to those governing the 
expression of the other 3 proteins. The precise nature of the factors 
governing expression of all of these proteins is not known. However in 
the following chapter the results of investigations into some of the 
environmental factors which may influence CR1 expression are reported.
CHAPTER jFOXJR
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4.1 Introduction
The results from the previous chapter demonstrated that E CR1 number 
could be measured by monoclonal anti-CRl. By this method E CR1 numbers 
were analysed on 122 sets of twins. This showed that the major factors 
governing CR1 expression are environmental and not genetic,
Patients with SLE have reduced numbers of E CR1 (Miyakawa et al 1981; 
Wilson et al 1982; Walport et al 1985a; Holme et al 1986). Recent 
experimental evidence suggests CR1 numbers are reduced as a consequence 
of the disease (Ross et al 1985; Walport et al 1985a; Holme et al 1986). 
If it is to be concluded that these numbers are not reduced by genetic 
factors but are acquired as a consequence of the disease, mechanisms must 
exist which modulate CR1 numbers,
One possibility may be that the E of SLE patients do not synthesise 
sufficient quantities of the receptor. Two main pieces of evidence exist 
to refute this possibility. Firstly, it was found that transfusion of E 
with high CR1 numbers into SLE patients expressing low CR1 numbers 
resulted in a gradual loss of CR1 from the transfused cells. There was a 
loss of 50% of CR1 during the first 5 days after transfusion (Walport et 
al 1985b). Secondly, E normally circulate in the bloodstream for over 3 
months before they are destroyed, however, serial studies on SLE patients 
have found that their CR1 numbers change by over 1007* in 2 months or 
less (Ross et al 1985; Holme et al 1986). This suggests that some 
mechanism operates in these patients to remove or block E CR1.
It has been reported that CR1 levels per E are higher on younger less 
dense E in both normal and patient groups than on older E (Wilson et al 
1982; Sim, Roord and Sim 1983; Ripoche and Sim 1986). Thus there exists 
in vivo a general nonpathological mechanism for causing a reduction in E 
CR1 numbers. Ripoche and Sim (1986) have suggested that this same 
mechanism may also be responsible for the accelerated loss of E CR1 
which is seen in SLE. They consider the most likely mechanism to be the 
removal of CR1 by proteolytic enzymes.
CR1 is known to be destroyed by proteases, Nelson and Nelson (1959) 
originally reported that as immune adherence was trypsin sensitive, this 
could indicate the destruction of a receptor responsible for the 
adherence. Four years later Nelson (1963) found that adherence was also 
destroyed by chymotrypsin and papain. As discovered earlier in attempts 
to purify CR1 (Chapter 2), the purified receptor is very sensitive to 
proteolysis. This sensitivity of isolated CR1 to proteolysis was also 
observed by Sim (1985). Ripoche and Sim (1986) have since found that CR1 
is sensitive to the plasma proteases, thrombin and plasmin and conclude 
that it is possible that proteolysis of CR1 occurs when E carrying 
immune complexes (Siegel et al 1981; Cornacoff et al 1983; Medof & Oger 
1982) come into contact with the proteinase-rich tissue phagocytes of the 
reticulo-endothelial system in liver and spleen. Such a mechanism of 
removal was also suggested by Ross et al (1985). Removal of CR1 in this
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manner may occur under normal physiological conditions but in SLE as the 
immune complex load is greater (Tan et al 1982) there would be an 
increased chance of CP.l removal.
Alternative explanations for the low E CR1 numbers in SLE patients 
include, (i) the internalisation of CR1 by E. This is a remote 
possibility as there is no electron microscopic evidence for the 
existence of endocytic vesicles in E (Dr I More, personal communication) 
and (ii) the blockade of CR1 by antigen/antibody complexes which may 
hinder access of the radiolabelled antibody to the receptor. Studies in 
our own department by Dr E Holme suggest that this may be the case. 
However, the situation appears to be complex as illustrated by the 
observation that when E from SLE patients were examined for the presence 
of immune complex material such as C3 antigens or IgG antigens, there 
was no correlation between IgG content and CR1 level but some correlation 
between C3 levels and CR1 numbers (Dr E Holme, personal communication). 
Thus it is possible that the receptors are not being blocked by immune 
complexes but by some other as yet unknown factor such as polysaccarides 
or histone complexes which activate complement (Robey, Jones and 
Steinberg 1985).
In this chapter I have investigated some of the more likely possibilities 
which might cause an alteration in CP.l expression. Firstly, the 
sensitivity of CR1 to enzymes was studied. The serum proteases, plasmin, 
thrombin and kallikrein, the leukocyte proteases elastase and cathepsins 
C and D and the pancreatic enzyme trypsin were examined for their 
ability to remove CR1 from E. This was achieved by measuring E CR1 
numbers by RIA before and after treatment with the enzymes. In addition 
the sensitivity to trypsin was assessed by immunoprecipitation of CR1 
from surface labelled E before and after trypsin treatment.
The possibility that an as yet unknown factor exists in SLE sera which 
can remove or block CR1 was investigated by incubating E overnight in 
SLE sera followed by analysis of CR1 by RIA and surface labelling.
A preliminary study was also undertaken to determine if blockade of CR1 
resulted from incubation of opsonised aggregated immune complexes with E. 
In addition studies on the modulation of CR1 expression in response to 
oral antigen (cows milk) challenge were performed.
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Materials and Methods
4.2 Che.mioals--and....R£aggnts.
Antisera were obtained from the following sources:
Pakopatts, Marcia ..Brocades .Ltd, Brocades -House, Pyrford Rd, Weybridge.
Surrey.
Mouse Monoclonal Anti-CRl
Miles Scientific. Stoke Court. Stoke ..Pages* Slough 
Rabbit Anti-Mouse IgG (H+L fractions)
Scottish Antibody Production ...Unit (SAPU). Law Hospital. Carluke.
Scotland,
Sheep Anti-Human IgG
Capp.el l abcr.ato.ries* Cochranville, PA 1933Q USA
Sheep Anti-Rabbit F(ab')s: Fragment 
Sheep Anti-Rabbit IgG
■University Animal Laboratory. Western Infirmary. Glasgow 
Mouse Serum
The following reagents were purchased from these companies:
SigmaJdhemical Company, Fancy Rd. Poole. Dorset
Aprotonin
Cathepsin C (from bovine spleen)
Cathepsin D (from bovine spleen)
Elastase (from porcine pancreas)
Glucose Oxidase 
Iodoacetamide
Kallikrein (from human plasma)
Lactoperoxidase (from bovine milk)
Pepsin
Plasmin (from human plasma)
Protein A Crude Cell Suspension (10% w/v) of S. Aureus 
Soybean Trypsin Inhibitor (SBTI)
Trypsin (from bovine pancreas)
Thrombin (from human plasma)
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BDH.. Chemical Company-Ltd, Emle, Pcr.se.t
Potassium Iodide 
Sodium Acetate
Kodak Ltd. Dallimore Rd. Manchester
X-Ray Developer LX24 
X-Ray Liquid FixerFX40 
X-AR5 X-Ray Film
¥hatjaan,_Laboratory Sales Ltd, Unit. 1, Coldred Rd,. Maidstone, Kent
DEAE52 Diethylaminoethyl Cellulose (DE52 Cellulose)
Pharmacia, Pharmacia House, Midsummer Boulevard. Central Milton
Keynes, Bucks
Sephadex G-150
4.3 SDS-PAGE..in...Glass..Tubes
Buffers 
Tank., buffer.
lOOmls of sodium phosphate buffer (1 mol I'"1 pH 6.5) and lOmls of 10% 
(w/v) SDS were made up to 1 litre with deionised water.
Gel Recipe (7%)
lOmls of acrylamide/bisacrylamide solution, prepared as described in 
chapter 2.6(h), 25,6mls of deionised water, 4mls of phosphate buffer (1 
mol I” 1), lOmls of 10%(w/v) SDS, 20p.l of TEMED and 40mg of ammonium 
persulphate were mixed together, the last ingredient being added 
immediately prior to pouring the gel.
Destain Solution, and Stain Solution
These solutions were prepared as described in chapter 2.6(h),
Sample Buffer
Sample buffer was prepared as described in chapter 2.6(h).
Procedure
The lower ends of glass gel tubes were sealed with Parafilm and placed 
into a rack. The gel mixture (.716%) was added to the tubes leaving a 
space of 1cm at the top. The gel was overlaid with water and left to
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polymerize at room temperature for 1 hour. The Parafilm was removed and 
the tubes were placed into an electrophoresis tank filled with tank 
buffer. An equal volume of sample and sample buffer were mixed and 
applied to each gel after removal of the water. The electrophoresis was 
run at a constant current of 6mA/tube until the bromophenol blue marker 
was almost at the end of the gel. The gels were then removed from the 
tubes and stained with coomassie brilliant blue before being destained 
and photographed.
4.4 InuaunQalectrophQr.es is.
Buffers. 
Tank ,Buffer
17g of sodium barbitone and 23.5mls of hydrogen chloride (1 mol I"1) 
were made up to 2 litres with deionised water to give a buffer with a pH 
of 8.4.
0. ,5%1m/v.) Brofflophenol-Blue
0.5g of bromophenol blue were dissolved in lOOmls of deionised water. 
Reagents
Agarose Gel was prepared as described for double immunodiffusion in
chapter 2.6(f).
Procedure
A glass plate (8x8cm) which had been washed in hot water and swabbed 
with alcohol was coated with lOmls of agarose gel. Wells and troughs 
were cut using a template and the wells were filled to the brim with 
sample using a micropipette. One well was filled with normal human
serum containing 0.5% (w/v) bromophenol blue which acted as a marker 
allowing the progress of the separation to be followed. The gel was
placed into an electrophoresis tank, filled with tank buffer, in direct 
contact with the wicks and electrophoresed at a constant current of 
1.5mA/cm of gel until the bromophenol blue marker was 1cm from the end 
of the plate. When the electrophoresis was complete the troughs were
filled with an appropriate antiserum and left at room temperature in a 
humid chamber for precipitin arcs to develop.
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4.5 Preparation of Fteb')^ anti-CRl and F (ab! ^ Normal- Rabbit. Serum-lSSSI 
Buffers
Phosphate Buffer
Phosphate buffer (0.01 mol l” 1 pH 7.6) was prepared as described in 
chapter 2.8.
PBS
PBS was prepared as described in chapter 2.6(c),
Sodium ...Acetate
Sodium acetate was prepared as a 0.1 mol I-1 solution at pH 4.5. 
Chromatograhpic. Material
DE52 was equilibrated in phosphate buffer (0.01 mol I"1 pH 7.6) and 
poured into a 60ml syringe barrel.
Sephadex.- Grlb.Q
Sephadex G-150 was equilibrated in PBS degassed and poured into a 
1.5x90cm column.
4.5(a) Preparation,of. IgG from Anti-CRl Antiserum and NRS
Before the preparation of F(ab')2 fragments the IgG fraction had to be 
extracted from the serum. The principal of this method depends upon the 
observation that during anion exchange chromatography on DE52 run at 
pH7.6 in the absence of sodium chloride, IgG does not bind to the 
exchange resin but passes directly through the column, The only minor 
contaminants being P and Clq.
Procedure
Ten millilitres of rabbit serum or anti-CRl antiserum were adjusted to a 
pH of 7.6 by addition of hydrogen chloride prior to dialysis overnight at 
4 ’C against 5 litres of phosphate buffer (0.01 mol I-1 pH7.6). Following 
dialysis the pH and the conductivity of the serum were checked to ensure 
that the dialysis was complete. The dialysed antiserum was passed over a' 
DE52 column and 5ml fractions were collected. The protein concentration 
of each fraction was then plotted (Fig 4.1) and the fractions containing 
a high IgG concentration were pooled.
Fig 4.1
Legend
Purification of IgG fractions from rabbit serum by anion exchange 
chromatography using a 60ml DE52 column. The OBzssonn-, of each 5ral 
fraction was plotted against the fraction number. The fractions 
containing the highest protein content (fractions 7-10) were pooled. 
The IgG content of these fractions was pure as determined by SDS-PAGE 
analysis.
Optical Density 280nm
0 .70
8.10
202 8 10 12 14 14 180 4
Column Fraction
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Vhen the pooled fractions were analysed by double immunodiffusion, a 
technique described in chapter 2.6(f), against sheep anti-rabbit IgG a 
single precipitin line was observed which showed that the pool contained 
IgG. The purity of the IgG preparation was assessed by analysis on a 
10% slab gel run under reducing and non-reducing conditions. Two bands 
were Seen on reduced samples after silver staining (Plate 4,1). The 
molecular weights of these bands were 50,000 daltons and 25,000 daltons 
which are the molecular weights of the heavy and light chains of IgG 
respectively. A single band of 150,000 daltons was seen on the non­
reduced sample (Plate 4.1). The protein concentration of the IgG pool was 
0.7mg/ml. This was concentrated to lOmg/ml by pipetting the material 
into a dialysis sac and placing the sac into a large volume of sucrose 
(sucrose concentration).
4.5(b) Preparation of F(ab')?- Fragments of IgG
The basis of this method is the digestion of IgG with pepsin at a low pH. 
Pepsin cleaves the IgG molecule between the Chi and Ch z  domains on the 
carboxy-terminal side of the interheavy-chain bridges to result in the 
production of a bivalent F(ab')z; fragment and small peptide fragments 
derived from the remainder of the Fc fragments.
Procedure
Two millilitres of IgG (lOmg/ml) from either NRS or anti-CRl antiserum 
were dialysed against 5 litres of sodium acetate (0.1 mol l-1 pH 4.5) 
overnight at 4*C. The pH of the IgG solution was adjusted to pH 4.5 (the 
optimal pH of pepsin) with acetic acid (0.1 mol I"1). The IgG was warmed 
to 3 7 ’C and pepsin was added so that an enzyme to substrate ratio of 
1:50(w/w) was achieved. The mixture was incubated overnight at 37*C 
after which insoluble material was removed by centrifugation (700g for 10 
min at room temperature). The supernatant was collected with a Pasteur 
pipette and the pH adjusted to 7.4 using solid Tris base. Following 
dialysis against 5 litres of PBS the preparation was subjected to gel 
filtration chromatograhpy on Sephadex G-150.
4.5(c) Gel Filtration on Sephadex G-150
High molecular weight F(ab ' ) 2 fragments (100,000 daltons) were separated 
from intact IgG and small degradation Fc peptides and pepsin on the 
basis of molecular weight on Sephadex G-150. Large molecules such as IgG 
(150,000 daltons) pass through in the void volume of the column while 
smaller peptides are retained in the gel and elute after the larger 
F(ab ' > 2 fragments.
PcQcedure
The Sephadex G-150 column was washed with 1 column volume of PBS before 
the application of 3mls of pepsin digested IgG anti-CRl or IgG HRS. One 
millilitre fractions were collected and following the measurement of the
Plate 4.1 SDS-PAGE Analysis of IgG.
Legend.
The purity of the IgG pool obtained from the DE52 column was assessed by 
analysis on a 10% slab gel, Samples were run under reducing and non­
reducing conditions. In the reduced form 2 bands were seen after silver 
staining (tracks c and d). These bands had molecular weights of 25,000 
and 50,000 daltons. They represent the light and heavy chains of the IgG 
molecule respectively. In the non-reduced form a single band with a 
molecular weight of 150,000 daltons was seen after silver staining 
(tracks a and b). This represents the whole IgG molecule.
Q.
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protein content of each fraction the elution profile was plotted (Fig 
4.2). This showed a major peak of protein which was F(ab\)z and a 
subsidiary peak eluting later in the chromatogram. Fractions 47 to 53 
were pooled. This pool had a protein concentration of 0.984mg/ml. When 
analysed by double immunodiffusion against sheep anti-rabbit F(ab')2 a 
single precipitin line was observed which showed that the pool contained 
F(ab')2 (Plate 4.2). A sample was also tested by immunoelectrophoresis 
and a single precipitin arc was formed between the purified F(ab')2 and 
sheep anti-rabbit F(ab')2 (lmg/ml). The F(ab')2 fragments being more 
electronegative than whole IgG migrated further towards the anode 
than the larger IgG molecules (Plate 4.3). The purity of the F(ab ' ) 2  
preparation was determined by analysis on a 716% tube gel run under non­
reducing conditions. A single band was seen after staining with 
coomassie blue. The molecular weight of this band was 100,00 daltons 
which is the molecular weight of bivalent F(ab')2 (Plate 4.4). This 
preparation contained no residual IgG.
4.6(a) EnumeratiQn_of E...CR1 Numbers Using F<ab'):a Anti-CRl 
Reagents
Dlbutylphthalate/dinoylphthalate
This solution was prepared as described in chapter 3.8(c).
IgjglcAnti-CRl F(ab,?g
12sI-anti-CRl F(ab ' ) 2 was prepared as described in chapter (2.6(d)) using 
the chloramine T method.
Buffers 
REMI/RSA
RPMI/BSA was prepared as described in chapter 3,6.
Procedure
Five millilitres of venous blood were transferred to a universal container 
containing lOO/il of sodium heparin to prevent clotting. The E were 
separated from the plasma and buffy coat by centrifugation at 4,000g for 
10 min at 4*C. The E were then washed 3 times in ice-cold RPMI/BSA and 
standardised to 2,5xlOs/ml in RPMI/BSA. Triplicate aliquots (200pl) of E 
(2,5xlOB/ml) were transferred to a series of 8 microcap tubes. 
Unlabelled non-immune NRS F(ab')* fragments (12.5pg/tube) were added to 
tubes 1 to 4 and unlabelled anti-CRl F(ab')s; fragments (12.5pg/tube) were 
added to tubes 5 to 8.
The tubes were rotated end over end at 4 ’C for 1 hour on a Matburn mixer, 
after which incremental quantities of 1 ^ I-anti-CRl F(ab')2
Fig 4.2 Sephadex G-150 Column
Legend
Purification of F(ab')2 fragments from anti-CRl IgG by gel filtration 
using a 15x90cm Sephadex G-150 column. The ODaeonm of each 1ml fraction 
was plotted against the fraction number. Two protein peaks were seen, the 
first of these contained F(ab’)s fragments as determined by double 
immunodiffusion in agarose gels against sheep anti-rabbit F(ab')2 and 
immunoelectrophoresis. Fractions 47 to 53 were pooled. The second peak 
contained smaller Fc degradation fragments.
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Plate 4 .2  Analysis o f  F (ab'),: Fragments by Double. -Immu_R Q . d i f . f u s iQ r L . - ia
Legend
Double immunodiffusion in agarose gel of : A, F(ab')s; fragments prepared 
from rabbit anti-CRl IgG(lmg/ml) (wells 1 and 2) against sheep anti­
rabbit F(ab ' > 2 (lmg/ml) (central well, a) and B, F(ab')2; fragments 
prepared from normal rabbit IgG (lmg/ml) (wells 1 and 2) against sheep 
anti-rabbit F(ab')z (lmg/ml) (central well b). Single precipitin lines of 
identity were formed in all cases.

Plate 4.3 Analysis of IgG-Anti-CRl and F <.ai2^^.n,tlz_QEl_j2X 
I m is u n oe lec t r Qp.hQr.eais.
Legen.<i
Immunoelectroplioretic analysis of whole IgG anti-CRl (lmg/ml) (well a) 
and F(ab')ss anti-CRl (lmg/ml) (well b) against sheep anti-rabbit FCab^a* 
(lmg/ml) (trough 1). As the F(ab')z fragments were more electronegative 
than whole IgG, they migrated further towards the anode (A) than the 
whole IgG molecule which remained closer to the cathode (C).
Plate 4.4 SDS-PAGE Analysis of F(ab')- Anti-CRl
A sample of F(ab')^ anti-CRl from the pool obtained from the Sephadex G- 
150 column was analysed on a 1W* tube gel run under non-reducing 
conditions. After staining with coomassie blue a single band of molecular 
weight 100,000 daltons was revealed. This is the molecular weight of 
purified F(ab')s fragments, Ro contaminating proteins were observed.
ab
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(lpg,2p.g,3pg,4p.g) were added to each set of 4 tubes. Following a further 
1 hour incubation period at 4*C the samples were layered onto 3Q0pl of a 
mixture of dibutylphthalate/dinoylphthalate in a microcap tube and the 
bound and free 1251-/^'^ separated by centrifugation at 10,000g for 2 min 
at room temperature. The supernatant was removed and the red blood cell 
pellet was cut from the bottom of the tube using a hot scalpel blade. 
The pellets were placed into glass carrier tubes and counted in an 
automatic If counter.
4.6(b) Calculation— of GEJL Sumber Using Scatchard Plot Analysis
(Scatchard 1949)
The amount of radioactivity bound to E in the presence of non-immune 
F(ab ');2 fragments, which represents the total binding of 1 I-anti-CRl 
FCab')^ and the amount bound in the presence of excess unlabelled anti- 
CRl FCab*)^ fragments, which represents the nonspecific binding were 
plotted against the total input of 1 2SI--anti-CRl F(ab')^ (Fig 4.3). Each 
point on the graph represents the mean ± the standard error of the mean 
(SEM) of 3 separate aliquots taken from the same sample and treated as 3 
individual samples. The cpm obtained from all 3 samples were analysed 
and if they all fell within a 10% range of one another the mean ± SEM 
of all 3 was calculated. If however 1 sample was outwith this range it
was discarded and the mean ± SEM of the remaining 2 was taken. If all 3
differed by more than 10% the mean ± SEM of all 3 was calculated.
The specific number of bound cpm were obtained by subtracting the lower 
nonspecific binding curve from the higher total binding curve and the 
number of free cpm were obtained by subtracting the specific number of 
bound cpm from the total radioactivity added to each tube. From this 
data a plot of bound cpm divided by free cpm against bound cpm was 
drawn (Fig 4.4). The point where this line crossed the Y axis was 
determined by linear regression analysis, with this point, (5450), 
representing the number of bound cpm to 200/il of the original E 
suspension in each tube, which comprises a total of 5xl07E. The points on
the Scatchard plot in Fig 4.4 were taken from the straightest part of the
original total binding curve shown in Fig 4.3.
To convert the bound cpm obtained from the linear regression analysis 
into CR1 antigenic sites per cell the following calculations were 
performed.
The number of molecules in 1 cpm =
6.03x1012
number of cpm in 1/j.g of F(ab')s anti-CRl
The number of antigenic sites per cell =
number of molecules in 1 cpm x number of bound cpm in 5xl07 cells
5xlO"7
Fig 4.3 Binding of 1 — -I-Anti - C E l , . — loJErythrqc.y.tfis.
Leganii
The amount of radioactivity bound to E in the presence of non-immune 
F(ab’> 2  fragments (tubes 1-4) and the amount bound in the presence of 
anti-CRl F(ab')=> fragments (tubes 5-8) we re plotted against the total 
input of anti-CRl F(ab')s fragments, with each point being performed in 
triplicate (the vertical bars represent the SEM). The binding curves show
the total amount of 12!r'I-anti-CRl F(ab ' ) 2 bound (tubes 1-4) (x x) and
the nonspecific binding of 125I-anti~CRl F(ab ' > 2 (tubes 5-8) (x x).
The ordinate axis shows the total input of 12sI-anti-CRl F(ab')a 
fragments (expressed as cpm) and the abscissa shows the total amount of 
12SI-anti-CRl F(ab')s fragments which were bound (expressed as cpm).
Fig 4.4 Scatchard Blot 
Legend
A Scatchard plot was constructed by plotting the number of specific 
bound 1 ^ I-anti-CRl F(ab ' ) 2 fragments (expressed as cpm) against the 
bound/free 12SI-anti-CRl F(ab' ) 2 fragments (expressed as cpm). The point 
where this line crosses the Y axis (5450) represents the number of bound 
cpm to 5xl07 E. The points taken for this graph were from the 
straightest part (from an input of 140,000 to 280,000 cpm of FCab')^ 
anti-CRl) of the total binding curve (Fig 4.3).
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The basis for this calculation was explained previously in chapter 3.8(d). 
In this case lpg of F(ab')s molecules contains 6.03x1012 molecules, 
Having obtained the number of molecules in 1 cpm it was then possible to
calculate the number of molecules contained in the number of bound cpm
calculated from the linear regression analysis which was the total E 
input of 5xl0_/. Division of this number by 5xl07 resulted in the number
of CR1 molecules (antigenic sites) per E.
4.7 Intra-Assav Variation
To assess the reproducibility of the assay a. blood sample was taken from 
1 donor and divided into 3 aliquots. Each aliquot was treated as a 
separate sample and the number of CR1 sites per E was calculated by 
Scatchard plot analysis. All of the assays were performed at the same 
time, Table 4.1 shows that the maximum intra-assay variation was ±5% of 
the mean.
4.8 Inter-Assay Variation
To assess the inter-assay variation a blood sample was collected from 1 
donor and CR1 number determined immediately. The remainder of the blood 
which had not been used in the assay was standardised to 2.5xl08 /ml in 
RPMI/BSA and stored overnight at 4 ‘C, The following day the number of CR1 
sites/E was determined. As is shown in Table 4.2 the maximum inter-assay 
variation was ±5% of the mean.
4.9 Stability _qjL.E...CR1
To assess the stability of E CR1, E were standardised to 2.5xlOs /ml in 
RPMI/BSA and CR1 sites/E calculated by RIA. The cells which were not used 
in the first assay were resuspended in either RPMI/BSA or a 1:4 dilution 
of autologous serum. These cells were kept overnight at 3 7 *C. The 
following day they were centrifuged at 2,000g for 5 min at 4*C, the pellet 
was washed twice in ice-cold RPMI/BSA and the cells resuspended in 
RPMI/BSA at 2.5x10®/ml whereupon the number of CR1 sites were calculated 
by RIA.
4.10 Ir<eatiaent-Pf ..E with Proteolytic Enzymes.
As discussed earlier removal of E CR1 by proteolytic enzymes is one of 
the methods whereby a reduction in CR1 numbers is thought to occur (4,1). 
To investigate this possibility E were treated with a number of enzymes.
Procedure
Erythrocytes were standardised to 2,5xlOs/ml in RPMI/BSA, The 
concentrations of enzymes shown in Table 4.3 were added to 5mls of the E 
suspension and the cells incubated for 1 hour at 37 *C in a shaking water 
bath. Following this incubation the cells were centrifuged at 2000g for 5 
min at 4 ‘C, the supernatant was removed and the cell pellet washed twice
CP.l Sites/E
First
Measurement
Second
Measurement
Third
Measurement
MeaniSD % Variation 
from Mean
Donor 1 1255 1248 1293 1267127 +2 -2
Donor 2 4341 4610 4474 44751134 +3 -3
Donor 3 5092 5600 5353 53481254 +5 -5
Note
The mean±SD was calculated for each set of measurements performed on 
the 1 donor. The highest and lowest CR1 numbers in each set of 
measurements were then expressed as a percentage of the mean. This 
result is tabulated in the end column (% variation from the mean).
Table 4.2 Inter-Assav Variation
CR1 Sites/E
First
Measurement
Second
Measurement
MeaniSD % Variation 
from Mean
Donor 1 3952 3543 37531289 +5 -5
Donor 2 1434 1563 1498191 +4 -4
Donor 3 1785 1983 13841140 +5 -5
late.
The first measurement was performed on freshly isolated E, while the 
second measurement was performed after overnight incubation of the E at 
4'C in RPMI/BSA. The mean±SD for the 2 measurements was calculated and 
then the percentage variation from this mean for each of the 2 numbers 
was determined.
Table 4.3 Treatment of E with Proteolytic
Enzyme Concentration
Plasmin 9. 1/j.g/ml
Thrombin 5 units/ml
Kallikrein 1. 8 )j g / ml
Cathepsin C* 9. 09/jg/ral
Cathepsin D* 9. 09/jg/ml
Elastase 54.4/jg/ml or 2.27mg/ml
Trypsin lmg/ml, 0. 0lmg/ml or O.OOOlmg/ral
Note
#• The RPMI/BSA was made to a pH of 5 (the optimal pH for these 2 
enzymes) using hydrochloric acid (0.1 mol I'"1).
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in ice-cold RPMI/BSA and the cells restandardised to 2,5xlOs7ml. In the 
experiments where trypsin was used a 2-fold molar excess of soybean 
trypsin inhibitor was added at the end of the 1 hour incubation. The 
cells were incubated for a further 2 rain and then treated as described 
above.
As none of the proteolytic enzymes used in the study are normally present 
in serum under physiological conditions a concentration within the 
physiolog'ical range of their proenzyme was selected. As there are 
approximately 5.5xl09 E in 1ml of packed red cells the proenzyme 
concentration was divided by 4,4 to adjust the concentration for the 
number of cells used in the assay < 1,25xl09/5mls).
4.11 q L  SLU-Sgra ..qd_ E CEL
This study was undertaken to investigate the- possibility that some 
component present in the sera of SLE patients could remove CR1 from E or 
block CR1. Blood was taken from donors who had the blood group 0 and 
who were rhesus positive (0,vr;> to prevent lysis of the E due to 
complement activation upon addition of heterologous serum.
Ten millilitres of blood were collected and 8mls of this was allowed to 
clot at 3 7 "C for the preparation of autologous serum as was described 
previously in chapter 2.6(a). The remaining 2mis were mixed with sodium 
heparin and the E isolated and standardised to 2.5xlOs/ml . in RPMI/BSA. 
Erythrocyte CR1 numbers were then calculated by RIA. The remaining blood 
not used in the assay was re-standardised to lxl.09 /ml in SLE serum 
(diluted 1:4 in RPMI/BSA) from patients who had active or inactive 
disease at the time of venous blood sampling. Cells were also 
resuspended in pooled heterologous normal serum (diluted 1:4 in 
RPMI/BSA).
This number of cells and this dilution of serum were used as they 
approximate to a physiological ratio of E to plasma, The blood was then 
stored overnight at 3 7 *C in an incubator. The following morning the E 
were centrifuged at 2Q00g for 5 min at 4 °C the supernatant was removed 
and the E were then washed 3 times in ice-cold RPMI/BSA, standardised to 
2.5xlOs/ml and the number of CR1 sites per E calculated by RIA.
4.12 Pr.2paratlQiLj^_C3b_CQated..-I.gG._A,ggrLe.g.atas.
One of the possible mechanisms for the reduction of E CR1 in SLE 
patients is the blockade of the receptor by large opsonised complexes.
In order to study this possibility it was decided to prepare such 
complexes and incubate them with E and then measure residual CR1 sites.
Reagents.
Human plasma was supplied by the Blood Transfusion Service Law Hospital 
Carluke Scotland,
Buffers
Saturated ammonium sulphate was prepared as described in Chapter 3.8(a). 
Phosphate Buffer
Phosphate buffer (0.01 mol l'1 pH 7.6) was prepared as described in 
Chapter 2.8
SxSBS.
5xVBS was prepared as described in Chapter 2.7(b).
4.12(a) Lyophilisation
The sample was put into a round bottomed flask and quickly frozen by 
placing the flask into a mixture of methanol and dry ice. The flask was 
attached to a freeze drier and dried under vacuum for 5 hours. The 
protein precipitate was redissolved in deionised water.
4.12(b) Sucrose.. Gradients
Sucrose solutions, 10%(w/v), 20%(w/v), 30%(w/v) and 40%(w/v) were made up 
in deionised water after which BSA (0.5%(w/v)) was layered on top and 
left to dissolve. The sucrose solutions were chilled on ice to 0 ’C. 
Using a 1ml syringe the 10% solution was added to an ultracentrifuge tube 
which was also an ice. The 20% solution was then carefully underlayed by 
gently injecting 1ml of the solution under the 10% solution. Following 
this the 30% and finally the 40% solutions were underlayed in a similar 
manner. All solutions were kept on ice.
4.12(c) Preparat ion .of IgG from Human ....Plasma
One pack of expired plasma (250mls) was thawed at 3 7 X  and placed into a 
volumetric flask. The plasma was allowed to clot by the addition of 4mls 
of calcium chloride (1 mol I'1) and the mixture stirred overnight at 4X. 
The serum was separated from the clot by filtration through a Buchner 
funnel, An equal volume of SAS was added dropwise to the serum which 
was being constantly stirred at room temperature. Stirring was continued 
for 30 min following the addition of the SAS. The precipitate was removed 
by centrifugation at lOOOg for 25 min at 4 X  and redissolved in 5xVBS. 
This was then dialysed against 24 litres of phosphate buffer (0.01 mol 
l” 1 pH 7.6) for 2 days at 4 X  and then passed over a DE52 column which 
had been equilibrated with the same buffer. The protein concentration of 
each fraction was measured spectrophotometrically at an absorbance of
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280nm and the exclusion peak was pooled and tested for IgG concentration 
and purity as described earlier (4.5(c)). Sheep anti-human IgG was used 
in the double immunodiffusion analysis instead of sheep anti-rabbit IgG.
4.12(d) Preparation of Alkali Aggregated IgG
Purified human IgG was lyophilised and reconstituted in deionised water 
to give a final concentration of 20mg/ml. To 5mls of the IgG solution, 
5mls of sodium hydroxide (0.2 mol 1~1) were added and the mixture was 
immediately dialysed against 5 litres of PBS pH7.2 at roam temperature 
for 2 hours, The buffer was then changed and the dialysis continued 
overnight at room temperature.
The aggregates (200pl) were applied to 10% to 40%(w/v) sucrose gradients 
(4ml) containing 0.5% BSA(w/v) and subsequently ultracentrifuged for 16 
hours at 288,000g in a SV41 Beckman rotor. After centrifugation the 
gradients were fractionated into 15 fractions using a Beckman fraction 
recovery system which punctures the bottom of the ultracentrifuge tube. 
Thus the fractions containing the larger aggregates are collected before 
the smaller aggregates which do not sediment as quickly. These fractions 
were dialysed against PBS overnight at 4°C to remove the sucrose and 
tested for protein concentration by Folin analysis as described in 
chapter 2.9 (Fig 4.5). The first 6 fractions containing the largest 
aggregates and the highest protein concentration (l,5mg/ml) were pooled.
4.12(e) Qp,sonisatiQn of Aggregated- IgG.Jttith...GB..b
The pool of aggregates were divided equally into 2 aliquots. To 1 of 
these aliquots an equal volume of fresh NHS was added and the mixture 
was incubated for 20 min at 3 7 eC. These aggregates were separated from 
free C3 and C3 degradation products by ultracentrifugation at 288,000g 
for 1 hour at 4 ’C on 10% to 40% discontinuous sucrose gradients 
containing 0.5%(w/v) BSA. The gradients were collected in 20 fractions 
which were then dialysed against PBS to remove the sucrose. Their protein 
concentrations were tested by Folin analysis as described in chapter 
2.6(c). Each fraction was then tested for C3b content by its ability to 
agglutinate human E.
4.12(f) Agglutination, of Human„E
Human E were washed 3 times in RPMI/BSA and standardised to 2.5x10®/ml. 
Each fraction from the sucrose gradient was then serially diluted to a 
1:256 dilution in a microtitre plate. Erythrocytes (50pl) were added and 
the was plate left to settle for 3 hours after which the agglutination 
pattern was noted. Controls using unopsonised IgG aggregates showed no 
agglutination while coated aggregates caused haemagglutination at up to a 
1:8 dilution. The agglutination of, E by C3b, coated aggregates could be
#  h-. I'We <:,cUlibo7)
inhibited by addition of 50/j.1^oi the C3b coated aggregates. This proved 
that the agglutination produced by the serum-treated aggregates was due 
to the binding of aggregate-bound C3b to E CR1.
Fig 4.5 Protein Content of Alkali Aggregated IgG
Legend
The protein content of the aggregated IgG fractions from the sucrose 
gradients were determined by Folin analysis and plotted against their 
fraction number. The first 6 fractions containing the heaviest IgG 
aggregates and the highest protein content were pooled. Fractions 10-15 
contained monomeric IgG.
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4.12(g) Measurement _Qf -CRl^Antlgeaic. Sites .in. the Presence of Aggregates
Human E (4.8mls) 2,5xlOl3/iiil were incubated with C3b coated aggregates (at 
the predetermined highest dilution which caused agglutination) at 3 7 ’C 
for 1 hour with end over end mixing. The same volume of E were incubated 
with . the same dilution of uncoated IgG aggregates from the pool 
described in 4.12(d). After 1 hour 200/j1 aliquots of E from both sets of 
cells were transferred to microcap tubes and the number of CR1 antigenic 
sites was measured as before (4.6(a)).
4.13(a) Modulation of E._£R1 Expression in Response to Oral Antigen
.(Cows MilJfcL .Challenge
High levels of circulating immune complexes have been detected following 
food consumption in some normal individuals (Paganelli et al 1979). 
Sandilands et al (1982) found that after consumption of 1.2 litres of 
cows milk by normal human adults that there was a rapid fall in the Fc H 
receptors on peripheral blood lymphocytes. It was thus decided to 
investigate the possibility that food antigens could block CR1 expression 
on E.
ErpGadure
Following an overnight fast 5 normal males and 1 normal female drank 1.2 
litres of cows milk over a period of 10 min. Heparinised (2mIs) and 
clotted (5mls) blood samples were collected immediately before milk
consumption and at 5 intervals thereafter. The heparinised samples were 
washed and standardised to 2.5xlOs /ml in RPMI/BSA and incubated on ice 
until all the samples had been collected. Thereafter CR1 number was 
determined on each aliquot using the monoclonal antibody Ell as described 
earlier in chapter 3.8(c). The serum for each time interval was stored at 
-70*C until required. The control for this experiment involved an
overnight fast with no milk consumption. Heparinised and clotted blood 
samples were then collected at similar time intervals to those in the 
previous experiment.
4.13(b) Incubation of E with Sera Collected from Donors after Ingestion 
of 1.2 Litres of CQwaJMilk
To investigate the possibility that immune complexes had formed after
milk consumption, E from a donor with the blood group 0 who was rhesus 
positive (0+"v'“s)were incubated with the serum from each of the different 
time intervals before and after milk consumption.
Er.Qcsdur.e
Erythrocytes from an 0"’"''“ donor were standardised to 2.5xlOe /ral in 
RPMI/BSA and aliquots (200pl) were placed into microcap tubes. These
tubes were centrifuged for 30 seconds at 10,000g at room temperature and 
the supernatant removed. Neat sera (9pl) from each time point in the milk
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experiment were added to a set of 6 E pellets. The E were resuspended in 
the serum and incubated for 30 min at 3 7 X  after which 200pl of RPMI/BSA 
were added to each microcap. To 3 of the sets of E for each time point 
700ng of '^I-Ell were added and to the remaining 3 sets a 10-fold molar 
excess of non-radioactive Ell was added. The number of CR1 sites per E 
was then determined as previously described in chapter 3.8(c),
4.14(a) Radioiodination and-IimunQpracipitatiQn of E. CR1
As an alternative means of studying E CR1 it was decided to label E CR1 
with 1:251. This provided a means of visualising CR1 on autoradiographs 
and gave an indication of any change in CR1 structure which may be 
brought about by treatment with serum enzymes or patient's serum.
Addition of D-glucose to E in the presence of |:2SI, lactoperoxidase and 
glucose oxidase, results in the formation of small amounts of hydrogen 
peroxidase (H2 O2 ) at a steady rate. The lactoperoxidase in turn catalyses 
the oxidation of the radiolabelled iodide to iodine which reacts with the 
E surface protein. This reaction may be summarised by the following 
equation.
J3-D Glucose + O2  Glucose Oxidase ^ = H2 O2  + Gluconalactone 
H20s + + protein lactoperoxidase ^ = Iodoprotein
Reagents 
Lastaperoxiflase
Lactoperoxidase was stored desiccated at -20X. Prior to use a lmg/ml 
solution was made up in deionised water.
Glucose Qxidase
Glucose oxidase was stored at 4 X  in acetic acid buffer at 12000 units/ml 
RrGlucose
A 50mg/ml D-glucose solution was made up in deionised water on the day 
before use to allow rotation to the j3 form.
Protein A Sepharose
A protein A crude cell suspension (10%w/v) of Staphylococcus aureus 
(Cowan strain) cells was stored in potassium phosphate buffer (0.05 mol 
I"”1 pH 7.5) at 4X. Prior to use the suspension was centrifuged at 10,000g 
for 2 min at room temperature and the pellet resuspended in 1ml of PBS. 
The pellet was washed twice in PBS and finally resuspended to a 10%(w/v) 
suspension in PBS.
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Destain Solution
Destain solution was prepared as previously described in chapter 2.6(f). 
Buffers.
Kater/Er.Qtease Inhibitors
Deionised water containing EDTA (3 mmol l"1) iodoacetimide (0.02 mol I”1) 
PKSF (2 mmol I'"1) and 0.33 units/ml aprotonin
Sodium-.ChlQride/P.r.QteaseL. Inhibitors
Sodium chloride (0.3 mol I"1) containing the same proteases as above.
!&.. HP-IQ/PBS
lml of NP-40 was mixed with lOOrals of PBS,
3Je...RP.-4Q/PBS/Prptease Inhibitors
1% UP-40/PBS containing EDTA (3 mmol l-1), IA (0.02 mol I"1), PMSF (2 
mmol I-1), 0.33 units/ml aprotonin, pepstatin A (25 pmol T-1),
Dissociating Buffer
3mls of 10%(w/v) SDS, 0.85mls of Tris (0.75 mol I'1 pH6.8), lml of 
glycerol, 150/j.l of bromophenol blue and 5mls of deionised water were 
mixed together.
Sample ..Buffer
Dissociating buffer was made up containing 0.5mls of 2-mercaptoethanol. 
Procedure
Ten millilitres of venous blood were mixed with 160 units of sodium 
heparin in a universal container and centrifuged at 2000g for 8 min at 
4*C and the plasma and buffy coat removed by aspiration. The cells were 
then washed 4 times in PBS and standardised to 1,25x10s*/ ml in PBS and 
4mls were transferred into a glass bijoux bottle containing 120p.l of 
lactoperoxidase, 25pl of potassium iodide (0.3 mmol I-1) and 5pl of 
glucose oxidase, 'l2SI (0.25mCi) and 120p.l of j3—D glucose were then added. 
The reaction mixture was rotated end over end an a Matburn mixer far 15 
min at room temperature after which the reaction was stopped by the 
addition of L-tyrosine to a final concentration of 2 praol I” 1 . The E were 
washed 3 times in ice-cold PBS by centrifugation at 2000g for 5 min at 
2°C. The E were chilled on ice for 15 min and then lysed by the addition 
of 15mls of ice-cold water/protease inhibitors. Two minutes later 15mls 
of sodium chloride/protease inhibitors were added to restore isotonicity. 
The lysate was centrifuged at 33,00Qg for 30 min at 4*C and following the
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removal of the supernatant the membrane pellet was resuspended in 1ml of 
1% RP-40/PBS. The solution was incubated on ice for 60 min to allow 
solubilisation of CR1. Erythrocyte CR1 was collected by centrifugation of 
the solubilised membranes at 10,000g far 30 min at 4*0. The clear 
supernatant containing CR1 was removed and stored at -70*0 and the 
membrane pellet discarded.
4.14(b) Ijamu.nQpreQipita.tiQn of RadiQla~bs.13.ed CR1 from Solubilised E
Membranes
The basis of the procedure is to add anti-CRl to the 12SI labelled 
solubilised membranes. CR1 binds to the antibody and can be removed from 
the mixture by binding to a protein A cell suspension. In preliminary 
experiments it was found that the monoclonal anti-CRl did not bind to 
the protein A, therefore a second antibody, the IgG fraction of rabbit 
anti-mouse globulin, was added to the incubation mixture before the 
addition of the protein A cell suspension.
Procedure
To reduce the problem of nonspecific binding of membrane proteins to 
protein A, the iodinated lysates were preabsorbed with 25/jil of a protein 
A cell suspension by incubation for 30 min at 4*0 with end over end 
mixing. The pellet was collected by centrifugation at 10,000g for 2 min 
at room temperature and the supernatant was removed and divided equally 
between 2 microcap tubes. To 1 of these tubes 5pl of normal mouse serum 
was added . This was designated the control tube. To the second microcap 
5pl of monoclonal anti-CRl IgG was added. This was designated the 
specific tube. These 2 tubes were incubated for 1 hour at 4*C with mixing, 
followed by addition of 5 pi of a second antibody, rabbit anti-mouse IgG 
(2.4mg/ml). The tubes were incubated for a further 1 hour at 4*0 after 
which 25pl of a protein A cell suspension were added and the incubation 
continued for 30 min at 4*0. The pellet was collected by centrifugation 
and washed 5 times with a 1% SP-40/PBS buffer. An aliquot of dissociating 
buffer (40pl) was then added to each pellet which was mixed tho -roughly 
and set in boiling water for 2 min . The pellets were centrifuged at
10,000g for 2 min at room temperature and the supernatants were removed
and diluted with an equal volume of sample buffer containing 2- 
mercaptoethanol. These were then subjected to SDS-PAGE on 5% slab gels. 
When the electrophoresis was complete the gel was incubated for 30 min 
in destain solution to fix the protein. The gel was then transferred to a 
slab gel drier and dried under vacuum for 2 hours at 70*0. After drying,
the gel was removed and placed in an X-ray cassette. A sheet of X-ray
film was placed on top of the gel and the cassette stored in the dark at 
room temperature for the required time. After this the film was removed 
and developed using Koda k developer and fixer according to the 
manufacturers instructions.
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4.15 S_e.pam t.iQn of CR1 from Solubilised E Membranes by Affinity
Chromatography
It was decided to use an alternative method of isolating CR1 from E for 2 
reasons, (i) to see if the protein immunoprecipitated by the monoclonal 
anti-CRl antibody was the same as the protein isolated by affinity
chromatography on C3-Sepharose and (ii> to determine if this method
would be quicker or more convenient than the alternative means.
Reagents. 
Igfi Sspharose
IgG Sepharose was prepared by Dr ¥ Mitchell.
C3-Sepharose
C3-Sepharose was prepared as described in chapter 2.9(b).
Borate Buffer
Borate buffer was prepared as described in chapter 2.9(b),
Elution Buffer
Acetic acid (0.1 mol I-1), sodium chloride (0.4 mol I"1) and 1ml of UP-40
were mixed together in lOOmls of deionised water.
neutralisation Buffer
Tris HC1 (2 mol I'-1 pH 8.6) and 1ml of UP-40 were made to a final volume 
of lOOmls in deionised water.
Procedure
Solubilised membranes from 2xl010 E were incubated with end over end 
mixing on a Matburn mixer at room temperature for 30 min with 400pl of 
IgG-Sepharose to absorb nonspecific proteins. The solution was 
centrifuged at 300g for 5 min at room temperature and the supernatant 
removed and diluted with 2 parts of deionised water containing 1% UP-40 
to reduce the conductivity of the solution. Half of this solution was 
added to 400pl of C3-Sepharose and half was added to 400pl of IgG-
Sepharose to provide a control for nonspecific binding. After a 1 hour 
incubation with end over end mixing on a Matburn mixer at room 
temperature the samples were centrifuged at 300g for 5 min at room
temperature and the supernatants removed. Six millilitres of borate buffer 
were added to the beads which were then transferred to a 2ml syringe
barrel and washed with 4mls of the same buffer. Each of the 1ml acid
eluates were collected into microcap tubes containing 125pl of
neutralising buffer for immediate neutralisation. Each eluate was
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precipitated with 5 volumes of acetone and after a 5 rain incubation at 
room temperature the samples were centrifuged for 5 min at 10,000g at 
room temperature. The supernatants were discarded and the pellets 
redissolved in Tris HC1 (2 mol T"1 pH 6.8). The protein was 
reprecipitated with acetone by mixing with 5 volumes of acetone for 5 
min at room temperature fallowed by centrifugation at 10,000g for 5 min 
at room temperature. The supernatant was removed and the pellet dissolved 
in 40pl of dissociating buffer prior to SDS-PAGE analysis on 5% slab 
gels.
4.16 Stability of E CR1
The stability of E CR1 was assessed after the E had been surface labelled 
by incubating the labelled E for a particular time interval before lysing 
the cells and immunoprecipitating CR1. If the receptor was shed within a 
certain time interval then the radiolabelled CR1 would be lost and would 
not show up on autoradiographs.
After having surface labelled E with 12:SI it was possible to study how 
the expression of CR1 was affected by treatment with various 
concentrations of trypsin. This particular study had 2 aims, (i) to 
discover if the concentration which removed all CR1 detectable by RIA was 
in fact removing all CR1 and (ii) to investigate the possibility that 
regeneration of E CR1 could occur after trypsinisation.
Procedure
Erythrocytes were standardised to 1.25x10s*/ml in PBS and warmed to 
37 X. Four millilitres of the appropriate concentration of prewarmed 
trypsin solution (O.lmg/ml, O.Olmg/ral, 0.005mg/ml, O.OOlmg/ml or 
O.OOOlmg/ml) were added to 4-mls of E in a universal container. The cells 
were incubated at 37 X  for 20 rain after which a 2-fold molar excess of 
SBTI was added. Incubation was continued for 2 min, the cells were then 
centrifuged at 2,000g for 5 min at 4X. The cell pellet was washed 3 
times in ice-cold PBS. The cells were finally resuspended in 4mis of PBS, 
surface labelled and CR1 immunoprecipitated,
In order to assess if trypsinised E could regenerate CR1, after the E 
were trypsinised, 1 aliquot was surface labelled and immunoprecipitated 
immediately. The remaining aliquots were incubated in either PBS, RPMI/BSA 
or plasma for different time intervals at 3 7 *C and then radiolabelled, 
lysed and immunoprecipitated for CR1.
4.18 Ineataent. of .£Miola3aaIled_E..w.ith SLE Sera and RA Sera
After surface labelling the E the cells were not lysed but were incubated 
overnight at 3 7 X  in 1:4 dilutions of normal sera or sera from either SLE 
patients or RA patients. Following this incubation the E were lysed as 
before, the membranes solubilised and CR1 immunoprecipitated.
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4.19 Determination of E CE1 lumber:
Erythrocyte CR1 could be measured successfully by polyclonal anti-CRl 
antiserum. The maximum intra-assay variation was ±5% of the mean (Table 
4.1) which indicated that the assay was reproducible. The range of E CR1 
numbers obtained from 27 individuals was large (1,255 to 33,854) with a
mean value of 3,773. A large range of E CR1 levels has also been found by
others using polyclonal anti-CRl to quantify CR1 (Wilson et al 1982; 
Holme et al 1986).
The maximum inter-assay variation was ±5% of the mean (Table 4.2). The 
fact that this variation in CR1 number was small after storage overnight 
at 4 X  in RPMI/BSA allowed E suspensions to be stored on ice for a 
number of hours or overnight at 4 X  before measuring CR1 numbers.
4.20 Stability., pf.. E CR1
The results from the inter-assay variation gave some indication that E 
CR1 was stable and was not affected by overnight storage at 4X. To 
determine if E CR1 numbers were stable at 37 X, E were incubated
overnight at 3 7 X  in RPI1I/ESA or autologous serum (Table 4,4). This
storage overnight at 37 X  did not affect E CR1 number.
4.21 Effac.t_.Qf Proteolytic Enzymes on E CR1 Levels
Erythrocyte CR1 levels were calculated on E after incubation with 
proteolytic enzymes at the concentrations indicated in Table 4,5, As can 
be seen from this table, when the physiological concentrations of these 
enzymes were used none of the enzymes reduced CR1 levels. However, high 
concentrations of elastase (2.27mg/ml) and trypsin (1 and O.Olmg/ml) 
removed all CR1 detectable by anti-CRl and at a trypsin concentration of 
O.lpg/ml, E CR1 receptors were reduced by 407*.
It is possible that some proteolytic component in SLE sera is able to 
remove or block CR1. Experiments were therefore performed in which E 
from 0‘+'v* blood group donors were incubated overnight at 37 X  in sera 
from patients with active or inactive SLE. The results of this study are 
shown in Table 4.6, As can be seen, CR1 numbers fell most after an 
overnight incubation in pooled heterologous sera, Erythrocyte CR1 numbers 
fell to a lesser extent in sera from a patient with active SLE.
Table 4.4 Stability of E CIU after Storage..Qv.ernight_at-.3Z,!G.
Medium for Overnight Humber of Mean percentage
Incubation Samples Change from Control±SE
RPMI 3 ~4±22
25% Autologous Serum 3 ~9±14
Note
CR1 levels were measured on the E of 3 individuals immediately after 
isolation or after storage of the E in RPMI or 25% autologous serum 
overnight at 37 °C. The change in E CR1 number after storage was 
calculated as a percentage of the E CR1 number on freshly isolated E 
(control). The mean percentage change of the 3 individual donors was 
then calculated.
Table 4.5
Enzyme Concentration Mean percentage Change 
from Control
Thrombin 5 units/ml 26±18
Elastase 45/ig/ ml -14±2
Elastase 2.27mg/ml -100±0
Kallikrein 1. 8/j.g/ml -5±9
Cathepsin C 9. 09p.g/ ml + 1±16
Cathepsin D 9.09pg/ml -4±15
Plasmin 9, ljjg/ml -11±1
Trypsin lmg/ml -100±0
Trypsin 0,Qlmg/ml -100±0
Trypsin 0.OOOlmg/ml -40±21
Eq±£
E CR1 levels were measured on E after incubation with the enzymes 
tabulated above. The change in E CR1 number caused by each enzyme was 
then expressed as a percentage of a control E sample from the same 
donor which had not been exposed to the enzyme. Each enzyme was 
incubated with E from 3 different donors and the mean percentage change 
from the control was determined,
Table 4,6 Eif^i_Ql_S.L£_SsLa_QiiJE_CEX
Medium for Overnight 
Incubation
Number of 
Samples
Mean Percentage Change 
from Control ±SE
25% Heterologous 2 -40±20
Normal Serum
25% Active SLE 4 -27±18
Serum
25% Inactive SLE 5 +5.2±24
Serum
Note
CR'l levels were measured on freshly isolated E (control) and on E which 
had been incubated overnight in the 3 types of sera indicated above. The 
change in E CR1 number caused by the incubation was expressed as a 
percentage of the control. The mean percentage change from the control 
was then determined for each group of samples.
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4.23 Measurement—of-.CR1 Numbers. in the Presence of Complement Coated 
IgG_Agg.regates
The number of CR1 detectable on the E of 2 donors fell considerably in 
the presence of large opsonised IgG aggregates as compared with the 
measurement in the presence of large unopsonised IgG aggregates (Table 
4.7).
4.24 Modulation— of— E— CR1 Expression in Response to Oral Antigen 
Challenge
Erythrocyte CR1 levels were measured before and after oral antigen 
challenge. The results are tabulated in Table 4.8 and presented 
graphically in Fig 4.6. The maximum drop in E CR1 levels was achieved 2 
hours after drinking 1.2 litres of cows milk. By 4 hours the E CR1 levels 
had returned to normal. Two control experiments were performed in which 
blood samples were collected after an overnight fast. These individuals 
did not drink any milk and no food was consumed until the last blood 
sample had been removed. As can be seen from Table 4.9, CR1 levels 
remained constant at all time points.
In order to determine if there were antigen/antibody complexes in the 
serum which could block E CR1 expression the sera from individuals who 
had ingested 1.2 litres of cows milk were incubated with E from 0+v,“ 
blood group donors. Erythrocyte CR1 number was then determined. The 
results showed that the sera do not produce E CR1 blockade (Table 4.10).
4.25 ImmunQprecipitatiQiL.of. CRl from E
Erythrocytes were radiolabelled and the membranes collected and 
solubilised. CR1 was immunoprecipitated from the supernatant of these 
solubilised membranes using both a commercially available monoclonal 
anti-CRl antibody and the IgG fraction of the antiserum to purified CR1. 
Both of these antisera precipitated a band of molecular weight 220,000 
daltons (Plate 4.5). A band of similar molecular weight was separated 
from solubilised membranes by affinity chromatography on C3-Sepharose 
(Plate 4.6). This indicated that CR1 could be isolated by both methods, 
however as purification of CR1 on C3-Sepharose was very time consuming 
it was decided to use the immunoprecipitation technique in all subsequent 
experiments.
4.26 Stability of E C.R1
The stability of CR1 on E was assessed by radiolabelling the E and 
incubating the ceils for 1 hour, 2 hours or 4 hours in PBS at 37 °C before 
lysing the E. Plate 4.7 shows that within a 4 hour incubation period a 
CR1 doublet of 220,000 daltons and 250,000 daltons could be seen at all 
times. When the cells were labelled and incubated for 48 hours at 3 7 *C or 
4 *C in autologous plasma or RPMI/BSA a band of 220,000 daltons could be 
seen indicating that the receptor had not been shed (Plate 4.8).
Table 4.7 Determination of E CR1 in the Presence of Opsonised IgG
CR1 Sites/E
Unopsonised IgG Opsonised IgG Percentage Change
Donor 1 4057 0 -100
Donor 2 5717 1621 -72
Note
CR1 numbers were measured on E in the presence of opsonised and 
unopsonised IgG aggregates, The change in CR1 levels caused by opsonised 
IgG aggregates was calculated as a percentage of the CR1 sites per E in 
the presence of unopsonised IgG aggregates.
Table 4.8 M odulation, of E CR1 Numbers in Response to Oral Antigen 
Challenge
Interval after Oral 
Antigen Challenge (min)
Number of 
Donors
Mean Percentage Change 
from Control±SD
30 6 -5±9
60 6 + 5±16
120 6 -33±13
180 6 -14±7.4
240 6 -4.6±10
Note
CR1 levels were measured on E at various time intervals up to 240 min 
after ingestion of 1.2 litres of cows milk. The change in E CR1 number 
at each time interval was calculated as a percentage of the CR1 sites 
present on the donors E immediately prior to milk consumption (control). 
The mean percentage change in E GR1 levels was calculated for each 
group of 6 donors at each time point.
Fig 4.6 Modulation of E CR1 Expression,..in. 
'' ive
Legend
Erythrocyte CR1 levels were measured on 6 individuals at various time 
intervals up to 240 min after ingestion of 1.2 litres of cows milk ( X 
axis). The change in E CR1 for these 6 donors was calculated as a 
percentage of the 0 time point ( Y axis). The 0 time point represents the 
number of CR1 sites per E present immediately prior to milk consumption. 
The plotted values represent the mean ± SEM for 6 donors.
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Table 4.9 M odulation of E CR1 Numbers in Fasting Individuals
Interval after Oral 
Antigen Challenge (min)
Number of 
Donors
Mean Percentage Change 
from Control
60 2 + 1. 75
120 2 -5.50
180 2 -3.50
Mote
CR1 levels were measured on E at various time intervals following an 
overnight fast. The change in E CR1 number at each time point was 
calculated as a percentage of the CR1 sites present on the donor's E 
when the first blood sample was collected (control). The mean percentage 
change at each time point was calculated for each 2 donors.
Table 4.10 Incubation of E with Sera Collected from Donors after 
Ingestion qJL L 2 Litres-q £_G.qw.s.. Milk
Interval after Ingestion Number of Serum Mean Percentage Change in ECR1
of 1,2 Litres of Milk (min) Samples Tested Levels on an Q+v" Blood DonortSE
30 2 -1,019,2
60 4 -10,019,5
120 4 +7,25111
180 4 +1,2517,0
240 3 -3,3118
Mote
CR1 number was calculated on the E of an 0'^irv blood group donor after 
incubation of their E in the sera from individuals who had ingested 1.2 
litres of cows milk. The number of CR1 sites present on E after 
incubation in sera collected before milk consumption was used as a 
control and the subsequent measurement of CR1 sites on E which had been 
incubated in sera collected after milk consumption were expressed as a 
percentage of this control.
Plate 4.5 ImmunopiecipitatiQn._Ql_CRl from lim a n — E.
Legasji
Immunoprecipitation of C.R1 from human E using an anti-CRl monoclonal 
antibody (track a) and polyclonal IgG anti-CRl (neat; track b and diluted 
1:10; track c). Samples were analysed on 5% slab gels run under reducing 
conditions, A band of molecular weight 220,000 daltons is seen in tracks 
a, b and c. Tracks d and e are controls immunoprecipitated with NMS.
Im munoprec ip i ta t ion Of CRI From 
Human RBC s
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A band with a molecular weight of 220,000 daltons was separated from 
solubilised E membranes by affinity chromatography on C3-Sepharose 
(tracks a and b). Bo bands were seen in the control samples (tracks c 
and d) which were eluted from IgG-Sepharose, Samples were analysed on 5% 
slab gels run under reducing conditions.
Elution 
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Legend
Erythrocytes were labelled with 12SI and either lysed immediately and 
immunoprecipitated with anti-CRl (track a) or incubated for 1 hour (track 
c), 2 hours (track e) or 4 hours (track g), before being lysed and 
immunoprecipitated with anti-CRl, Tracks b, d, f and h are controls 
immunoprecipitated with M S ,  When samples were analysed on 5% slab gels 
run under reducing conditions, 2 bands with molecular weights of 220,000 
and 250,000 daltons were immunoprecipitated from E treated with anti-CRl, 
This represents 1 of the structural polymorphic variants of CR1 (Dykman 
et al 1983a),
Immunoprecipitation Of CR1 At V ariou s  Intervals 
After labelling Of R B C s
-250K 
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Plate 4,5 CPI on B Labelled and Incubated for 46 Hours in rlasma or PPKI
Lepmd
Erythrocytes were labelled and incubated for 48 hours in RPMI/BSA at 4°C 
(track b), autologous plasma at 37 °C (track d) or autologous plasma at 
4°C (track f), before being immunoprecipitated with anti-CRl. Track h 
shows E with no incubation. Tracks a, c, e and g are controls 
immunoprecipitated with M S .  Samples were analysed on 5% slab gels run 
under reducing conditions. A band of molecular weight 220,000 daltons was 
immunoprecipitated from each of the samples which were treated with 
anti-CRl. Uo specific bands were immunoprecipitated with M S .
CR1 
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4.27
The same concentrations which were used to study the removal of all CR1 
detectable by RIA were used to study removal of CR1 on surface labelled 
cells. A concentration of 0.0 lmg/ml was found to be the minimum 
concentration which removed all CR1 (Plate 4.9). This is the same 
concentration which removed all CR1 detectable by RIA (Table 4.5).
4.28
To investigate whether some component of patients serum could cause 
partial proteolysis of CR1, E from a donor known to have CR1 numbers in 
the middle of the normal range were radiolabelled and incubated overnight 
at 37 X  in serum from a patient with SLE in the active phase.
As can be seen from Plate 4.10 a band of molecular weight 220,000 daltons 
representing CR1 was immunoprecipitated from the E after an overnight 
incubation at 3 7 X  in this serum. There were no other specific bands 
evident indicating that the SLE serum did not contain any component 
which altered CR1 structure. Radiolabelled E were also incubated overnight 
at 3 7 X  in the serum from 2 patients with RA, 1 in an active state of 
disease and 1 in an inactive state of disease. Patients with RA have been 
shown to have slightly reduced E CR1 levels as compared with normal 
individuals (Ross et al 1985; Holme et al 1986).
Plate 4.11 (tracks a, c and e) shows that a band of 220,000 daltons could 
be immunoprecipitated from the E in each case. Ho other specific bands 
were seen indicating that the CR1 structure had not been altered.
The cells from the donor used in this experiment were also treated with 
O.Olmg/ml of trypsin which removed all CR1. After removal of CR1 the E 
were not surface labelled but incubated overnight at 37 X  in PBS or sera 
from RA patients in active and inactive states of disease to see if 
reconstitution of CR1 occured after removal of CR1 by trypsin. Ho 
regeneration of the receptor was found on the E incubated in any type of 
medium (Plate 4.11 tracks f, h and i). Even when trypsinised E were 
incubated for 3 days at 3 7 X  in autologous plasma, PBS or RPMI/BSA no 
regeneration of CR1 occurred (results not shown).
Plate 4.9 Effect of Varying Concentrations of Trypsin_QiLExpresslD.ii-Qi 
CRl
Legend
Erythrocytes were trypsinised with various concentrations of trypsin, 
lmg/ml (track c), O.Olmg/ml (track e) and O.OOlmg/ml (track g), 
radiolabelled and immunoprecipitated with anti-CRl, Track a shows 
untrypsinised E and tracks b, f and h are the controls immunoprecipitated 
with NMS. Samples were analysed on 5% slab gels run under reducing 
conditions. A band with a molecular weight of 220,000. daltons was 
immunoprecipitated with anti-CRl from untrypsinised E (track a) and E 
trypsinised with O.OOlmg/ml of trypsin.
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E were radiolabelled and incubated overnight at 37 X  in serum from a 
patient with SLE in an active phase. The E were then lysed and 
immunoprecipitated with anti-CRl (track b) and M S  (track a). The 
samples were analysed on a 5% slab gel run under reducing conditions, A 
specific band with a molecular weight of 220,000 daltons, representing 
CR1, was seen on the E immunoprecipitated with anti-CRl (track b). No 
other specific bands were seen.
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Erythrocytes were radiolabelled and incubated overnight at 37 "C in PBS
(track a) or serum from a RA patient whose disease was in remission
(track c) or serum from a RA patient whose disease was in an active
phase (track e), The E were then lysed and immunoprecipitated with anti- 
CRl
Erythrocytes from the same donor were treated with O.Qlmg/ml of trypsin 
and incubated overnight in PBS (track f) or in sera from RA patients in 
an inactive (track h) or an active (track i) state of disease. These E
were then lysed and immunoprecipitated with anti-CRl. Tracks b, d, g and 
j are controls immunoprecipitated with M S .
All samples were analysed by SBS-PAGE (5% slab gels) run under reducing 
conditions, A band with a molecular weight of 220>000 daltons was seen on 
E immunoprecipitated with anti-CRl after incubation overnight in PBS or 
in sera from RA patients (tracks a, c and e), 3Jo specific bands were 
immunoprecipitated from trypsinised E (tracks f, h and i).
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4.29 Discussion
The results of the twin study showed that in an normal population E CR1 
were regulated by environmental factors. The experiments described in 
this chapter were performed to investigate possible mechanisms which may 
account for the reduced E CR1 expression which is seen in patients with 
SLE. Three possibilities were examined, (i) CR1 stability, (ii) CR1 
sensitivity to proteolytic enzymes, and (iii) CR1 blockade by opsonised 
immune complexes.
The 2 methods selected to investigate these possibilities were (i) 
quantification of E CR1 using a polyclonal or monoclonal antiserum and 
(ii) surface labelling of E CR1 and analysis of the receptor visually by 
autoradiography.
Using the polyclonal antiserum a mean of 3,773 CR1 sites/E was obtained. 
This is within the normal range of that reported by Holme et al (1986) 
using the same polyclonal antiserum (range 335-8,009). The polyclonal
antiserum was used in some instances as supplies of the monoclonal 
antibody Ell were limited.
Surface labelling of E and immunoprecipitation of CR1 with a monoclonal 
anti-CRl antiserum resulted in the precipitation of 2 polymorphic forms 
of CR1. One with a major band of molecular weight : 220,00 daltons 
(Plate 4,5) and 1 with 2 major bands of molecular weight 220,000 and
250,000 daltons (Plate 4.7), The 250,00 dalton band represents a less 
common phenotypic variant of CR1 and the individual from whom these E 
were obtained is heterozygous expressing 1 allele for the common CR1 
form and 1 for the less common higher molecular weight variant. These 
bands are 30,000 daltons higher than the bands reported by Dykman et al 
(1983(a)) who ran gels under non-reducing conditions. In reduced gels the 
estimated molecular weight of CR1 is 30,000 daltons greater than that 
which is estimated in gels run under non-reducing conditions. In some 
instances a less intense band was seen which was 15,000 daltons higher 
than the major band (Plate 4.11). This is similar to a band described by 
Dykman et al (1983(a)). However, the nature of this band is unknown. 
CR1 was also successfully isolated from radiolabelled E by C3-Sepharose 
affinity chromatography (Plate 4,6).
Having established that the 2 methods were valid for detecting E CR1, the 
stability of the receptor was investigated. Storage overnight at 4'C or 
37 *C in RPMI/BSA or autologous serum did not result in a significant 
reduction in CR1 sites/E (Table 4.2; Table 4,4). This conclusion was 
supported by the finding that CR1 could be immurioprecipitated 
successfully from surface labelled E after incubation for 2 days at 37 *C 
in autologous plasma (Plate 4,8). Thus in normal individuals it would 
appear that shedding of E CR1 is unlikely. It has been reported that E 
with low CR1 activity show high osmotic fragility (Inada et al 1983a) and 
it is known that anaemia is a common manifestation in SLE appearing in 
approximately 80% of patients. Thus it is possible that alterations in
the membrane physiology of the E of patients with SLE does result in a 
spontaneous release of CR1. In this respect it would be interesting to 
measure the serum concentrations of the soluble form of CR1 to see
whether they are higher in patients with SLE in an active phase than 
they are in normal individuals (Yoon and Fearon 1985) or in patients
with SLE in remission.
The removal of CR1 by proteases is at present thought to be the most 
likely explanation for reduced E CR1 numbers (Ross et al 1985; Ripoche 
and Sim 1986). Proteolytic enzymes such as thrombin, plasmin and
kallikrein normally circulate as inactive precursors and not in their 
active form. However when tissue damage occurs such as in immune complex 
disease, activation of the plasma mediator systems occurs so that plasma, 
thrombin and kallikrein are present in their active form for short
periods. It is possible that these enzymes could proteolytically strip CR1 
from the surface of E membranes.
Experiments were performed to determine if these proteases could remove 
CR1 in vitro. It was found that at the physiological concentrations used 
thrombin, plasmin and kallikrein did not significantly reduce E CR1 
numbers (Table 4.5). This is in contrast to the findings of Ripoche and 
Sim (1986) which showed that in vitro CR1 was sensitive to physiological 
concentrations of plasmin (1.56-100pg/ml) and thrombin (1.25-20 
units/ml). At. these concentrations CR1 was removed from E as assessed by 
the appearance of a form of CR1 in the supernatant which had a cofactor 
activity for the I mediated cleavage of C3b to iC3b, However they could 
not demonstrate the loss of CR1 from E during clotting in whole blood 
which is an indication that during clotting in vitro there is an 
insufficient amount of free thrombin and plasmin generated to cause 
removal of CR1 from E.
The leukocyte proteases cathepsins C and D were also included in the 
study but they were not found to have any effect on CR1 (Table 4.5).
The trypsin sensitivity of CR1 has been well documented (Kelson and 
Kelson 1959; Sira 1985; Ripoche and Sim 1986) and in this study I have 
shown that trypsin could remove CR1 from E at a concentration of 
O.Olmg/ml. Elastase, a protease secreted by leukocytes also caused removal 
of CR1 when it was used at a high concentration (Table 4.5). It is 
unlikely that the amount of elastase or trypsin in the serum would be 
sufficient to remove CR1 as the serum protease inhibitors a l  - 
macroglobulin and a 1-anti-trypsin are present in serum in such high 
concentrations that they would inactivate these enzymes. However if E 
were in intimate contact with phagocytic leukocytes such as is the case 
when E carrying immune complexes pass through the liver and the spleen 
(Cornacoff et al 1983) removal of CR1 may occur randomly through contact 
with the proteinase-rich tissue phagocytes. In patients with SLE the 
extent and duration of contact between E and tissue phagocytes might 
increase due to the elevated levels of immune complexes present on the E 
surface.
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The experiments with trypsin also indicated that once CR1 was removed no 
new receptors could be brought to the cell surface (Plate 4.11). This 
indicates that there is no obvious internal pool of CR1 or that if one 
does exist, that under the in vitro conditions used, the E were unable to 
mobilise the pool perhaps due to membrane damage caused by trypsin. Sim 
and Sim (1983) also concluded that there was no internal pool of CR1 in 
E after the observation that the cofactor activity of CR1 for the I 
mediated cleavage of C3b on intact E was comparable to that of soluble E, 
indicating that all of the E CR1 was expressed on the cell surface.
Treatment of soluble CR1 with trypsin results in its breakdown to 
disulphide-linked fragments with molecular weights of 65,000 and 160,000 
daltons. These fragments are subsequently degraded to lower molecular 
forms upon prolonged treatment with trypsin (Sim 1985), CR1 was 
immunoprecipitated from E after an overnight incubation at 37 °C in serum 
from patients with active SLE (Plate 4.10) and active RA (Plate 4.11). Ho 
lower molecular weight degradation fragments of CR1 were observed 
indicating that these sera did not contain active proteases.
The final aspect which was looked at was the ability of the receptors to 
be blocked by immune complexes. It has been documented that E CR1 is
not a stable phenotype in patients with SLE as the CR1 levels on the E 
of these patients can increase or decrease as a patient enters an active
or inactive state of disease. Ross et al (1985) and Holme et al (1986)
have shown that when a patient enters remission, E CR1 numbers increase 
within a time interval which is incorapatable with entry of newly 
synthesised E into the blood stream. Thus the possibility exists that 
complexes may have been blocking the access of radiolabelled probes to 
the receptor when the disease was in its active phase with high levels of 
circulating immune complexes and as the patient went into remission that 
the complexes were removed leaving the CR1 binding site free. In favour 
of this hypothesis Inada et al (1982) observed that the E from SLE
patients showed defective CR1 activity when immune complexes were 
present in the serum and Wilson et al (1985b) found that high titres of 
an autoantibody to CR1 were correlated with the absence of CR1 from E 
and heightened disease activity in 1 SLE patient.
However Wilson et al (1982), Minota et al (1983) and Ross et al (1985) 
published findings which were inconsistent with blockade of existing 
receptors by immune complexes. Ross et al (1985) failed to find evidence 
that E from SLE patients contained abnormal amounts of C3 antigen an 
indication that E did not contain surface bound C3b or iC3b and therefore 
could not contain CR1 bound complexes which required either C3b or iC3b 
for attachment. CR1 sites could also be detected with 125i— Ell even when 
E had bound dsDKA/anti-DKA complexes. However the concentration of 
complexes may have been too small to cause blockade of CR1 sites. 
Experiments in our laboratory by Dr E Holme suggest that the size of 
immune complex is crucial as E CR1 numbers were unchanged by small 
complexes but could be blacked completely when large complexes were
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bound, This was probably as a result of steric hindrance between the
complexes and 1-asI-Ell which was used as the probe.
The results of an in vivo and an in vitro experiment are presented in
this chapter. Both suggest that blockade of CPI by complexes could occur.
In vitro it was shown that CR1 number on the E of 2 individuals were
considerably reduced in the presence of large opsonised IgG aggregates as 
compared to the levels in the presence of large unopsonised complexes
(Table 4.7).
Food consumption is one aspect of daily living which results in the 
formation of immune complexes containing food antigens (Paganelli et al 
1979). It was therefore decided to study CR1 levels on the E of 
individuals after they had consumed 1.2 litres of cows milk which is an 
easily absorbed rich source of food antigens to see if in vivo formation 
of complexes would reduce E CR1 levels. It was shown that 2 hours after 
milk consumption E CR1 levels were reduced and by 4 hours they had 
returned to normal (Table 4.8). The E used in control experiments where
no milk was consumed showed no change in E CR1 number (Table 4.9).
To test for the presence of complexes containing food antigens in the
sera from individuals after milk consumption the sera were incubated with 
E from donors with an 0+ve blood group. The results showed that there 
was no significant change in E CR1 numbers caused by any of the sera 
(Table 4.10). This does not necessarily imply that the sera did not 
contain complexes. The complexes may have been in a form which were 
unable to rebind E CR1 as a result of processing of C3b into smaller
fragments such as C3dg which is not a ligand for CR1,
Time did not permit further investigation of this phenomenon. Future 
studies could look for the presence of C3 and IgG on the surface of E 
after milk consumption and also for the presence of complexes containing 
the milk antigens caesin and lactalbumin on the surface of E and in the 
serum. Even if these studies could not show the presence of complexes on 
the cells the results from the experiment indicate that some mechanism 
must exist which allows rapid increases and decreases in E CR1 numbers 
which can definitely not be accounted for by proteolysis.
Thus the situation would appear to be complex and at the present moment 
it is not possible to determine if blockade by complexes or enzymatic
removal of CR1 is the cause for reduced E CR1 numbers in E SLE. The 
fact that serial studies show that E CR1 levels can return to normal
before new E can be produced (Ross et al 1985, Holme et al 1986) argues 
against the theory that proteolytic stripping of CR1 is the mechanism; 
however it cannot be excluded that proteolysis contributes towards the 
extent of reduced CR1 expression in SLE. The results presented in this 
chapter indicate that CR1 levels can be modulated by environmental 
factors such as the presence of high concentrations of pro teases or the 
presence of large immune complexes. They also lend support to the theory 
that E CR1 numbers are not a stable heritable characteristic but that
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they may be strongly influenced by simple environmental effects such as 
eating a meal.
CHAPTER FIVE
In the previous chapter I discussed mechanisms whereby E CR1 levels may 
be reduced in patients with SLE. There are few published studies of CR.l 
numbers on the peripheral blood leukocytes of patients with SLE. Such 
studies are important as leukocytes play a major role in host defence and 
thus leukocyte CR1 deficiency might produce serious impairment of the 
ability of the individual to combat infection. As discussed in the 
introduction CR1 plays a ■ number of important roles on phagocytic cells 
(1.28). It has the ability to promote endocytosis of small immune 
complexes (Abrahamson and Fearon 1983) and when CR1 becomes activated 
it can directly mediate the phagocytosis of large particles such as E and 
bacteria (Griffin and Griffin 1979; Vright and Silverstein 1982; Vright et 
al 1983a; Pommier et al 1984) Phosphorylation of CR1 on phagocytes may 
account for the transition of CR1 from an inactive to an active 
phagocytic state (Changelian and Fearon 1985)).
In order to gain an understanding of possible defects in CR1 levels on 
the PMN of patients with SLE it was first of all important to define more 
closely the distribution of CR1 on normal PMN, CR1 levels on PMN have 
been quantified previously using both polyclonal and monoclonal anti-CRl 
antisera. Fearon (1980) reported that PMN expressed approximately 57,000 
binding sites for CR1 using a polyclonal antiserum, whilst Hogg et al 
(1984) reported 46,000 using the monoclonal Ell. Early studies with 
rosettes revealed that the number of CR1 on the surface of PMN could be 
increased significantly by exposing the cells to chemotactic stimuli such 
C5a, histamine or FMLP (Anwar and Kay 1978; Kay et al 1979), It is now 
known that CR1 numbers on PMN will spontaneously increase when PMN are 
warmed to 37 *C (Fearon and Collins 1983) and increase a further 2- to 3- 
fold when stimulated with FMLP (Berger et al 1984; Richerson et al 1985) 
or with low concentrations of phrobolmyristate acetate (PMA), a tumour 
promoting phorbolester (Changelian et al 1985). This increase in CR1 
number is not accompanied by an increase in total cellular CR1 indicating 
that the additional receptors are being translocated from an internal 
pool (Changelian et al 1985; O'Shea et al 1985a).
In this chapter I will describe attempts which were made to establish 
how many pools of CR1 were contained within PMN, The cytoskeletal and 
energy requirements for expression of these pools were also investigated,
This was achieved in 2 ways, (i) removing the receptors from the surface 
membrane by trypsinisation and then quantifying the receptors which were 
regenerated and (ii) treating PMN with FMLP in order to allow maximum 
expression of CR1. In addition various drugs which cause inhibition of 
protein synthesis or inhibition of energy production or disruption of 
cytoskeleton assembly allowed the mechanisms which control the 
translocation of intracellular CR1 to the surface to be investigated.
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Having defined the number of CR1 pools and the conditions under which 
they were expressed it was then possible to study CR1 on the PMN of 
patients with SLE to determine if there were any major differences.
5.2 Chemicals and Reagents
Chemicals and other reagents were obtained from the following companies:
Sterling ,ILese.ar.c.h.t. .Qnslo.K -Street, Guilford., Surrey. England
Hypaque (Sodium Diatrizoate injection BP) 45%
Eharmacia-HQUse,-Midsummer...Boulevard. Milton Keynes. England
Ficoll
Sigma. Chemical GchJr.anc.y.. Road..focala*.Dorset.
Colchicine 
Cycloheximide 
Cytochalasin B 
Dextran
Dinitrophenol (DNP)
JT-Forrayl-Methianyl-Leucylphenylalanine (FMLP)
Leupeptin 
Lummicolchicine 
Pepstatin A 
Puromycin
Soybean Trypsin Inhibitor (SBTI)
Trypan Blue 
Trypsin
BlflQd„Txaasf.us.ion - JSsryice. Law Hospital, Carluke. Scotland
AB plasma pack
Millipore.JUD Limited. Peterborough Road. Harrow, Middlesex
Sterile Millipore Filters
GihcQ Biocult, Paisley.. Renfrewshire. Scotland
Hepes Buffered Earles Minimal Essential Medium (HEM)
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Ficoll-Hypaque (SG 1.077) was prepared by mixing 20mls of 45% Hypaque 
with 6.5mls of deionised water to achieve a 33.9% solution. After removal 
of 1.5mls of this solution 60mls of 9%(w/v) Ficoll were added.
3Sf.or.jp.aL.. Saline.
Jformal saline was prepared as described in chapter 2.7(b).
Dsadxan-Salut  i on
Dextran solution was prepared by mixing 6g of dextran in lOOrals of 
normal saline.
Twice Normal Saline (23Sf Saline)
Twice normal saline (0.3 mol l-1) was prepared by mixing 1.8g of sodium 
chloride in lOOmls of deionised water.
RPMI-1640 containing 0.5%(w/v) BSA and EDTA (0.02 mol I” 1)
Procedure.
Sixty millilitres of fresh venous blood were transferred to 3 universal 
containers containing lOOpl of sodium heparin(1000 units/ml) to prevent 
clotting. The blood was then layered onto 15mls of Ficoll-Hypaque in 2 
sterile Falcon tubes. The tubes were centrifuged at 400g for 30 min at 
room temperature. The mononuclear cells were removed and the remaining 
blood was mixed with an equal volume of autologous plasma, which had 
been removed from the top of the Ficoll-Hypaque column, and allowed to 
sediment at 3 7 °C in the presence of 6%(w/v) dextran. The PMR enriched 
supernatant was removed and the cells pelleted by centrifugation at 200g 
for 5 min at 4'C. Contaminating E were lysed by resuspending the cell 
pellet in deionised water for 10 seconds followed by the addition of an 
equal volume of 2N saline to restore isotonic conditions. The cells were 
centrifuged at 200g for 5 min at 4'C and the lysed E removed with a 
Pasteur pipette. The PMN were resuspended in 20mls of RPMI/BSA/EDTA, lOpl 
of this suspension were diluted with 180/j.l of white cell counting fluid 
and the number of cells counted using an improved Neubauer 
haemocytometer. The PMN were then resuspended in RPMI/BSA/EDTA at 
5xlOe /ml,
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5.4 Enumeration of PMN CR1 Numbers with F Cab'ha. anti-CRl.
Reagents 
Peps tat in.. A
Pepstatin A was stored at -20 °C at 1 mg/ml in DMSO.
Le.upepU.il
Leupeptin was stored at -20*C at lmg/ml in deionised water.
Buffers 
RPMI/.BSA/EDIA/.I
0.1%(w/v) soybean trypsin inhibitor (SBTI), 25ug/ml pepstatin A and 
25ug/ml leupeptin were added to a volume of RPMI/BSA/EDTA. These 
inhibitors were added to prevent proteolytic degradation of CR1 by 
enzymes released from the PMN during the assay.
Erosedura
Triplicate aliquots <200ul) of PMN <5xl0'?W in RPMI/BSA/EDTA/1 were 
transferred to a series of 8 microcaps. Unlabelled nonimmune rabbit
F(ab’)2 fragments (12.5ug/ml) were added to tubes 1 to 4 and unlabelled 
anti-CRl F(ab ' > 2 fragments (12.5mg/ml) were added to tubes 5 to 8. All of 
these additions were made while the microcap tubes were being incubated 
on ice. The cells were then mixed on a Matburn mixer at 4 X  for 30 min 
after which incremental quantities (lug,2ug,3ug,and 4ug) of 12eI-F(ab'):2 
anti-CRl were added to each set of 4 microcap tubes. Again these
additions were performed on ice. The cells were mixed on a Matburn mixer 
for 1 hour at 4 X  after which each sample was layered over 300ul of
dibutylphthalate/dinonylphthalate in microcap tubes and centrifuged at 
10,000g for 2 min at room temperature. The cell pellets were cut from the 
microcap tubes as before and counted in an automatic V counter. This
procedure for measuring PMN CR1 numbers is essentially the same as that 
adapted for measuring E CR1 numbers there are however 2 major 
differences. Firstly, all additions to the PMN were made on ice, this 
prevented internalisation of the FC.ab')^ anti-CRl fragments. Secondly, the 
first incubation time was shortened from 1 hour to 30 min to lessen the 
chance of CR1 being degraded by PMN proteolytic enzymes or F(ab')2 anti- 
CRl fragments being internalised.
Calculation of CR1 Sites per PMN
Total binding and nonspecific binding curves were constructed as 
previously described in chapter 4.6(b) and a linear regression analysis
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performed. The number obtained from this analysis was converted into CR1 
sites per PMN according to the following formula:
The number of molecules in lcpm (N) =
6.02x10’2 
cpra in lug of F(ab')2 anti-CRl
The number of CR1 molecules/PMN =
N x the number of bound cpm in 1x10s 
1x10s (number of cells/microcap tube)
Intra-Assay Variation
Reproducibility of the assay was assessed by calculating the CR1 number 
on 3 separate aliquots of an individual blood sample all at the same 
time. The mean of the 3 numbers obtained in this manner was calculated 
(Table 5.1). The intra-assay variation was ± 9%.
5.5 Measurement of P M X R l J u m b e r s  using the Monoclonal Antibody Ell
Triplicate aliquots (200ul) of PMN (5xl0s /ml) in RPMI/BSA/EDTA/1 were 
mixed on a Matburn mixer with incremental quantities of 12SI-E11 (0.07, 
0.7 and 1.4pg) for 1 hour at 4X, Nonspecific binding was assessed by 
firstly incubating triplicate aliquots of PMN (5xl0s/ml) with a 10-fold 
molar excess of unlabelled Ell for 30 min at 4 'C before addition of 0.7pg 
of 1:2SI-E11. As with the polyclonal anti-CRl all additions to the cells 
were made on ice. The cells were layered over dibutylphthalate/ 
dinonylphthalate in microcap tubes, centrifuged at 10,000g for 2 min at 
room temperature and the cell pellets collected and counted in an 
automatic X counter.
Calculation of CR1 Sites per FMN
The amount of radioactivity bound in the absence of cold Ell represents 
the total amount of 1:2:£“I-E11 bound to the PMN. The amount bound in the 
presence of 0.7 pg of cold Ell represents the nonspecific binding of 
1SSI-E11. The nonspecific binding of 1:25I-E11 increased in a linear 
fashion (Table 5.2) and therefore to conserve supplies of Ell which were 
limited, the nonspecific cpm obtained from this 1 point were doubled and 
plotted against the total input in order to draw a line representing 
nonspecific binding of ,2SI-E11 (Fig 5.1(a)). The total amount of '**1- 
Ell bound was then plotted against the total input of 1:ZSI-E11 (Fig 
5.1(a)). From this data a Scatchard plot was constructed as previously
Table 5.1 Intra-Assay Variation
CR1 Sites/PMN
First Second Third MeaniSD % Variation
Measurement Measurement Measurement from mean
Donor 1 52,566 58,637 53,363 56,52212,787 ~4 +4
Donor 2 158,468 155,271 178,373 164,037112517 -9 +5
gate: The mean of the 3 measurements was calculated and the percentage 
variation of the highest and lowest measurement from the mean was 
calculated.
Table 5.2 Nonspecific Binding of 1SSI~E11
Bound cpm to 1x10s PMN incubated with 7pg of cold Ell
\ Donor 1 Donor 1251-11(pg) 2 Donor 3
0.7 386 331 
1,4 666 710
319 
620 .
Fig 5.1(a)
Legend
The amount of radioactivity bound to PMN in the presence of incremental 
quantities of 12SI-E11. (0.07, 0.7 and 1.4pg> and the amount bound in the 
presence of a 10-fold molar excess of unlabelled Ell were plotted against 
the input of Ell, with each point being performed in triplicate (the 
vertical bars represent the SEM). The binding curves show the total
amount of 12:GI-E11 bound (______) and the nonspecific binding of 12SI-E11
(- - -). The ordinate axis shows the total input of 12:SI-E11 and the 
abscissa shows the total amount of ,:25I-E11 which was bound expressed 
as cpmxlO-2-.
Fig 5.1(b) Scatchard Plot 
Legend
A Scatchard plot was constructed by plotting the number of specific 
bound 12:®I-E11 against the bound/free 1!2SI-E11 cpm. The point where this 
line crosses the Y axis, represents the number of bound cpm to 1x10s p/i/J.
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described in chapter 4.6(b) (Fig 5.1(b)). The point where this line 
crossed the Y axis was determined by linear regression analysis with 
this point representing the number of bound cpra to 1x10s PMN. This 
number was converted into CR1 sites per PMN according to the formula 
shown below.
The number of molecules in lcpm (N) =
2.81xl012 (number of molecules in 0,7/ig) 
cpm in 0,7pg of F(ab ' > 2  anti-CRl
The number of molecules per PMN =
N x the number of bound cpm in 1x10s cells 
1x10s (number of cells per microcap tube)
IiitrazAssay...lariatiQn
The reproducibility of the assay using the monoclonal antibody was 
assessed by calculating the CR1 number on 3 separate aliquots of an 
individual blood sample all at the same time (Table 5.3) The intra-assay 
variation was ±8%.
5.6 CamparisQiLQi....EalyclQnal Antiserum with Monoclonal Antiserum
When binding of the polyclonal F(ab')s anti-CRl antibody to PMN of 3 
normal donors was compared with that of monoclonal anti-CRl antibody a 
mean of 2.2 molecules of F(ab ' ) 2 polyclonal antibody was bound per 
binding site for monoclonal antibody Ell. Thus it is possible to compare 
results obtained by both methods.
5.7 Study Qf.PM.CRL. Number Changes in Response to Drugs 
Reagents
gzEor-mylzMethionyl-Leucy 1-Phenylalanine (FMLP)
FMLP a synthetic chemotactic peptide which causes chemotaxis of PMN and 
other phagocytic cells, was stored at -70°C as a 10~2 mol I"1 stock 
solution made up in dimethyl sulphoxide (DMSO). This stock solution was 
diluted to a final concentration Df 10~e mol I-1 when added to PMN 
(Atkinson et al 1977).
Table 5.3 Intra-Assay..Variation.
CR1 Sites/PMN
First Second Third MeaniSD % Variation
Measurement Measurement Measurement from Mean
Donor 1 34,159 39,879 37,863 37,30012,901 —1
 
1 C
O
Donor 2 53,059 55,971 62,615 60,54813,970 +4 -8
Note: The mean of the 3 measurements was calculated and the percentage 
variation of the highest and lowest measurement from the mean was 
calculated.
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Colchicine is an alkaloid derived from the autumn crocus c
autumnal. It binds to tubulin dimers and causes depolymerisation of 
microtubules (MT). It was stored desiccated at 4°C. Prior to use a stock 
solution of 10”a' mol I"'1 in RPMI/BSA/EDTA was made and diluted to a 
final concentration of 10""5 mol I-1 when added to PMN (Atkinson et al 
1977).
Lummicolchicine
Lummicolchicine a functional analogue of colchicine, which does not affect 
MT structure, was stored desiccated at 4°C. Prior to use a stock solution 
of lO"-12 mol-1 in RPMI/BSA/EDTA was made and diluted to a final 
concentration of 10” 5 mol l” 1 when added to PMN.
Cytflshalasin. B
Cytochalasin B derived from the fungus, HelmlnthQsporium dematioideum is 
thought to bind to act in and dissociate microfilaments. It was stored 
protected from light at -70’C as a 10"2 mol T"1 stock solution in DMSO. 
This stock solution was diluted to a final concentration of 10~s mol l-1 
when added to PMN (Atkinson et al 1977).
Puromycin, a protein synthesis inhibitor, was stored desiccated at -20 *C 
at 25mg/ml in deionised water. It was diluted to give a final 
concentration of 40p.g/lxl0e PMN (Rosso di San Secondo et al 1979).
Cycloheximide, a protein synthesis inhibitor, was stored desiccated at 
4°C. Prior to use a stock solution of 5mg/ml was made in RPMI/BSA/EDTA. 
This was diluted to give a final concentration 200/j.l/lxl0e (Rosso di San 
Secondo et al 1979),
DNP was stored desiccated at room temperature prior to use a stock 
solution of 3 mol I"1 was made in RPMI/BSA/EDTA and diluted to a final 
concentration 3x10~s mol I” 1 when added to PMN.
Rotenone, which is light sensitive, was stored (protected from light) 
desiccated at -20°C, Prior to use a stock solution of lO-2 mol I"1 was 
made in acetone and diluted to a final concentration of 10~4 mol I” 1 when 
added to PMN,
Puromycin
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Antlmyc.inJl
Antimycin A was stored desiccated at -20 X. Frior to use a stock solution 
of 0.1%(w/v) was made in DMSO and diluted to a final concentration of 
0.01%(w/v) when added to PMN.
DMSO
At the concentration used (0.1%(v/v)) DMSO had no effect on CR1 number 
(Table 5.4).
Trypan Blue
0.75g of trypan blue were dissolved in lOOmls of normal saline to result 
in a 0.75 (w/v) solution.
Increase in CR1 Number in Response to Vanning t o 3 7 X  or tbe__Addition 
EML.P
CR1 numbers on PMN are reported to increase spontaneously by warming to 
37 *C or by treatment with FMLP (Fearon and Collins 1983; Berger et al 
1984; Richerson et al 1985),
PMN (5xl0®/ml) in RPMI/BSA/EDTA were incubated on ice for 30 min after 
which an aliquot was removed, centrifuged at l,000g for 3min at 4X, 
resuspended in RPMI/BSA/EDTA/I (5xl0e /ml) and CR1 numbers determined. 
The remaining cells were then incubated at 37 X  in a shaking water bath 
for 30 min alone or in the presence of FMLP after which the cells were 
collected by centrifugation at l,000g for 3 min at 4 X  and resuspended in 
RPMI/BSA/EDTA/I (5xlOe /ml) and CR1 numbers determined.
Treatment of PMN with Drugs
PMN were treated with drugs to determine what effect protein synthesis 
inhibitors, energy inhibitors and inhibitors of cytoskeleton assembly 
would have on expression of CR1.
Procedure
PMN (5xlO'Vml) in RPMI/BSA/EDTA were incubated on ice for 30 min after 
which an aliquot was removed and CR1 numbers determined. The remaining 
cells were divided into separate aliquots and the following drugs were 
added, colchicine, lummicolchicine, cytochalasin B, puromycin, 
cycloheximide, DNP, rotenone and antimycin A. The incubation on ice was 
continued for 10 min to allow absorption of these drugs before the cells 
were transferred to a 3 7 *C shaking water bath and incubated for 30 min. 
The cells were then centrifuged at l,000g for 3min at 4X, resuspended in 
RPMI/BSA/EDTA/I at 5xl0s7ml and CR1 numbers determined.
Table 5.4 Effect of DMSO on PMN CR1. Numbers.
Donor1 
Donor2
CR1 Sites/PMN 37 °C + DMSO Percentage
37*C (0.1% (v/v)) Change
60,586 56,731 -6
31,977 36,187 +13
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After treatment with drugs a small aliquot of the PMN suspension was 
removed and diluted 1:20 with 0.75%(w/v) trypan blue. The cells were then 
mixed for 2 min before being placed on a slide and counted under a light 
microscope, The number of cells which excluded trypan blue were divided 
by the total number of cells counted and this number was expressed as a 
percentage. The proportion of viable cells in each PMN preparation was 
always greater than 95% when assessed by trypan blue exclusion.
5.8 Treatment of PMN with Trypsin
Reagents
AB-Elasaa
One unit (200~250mls) of AB plasma was thawed at 3 7 'C and the plasma 
placed into a volumetric flask. The plasma was allowed to clot by the 
addition of 4 mis of 1 mol l-1 calcium chloride and the mixture stirred 
overnight at 4'C. The serum was separated from the clot by filtration 
through a Buchner funnel. The serum was heat inactivated at 5 6 'C for 2 
hours to destroy endogenous complement activity and dialysed against PBS 
(lOOx the serum volume) overnight at 4*C before ultracentrifugation at 
28,000g to remove lipid and particulate material. The serum was then 
filtered through a sterile Millipore filter and stared at -20°C.
Trypsin
Trypsin was stored desiccated at -20°C. Prior to use, trypsin was made 
up to a stock solution of lOmg/ml in RPMI/BSA/EDTA and diluted to 
0.2mg/l x 10® cells for use.
Buffers 
PBS.
PBS was made as previously described in chapter 2.6(c),
BEMI/BSA/EPTA/AB
A volume of RPMI/BSA/EDTA was made up containing 5%(v/v) AB serum. The 
AB serum was added to prevent clumping of the PMN.
RPMI/BSA/EDTA/AB/.SBTI
A volume of RPMI/BSA/EDTA/AB was made up containing 0,lmg/ml SBTI.
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Trvpsinisatian of PMN
PMN were trypsinised to remove all surface CR.l so that regeneration, of 
CR1 could be studied.
PMN were suspended in RPMI/BSA/EDTA/AB at 4xl06/rol and prewarmed to 
37 X  in a shaking water bath. Prewarmed trypsin solution was added to 
the cells and incubation continued for 15 min after which a 2-fold molar 
excess of SBTI was added to inactivate the enzyme. The cells were 
incubated for 2 min, then centrifuged at l,000g for 5 min at 2X. The 
cell pellet was given a further 3 washes in ice-cold RPMI/BSA/EDTA and 
the cells resuspended in RPMI/BSA/EDTA at 5xlOs /ral.
Regeneration of PMN CR1 following Trypslnisatipn
An aliquot of trypsinised cells was removed immediately following 
trypsinisation and CR1 antigenic sites measured by RIA. The remaining 
PMN were incubated at 3 7 X  in RPMI/BSA/EDTA/SBTI for 1 hour in a shaking 
water bath to allow regeneration of PMN CR1. Vhen the incubation was 
complete the cells were centrifuged at room temperature for 5 min at 
l,000g, resuspended in RPMI/BSA/EDTA/I (5xlOG /ml> and CR1 number 
determined by RIA.
To determine if PMN CR1 were regenerated at O X  the cells were incubated 
on ice for 15 min following trypsinisation. After the incubation was 
complete the cells were centrifuged at 4 X  for 5 min at lOOOg and 
resuspended in RPMI/BSA/EDTA/I (5x10®)/ml. CR1 number was then 
determined by RIA.
Inhibition of PMN CR1 Regeneration
After trypsinisation PMN were incubated at 3 7 X  in RPMI/BSA/EDTA/AB/SBTI 
(5xl0G/ml) and puromycin, cycloheximide, cytochalasin B, or colchicine, at 
the same concentrations used previously (5.7) were added to the PMN 
suspension to see if they could inhibit the reappearance of CR1. After a 
1 hour incubation the cell pellet was collected by centrifuged at l,000g 
for 5 min at O X  and given 3 washes in RPMI/BSA/EDTA/ before being 
resuspended RPMI/BSA/EDTA/I (5xl0G /ml and CR1 number determined by RIA.
5.9 Rosette Assays
EAIgMC43b
EAIgMC43b were prepared as described in chapter 2.7(b).
EAIgQ
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EAIgG prepared with rabbit IgG anti-sheep red blood cells were kindly 
donated by Mrs .J Veitch,
Vaseline.
Vaseline for sealing the coverslips was melted at 80 °C on a hot plate. 
Buffer.s....and Solutions 
3 % (w/v) Gluteraldehyde
3mls of gluteraldehyde was added to lOOinls of normal saline. 
HEMZ-EPIAZflaSa
Hepes Earles Medium (HEM) containing EDTA (0.02 mol l"'1) and 0.2%(w/v) 
sodium azide (NaNs). These inhibitors were added to prevent PMN proteases 
from cleaving C3b to iC3b. If this were to happen then both CR3 and CR1 
rosettes would be measured (Ross et al 1983).
G3EE£L
GVB-2'*’ was prepared as described in chapter 2.7(b)
Er.Qcad.ur.e
Rosette assays were performed as an additional means of studying removal 
and regeneration of PMN CR1. Rosettes with EAIgG showed the proportion 
of PMN which bound EA by Fc^ receptors and rosettes with EAIgMC3b 
showed the proportion of PMN binding EAIgMC3b through CR1.
Before trypsinisation, immediately after trypsinisation and 1 hour after 
trypsinisation, PMN were standardised to 4xlOe/ral in HEM/EDTA/NaNa. Equal 
volumes of the PMN suspension (250/j.l) and EAIgGj ^*^(1x10®/ml in GVB2^) 
were mixed in round bottom test tubes and centrifuged at 200g for 5 min 
at room temperature. The ceils were resuspended in the original 
supernatant and 500pl of 3% (w/v) gluteraldehyde were added to fix the 
cells. After incubation for 20 min at room temperature, 2mls of deionised 
water were added to the test tubes and the contents mixed by inversion. 
The cells were centrifuged at 200g for 5 min at room temperature and the 
supernatant discarded. The cells were resuspended in 250/il of 0,75%(w/v) 
trypan blue and a drop of this suspension was placed onto 3 glass slides. 
Rosettes were examined under coverslips sealed with melted vaseline, At 
least 200 cells were counted per slide and the mean percentage of cells 
forming rosettes with 3 or more E was calculated.
5.10 Batients. with. SLE .and Normal Controls
15 patients with SLE (1 male and 14 females) (Tan et al 1982) and 14 
healthy normal controls (5 males and 9 females) were included in the
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study. Immediately prior to venous blood sampling the SLE patients were 
examined for evidence of disease activity, which was defined as 
continuing clinical activity of involved organ systems. These features 
included polyarthritis, rash, continuing active urinary sediment with 
cells and casts alone or in addition to proteinuria when present. Seven 
of the patients were in active phase of disease and 8 were in inactive 
disease at the time of study.
Fifty millilitres of venous blood were collected from each individual, 
40mls of this were mixed with a 100 units of sodium heparin in a 
universal container and the PMN isolated as previously described (5.3). 
The isolated PMN were suspended in RPMI/BSA/EDTA at 5x106 /ml and PMN 
CR1 number was determined at 0°C, 37 "C and in the presence of FMLP as 
previously described (5.7). The remaining lOmls of blood were centrifuged 
at lOOOg for 5 min at 4°C and the plasma and buffy coat removed. The red 
cell pellet was then washed 3 times in RPMI/BSA, the cells were 
standardised to 2.5xlOs /ml and E CR1 number determined by RIA.
5.11 Serial-Studies
The CR1 number on E and PMN (at 37 °C) were measured on 3 patients during 
periods of disease activity and also during remission.
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5.12 Quantification and Distribution of PMN CR1 at 37 X
A method for quantifying CR1 on PMN was successfully adapted from the 
method used for quantifying E CP.l. Using this method the average number 
of PMN CR1 sites per cell on 33 normal individuals at 37 X  was calculated 
to be 198,000 ± 33,000 using the polyclonal anti-GRl F(ab')2 antiserum. 
The average number on 14 normal individuals at 37X  was 75,000 ± 7,000 
as determined by the monoclonal antibody Ell. When the number of 
receptor sites per cell among these normal individuals were depicted as 
frequency histograms (Fig 5.2(a) and Fig 5.2(b)) they were distributed in 
a logarithmic fashion.
The number of PMN CR1 sites per cell was calculated on 14 normal 
individuals using 12SI-Ffab');? anti-CRl, at OX, 3 7 X  and at 3 7 X  in the 
presence of FMLP. At O X  PMN expressed 87,000 ± 7,000 CR1 antigenic sites 
per cell, at 37 X  125,000 ± 16,000 CR1 sites per cell and in the presence 
of FMLP (10 * mol I"1) 206,500 ± 21,000 sites per cell (Fig 5.3). The 
difference in CR1 number at O X  and at 37X  was significantly different 
(P<0.05). The increase in expression of CR1 seen in the presence of FMLP 
was significantly different from the spontaneous increase at 37 X  
(P<0.05).
PMN were stimulated with FMLP in the presence of cycloheximide and 
puromycin and GR1 numbers calculated using 1:"SI-E11. Neither of these 2 
protein synthesis inhibitors were found to have any effect on the 
stimulation of CR1 expression with FMLP (Fig 5.4) (P>0.05 in both cases).
As protein synthesis inhibitors did not reduce CR1 expression in the 
presence of FMLP no studies were performed on the effect of these drugs 
on CR1 expression at 37X.
Expression
Cytochalasin B and colchicine did not affect the increase in CR1
expression which was seen upon warming PMN to 37X  (Fig 5.5(a)) (P>0.05 
in both cases), However both of these drugs abrogated the increased 
expression of CR1 seen in the presence of FMLP (Fig 5.5(b).
Lummicolchicine a functional analogue of colchicine which does not affect 
microtubule structure (Wilson and Friedkin 1967) had no effect on FMLP.
stimulated expression of CR1 (Fig 5.6) (P/0.Q5). These results indicate
that microtubule and microfilament assembly are important for the
mobilisation of CR1 in response to FMLP, The specificity of the
colchicine response is indicated by the observation that lummicolchicine 
did not prevent the FMLP induced increase in CR1 numbers.
Figure 5.2(a) Distribution of PMN CR1 in 3.3.NQi:ml Individmls. 
)e ter miner
Legend
Histogram showing the frequency distribution of the number of binding 
sites on PMN for 12SI-F(ab')2: anti-CRl among 33 normal individuals. The 
intervals are 50,000 sites/PMN.
Figure 5.2(b) Distribution of PMN CPI in 14 Normal Individuals 
Determined by Ell
Legend.
Histogram showing the frequency distribution of the number of binding 
sites on PMN for 12S1-E11 among 14 normal individuals. The intervals are
10,000 sites/PMN.
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Figure 5.3 Distribution of P M  CR1 at-Q..X>-J37X  and in the..Rr.esence. .o£ 
EHLE.
LegsnA.
Distribution of CR1 number (determined by polyclonal F(ab')2 anti-CRl) on 
PMN from 14 normal individuals after incubation at OX, . 37 *C or
in the presence of FMLP (10~* mol I-1). The top of each bar
represents the mean and the horizontal line represents the SEM.
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Fig 5.5(a) Effect o f Inhibitors o f X y i o s M l^tmJlsgembly on .PMtLCRl-aiL
FMN CR1 number was measured using 12eI~Ell at O ’C and at 37 *C in the 
presence of colchicine (10~s mol I- 1 ) and cytochalasin B (1 O'-55 mol l"1). 
The top of each bar represents the mean of 4 experiments and the 
vertical line the SEM.
Fig 5.5(b) Effect of Inhibitors of Cytoskeleton Assembly on. P M .  OKI in 
the presence of FMLP
Legend
Distribution of CR1 number (determined by polyclonal F(ab'):z anti-CRl) at 
0°C, at 3 7 *C, at 37 ‘C- in the presence of FMLP (10“s mol I'1) and at 3 7 *C 
in the presence of FMLP plus colchicine (10~s mol I- 1 ) or cytochalasin B 
(cyt B 10~s mol I-1). Each bar represents the mean ± SEM of 9 
experiments.
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Fig 5.5 Effect of Lummicolchicine .Qn_EM . CR1. EspLfts.siQn
Legend
PMN CPI number was measured using 12:SI-E11 at 0°C), 37X, 3 7 X  in the 
presence of FMLP (10“s mol 1“ 7) and at 37 X  in the presence of FMLP plus 
colchicine (10""s mol l-1) or lummicolchicine (10~s mol I-1). The top of 
each bar represents the mean of 3 experiments and the vertical line the 
SEM.
CR1 Sites (xlO-4) /PMN
14
12
EZZ30  C 
E M  37 C 
E M ) FMLP 
EaH3 COLCH10
8 vrtijiritliiiiilI1 „il, ,i',"Will i "i , r .ii,;" tiWiimh'fllMqJir
6
4
2
0
Page 172
5.16 Suppress ion.-Qi-EMLP Induced .Increase of CR1 with Energy Inhibitors.
The energy inhibitors, DNP, rotenone and antimycin A did not affect the 
increased expression of PMN CR1 which was seen upon warming the cells 
from O X  to 3 7 X  (Fig 5.7(a)) (P>0.05 for all inhibitors). However in the
presence of FMLP these drugs inhibited the FMLP induced expression of
CR1 at 3 7 X  (Fig 5.7(b)) (P<0.05 for all inhibitors).
5.17 Effect of Trypsin on PMN CP.l
Incubation of PMN with 0.08%(w/v) trypsin removed all CR1 detectable by 
radioimmunoassay using F(ab')z anti-CRl (Fig 5.8). After incubation at
37 X  for 1 hour the surface expression of CR1 was restored almost to
normal levels (Fig 5.8) ( P<0.05). CR1 number was not restored if PMN
were incubated at O X  (Table 5.5). That CR1 were being removed was
substantiated by the finding that while the percentage of PMN rosetting 
with EAIgG (which measures the binding of the PMN FcK receptors)
remained the same before and after trypsinisation, the percentage of PMN 
rosetting with EAIgMC3b (which measures the binding of the PMN CR1) fell 
significantly (Table 5.6). After incubation for 1 hour at 3 7 X  the 
percentage of PMN rosetting with EAIgMC3b increased significantly, again 
indicating that CR1 were being translocated from an intracellular site to 
the cell surface (Table 5.6).
5.18 Effect on Drugs on the Regeneration of CR1 on Trypsinised PUN
Addition of the protein synthesis inhibitors puromycin or cycloheximide 
to trypsinised PMN did not affect the reexpression of CR1 which was seen 
after 1 hour (Fig 5.9) (P>0.05 in both cases). Addition of colchicine or
cytochalasin B to trypsinised PMN also had no effect on the return of
Oil to the membrane over 1 hour (Fig 5.10) (P>0.05 in both cases)
The mean number of E CR1 on 9 normal individuals was 2,516 ± 826 sites 
per cell whereas the mean number of E CR1 from the 7 patients with 
active disease was significantly lower (393 ± 370 sites per cell)
(P<0.001). This number was also significantly lower than the mean number 
of E CR1 from the 8 patients with inactive disease (2,795 ± 814
sites/cell) P<0,001 (Fig 5.11). The difference in E CR1 numbers between 
normal individuals and those with inactive SLE was not significant 
(P>0.05). This reduction of E CR1 in SLE patients with active disease is 
in agreement with the findings of others (Ross et al 1985; Holme et al 
1986).
The number of CR1 sites on patients PMN was measured at O X  and at 3 7 X  
in the absence and presence of FMLP. In patients with inactive SLE the 
numbers of CR1 sites at those temperatures were 124,528 ± 37,298,
165,672 ± 62,932 and 209,344 ± 57092 respectively (Fig 5.12). These
5.7(a) Effect pf Energy -InhibltorS-.qii X:M„XRl-..ExpressiQii_at.„..3.7X.
Lagand.
PMN CR1 expression was measured using 1:Z5I-E11 at OX, 3 7 X  and at 3 7 X
in the presence of rotenone (10~4 mol I"1), antimycin A (0.01%) or DNP
(3xl0~s mol l-1). The top of each bar represents the mean of 3
experiments and the vertical line represents the SEM,
5.7(b) Effect of Energy Inhibitors on PMN CPI expression in the Presence 
of FMLP
Lagand.
Distribution of CPI number at OX, at 3 7 X, at 3 7 X  in the presence of 
FMLP (10~s mol I-1) and at 3 7 X  in the presence of FMLP plus DNP (3xl0~® 
mol l-1) or rotenone (10~4 mol l- 1 ) or antimycin A (0,01%(w/v)), CR1 
number for rotenone and antimycin A treated PMN were determined by Ell 
and CR1 number for DNP treated PMN was determined by polyclonal F(ab ' ) 2  
anti-CRl, Each bar represents the mean±SEM of 5 experiments.
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Fig 5.8 Incubation of Trypsinised PMN for 1 Hour at 3.7-1C.
Legend.
PMN CR1 number was measured on control cells at 37 X, on trypsinised PMN 
immediately after trypsinisation and after the trypsinised cells had been 
incubated at 3 7 X  for 1 hour. The top of each bar represents the mean of 
12 experiments and the vertical lines the SEM. CR1 was measured using 
125I-F(ab')2 anti-CRl.
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Table 5 .5  GR1 .A n t ig e n ic. S ites... on J M .
CR1 Antigenic Sites on PMN 
Normal(37#C) T9 15 min(37*C) 15 min(0*C)
Donor 1 232,434 20,313 97,544 20,299
Donor 2 94,196 0 36,960 0
Donor 3 820,403 0 202,908 0
Note: T9 = Trypsinised PMN at time 0 hours.
Table 5.6 EfflLRoasttea with-EA l&MG3.t^and..J&AlgG.
Percentage of PMN Rosetting with;
EAIgMC3b TEAIgMCSb TEAIgMC3b 
(lhr incub)
EAIgG TEAIgG TEAIgG 
(lhr incub)
Donor 1 2718 911 2714 66112 75110 70110
Donor 2 3215 412 2414 6515 6116 6614
Donor 3 4315 511 1111 7315 7318 8018
lobe: T = Trypsinised PMN; lhr incub = 1 hour incubation
5.9 Effect of Protein Synthesis Inhibitors on Trypsinised .PM .
Legend.
PMN CR1 was measured on control cells at 37 X, on trypsinised PMN 
immediately after trypsinisation and on trypsinised PMN after a 1 hour 
incubation at 3 7 'C alone or in the presence of cycloheximide 
(200/j.g/lxl0s cells) or puromycin (40pg/lxl0® cells). CR1 was measured 
using 12SI-F (ab‘)z anti-CRl. The top of each bar represents the mean of 4 
experiments and the vertical lines the SEM.
5.10 Effect of Inhibitors of Cytoskelebon Assembly _ on Trypsinised ...'EM. 
Legend
PMN CR1 number was measured on control cells at 37X, on trypsinised PMN 
immediately after trypsinisation and on trypsinised PMN after a 1 hour 
incubation alone or in the presence of colchicine (10~5 mol I-1 ) or 
cytochalasin B <10-5 mol I-1). The top of each bar represents the mean of 
4 experiments and the vertical lines the SEM. CR1 was measured using 
,a5I-F(ab')2 anti-CRl.
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5.11 E CR1 on SLE Patients
Legend
Distribution of CR1 on E determined by polyclonal F(ab')5t anti-CRl on 9 
normal individuals/ on 7 SLE patients with active disease . and on
8 SLE patients with inactive disease.
EEH3 Normal 
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■ ■ in a c t iv e  SLE
Fig 5.12 PIN CR1 Number on SLE Patients
Legend
Distribution of CR1 number determined by polyclonal FCab'^ anti-CRl on 
PIN from 7 SLE patients with active disease (•), and 8 with inactive 
disease CO) after incubation at 0*C, 3 7 "C or in the presence of FMLP (10“ 
5 mol I” 1). Assays on FMLP treated PMN were performed on only 6 patients 
with active SLE.
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numbers were not significantly lower than the numbers expressed on 
normal individuals (Fig 5.3) (P '> 0.05 in all cases).
However in patients with active SLE the numbers expressed at O X  and at 
37 X  in the absence and presence of FMLP were 15,394 ± 7809, 68,388 ± 
2,2921 and 69,361 ± 2,2972 respectively (Fig 5.12). These numbers were 
significantly lower than normal FMN CPI and lower than PMN CR1 patients 
with inactive SLE (P<0,05 in all cases). In the SLE patients with active 
disease the level of expression of CPI following exposure to FMLP was not 
significantly different from that expressed at 37 X.
CR1 numbers on E and PMN were measured on 3 patients during periods of 
disease activity and also during remission. In the active state CR1 
numbers were low on both E and PMN whereas they increased on both cell 
types when the disease became inactive (Table 5.7).
5.21 Correlation
In normal individuals there was a significant correlation <r = 0.77) 
between the number of CR1 expression on PMN at 37 X  and the number of 
CR1 sites per E (F < 0,05), (Fig 5.13(a)). Similar results were found in 
SLE patients where the number of PMN CR1 expressed at OX, at 37 X  and 
in the presence of FMLP correlated significantly with the number of CR1 
sites per E (r - 0,57, 0.57 and 0.59 respectively), (Fig 5.13(b),(c)
and(d)), (P < 0,05 in all cases). In SLE patients correlations were found 
between PMN CR1 expression at OX- and at 3 7 X  (r = 0,945; P ( 0.001), 
(Fig 5.14(a)), between CR1 expression at O X  and in the presence of FMLP 
(r = 0.954; P < 0.001), (Fig 5.14(b)) and between CR1 expression at 3 7 X  
and in the presence of FMLP (r = 0.96; P < 0.001), (Fig 5.14(c)).
In normals correlations were not significant between PMN CR1 expression 
at O X  and at 3 7 X  (r = 0.434; P > 0.05), (Fig 5.15(a)) or between PMN 
CR1 expression at O X  and in the presence of FMLP (r = 0.434; P > 0.05), 
(Fig 5.15(b)). However there was a significant correlation between 
expression at 3 7 X  and in the presence of FMLP ( r=0.7055; P < 0.01), 
(Fig 5.15(c)).
Table 5.7 Serial...Study
CR1 sites/cell
P M E
Patient Active Inactive Active Inactive
1 41,847 53,146 0 440
2 0 257,927 361 2859
3 70,048 185,669 2876 9526
Fig 5.13 (a) Correlation .b.^ ttteeiiJE31]L-£El-£spr.essiQiL-at 37 X  .a m j J L & B l
The number of CR1 sites on the E and PMU of 9 normal individuals was 
determined and then the number of CR1 sites per E was plotted against 
the number of PjM  CR1 sites. The line obtained from linear regression 
analysis had a significant correlation coefficient, (r = 0.77; P < 0.05).
Fig 5.13(b) Correlation between P M  CP.l Expression at O X  an E CR1.
Expression in SLE Patients.
Legend
The number of CR1 sites on the E and P M  of 13 patients with SLE was 
determined and then the number of CR1 sites per E was plotted against 
the number of P M  CR1 sites. The line obtained from linear regression 
analysis had a significant correlation coefficient (r = 0.57; P < 0.05),
Fig 5.13(c)
Expression in SLE Patients
Legend
The number of CR.l sites on the E and P M  of 8 patients with SLE was 
determined and then the number of CR1 sites per E was plotted against 
the number of PMN CR1 sites. The line obtained from linear regression 
analysis had a significant correlation coefficient (r =0,57; P < 0.05).
Fig 5.13(d) Correlation between P M  CR1 Expression in the Presence of
The number of CR1 sites on the E and P M  of 10 patients with SLE was 
determined and then the number of CR1 sites per E was plotted against 
the number of FMH CR'l sites. The line obtained from linear regression 
analysis had a significant correlation coefficient (r = 0.59; P < 0.05).
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Fig 5.14(a) Correlation between FCT CR1 Expression_&t Q X  and-&t 37X  in.
The number of CR1 sites on the PMM of 5 patients with SLE was determined 
at O X  and at 3 7 X. The number of P M  CR1 sites at 3 7 X  was then plotted 
against the number of P M  CR1 sites at OX. The line obtained from linear 
regression analysis had a significant correlation coefficient (r = 0.945; 
P < 0.001).
Fig 5.14(b) Correlation between P M  CR1 Expression at O X  and in ■the 
Presence of UMLP.in SLE-Patients
The number of CR1 sites on the P M  of 10 patients with SLE was 
determined at O X  and in the presence of FMLP. The number of P M  CR1 
sites calculated in the presence of FMLP was then platted against the 
number of PMM CR1 sites at OX, The line obtained from linear regression 
analysis had a significant correlation coefficient (r = 0.954; P < 0,001).
The number of CR1 sites on the PMM of 9 patients with SLE was determined 
at 3 7 X  and in the presence of FMLP. The' number of FMU CR1 sites 
calculated in the presence of FMLP was then plotted against the number of 
PMN CR1 sites at 37 X. The line obtained from linear regression analysis 
had a significant correlation coefficient (r = 0.96; P < 0,001).
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Fig 5.15 (a) Correlation between PHI CR1 Expression, at- 0 "0..-aafl_a.l-.37,X._ in 
Normals
Legaad.
The number of CR1 sites on the PMN of 12 normal individuals was 
determined at O X  and at 3 7 ’C. The number of PMN CR1 sites at 3 7 "C was 
then plotted against the number of PIQI CR1 sites at OX. The line 
obtained from linear regression analysis did not have a significant 
correlation coefficient (r = 0.434; P > 0.05).
Fig 5.15(b) Correlation between P M  CR1 Expression, at Q X  and in. the. 
Presence of FMLP in Normals
The number of CR1 sites on the PMN of 12 normal individuals was 
determined at O X  and in the presence of FMLP, The number of PMN CR1 
sites calculated in the presence of FMLP was then platted against the 
number of PMN CR1 sites at OX. The line obtained from linear regression 
analysis did not have a significant correlation coefficient (r = 0.434;
P > 0.05).
The number of CR1 sites on the PMM of - 14 normal individuals was 
determined at 37 X  and in the presence of FMLP. The number of PM.N CR1 
sites calculated in the presence of FMLP was then platted against the 
number of PMI CR1 sites at 37 X. The line obtained from linear regression 
analysis had a significant correlation coefficient (r = 0.7055; P < 0.01).
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The average number of CR1 sites per PMN on 33 normal individuals 
calculated at 37 X  using a polyclonal antiserum was 197,715 ± 33,577 
(range 50,000-500,000). This is higher than that reported by Fearon who 
using a polyclonal antiseru.m found only 57,000 CR1 sites per PMN. 
However this was calculated on 1 sample and falls within the range of 
PMN numbers quoted above. Using a monoclonal anti-CRl antibody, 57F, 
Iida et al (1982) reported that there were 140,000 CR1 sites per PMN. 
This calculation was performed on PMN which had been detergent 
solubilised therefore intracellular CR1 would have been included in this 
estimation. Hogg et al (1984) reported an average of 46,000 CR1 sites 
per PMN on 4 normal individuals at room temperature, I have found using
the same monoclonal, that on 14 normal individuals the average number of
CR1 sites per PMN was 75,558 ± 7,613 at 37X  (range 40,000-140,000). The 
higher temperature which I calculated PMN CR1 may have been responsible 
for this difference.
The range of CR1 sites per PMN calculated by both methods was large. A 
large range of CR1 sites is also found on E. (Wilson et al 1982; Holme 
et al 1986)*
The distribution of PMN CR1 number calculated by both polyclonal and
monoclonal antisera was logarithmic (Fig 5,2(a)&(b)) like that found on E 
by Holme et al (1986), Studies on the distribution of E CR1 have yielded 
conflicting results. In some, E CR1 levels were reported to be trimodally 
distributed (Wilson et al 1982; Minota et al 1984; Nojiraa et al 1985). As 
previously described in chapter 3.1 this distribution originally led to 
the hypothesis that CR1 levels on E were inherited with the level of
expression being controlled by 2 codominant alleles at a single locus. 
More recent studies have found that E CR1 are distributed in a normal 
fashion (Walport et al 1985; Ross et al 1985).
It would be interesting to determine which of these categories of
distribution PMN CR1 falls into, Although the size of sample in my own 
study was small in comparision to the size of samples used in E studies, 
as the number of E CR1 and PMN CR1 number on normals appears to
correlate (r=Q,77) the distribution of PMN CR1 probably parallels E CR1 
distribution in being distributed in a logarithmic fashion (Holme et al 
1986).
In agreement with the work of others (Fearon 8s Collins 1983; Berger et al 
1984; Richerson et al 1985) I have found that PMN CR1 expression can be 
increased by warming PMN to 37 X  and further increased by stimulation 
with FMLP (10“5 Mol I"1) (Fig 5.3). This increased expression was not 
as a result of de novo protein synthesis as it was not inhibited by the
presence of puromycin or cycloheximide indicating that the additional
receptors were probably being translocated from an intracellular pool 
such as was described by O'Shea et al (1985a).
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The results with the energy inhibitors DNP, rotenane and antimycin A and 
inhibitors of cytoskeleton assembly, colchicine and cytochalasin■ B 
suggest that CR1 which are brought to the surface upon warming to 37X  
come from a different source than do CR.l which are expressed after 
stimulation with FMLP, DNP is a drug which uncouples the election 
transport chain from the production of energy by preventing the 
phosphorylation of ADP to ATP. Hotenone and antimycin A both inhibit 
energy production by blocking election transport flow between the reduced 
form of nicotinamide adenine dinucleotide (NADH) and cytochrome b and 
between cytochrome b and cytochrome c respectively. In the presence of 
these drugs expression of CR1 at 37X  was normal (Fig 5.7(a)). However, 
the increased expression following exposure to FMLP did not occur (Fig 
5.7(b)). This finding implies that translocation of CR1 from an internal 
pool is an energy dependent process, while CR1 brought to the surface in 
response to warming to 37X  does not require energy,
In support of the theory that intracellular CR1 comes from 2 different 
sources it was found that cytochalasin B and colchicine had no effect on 
the expression of CR1 at 37 X  while they abrogated the increase seen in 
the presence of FMLF at 37 X, Therefore an intact cytoskeleton was not 
required for the spontaneous increase (Fig 5.5(a)) at 37X  but it was 
required for the mobilisation of CR1 in response to FMLF.
The cytoskeleton has been shown to play a role in the distribution of CR1 
in the plane of the membrane as cross-linking of PMN CR1 by F(ab')s 
anti-CRl resulted in an association of CR1 with the underlying 
cytoskeleton (Jack and Fearon 1933). In addition treatment of monocytes 
with colchicine resulted in the inhibition of the activation of CR1 which 
follows stimulation with fibronectin (Wright et al 1984). Therefore 
intact raicrotubules may be a prerequisite for activation of C-Rl as well 
as for responding to cheinotactic stimuli such as FMLP. Lummicolchicine is 
a functional analogue of colchicine, produced by irradiation of colchicine 
with longwave ultraviolet light. It has no measurable affinity for 
microtuble subunits and does not affect rcicrotubule polymerisation. This 
drug had no effect on the FMLP stimulated increase (Fig 5.6) indicating 
that it is specifically disruption of microtubules which is responsible 
for the lack of response to FMLP, Similar results were found with 
cytochalasin B which inhibits polymerisation of microfilaments.
These results may indicate that there are 3 distinct pools of PMN CR1. 
One pool is expressed on the membrane at OX, a second is expressed at 
37 X  and does not require energy or an intact cytoskeleton for its 
expression, while a third pool which is expressed in the presence of 
chemotactic agents such as FMLP depends upon energy and an intact 
cytoskeleton for translocation to the membrane. Whether differentiation 
between pools 1 and 2 is of any valu-e is questionable as PMN in vivo 
circulate at 37X.
Further evidence for the existence of an internal pool of CR1 in PMN 
comes from the trypsinisation studies, It was found that trypsinised PMN
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which were depleted of CR1 on the membrane surface, could regenerate CR1 
following an incubation of 1 hour at 3 7 X  (Fig 5,8; Table 5.6). The 
trypsinisation was carried out by incubation at 37 X- tor 15 rain.
Richerson et al (1985) studied the time course of temperature induced 
complement receptor enhancement. They found that warming to 37X  alone 
rapidly enhanced CR1 to nearly maximum levels within 5 min although 
further incubation up to 1 hour resulted in further slight enhancement. 
Thus during the trypsinisation process additional CR1 would have been 
translocated from an internal pool to the surface and removed by trypsin. 
Although this was the case, the pool of intracellular CR.l could not have 
been completely depleted as regeneration' of CR1 did occur after 
incubation for 1 hour. Expression of this pool did not occur when the 
trypsinised PMN were held at O X  indicating that the regeneration of CR1 
was temperature dependent (Table 5.5). Cytochalasin B and colchicine did
not affect regeneration of CRl on trypsinised PMN (Fig 5.10) suggesting 
that an intact microfilament and microtubule system were not important 
for expression of this pool of CRl.
This observation lends further support to the theory that 2 intracellular 
pools of CRl exist. The CRl pool expressed after trypsinisation of PMN 
is different to that expressed after stimulation with FMLP as the former 
is not sensitive to inhibitors of cytoskeleton formation whereas the 
latter is, Further support for this may be provided by experiments in
which trypsinised PMN are stimulated with FMLP to see if enhanced 
expression of CRl over and above that seen at 37 X  is observed and if 
this enhanced expression can be inhibited by cytochalasin B and 
colchicine.
It is now well established that patients with SLE have reduced E CRl
(Miyakawa et al 1981; Wilson et al 1932; Inada et al 1982; Iida et al 
1982; Walport et al 1985; Ross et al 1985; Holme et al 1986). This 
deficiency is now known not to be restricted to E. Emancipator et al 
(1983) showed that patients with SLE proliferative nephritis had a 
deficiency of CRl on their glomerular podocytes. Hurst, Nuki and 
Vallington (1984) reported a significant reduction in the rate of
complement mediated phagocytosis by blood monocytes in patients with
SLE. This reduction was most evident in patients with active disease.
Wilson et al (1986b), evaluated the expression of CRl on B cells by 2 
colour fluorescent flow cytometry and found that the mean relative 
fluorescence in 17 SLE patients was 39% lower than in 17 normal 
individuals. They also studied the CRl content of detergent lysates of
patients neutrophils and found them to be 41% lower than normal.
However they could not find any relationship between CRl number and 
laboratory parameters of disease activity such as auto-anti-CRl, C4, C3 
and immune complex levels.
I have found that all 3 pools of PMN CRl were reduced in SLE patients 
with active disease (Fig 5.12). In fact there was no significant increase 
in PMN CRl expression found by stimulation with FMLP in patients in an 
active state of disease over the spontaneous increase seen at 37 X  (Fig
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5.12). This may indicate that, (i) the FMLP CPI pool in these patients is 
severely depleted or (ii) that these patients have a defect in the 
mechanism leading to translucation of CRl or (iii) that there are a 
diminished number of chemotactic receptors for FMLP on the surface of 
the PMN from patients with SLE. If this last possibility was found to be 
true it may be that a CRl deficiency is only one representation of a 
wider membrane defect on the PMN of these patients.
In SLE patients there were significant correlation coefficients between 
levels of E CRl and levels of CR.l in each of the 3 PMN pools, (Fig 
5.13(b), (c) and (d)). In addition there were also significant
correlations coefficients between each of the 3 pools of PMN CRl, (Fig 
5.14(a), (b) and (c). Before beginning this study on PMN it was not
known if the reduction in CRl on. the E of patients with active SLE could 
be compensated by higher CRl levels on their peripheral blood cells. The 
significant correlation coefficients between the differing pools of PMN 
CRl and between E CRl levels and PMN CRl levels indicate that a 
deficiency in E CRl is not compensated by increased PMN CR.l levels nor 
is a deficiency in surface expression of PMN CRl compensated by larger 
internal pools of PMN CRl.
The finding that SLE patients in remission had increased CRl expression 
in all 3 pools (Fig 5.12) and that PMN CRl numbers rose when the disease 
entered phases of remission (Table 5.7) suggests that this abnormality is 
an acquired defect.
The role of CRl on PMN in the process of phagocytosis is still unclear, 
Unstimulated PMN will not ingest sheep EAIgMC3b but require first to be 
activated by chemotactic factors such as FMLP or C5a des Arg followed by 
stimulation with PMA or fibronectin (Pommier et al 1984 and Changelian et 
al 1985), This acquisition of a phagocytic function correlates with 
phosphorylation of CRl (Changelian and Fearon 1985) which may represent
the structural basis for the activated state of the receptor. Both
chemotactic factors and fibronectin are present at sites of tissue injury 
and they may represent an impor tant in vivo mechanism for the
augmentation of CRl expression and activation at these sites. A reduced 
number of CRl on the surface of PMN of patients with SLE and a depleted 
internal CRl pool available for translocation may result in the inability 
of these cells to d.eal efficiently with the internalisation and
degradation of immune complexes and the phagocytosis of opsonised 
bacteria. This in turn may predispose to bacteria/* infection a well known 
complication of SLE (Steinberg 1985) and also to the severity and 
duration of immune complex mediated tissue injury.
CHAPTER SIX
In the previous chapter it was shown that the PMN from patients with 
active SLE were not only deficient in surface expression of CRl but the 
internal pools of CRl were also depleted, One possible explanation for 
such a depletion could be that some abnormality exists in the 
biosynthesis of the receptor.
To date little is known of the biosynthesis of the receptor. One study 
on the human promyelocytic leukemia cell line has revealed that CRl may 
be initially present as a 188,000 dalton intracellular precursor 
(Atkinson and Jones 1984); however no data exists on the synthesis, 
secretion and turnover of CRl in cells from normal individuals and SLE 
patients. It was decided that as PMN are difficult to culture for long 
periods of time, to initially try to study the rate of synthesis of CRl 
in cultured monocytes and lymphocytes from normal individuals. If this 
proved to be successful cells from patients with SLE could then
be cultured and the rate of CRl synthesis in these patients compared 
with normal individuals.
As there was no established method available for the immunoprecipitation 
of CRl’ from 3SS-methionine labelled monocytes, the optimal conditions 
for this technique had first to be characterised.
It was first necessary to optimise the culture conditions for protein 
synthesis by monocytes and lymphocytes before pulsing the cultures. In 
the case of monocytes the production of C2 was used as an indication 
that the monocytes were healthy and synthesising proteins. The 
stimulation of lymphocytes with mitogens ensured that the lymphocytes 
were synthesising an increased amount of protein. The 
immunoprecipitation of C3 from monocyte culture supernatants was an 
indication that the immunoprecipitation technique was reliable.
In this chapter I will present the methods used and the results obtained 
in attempting to establish optimal conditions for pulsing lymphocytes 
and monocytes and I will discuss the difficulties which were found in 
trying to immunoprecipitate CRl from those cells.
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6.2
Chemicals and other reagents were obtained from the fallowing companies: 
Gibco Biocult, Paisley. Renfrewshire
Antibiotic-Antimycotic Solution (lOOx) containing 10,000units Penicillin, 
10,000p.g Streptomycin and 25pg Fungizone
Basal Medium Eagle (BME) with Hepes (0.025 mol l"1), without L- 
Glutamine
Dulbecco's Modified Eagles Medium (DMEM) with Sodium Bicarbonate, 
without Methionine, without L-Glutamine 
Foetal Calf Serum (Sterile) (FCS)
Hanks Balanced Salt Solution (HBBS) without Sodium Bicarbonate 
L-Glutamine (lOOx)
Sterile Nunclon Microtitre Plates (96 round bottomed wells with lid) 
Sterile Hunclon Screw Cap Test Tubes (vol 13mls)
S-igma-.Cheia.ica l- Company, .Fancy. Rd. Poole ,.. Dorset,
1,4 bis [2(4 methyl-5-phenyloxazolyl)] benzene (Dimethyl PQPQP)
Deoxyribonucleic Acid (DMA) from Calf Thymus
L-Methionine
Phytolacca americana Mitogen (Pokeweed Mitogen (PWM))
Polyguanylic Acid (Poly G)
Flow Laboratories. Irvine.,- Ayrshire.
Linbro (24 well plates 16mm diameter) Tissue Culture Plates 
Titerteck Cell Harvester Filter Paper
Aldrich Chemical Company. Gillingham, Dorsal
3'-5-Diaminobenzoic acid dibydrochloride (DABA)
2-5-Diphenyloxazole, Scintillation Grade (PPO)
Gallenkamp, East, .itibride.,_.-GlasgQVL
G/Fibre Filter Circles (GF/C) 25mm 
Whatman Grade 1 Filter Paper
M illip o re  UK L td . M illip o re , Giy.seiiul.bil5 Pe terborough M *— Barxfl.vu.
Middlesex
Millex-GS Sterile Filter Units (0.22pm pore size)
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British. Drug Houses (BDH) Chemicals__Ltd^_JEaQle. Dorset.
Sodium Deoxycholate
Toluene
Triton X-100
Mav and Baker Ltd. Liverpool Ed., Barton Moss. Eccles, Manchester
Acetone
Methanol
James Burrough. 60 Montford Place. London 
Ethanol
Pharmacy. Western Infirmary. Glasgow.
Mannitol Injection BP 20%(w/v) in water
6,3 Monocyte Culture from Buffv Coat Blood Pack
Reagents 
Buffy Coats
Buffy coats from fresh (citrate phoshate dextrose anticoagulated) blood 
donations were supplied by the Blood Transfusion Service, Law Hospital, 
Carluke.
AB Plasma
AB plasma was prepared as previously described in chapter 5.9.
Foetal Calf Serum
Sterile foetal calf serum was heat inactivated at 56 “C for 2 hours to 
destroy endogenous complement activity,
Buffers and Solutions
Sodium Bicarbonate.
A 7.5%(w/v) sodium bicarbonate solution was made up in deionised water. 
This solution was sterilised by passing through a Millex-GS filter.
FicQll-Hypaq.us
Ficoll-Hypaque was prepared as previously described in Chapter 5.3.
One packet of powdered HBBS was dissolved in 80rals of deionised water 
and 5mls of 7,5%(w/v) sodium bicarbonate were added. This solution was 
then made to lOOmls with deionised water and filtered through a Millex- 
GS sterile filter into 900mls of sterilised deionised water.
RPMI
500mls of RPMI-1640 were supplemented with 5mls of antibiotic-
antimycotic solution (lOOx), 5mls of L-glutamine (lOOx) and 5mls of
7.5%(w/v) sodium bicarbonate.
R E M I T S
lOmls of AB serum were added to lOOmls of RPMI to give a 10%(w/v) 
solution.
REMI/JFCS
20mls of FCS were added to lOOmls of RPMI to give a 20%(v/v) solution. 
Procedure
Thirty millilitre aliquots of blood were centrifuged at 600g for 10 rain 
at room temperature in sterile 55ml Falcon tubes and the plasma removed. 
The white cells were removed carefully from the top of the red cell 
pellet and made up to a volume of 40mls with HBBS. Twenty millilitres 
of this cell suspension were layered on to 15mls of Ficoll-Hypaque and 
centrifuged at 500g for 30 min at room temperature. The cells were 
collected from the interfacial layer and washed 4 times in HBBS. The 
first wash was for 10 min at 400g at room temperature and the remaining 
ones were washed for 5 min at 200g at room temperature. The cells were 
resuspended in RPMI containing 10% AB, counted in an improved Neubauer 
haemocytometer and standardised to 6x10s cells/ml in the same medium. 
One third of the cells were plated directly into Linbro wells
(500pl/well) and incubated at 37 X  in a humidified atmosphere of 5% CCb
in air. After 30 min the non-adherent cells were removed from the wells 
by aspiration and the second third of the cells (which had been kept on 
ice for 15 min before warming to 37 X  for 15min) were plated out onto 
the same Linbro wells at 500pl/well. This procedure was repeated for 
the last third of the cells which were kept on ice until 15 min prior to 
plating out where upon they were warmed to 37 X. After the final 30' min 
incubation the cells were washed gently 3 times in warm RPMI and 
finally cultured in 1ml of RPMI plus 10%AB. After 3 days in culture the 
culture medium was removed, the monolayer was washed 3 times in warm 
RPMI and cultured thereafter in 1ml of RPMI containing 20% FCS/well.
EAC4 Intermediate.
EAC4 intermediates were prepared by Mrs L Jones.
Human . .Cl and.._.C2-
Human Cl and C2 were prepared by Mrs L Jones.
Buffers., and Solutions.
D5QS.
50g of glucose plus 5.95g of sodium chloride were dissolved in lQOinls of 
deionised water,
QVB?_1
GVB2^ was prepared as previously described in Chapter 2.7(b),
DGVB^.1
DGVB3'*' was prepared as previously described in Chapter 2.7(b).
Mannitol GVB2"
Three volumes of 20% mannitol solution were added to one volume of 
GVB2-.
C-Rat
C-rat was prepared as previously described in Chapter 2.7(c).
Salina
Saline was prepared as previously described in Chapter 2.7(b).
Procedure
To ensure that the monocytes were healthy and synthesising protein, 
lOOpl samples of the culture supernatant were removed from each Linbro 
well on day 6 and day 11 of culture. One hundred microlitres of fresh 
culture medium was then added back to the wells. The removed culture 
samples were centrifuged for 2 min at 10,000g at room temperature to 
remove loose cellular debris and the supernatants were either stored at 
-70*C or transferred to an ice bath for immediate assay.
Frozen. EAC4 intermediates were quickly thawed at 37 X  in a shaking 
water bath and reconstituted according to the procedure shown below:
Additions Volume (ml) Length of Incubation (min)
D50S 0. 23 5
Mannitol GVB3 " 1. 0 2
Mannitol GVB": '■ 2. 0 2
Mannitol GVB3 '■ 8. 0 5
BGVB3 " 5. 0 2
DGVB3'1 10. 0 2
BGVB3 1 10. 0 2
DGVB 3 ‘ 10. 0 5
All additions were made dropwise while the cells were being shaken 
constantly. After the final addition of DGVfF' the cells were 
centrifuged at 2,000g for lOmin at 2X, The cell pellet was washed 3 
times in DOVE-3"*', resuspended to lxlOOml in DOVE2* and warmed to 30 X  
in a shaking water bath. An equal volume of functionally purified human 
Cl in DGVB2'1' (lOOunits/ml) was pre-warmed to 30°C and added to the 
EAC4 with constant shaking. The cells were incubated at 30X  for 15 
min before centrifugation at 200g for 5 min at 20X. The cell pellet 
was resuspended to lxl0®/ml in DGVB24 and warmed to 30X,
Twenty five microlitre aliquots of the supernatant from the monocyte 
cultures were added to a series of test tubes containing lOOpl of DGVB24" 
and the tubes were warmed to 30X. One hundred microlitres of EAC14 
were added to each tube and incubated for a pre-determined T max of 2te 
min after which 300p.l of C-rat were added and the tubes incubated at 
37 X  for 1 hour in a shaking water bath for lysis to occur. The 
reaction was stopped by addition of 2mls of saline to all tubes except 
the 100% lysis control, to which 3 in Is of water were added, The tubes 
were centrifuged at 2,00 Og for 5 min at 4 X  and the of the
supernatant was measured.
A series of control tubes containing the additives shown below were 
measured along with the culture samples.
Control Tubes Reagents Added to the Control Tubes
BGVB* + 'j1 EAC14jj.1 C-Ratjil
Cell Blank (CB) 400 100
Reagent Blank (RB> 100 100 300
100% Lysis 100 100 300
Complement Colour (CO 200 - 300
A standard C2 curve was also prepared by doubly d iluting' p u rified  C2 of 
a known number of e ffe c tiv e  un its 'm l, in DGVB2"1' . One hundred m ic ro litre  
aliquots of these d ilu tio n s  <1/200-1/5000) were added to separate tes t 
tubes and the tubes were treated in the same manner as the samples, 
th is  providing a p o s itive  contro l fo r the assay.
The resu lts  were calculated according to the formula:
y =
OD sample -  QDr© 
OD 100% lys is -O D rs
Percent ly s is  - 100 x Y
The number of haemolytic units (Z> was calculated using the formula:
Z = - In  Cl-Y)
The em of C2/ml of culture flu id  fo r a 25;; 1 sample (corrected fo r  the 
number of EAC4 added to each tube ~
IQOOul 
Z x ----------- x 107
25)J 1
The em of C2/well are expressed per microgram of DNA, therefore:
em of C 2 /w e ll 
pg DM/we 11
= C2 em /w ell/pg  DM
6.5 D¥A Assay
2 % (w /v) SDS
2g of SDS were added to lOOmls of deionised water
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Tris (0,1 mol I 1) EDTA pH 7.5
121g of T ris  were dissolved in lOrnls of deionised water and the pH
adjusted to 7.5 using concentrated HC1. 57.5mls of EDTA (0.086 mol I " 1) 
(prepared as described in Chapter 2 .7 (b )) were added and the solution  
was made up to 1 l i t r e  w ith  deionised water.
Polyguanylic Acid (Poly G.) Soluti on
lOmg of Poly G were added to  lOrnls of T ris  (0.1 mol'''1) EDTA pH 7.5. 
Deoxyribonucleic Acid (DMA) Solution
DNA from c a lf  thymus was made up to a lmg/ral stock solution in  2%(w/v) 
SDS and d ilu ted  as appropriate.
Procedure
In order to quantify  the number of adherent monocytes in the Linbro
wells the culture medium was removed from 6 sample wells and the
monolayer washed gently  w ith warm RPMI to remove debris and
nonadherent c e lls . One m i l l i l i t r e  of SDS(2%(w/v) in water) was added to  
each of the wells and the p la te  incubated fo r 1 hour a t 37 °C. The c e ll 
lysates* were removed and 460pl of each were transferred  to microcap 
tubes , To p re c ip ita te  the DNA from these c e ll lysates, 10pl of poly-G  
solution and 9Q0pg of ice-co ld  ethanol were added to the tubes which
were vortexed and stored for 10 hours a t -20  °C. Upon thawing, the
microcap tubes were centrifuged at 900g fo r 5 min a t room temperature, 
the supernatants were discarded and the p e lle ts  washed 3 times in 500pl 
of absolute ethanol and dried fo r 30 min a t 100’C. F if ty  m ic ro litre s  of 
deionised water were added to each p e lle t, which was then resuspended 
and incubated a t room temperature fo r 30 min. Twenty f iv e  m ic ro litre s  
of diaminobenzoic dibydrochloride (DABA) an agent which fluoresces when 
bound to DNA was added, the tubes were vortexed and incubated fo r a 
fu rth er 30 min a t 60 X  a fte r  which 500pl of hydrogen chloride (1 mol 1 
1 ) were added to s o lu b ilis e  the p e lle t. The tubes were centrifuged at 
9,000g fo r 5 min a t room temperature and the supernatants were then 
read' using a Perkin Elmer 100 Spectrofluorim eter w ith exc ita tio n  at 
400nm and emission a t 500nm.
A standard DNA curve was constructed by preparing samples containing 5, 
2,5, 1.25, 0.625 and 0.312/jg of DNA/ml in 460pl of 2%<w/v) SDS. These
samples plus a blank containing only 460;j.1 of 2% (w/v) SDS were treated
in the same way as described above. The fluorim eter was zeroed w ith the 
blank and the standard containing 5pg/ml DNA was read on the 
fluorim eter. This standard was used to c a lib ra te  the machine and once 
calib ra ted  the concentration of DNA/ml in the remaining standards and 
samples were read d ire c tly  from the flu o rim e te r. The number of ce lls  
per w ell could be estimated from the DNA content, 1 to 1.5pg of DNA 
being equivalent to lx l0 's monocytes,
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lOOmls of DMEM without methionine, without sodium bicarbonate and with  
L-glutam ine were supplemented with lm l of a n tib io tic  antim ycotic  
solution c.lOOx) and lm l of L~;glutamine (lOOx).
30pg of methionine were added to lOrnls of m ethionine-free DMEM 
supplemented with a n tib io tic  antim ycotic solution and L-glutam ine as 
before.
PBS (prepared as described in Chapter 2 .6 (e )) containing l% (v /v ) NP-40 
0.5% (w/v > SDS, EDTA (3 mmol I " 1) and PMSF (2 mmol I " 1),
35S-Methionine was made to a concentration of 500 pCi/m l in methionine- 
free  DMEM.
Procedure
The culture flu id  was removed from each Linbro well and the monocyte 
monolayers were washed 3 times w ith warm m ethionine-free DMEM. Two
hundred m icro litres  of the same medium were then added to each w ell and
the monolayers were incubated a t .37°C fo r 15 min. The medium was 
removed and 333pi of 35S-methionine were added. The monocytes were 
incubated fo r the desired pulse times a t 37 °C in a hum idified atmosphere 
of 5% CO-2 in a ir . When the pulse was complete the supernatant was 
removed from each w ell, placed in to  a microcap and centrifuged at 
10,000g fo r 5 min a t room temperature to remove c e llu la r debris. The 
supernatant was placed in to  a fresh microcap and 5p i of FMSF (.1 mol 1 
’ ) and 5pl of EDTA (0.086 mol I - '1) were added. These proteases were 
added to prevent pro teo lysis  of soluble CRl which may have been present 
in  the supernatant.
The c e lls  in the monolayer were washed once in m ethionine-free DMEM and 
then incubated in DMEM containing methionine (5 pg/ml) to "chase" the 
3SS-methionine through the protein synthetic  pathway. Once the chase 
was completed the supernatant was removed and treated  in a s im ila r way 
to th a t described previously. The remaining monocytes were lysed by 
incubation fo r 1 hour a t 37 ”C in of ly s is  buffer. The lys is
buffer was then removed and placed in to  microcaps. These were
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centrifuged a t 10,000g fo r 5 min a t room temperature to remove the 
insoluble membranes, The lysates containing so lub ilised  proteins were 
transferred  to fresh raicrocaps and protease in h ib ito rs  were added as 
before, The lysates were stored at; - 7 0 'C,
6.7 Determination of :Methionine Incorporation in to  C ell Lysates and
Reagents
GF/C c irc le  f i l t e r s  were soaked in  methionine (1 mmol 1 1 ) and dried  
overnight a t room temperature.
Solutions
iqjL . 1 ~1).
A 1 mmol l " 1 methionine solution was made up in  deionised water,
A stock solution of 20% (w/v) TCA in  deionised water was prepared and 
d ilu ted  as appropriate.
Acetone/Ethanol Solution
An equal volume of acetone and ethanol were mixed together.
0.18 of 1.4 bis [2 (4 raethyl-5-phenyloxazolyl) 1 benzene (POPOP) and 3g 
of 2 -5  Di-phenyloxazole (FFO) were dissolved in 600mls of toluene at 
56 °C, 300mls of T rito n  X-100 were then added and the solution was mixed 
thoroughly,
Procedure
In order to determine the amount of rad ioactive  methionine which had 
been incorporated in to  the c e llu la r  proteins during the pulse-chase 
experiments, 5pl of the supernatant or lysate were spatted onto the pre­
soaked f i l te r s .  These were then dried in  an oven a t 8 0 °C. The f i l t e r s  
were then given a series of 1 min washes in  each of the following  
solutions, ( i )  10% TCA, (i.i) 5% TCA, ( i i i )  acetone, (iv ) acetone/ethanol 
solution and (v) 100% ethanol. These washes resu lt in the p rec ip ita tio n  
of protein  including th a t which has incorporated 3SS-methionine. This 
protein  remains bound to the f i l t e r  while free 3-'S-methionine is  washed 
away. A fter the f in a l wash in ethanol, the f i l t e r s  were dried in an oven 
and then placed in to  s c in t il la t io n  v ia ls  containing 5mls of s c in t il la t io n  
flu id . The amount of incorporated 35S-inethionine was then determined by
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counting the s c in t i l la t io n  v ia ls  in  a P counter. The e ffic ien cy  of 
incorporation was determined by the follow ing equation:
T o ta l cpra in  the ly s a te
 £------------i----- x 1 0 0
T o ta l cpm input
6.8 V ia b il ity  of Monocytes I n  Methionine-Free M E E
Trypan Blue (Q.7 5 (w /v )).
Trypan blue solution was prepared as described in  chapter 5.7. 
floras! Saline
Normal sa line  was prepared as described in  chapter 2 .7 (b ).
Procedure.
In order to assess how long the monocytes could be pulsed in  
m ethionine-free DMEM w hile s t i l l  remaining v iab le  the follow ing  
experiment was performed. The culture medium was removed from 8 wells  
of a monocyte culture. To 7 of these w ells lOOpl of 3SS-methionine 
(5'00pl/ml) were added a fte r  washing the monolayers once w ith  
m ethionine-free DMEM. Trypan blue (200pl) was then added to  the eighth  
w ell which was the contro l and the c e lls  were incubated fo r 2 min. A fter  
removal of excess trypan blue by asp ira tion  the v ia b i l i ty  of the 
monocytes was assessed by observing under a l ig h t microscope the number 
of c e lls  which had excluded trypan blue. The w ells to which 3BS- 
methionine had been added were pulsed fo r a varie ty  of time in te rva ls , 1 
hour, 2 hours, 3 hours, 4 hours and 6 hours. At the end of each time 
in te rv a l the medium was removed and 200/il of trypan blue were added to  
the w ells. The v ia b i l i ty  of the monolayer was then assessed by trypan  
blue exclusion.
6 *9 I mmunQprecipitatiQH Of C3 f rom Monocyte Supernatants 
Reagents
Anti-C3 Antiserum and Anti-BSA Antfserum
Anti C3 antiserum and anti-BSA antiserum were donated by Mr A Hamilton. 
These were d ilu ted  1:10 in  PBS fo r use.
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Protein A Cell Suspension
A prote in  A c e ll suspension was prepared as described in chapter 
4 .14(a ).
Procedure
Monocytes are known to synthesis C3 in  nanogram q u a n titie s ,( Strunk, 
Kunke and Giclas 1983). I t  was therefore decided to imraunoprecipitate 
th is  prote in  from the supernatants of monocytes which had been pulsed 
w ith 3BS-methionine to estab lish  th a t the immunoprecipitation technique 
was re lia b le .
One m i l l i l i t r e  of a monocyte supernatant from a monolayer which had 
been pulsed fo r 2 hours was absorbed w ith 25/j.l of a prote in  A c e ll
suspension as was described in chapter 4 .14 (b ). The supernatant was then 
divided equally between 2 microcap tubes. To 1 of these microcaps 5p l of 
a 1:10 d ilu tio n  of an ti-C 3  antiserum was added and 5/j.l of a 1:10
d ilu tio n  of anti-BSA antiserum was added to the second microcap tube, 
These tubes were ro ta ted  end over end on a Matburn mixer fo r 1 hour a t
room temperature a fte r  which 25 pi of a prote in  A c e ll suspension was
added and the incubation continued fo r 30 min a t room temperature. The 
proteins which had bound to the prote in  A c e ll suspension were eluted  
as described in  chapter 4 .14 (b ).
6.10 Immunoprecipitation. of ...CRL.imia Monocytes.
Reagents. 
Antiz£Sl
A commercially ava ilab le  monoclonal an ti-C R l antibody was u tilis e d . 
Normal Mouse Serum (NMS)
NMS was supplied by the Animal Laboratory, Glasgow U nivers ity .
Er.ofie.dure
The monocyte lysate (lm l) was absorbed w ith 25pi of a protein  A c e ll 
suspension. The lysate  was then divided equally between 2 microcap 
tubes, To 1 of these tubes 5p.l of neat mouse an ti-C R l ascites f lu id  were 
added and 5p l of NMS were added to  the other. These tubes were rotated  
end over end on a Matburn mixer fo r 1 hour a t 4°C a fte r  which 5pl of 
the second antibody ra b b it anti-mouse IgG was added to both tubes and 
the incubation continued fo r 1 hour a t 4°C. Following th is , 25/j.l of a 
protein  A c e ll suspension were added and the tubes were incubated fo r a 
fu rth er 30 min a t 4*C. The proteins which had bound to the protein  A 
c e ll suspension were eluted as previously described in chapter 4 .14(b ).
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CRl was immunoprecipitated from monocyte supernatants using an 
id e n tica l procedure to th a t described fo r the lysates,
6.11 SfiSz£&GE.
Samples were electrophoresed on 5 and 7W, s lab gels as described in  
chapter 2 .6 (h ) and then subjected to  fluorography.
Solutions.
Destain .Solution.
Destain solution was prepared as previously described in  chapter 2 .6 ( f ) .  
PPQ-PMSQ (24%(w /v ))
24g of 2 -5  diphenyloxazole (PPG) were dissolved in lOOmls of pre-heated  
DMSO.
Glycerol Solution
2.4mls of g lycero l were mixed w ith 97.6rals of deionised water.
The slab gel was fixed  fo r 30 min in  destain and then given 2 500rals 
washes in DMSO fo r  30 rain each. This was removed and the gel was 
incubated in 200inls of PFO-DMSO solution fo r 45 min a fte r  which the gel 
was washed in deionised water fo r 1 to 2 hours. F in a lly  the gel was 
soaked in g lycero l solution fo r 30 min to prevent cracking.
The gel was tran sferred  to a sheet of Whatman No 1 f i l t e r  paper and 
placed on a drying board. The board was sealed with cellophane and 
the gel dried overnight under vacuum on a freeze d rie r .
The dried gel was then placed in to  a X -ray cassette in  contact w ith a 
sheet of X Ray film  and placed at -70*0  fo r the required time. The 
exposure time required was estimated from the 35S-raethionine 
incorporation into  the sample put onto the gel, A period of 2 weeks was 
usually s u ffic ie n t to allow development of bands containing more than 
3,000cpm. The film  was then developed as previously described in  
chapter 4 .14(b ).
6.12
EEQcedura
6.13
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Saline was prepared as described previously in Chapter 2.7(b). This was 
then filtered through a Millex-GS sterile filter unit.
FicQll-Mgtr.iz.Qate
30mls of sodium metrizoate 32% (w/v) were mixed with 72ml-s of Ficoll 
8 % (w/v) (SG 1.077).
Basal Medium Eagle...._(BME)_
BME with Hepes (0.025 mol l"1).
REMIZAB
RPMI was supplemented as previously described in (6,3) and 5%(v/v) AB 
serum was added.
Procedure
60mls of venous blood were collected into 3 universal containers 
containing 300/j.l of sodium heparin (1000 units/ml). The blood was then 
placed into a beaker and diluted 1 in 2 with sterile saline and 15ml 
aliquots were layered over lOrnls of Ficoll-Metrizoate in sterile 
universal containers. The blood was centrifuged at 400g for 30 min at 
room temperature after which the white interfacial layer composed of 
mononuclear cells was removed and placed into a universal container. 
The cells were made up to a volume of 20mls in BME and centrifuged at 
200g for 30 min at room temperature. The supernatant was discarded and 
the cell pellet washed by resuspension in BME and centrifugation at 200g 
for 10 min at room temperature and then at 200g for 5 rain at room 
temperature, The cells were resuspended in 20mls of RPMI. A 10pl 
aliquot of the cell suspension was diluted with 190pl of white cell 
counting fluid, the mononuclear cells were counted in an improved 
ITeubauer haemocytometer and standardised to lxl06 /ml in RPMI/AB. Five 
millilitres were added into sterile culture test tubes and incubated at 
37*C in a humidified atmosphere of 5% C02 in air.
Stlmulation_flf ..Lymphocytes with Pokeweed Mitogen (PWM)
Reagents
ROL
PVM was stored at -20X  as a stock solution of Img/ml in RPMI. It was 
then diluted as appropriate.
3B-thymidine was supplied by the Radioisotope Dispensary, Western 
Infirmary Glasgow. II; was stored at 4 X  as a lOuCi/jtil solut Lon tu 
SPIT,
Scintillation Fluid
Scintillation fluid was prepared as described earlier (6,7).
Erocedura
Lymphocytes (lxlOs/ml) in BPMI/AB were plated out into sterile 
microtitre plates (200p.l/well), Ten microlitres of a range of 
concentrations of PWM (1.25-5Q0ug/ml> were then added in triplicate to 
the wells, leaving 6 wells as controls. The cells were incubated for 48 
hours at 37*C in a humidified atmosphere of 5% COa in air. On the third 
day the lymphocytes were pulsed by the addition of 0,1/j.Ci 3H-thymidine 
and incubation continued for 12 hours, The cells were harvested onto 
filter papers using a 12-well multimesh cell harvester. The harvesting 
process consisted of a series of washes in deionised water followed, by 
5% TCA and finally by methanol, The filters were dried at 37T, for 30 
min, each filter was then placed into a vial containing 5m is of 
scintillation fluid and counted in a liquid scintillation 0 counter, A 
plot of the PWM concentration per 1x10s cells against the number of cpm 
was then drawn (Fig 6,1). As a concentration of 0.5p.g/lxl0e cells 
resulted in the greatest amount of 3H-thymidine incorporation, this was 
used in ail subsequent lymphocyte transformations.
Internal Labelling of ly m p hocyte Proteins wlth3,HrThymidiae
Before a lymphocyte culture was pulsed it was first of ail established 
that the cells had been stimulated by the PWM, This was accomplished 
by setting up a microtitre plate containing lymphocytes <lxlOe/ml, 
200p.l/well) at the same time as the lymphocyte cultures were sec up. 
The lymphocytes in the microtitre plate were treated with PWK 
(0,5pg/lxl0e cells) and pulsed with 3H-thymidine on the third day, The 
incorporation of 3H~thymidine into these cells indicated whether the 
cells had. been stimulated, or not. If they had, then it was assumed “chat 
the lymphocytes in culture had also been stimulated and the culture was 
then pulsed with SSS-methionine.
6.15 Internal Labelling of Lymphocyte Proteins with 3SS-lethlonine
Sterile culture test tubes containing 5x10s lymphocytes which had been, 
stimulated with 0,5jjtg of PWM/lxlO,B cells were centrifuged at 400g for 5 
min at room temperature. The supernatant was carefully removed and the 
cells were resuspended in 500/j.l of warm methionine- free DMBH and 
incubated for 15 min. The cells were centrifuged at 400g for 5 min at 
room temperature > the supernatant was removed and the cells were
Thymidine cpm x 10~2
6
4-
2
o ------------------ :__________________ 1 .......
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resuspended in 400pl of the above medium. One hundred microlitres of 
3BS-methionine (lmCi/ml) were added to each tube and the cells were left 
to incubate, for the desired pulse time.
Once the pulse time was completed the cells were washed twice in DMEM 
containing methionine (3pg/ml), resuspended in 500pl of this medium and 
incubated at 37 X  for the appropriate chase time. When the chase period 
was completed the supernatant was removed and placed into a microcap 
tube which was then centrifuged at 10,000g for 5 min to remove any cell 
debris. The supernatant was removed and 5pl of PMSF (1 mmol l"1) and
5pl of EDTA (0.086 mol I"1) were added and this was stared at -70X.
The cell pellets were resuspended in 500/j.l of lysis buffer and the 
lysates were mixed overnight at 4 X  to allow solubilisation of CR1, 
finally they were centrifuged at 10,000g for 2 min at room temperature
to remove the membranes. The clear lysate was then stored at -70X.
6.16 IminunQpxec ipitation of CHI fim Lymplm.cy±e Lysates and 
Supernatants
An identical protocol to that described earlier for monocytes was used 
(6.10). However, as the lymphocytes lysates and supernatants were in a 
total volume of 500pl and not 1ml which was the case for monocytes, a 
separate sample was used for the control and specific precipitation 
instead of dividing the lysates and supernatants after the first 
absorbtion with the protein A cell suspension.
6.17
As an alternative means of isolating CR1 from the lysates of 
lymphocytes it was decided to try a series of purifications steps on a 
Biorex column and a C3-Sepharose column.
Chromatographic-Material 
Biorex Column
A 1ml Biorex column was poured in a 2ml syringe barrel. This column 
was equilibrated with Biorex equilibration buffer as described in 
Chapter 2.9(a).
C3-Sepharose
C3-Sepharose was prepared as previously described in Chapter 2.9(b), 
IgG-Sepharose
IgG-Sepharose was prepared by Dr W litchel.
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Bufian
Borate buffer was prepared as described in Chapter 2.9(b) and sodium 
chloride (0.05 mol I"'1) and NP-40 l%(v/v) were then added.
Acetic Acid--So.lut.iQn
Acetic acid (0.1 mol I"1) containing sodium chloride (0.4 mol l” 1) and 
IP-40 1 %(v/v).
geutralisatiQH Buffer
Tris HC1 (2 mol I” 1 pH 8.6) containing 1% NP-40,
EnQC.edu r.e.
Fourteen test tubes containing 5x10s lymphocytes were pulsed separately 
for 2 hours and chased for 1 hour. Five hundred microlitres of lysis 
buffer were then added to each cell pellet and the cells were stirred on 
a magnetic stirrer overnight at 4*C. The lysates were then pooled and 
centrifuged at 10,000g for 10 min at room temperature to remove the 
membranes. Sufficient deionised water to lower the conductivity to 
below 6mS at 0*C was added to the lysate before it was put over the 
Biorex column. The column was washed with 10mis of equilibrating buffer 
and CR1 was eluted with equilibrating buffer containing sodium chloride 
(0.6 mol I” 1).
Fractions (1ml) were collected and the column was screened by 
measurement of TCA precipitable protein as described previously (6.7). 
The fractions from the Biorex column which contained the highest 
incorporation of 35S-raethionine were pooled and preabsorbed with 25/j.I 
of a protein A cell suspension and then divided equally between 2 tubes. 
One hundred microlitres of C3-Sepharose were added to 1 tube and lOOpl 
of IgG-Sepharose were added to the remaining tube. Both were mixed for 
2 hours at 4*C and both pellets were then collected by centrifugation at 
10,000g for 2 min at room temperature. The pellets were washed 4 times 
in borate buffer and bound protein was eluted by 10 washes of 40pl each 
with acetic acid solution, Each 40p.l was neutralised by addition of 5pl 
of neutralisation buffer.
A 5pl sample was measured for TCA precipitable counts and the remaining 
40pl were mixed with sample buffer and analysed by SDS-PAGE.
6,i<3 Synthesis of C2 by Monocyte Cultures
H a e m o lv tic  a s s a y s  for G2 were p e rfo rm e d  on th e  m onocyte c u ltu r e
supernatants to establish that the cells were synthesising p r o te in
before exposing them to 3BS~ methionine. The mean amount o f C2
production from 6 wells of a sample culture after 6 days synthesis was
42±12xl(F effective molecules (em) of C2 per well and the DU A COTV*I0Ti't 
of these wells was 1,4/j.g/ml, Thus after 6 days there were 3Q±8.5xlO'7 em 
of C2 per ,ug of DIA in each well, This was comparable to that found  by  
Einstein, Schneeberg and Colten (1976). The culture was incubated fo r  a 
further 5 days and the C2 content was measured again after 11 days  
synthesis and found to be SS+GxlO7 em C2/pg DfA/well, It was th e r e f o r e  
decided to measure the C2 production of ail subsequent cultures on day 6 
and if this production was normal they would be pulsed with 3SS~~ 
methionine on day 7.
6.19 Pulse-Chase Study in Monocytes
As shown below the viability of the 2iionocytes as assessed by trypan 
blue exclusion decreased after the monocytes had been pulsed for 2 hours 
in methionine-free DMEM containing 3SS-methionine,
Length of Pulse (hours) 0 1 2  4
Percentage Viability 100 100 100 64
It was therefore decided to pulse 7 day old monocytes for a "maximum of 
2 hours and to chase them for up to 2 hours in DMEM containing 
methionine. Incorporation of 3ES-methionine was then measured in both 
the cell lysates and the culture supernatants, As might be expected, 
with increasing chase time the TCA precipitable protein in the cell 
lysate fell while that of the supernatant increased, indicating that 
radiaiabelled proteins were being secreted from the monocytes into the 
surrounding culture medium (Fig 6.2).
Having established a method which resulted in the incorporation of 
between 5% and 12% of the added radioactive methionine into cellular 
proteins it was decided to immunoprecipitate the lysates and 
supernatants for C3 and CR1.
6.20 Immunoprecipitation of C3
Immunoprecipitation of C3 from the supernatant of a culture which had. 
been pulsed for 2 hours revealed 2 specific bands of molecular w e ig h t  
116,000 daltons and 75,000 daltons (Plate 6.1), which represent the a
Fig 6.2 Pulse-Chase Study in Monocytes
LegemdL
Five microlitres of supernatant or lysate from a monocyte culture, which 
had been pulsed far 2 hours and chased for up to 240 min, were spotted 
onto filter papers pre-soaked with methionine (1 mmol I- ’ ) and the 
amount of 35S-methionine incorporation was determined using the filter 
TCA protein precipitation technique. The number of cpm in each was then 
plotted against the chase time. As can be seen from the graph with 
increasing length of chase time the TCA precipitable protein in the cell 
lysate fell (_____ ), while that in the supernatant increased (- - ->.
355-Methionine cpm x10-7
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Plate 6 .1  Immunoprecipitation o£ C3 from Jfonpcvtg C u l t u r e . S u p e rn a ta n ts .
Monocyte culture supernatants were immunoprecipitated with. anti-C3 
antiserura. Samples were then analysed by SDS-PAGE on a 7WU slab gel run 
under reducing conditions. Tracks d, e and f show purified radiolabelled 
C3, track b shows the sample from the culture supernatant 
immunoprecipitated with anti-C3 antiserura and track c shows the control 
sample immunoprecipitated with anti-BSA. The oc and |3 chains of 03 with 
molecular weights of 116,000 and 75,000 daltons can be seen in tracks d, 
e and f and very faintly in track b. No specific bands were seen in the 
control track. ,
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and J3 chains of C3. This established that the immunoprecipitation 
method was working.
6.21
Immunoprecipitation of CR1 was performed for each supernatant and 
lysate of a monocyte culture which had been pulsed for 2 hours and 
chased for 15, 30, 60, 120, 240 and 360 rain.
The immunoprecipitation samples were subjected to SDS-PAGE on 5% slab 
gels followed by fluorography. Plate 6.2 shows that a specific band of 
molecular weight 230,000 daltons was seen in each of the lysates 
precipitated with anti-CRl. This band was not seen in the controls 
which had been iramuno-precipitated with RMS. Precipitation of the 
culture supernatant did not result in any specific bands.
Unfortunately, the precipitation of CR1 from 8 subsequent pulse-chase 
experiments did not result in any obvious specific bands apart from in 
one other case where a specific band of molecular weight 225,000 daltons 
was immunoprecipitated by anti-CRl from a monocyte culture which had 
been pulsed for 3 hours with no chase (Plate 6.3).
Vhen a mitogen such as PWM binds to T and B lymphocytes the cells are 
stimulated to increase protein synthesis and to undergo cell division. 
Lymphocyte cultures were therefore treated with PWM to ensure that 
synthesis of protein by the lymphocytes would be maximised. The degree 
to which the lymphocytes were stimulated was determined by measuring 
the amount of 3H - thymidine which was incorporated into newly 
synthesised BRA. Lymphocytes which had been stimulated with PWM 
incorporated more than 30-fold more 3H — thymidine than unstimulated 
lymphocytes. Prior to pulsing lymphocyte cultures with 35S-methionine, 
incorporation of 3H-thymidine was measured in the test microtitre plate 
set up at the same time as the culture, if transformation had occured 
the lymphocytes in the sterile culture test tubes were pulsed with 3SS- 
methionine. Pulsing PWM stimulated lymphocytes resulted in a 6-fold 
greater incorporation of 35S-methionine into the cells (Fig 6.3).
6.23 Optimal Culture Conditions for Pulsing Lymphocytes
Pulse-chase studies were performed on stimulated lymphocytes on day 1, 
3 and 5 in culture in order to determine which period of culture 
resulted in maximum incorporation of 35S-methionine. The maximum 
percentage of 3SS-raethionine incorporation into the lysates of 3 
lymphocyte cultures which had been given a 2 hour pulse followed by a 2 
hour chase was on day 3 in culture.
Plate 6.2 ImmunQprecipitation of CR1 iTum.Hgn.gc;
CR1 was immunoprecipitated from the cell lysates of a monocyte culture 
which had been pulsed for 2 hours and chased for 15 rain track a, 30 rain 
track b, 60 min track c, 120 min track d, 240 min track e and 360 rain 
track f. Tracks h and i represent the control precipitations with NMS and 
track g the HMW markers. Samples were analysed on a 5% slab gel run 
under reducing conditions. A specific band of molecular weight 230,000 
daltons was immunoprecipitated from lysates which had been chased for 15 
min, 30 min, 60 min, 120 rain and 240 min. Ho specific band was seen in 
the lysate chased for 360 min or in the 2 control precipitations,

C Ri was im m u n o p re c ip ita te d  fro m  th e  c e l l  ly s a te s  o f  a m onocyte c u ltu r e  
which had been p u ls e d  f o r  3 h o u rs  w i th  no chase  ( t r a c k s  a , b and. c ) ,  
Track d represents the control precipitation with IMS. Samples were 
analysed on a 5% slab gel run under reducing conditions, A specific band 
o f  2 2 5 ,0 0 0  daltons was seen in each of the lysates immunoprecipitated 
with monoclonal anti-CRl. lo specific bands were seen in the control.
225k-
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Lymphocytes which had been treated with PWM (0,5pg/lxlQs cells) and 
unstimulated’ control lymphocytes were pulsed with 3SS-methionine for 2 
hours and chased for up to 240 min. The amount of 3SS-methionine 
incorporation into the lymphocyte cell lysates was determined for the PVM
stimulated lymphocytes (- ~ -) and for the control lymphocytes (______ ).
This number was then plotted against the chase time. The graph indicates 
that PWM stimulated lymphocytes can incorporate approximately 6-fold 
more 3SS-methionine than control lymphocytes.
35S—Methionine cpm xlO -3
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A lymphocyte culture which had been stimulated with PVM was pulsed for 
2 hours and chased for 30, 60, 120 and 240 min on day 3 in culture. 
The lysates and supernatants were measured by TCA precipitation for 
incorporation of 3SS-raethionine. As with the monocytes (Fig 6.2), TCA 
precipitable protein in the lysate fell with increasing chase time, while 
those in the supernatant increased indicating that radiolabelled proteins 
were being secreted.
The lysates and supernatants were immunoprecipitated with anti-CRl and 
the samples obtained were run reduced on a 7te% slab gel followed by 
fluorography. No specific band were detected in the lysates or 
supernatants (Plate 6.4). Numerous repeat pulse-chase experiments, with 
minor modifications in pulse and chase time were performed but no 
evidence of CR1 labelling was obtained.
6.25 Isolation of CR1 from Lymphocyte Lysates by Chromatography
Following the failure to isolate CR1 from lymphocyte lysates by 
immunoprecipitation it was decided to try to isolate the receptor using 
similar chromatographic procedures to those employed in the purification 
of CR1 (Fearon 1979). The method chosen was a modification of the one 
described by Dykman et al (1984) which had resulted in the successful 
isolation of CR1 from 135I~surface labelled PMN and monocytes.
The 35S-methionine labelled lysates from 14 separate lymphocyte culture 
tubes were put over a Biorex column which was then screened by 
measurement of TCA precipitable protein (Fig 6.4). The 2 elution 
fractions containing the most precipitable protein were pooled and then 
mixed with either C3-Sepharose or IgG-Sepharose.
The first 2 elution fractions from both the C3~Sepharose (Fig 6.5) and 
the IgG-Sepharose were subjected to SDS-PAGE on a 5% slab gel and 
fluorography. A faint band of approximately 210,000 daltons molecular 
weight was seen in the elution fractions from the C3-Sepharose. This 
band was not seen in the elution fractions from the IgG-Sepharose (Plate 
6.5).
Plate 6.4
Supernatants
Immunoprecipitation of OIL! ftoii
Cell lysates and supernatants from a lymphocyte culture which had been 
pulsed for 2 hours with variable chase periods were immunoprecipitated 
with monoclonal anti-CRl. Tracks a to d represent the lysates chased for 
30, 60, 120 and 240 min respectively. Tracks f to h represent the
supernatants chased for 30, 60 and 120 min respectively. Track e is the 
lysate control and track i is the supernatant control which were 
immunoprecipitated with NMS. Samples were analysed on a 7&% slab gel run 
under reducing conditions. No specific bands were seen in any of the 
tracks.

Purification’ of CSX from PWM stimulated lymphocytes (which had been 
pulsed with 3BS-methionine for 2 hours and chased for 60 min), by cation 
exchange chromatography on a 1ml Biores column. One millilitre fractions 
were collected and screened for CR1 by measurement of TCA precipitable 
protein, The number of 3BS-methionine cpm in each fraction was then 
plotted against the fraction number. The arrow marked 1 on the X axis 
represents the application of the elution buffer. Fractions 9 and 10 were 
pooled as they contained the highest incorporation of 3 5 S-methionine 
labelled protein.
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The pool from the Biorex column was absorbed with 25pl of a protein A 
cell suspension and then divided equally between 2 raicrocaps. To 1 of the 
microcaps lOOpl of C3-Sepharose was added and to the other lOOpl of IgG- 
Sepharose was added. After incubation for 2 hours bound protein was 
eluted by a series of 10 washes in elution buffer. The number of 35S- 
methionine incorporation into the eluted proteins was then plotted 
against the wash number.
S—Methionine cpm x10~s
8
6
4
2
e
1 2 3 4 5 6  7 8 ?  10
Number of Washes with Elution Buffer
Plate 6.5 Chromatographic Purification of CPI from Lymphocy-teJhysaifiS.
CR1 was purified by chromatographic procedures from the cell lysates of 
a lymphocyte culture which had been pulsed for 2 hours and chased for 1 
hour. Tracks a and b show the first and second elution fractions from the 
C3-Sepharose pellet while tracks c and d show the first and second 
elution fractions from the IgG-Sepharose pellet. Samples were analysed on 
a 5% slab gel run under reducing conditions, A very faint specific band 
with a molecular weight of 210,000 daltons can be seen in tracks a and b 
(the bands in track b is marked with a dot). This band was not seen in 
the elution fractions from the IgG-Sepharose pellet, although 2 very faint 
bands may be seen (these bands in track d are marked with a dot). The 
nature of these bands is unknown.
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6.26 Discussion
The original intention of this study had been the comparison of CR1 
synthesis in cultured monocytes and lymphocytes from normal individuals 
with the synthesis of CR1 in the same cells from patients with SLE. 
Before this could be attempted the conditions which would result in good 
incorporation of 3SS-methionine into CR1 had to be established, as had 
the ability to immunoprecipitate CR1 from culture supernatants and cell 
lysates.
Monocytes were pulsed on day 7 of culture as C2 production (a measure 
of monocyte viability and ability to synthesis protein) is maximal at 
this time. Lymphocytes were pulsed on day 3 in culture after they had 
been stimulated with a concentration of PWM which was sufficient to 
produce maximum protein synthesis by the cells.
The immunoprecipitation method used was one which had resulted in the 
successful precipitation of CR1 from surface-labelled E using both a 
monoclonal and a polyclonal anti-CRl antiserum (Plate 4,5). This method 
was also successfully utilised in the precipitation of C3 from 35S- 
methionine labelled monocyte supernatants (Plate 6,1). Thus the 
precipitation method was considered to be suitable for obtaining CR1 
from cell lysates and culture supernatants.
CR1 was successfully immunoprecipitated from 2 of the 10 monocyte cell 
cultures set up (Plates 6.2 and 6,3), The molecular weights of these
bands were 230,000 daltons and 225,000 daltons respectively. As 
previously discussed E CR1 expresses a size polymorphism. The most 
common of the E CR1 size variants has a molecular weight of 190,000 
daltons when analysed under non-reducing conditions on SDS-PAGE, 
Analysis under reducing conditions increases the molecular weight of 
this band by 30,000 daltons. Dykman et al (1983b) showed that CR1 on 
the surface of monocytes had an identical molecular weight to that of 
the donors E, thus it may be that these bands represent the 190,000 
daltons form of CR1. That the molecular weights of these bands are
slightly higher than 190,000 daltons may be due to differences in the 
analytical systems used or they may indicate that there is a, higher
molecular weight intracellular form of CR1, which may result from the 
presence of a signal sequence which allows the receptor to become 
properly inserted into the membrane after which it is removed, To 
investigate this possibility more fully it would be necessary to compare 
the molecular weights of surface labelled monocyte GR1 with 
biosynthetically labelled monocyte CR1 to see if there was indeed a 
difference,
Atkinson and Jones (1984) studied the biosynthesis of CR1 in the HL-60 
promyelocytic cell line and they have reported that there is an 
intracellular deglycosylated precursor form of CR1 with a molecular
weight of 188,000 daltons which is 22,000 daltons smaller than the
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surface CF.l form. The fact that these studies were performed on a cell 
line may account for the difference between this observation and my own.
ITo CR1 v/ as immunoprecipitated from any of the monocyte culture 
supernatants. There is one report of a soluble form of CR1 (Yoon and 
Fearon 1985) but from the negative results of these experiments it was 
not possible to say if this could have arisen by secretion of CR1 from 
monocytes.
CR1 could not be immunoprecipitated from any of the 30 lymphocyte 
cultures using monoclonal or polyclonal anti-CRl antisera. However, on 
one occasion when CF.l was isolated from lymphocyte cultures by cation 
exchange on Biorex and affinity chromatography on C3~Sepharose, a 
specific band with a molecular weight of 210,000 daltons was observed 
(Plate 6.5). In the non-reduced form this band would be equivalent to 
a band with a molecular weight of 180,000 daltons. A CPI precursor 
(pro-CRl) can be immunoprecipitated from Epstein Barr virus transformed 
lymphocytes. The molecular weight of pro-CRl was 9,000 daltons lower 
than the membrane-bound form of 190,000 daltons (Lublin et al 1985). 
Thus the band immunoprecipitated from the lymphocytes may be the 
proform of the 190,000 dalton CR1 variant. However, from the results of 
1 culture it is not possible to make any conclusive statement.
This means of isolating lymphocyte CR1 was only attempted after the 
failure to immunoprecipitate the receptor by means of anti-CRl 
antiserum. It proved to be a very time consuming procedure and to 
require the use of a large quantity of cells and other reagents. As time 
was limited it was not possible to continue this line of study although 
it may be that this method could be used to isolate CR1 from
lymphocytes in future studies.
There are a number of explanations which may account for the inability 
to reproducibly immunoprecipitale CR1 from 3SS~methionine labelled 
monocytes and lymphocytes. Firstly, synthesis of CR1 in these cell may 
normally proceed at a very low level, such that during the pulse period 
of 2 hours minimal amounts of CR1 were being synthesised. A low level 
of CR1 synthesis could arise if the monocytes and lymphocytes have
internal reserves of CR1 as does the PNN (O'Shea et al 1985a). Sim and 
Sim (1983) were able to show that solubilised lymphocytes possessed 
more cofactor activity for the I mediated cleavage of C3b than did whole 
lymphocytes suggesting that lymphocytes have intracellular reserves of 
CR1 and Fearon and Collins (1983> ieported that monocytes could up- 
regulate CR1 expression in response to chemotactic agents. Rapid
synthesis of CR1 would not be required in the presence of large
intracellular pools of the receptor. Thus in future studies it may be 
necessary to stimulate the monocytes with compounds which are known to 
increase the synthesis of CR1.
Secondly, CR1 may not contain enough methionine residues to allow 
sufficient incorporation of 3SS-methionine into the molecule within the
Page 200
short pulse time. Wong et al (1985) determined the amino acid 
composition of purified CR1 and found that methionine was the least 
abundant of the amino acids. Thirdly, Esparza, Fox and Schreiber (1986) 
showed that cell surface expression of CR1 on monocytes could be down- 
regulated by exposure of the cells to recombinant interferon K. This 
down-regulation was considered to be due to shedding of the receptor as 
the total cellular levels of CR1 were also decreased. Sztein et al (1984) 
have shown that isolated human lymphocytes produce interferon K
constitutively. Thus if some lymphocytes were present as contaminants in 
the monocyte cultures they may have been producing sufficient quantities 
of interferon to cause down-regulation of CR1. This may have been a
third contributory factor to low CR1 levels. This down-regulation of CR1 
may have also applied in the lymphocyte cultures.
Although there was some degree of success in isolating CR1 from 
biosynthetically labelled monocytes and lymphocytes it was not a
sufficiently reliable method to be considered suitable for the study of 
CR1 abnormalities in SLE patients. However I feel that this is an
important area in which further research would be valuable as it may 
perhaps answer the question as to whether lower CR1 levels on these 
cells are caused by environmental factors or by a primary cellular 
defect.
In the late 19th" century it 'was noted that there seemed to be a
protective substance in blood serum which could kill and lyse bacteria 
(Nuttal 1888; Buchner 1889). This protective substance was called 
complement (Ehrilch and Morgenroth 1906). In the first half of this 
century it was discovered that complement was a system comprising a 
number of proteins which interacted in sequence to cause lysis of
sensitised E, In the latter half of this century research has shown that 
the complement system is comprised of at least 20 proteins which form 
the classical pathway, the alternative pathway, the terminal sequence and 
a group of control proteins. The end result of the activity of both the 
classical and alternative pathways is the cleavage of C3 which is the 
most abundant of the complement components being present in plasma at a 
concentration of l-2rag/ml. This cleavage allows the assembly of the
proteins of the terminal sequence into membrane attack complexes which 
result in the lysis of cells and invading microorganisms, In addition to 
this major function complement has a number of other biological 
activities (Table 1.1). One of the most important of these is the 
coordination of interactions between appropriate host cell types and 
pathogenic substances. This is achieved by means of complement 
receptors on the surface of host cells which can bind to fragments of 
complement proteins which are covalently attached to activators of
complement.
Research into complement receptors was initiated in 1953 when Nelson 
(1953) described an adhesion phenomenon between human E and 
presensitised Treponema pallidiuin. As this adhesion was shown to be 
heat labile and destroyed by trypsin it was postulated that a receptor 
was responsible for the bond (Nelson and Nelson 1959). A few years 
later Nishioka and Linscott (1963) and Gigli and Nelson (1968) were able 
to demonstrate that C3 was the ligand responsible for immune adherence. 
This receptor has since become known as the immune adherence receptor, 
the C3b receptor or CR1. CR1 has now been shown to bind to a number of 
ligands apart from its major ligand C3b; these are: C4b, iC3, C3c and 
iC3b (Cooper 1969; Bokish and Sobel 1974; Ross and Polley 1975; Berger 
et al 1981; Medof and Nussenzweig 1984).
In the last few years much progress has been made in defining the 
receptor in molecular terms. The receptor was first isolated from E in 
1979 and shown to be a large single chain polypeptide glycoprotein 
with a molecular weight of 205,000 daltons (Fearon 1979). There is now 
known to be a size polymorphism of CR1 with 4 separate allotypes 
having molecular weights of 190,000, 220,000, 250,000 and 160,000
daltons (Dykman et al 1983a and b; Wong et al 1983; Dykman et al 1984;
1985). This difference in size is not thought to be due to variations in 
the carbohydrate structure of the molecule (Vang et al 1983; Atkinson 
and Jones 1984; Dykman et al 1985), It may however be due to differences 
in the amino acid structure of the polypeptide chain. Klickstein et al 
(1985) have partially sequenced CR1 and shown that the polypeptide
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chain consists of repeating homologous amino acid sequences. They 
therefore suggested that differences in size could be accounted for by 
addition or deletion of groups of repeat units of amino acids.
Although there are differences in size the functional capacities of the 
variants are similar (Seya et al 1985). These functions have been 
described in detail in the introduction. Briefly, CR1 isolated from E 
membranes has been shown in vitro to possess cofactor activity for the 
I mediated cleavage of soluble and surface-bound C4b and 03b to iC4b 
and iC3b respectively (Fearon 1979; Iida and Nussenzweig 1981). It may 
also act as a cofactor for the I mediated further cleavage of surface- 
bound iC3b to C3c and C3dg (Medof et al 1982) and substrate-bound 04b 
to C4c and C4d (Medof and Nussenzweig 1984) and it plays a role in the 
prevention of lysis of bystander cells by its ability to decay 
dissociate C4b2a3b and C3bBb formed on these cells (Fearon 1979; Fearon 
1980). In vivo E CR1 is thought to play a role in transporting opsonised 
immune complexes from the circulation to the reticules— endothelial 
system where they can be removed (Siegel et al 1981; Medof and Qger 
1982; Cornacoff et al 1983; Jepson et al 1986; Sherwood and Virella
1986). The removal of complexes from the E is facilitated by the ability 
of CR1 to process the fixed C3b and C4b on the surface of the complexes 
to iC3b and C-3dg and iC4b and C4d respectively. That this processing 
occurs is indicated by the observation that complexes which have been 
released from E show enhanced binding to CR2 bearing cells (Lam and 
Medof 1982), This capacity of E GR1 may therefore be of importance in 
the transfer of complexes from one cell type to another, as is the case 
where E transfer complexes to the cells of the liver during the passage 
of blood from the . portal vein to the hepatic vein (Cornacoff et
al 1983).
The primary function of CR1 on phagocytic cells is the binding of 
complexes opsonised with fragments of C3 and C4 degradation 
(Ehlenberger and Nussenzweig 1977). On stimulated phagocytes CR1 is 
also able to directly mediate phagocytosis of opsonised particles 
(Wright and Silverstein 1982; Pomraier et al 1984; Changelian and Fearon 
1985), and on unstimulated phagocytes CR1 can pinocytose small particles 
and soluble complexes into clathrin-coated pits (Fearon and Abrahamson 
1983). This function of phagocytes may be important for the elimination 
of soluble immune complexes at sites of tissue inflammation.
Although the function of CR1 on B lymphocytes is still largely 
speculative it may play a role in the triggering of antigen-specific 
responses by binding to immune complexes containing C3 and activating 
B cell proliferation (Daha et al 1984).
CR1 on kidney podocytes may serve to prevent complement activation on 
the basement membrane of the glomerulus. It may also be able to 
directly mediate adsorbtive endocytosis of soluble immune complexes 
(Fischer et al 1986).
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On nonphagocytic dendritic reticular cells CR1 may play a role in the 
retention of complement coated immune complexes in lymphoid follicles. 
(Klaus et al 1980) thus allowing the production of B memory cells (Klaus 
and Humphrey 1977).
Accordingly the main physiological functions of CR1 may be summarised 
as, (i) regulation of complement activation on adjacent cell surfaces, 
(ii) transport of immune complexes to suitable sites of removal, (iii) 
ingestion of opsonised particles and immune complexes and (iv) 
regulation of B lymphocyte function.
In the 4 years since this study was first initiated knowledge concerning 
the properties and functions of CR1 has considerably expanded. However 
one of the main issues to which this thesis addressed itself, that is, 
what is the cause of the reduced levels of E CR1 seen in patients with 
SLE, is still controversial. Originally the problem was deciding if the 
reduced levels were inherited or if they were acquired as a result of 
the disease process, Consequently one of the main aspects of this study 
was the comparison of CR1 expression on the E of identical and 
nonidentical twins in order to establish the relative roles of genetic 
and environmental factors in the regulation of E CR1 numbers in the 
normal population.
Prior to the twins study a polyclonal antiserum to CR1 was successfully 
raised. It was proposed to use this antiserum to measure E CR1 levels on 
the twins, However when the monoclonal antibody, Ell, became available 
it was decided to use this instead of the polyclonal as one point 
determinations could be performed on the E. The conclusion from this 
study, which involved the measurement of E CR1 sites on 244 individuals 
(the largest number of individuals included in any E CR1 study thus 
far), was that genetic factors did not play a significant role in the 
regulation of CR1 expression on E. Thus CR1 numbers appeared to be 
regulated entirely by environmental factors, This finding is difficult to 
interpret in the light of recent findings by Wilson et al (1986a). In 
1982 this group proposed a model which could account for the numerical 
polymorphism seen in the normal population. They showed that when CR1 
sites on the E of 113 normal individuals were measured that the numbers 
appeared to fall into 3 groups, those with high numbers of E CR1, those 
with low numbers and those with intermediate numbers. This suggested 
that in the normal population there were 3 phenotypes, one for high (HH) 
CR1 expression, one for low (LL) CR1 expression and one for intermediate 
(HL) CR1 expression. The frequencies of these phenotypes in the normal 
population did not differ significantly from the frequencies predicted 
by the Hardy-Weinberg equilibrium for a 2 codominant allele model of 
inheritance and pedigree analysis of 7 families supported this 
conclusion. They went on to suggest that low levels of E CR1 expression 
seen in SLE patients were as a result of the prevalence of alleles 
determining low CR1 expression (Wilson et al 1982). In the past year 
this same group have published findings which lend further support to 
this 2 codominant allele model (Wilson et al 1986a). They have reported
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the discovery of a restriction fragment length polymorphism of the CR1 
structural gene which appears to correlate with low E CR'l expression: 
Individuals with low E CR1 expression have a 6.9 kb fragment, 
individuals with high CR1 expression have a 7.4 kb fragment and 
individuals with intermediate CR1 expression have both fragments. On 
analysis of their data it is difficult to ignore the evidence for the 
possession of only the 6.9 kb fragment resulting in low E CR1
expression. However the numerical expression of E CR1 in individuals 
with both fragments or individuals with only the 7.4 kb fragment was 
not quite so convincing as there was a considerable degree of overlap 
between the two groups. A possible reason for this overlap may be that 
CR1 numbers on individuals who are genetically predisposed to express 
high CR1 numbers on their E may have their E CR1 numbers reduced by
environmental factors. In contrast individuals who express low CR1 
numbers because of genetic factors, may have fairly constant CR1 
numbers because they cannot be reduced significantly by environmental
factors and they cannot be increased because of genetic control. This 
may explain the close correlation between the presence of the 6,9 kb 
fragment and low E CR1 numbers. If environmental influences were such 
that modulation of receptor numbers could occur easily in normal 
individuals this may be one explanation for the observation that no 
genetic influence could be demonstrated on E CR1 expression in twins, To 
test this hypothesis it may be interesting to study the influence of
genetic and environmental factors on the expression of E CRi only on 
those twins who have low CRI numbers since these receptors may be less 
susceptible to modulation by environmental factors.
Having shown that environmental factors play a role in the regulation of 
E CRI numbers in the normal population, it was decided to investigate 
possible environmental factors which could modulate CRI expression on 
normal ■ E in an attempt to determine if these same factors could 
contribute towards the low numerical expression of CRI seen on the E of 
patients with SLE.
At the present moment the most likely explanation for reduced CRI levels 
on the E of patients with SLE is the proteolytic stripping of CRI from 
E as the E carrying immune complexes come into contact with the 
protease rich reticulo-endothelial cells. Thus the, ability of a selection 
of proteolytic enzymes to remove E CRI was investigated. It was found 
that at physiological concentrations none of the enzymes tested had the 
capacity to decrease E CRI (Table 4.5), At high concentrations, trypsin 
and elastase could significantly decrease CRI sites (Table 4.5h however 
it was considered unlikely that these concentrations of proteases would 
be present in the plasma and in any case the plasma contains a variety 
of protease inhibitors which would rapidly inactivate these proteases. It 
could not however be ruled out that E CRI could be removed when the 
cells come into close contact with the proteinase rich phagocytes during 
transfer of immune complexes in the liver and spleen.
The blockade of E CRI sites by immune complexes is considered by most 
to be a less likely explanation for reduced E CRI levels (Wilson et al 
1982; Minota et al 1983; Ross et al 1985). However experiments performed 
in this thesis would seem to indicate that such a mechanism may indeed 
result in the inability to detect E CRI. In vitro, it was shown that E 
CRI could be blocked by large opsonised IgG aggregates (Table 4.7) and 
in vivo it was shown that E CRI expression on 6 individuals was reduced 
by the consumption of 1.2 litres of cows milk, a rich source of food 
antigens (Fig 4,6; Table 4,8). This latter experiment in particular 
indicated how easily CRI expression could be modified by environmental 
influences. Further experiments in this particular aspect might be of 
value in deciding if blockade of E CRI does truly constitute the 
mechanism of reduced CRI levels on the E of SLE patients.
Although it has been known for a number of years that patients with SLE 
have low CRI levels, at the start of this study it was not known if CRI 
was reduced on other cell types, One of the aims of this study was the 
measurement of CRI on the PMN of normal individuals and on patients 
with SLE in order to determine if both cell types in these patients had 
reduced levels of CRI expression in comparison to normal. It was shown 
that PMN from normal individuals expressed 3 distinct pools of PMN CRI. 
One of these pools was expressed at O ’C, a second was expressed after 
warming the cells to 3 7 ’C and the third was expressed in response to 
stimulation with the synthetic chemotactic agent FMLP. Expression of the 
pool at 37 °C was not dependent upon protein synthesis, an intact 
cytoskeleton or energy while the pool expressed in response to FMLP was 
dependent upon an intact cytoskeleton and energy but did not require de 
novo protein synthesis.
All 3 of these pools were found to be reduced in patients with active
SLE but were normal in those with inactive SLE (Fig 5.12). The most
severely depleted pool was that which was expressed in response to 
stimulation with FMLP. If this mechanism of increasing CRI expression in 
response to chemotactic stimuli released at sites of tissue inflammation 
is defective then it may indicate that the recognition of and phagocytic 
function for pathological particles by those PMN may be impaired. If 
this were so it would contribute to the tissue deposits of immune 
complexes seen in SLE,
The mechanism whereby this reduction is brought about is unknown. As in 
the study of reduced levels of E CRI expression in SLE the question
arises whether reduced levels result from a genetic defect or are caused 
by the disease process. PMN show a numerical polymorphism in CRI 
expression with numbers varying widely among individuals. These numbers 
do not appear to fall into distinct groups of individuals having high, 
medium or low CRI expression. Wilson et al (1986a) reported that the 
presence of restriction fragments (6.9 kb and 7.4 kb) did not influence 
expression of CRI on neutrophils as they did on E although these 
fragments are linked to the same structural gene which controls the
structure of both E and PM.N CRI, Thus there is no evidence as yet to
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suggest that PMN CRI expression is genetically controlled in the normal 
population. The results from my studies do however suggest that in, 
patients with SLE CRI expression on PMN can be modulated by factors 
associated with the disease as it was found that the number of PMN CRI 
correlated significantly with the number of E CRI in SLE patients (Fig 
5.13 b, c and d) and both changed in parallel with disease activity 
(Table 5.7). In addition it was shown that SLE patients who were in an 
inactive phase of disease had levels of FMN CRI expression which did 
not differ significantly from normal (Fig 5.12.). This suggests that the 
decrease in PMN CRI number is an acquired defect. The precise mechanism 
whereby this occurs is outwith the scope of this thesis howevery it must 
merit further investigation.
It may be possible that loss of the receptor occurs after binding to 
opsonised immune complexes bearing C3 fragments. It has been shown by 
a number of groups that P M  can internalise CRI bound to its ligand by 
the process of endocytosis ((Fearon et al 1981; Abrahamson and Fearon 
1983; Hogg et al 1984), Abrahamson and Fearon (1983) showed that once 
the receptor-ligand complexes had been taken into clathrin-coated 
vesicles they were transported to azurophile granules where they were 
degraded. Thus the receptors were not recycled. This might imply that as 
the immune complex load is greater in SLE patients more receptors are 
internalised and degraded* "Thus there is an increased demand for 
receptors to be brought to the surface from internal pools and therefore 
both surface expression of CRI and internal pools of CRI eventually 
become depleted. As the disease becomes inactive less complexes are 
available for clearance and so the demand for receptors is reduced and 
expression of P M  CRI can return to normal.
However Taylor et al (1983b) has reported that there was no significant 
internalisation of soluble immune complexes which contained dsDNA and 
anti-dsDNA from fSLE patients, after they had bound to FMN through CRI. 
It may therefore be possible that internalisation of CRI-ligand 
complexes in SLE patients occurs not by endocytosis but by phagocytosis. 
P M  stimulated with FMLP and soluble fibronectin are able to phagocytose 
particles by means of CRI (Pommier et al 1984), As chemotactic factors 
are released at sites of tissue inflammation and soluble fibronectin is 
also present PMN may become phagocytically activated and internalise 
complexes with the same resultant depletion of internal pools. Taylor 
et al (1983b) may not have observed internalisation of complexes because 
the conditions were not appropriate for activation of PMN CRI.
An alternative explanation for the depletion of PMN CRI expression is 
that there is a defect in the ability of the cell to synthesise CRI as a 
result of a primary abnormality in the CRI gene or in its expression. To 
investigate this possibility monocyte and lymphocyte cultures were 
pulsed with 3GS-methionine with the aim of immunoprecipitating CRI from 
cell lysates and supernatants, Both of these cell types have been shown 
to be defective in CRI function or CRI expression in SLE patients. Hurst 
et al (1984) reported a significant reduction in the rate of complement
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mediated phagocytosis by blood monocytes in patients with SLE. This 
reduction was most evident in patients with active disease and Wilson et
al (1986b) reported that B cells from 17 SLE patients had significantly
reduced CRI expression in comparison to normal individuals.
CRI was successfully immunoprecipitated from 2 normal monocyte culture 
lysates (Plate 6.2 and Plate 6.3) and was isolated from 1 normal 
lymphocyte culture lysate by affinity chromatography on C3-Sepharose 
(Plate 6.5). For reasons discussed in chapter 6.26 it was not
considered to be a viable method for studying the biosynthesis of CRI 
in patients with SLE. This is unfortunate as the ability to do so may 
provide a valuable insight into the mechanism of reduced CRI numbers on 
peripheral blood leukocytes
In conclusion therefore the different aims of this study have been 
achieved though in varying degrees. Although 4 years have passed since 
the start of this investigation the questions which were raised at the
beginning are still extremely topical. Thus far no one has been able to
study the biosynthesis of CRI in normal leukocytes nor in leukocytes 
from patients with SLE. Therefore the question still remains unanswered 
as to whether there is a defect in the biosynthesis of CRI in SLE 
patients. The few results obtained from the biosynthetic study in
chapter 6 show that it is possible to immunoprecipitate CRI from normal 
cells and perhaps studies in the future should continue to look at this 
aspect.
Although in the past year one group has published a report on the
reduction of CRI on the neutrophils of SLE patients no one has defined
the pools of CRI which exist in normal PMIJ. In this thesis I have been 
able to show that there are 3 pools of CRI which all have different 
requirements for their expression. In addition I have shown that there 
is a numerical polymorphism of CRI on PMN and that the numbers of CRI 
on PMN of patients with SLE are severely depleted. This depletion seems 
to correlate with disease activity. The cause of this depletion still 
remains to be investigated.
In conclusion therfore we have been unable to find genetic control of E 
CRI expression in normal individuals. However it is quite possible that 
regulation of the expression of the CRI structural gene is under genetic 
control and at some time in the life span of the E the CRI genotype
reflects the phenotype, but at other times as environmental factors have 
a significant influence on E CRI numbers the phenotype is altered. It 
may be that the suseptibility of the phenotype to environmental factors 
is exaggerated on the E of patients with SLE where levels of CRI can be 
reduced dramatically during periods of disease activity and return to
normal when the patient is in an inactive phase of disease (Ross et al 
1985; Holme et al 1986). The factors which reduce E CRI numbers have
still not been characterised and must therefore merit further
investigation.
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